

2009


AMERICAN EPILEPSY SOCIETY

63RD ANNUAL MEETING

BOSTON, MA

HYNES CONVENTION CENTER

December 4 - 8, 2009



PROGRAM BOOK

WELCOME MESSAGE

Welcome to the AES 63rd Annual Meeting. The AES Annual Meeting and Scientific Program Committees have organized an exciting schedule of educational programs, exhibits, social events and networking opportunities for your participation.

A diversity of educational options

This year's meeting is packed with sessions of interest to all, whether they focus on basic science, clinical research, clinical practice for adults or children, psychiatry, surgery, nursing and professionals in epilepsy care, or students considering a career in the field of epilepsy.

An evening of music and support for research

On Saturday evening, December 5, the Longwood Symphony Orchestra will perform a benefit concert at the New England Conservatory to help establish the Dr. Susan Spencer Memorial Research Fellowship Fund. Over 75 percent of orchestra members are health care professionals. Check at registration for last-minute availability of tickets.

Also, don't miss the all-attendee reception in honor of the Lennox and Lombroso Trust for Research & Training which will be part of the Exhibit Hall Opening on Sunday, December 6. Donations to support this trust can be made through the Web site, aesnet.org.

Thank you for participating in our meeting!



Steven C. Schachter, M.D.
President, American Epilepsy Society

2009 AES BOARD OF DIRECTORS

PRESIDENT

Steven C. Schachter, M.D.

FIRST VICE PRESIDENT

Jaideep Kapur, M.D., Ph.D.

SECOND VICE PRESIDENT

John M. Pellock, M.D.

TREASURER

Michael D. Privitera, M.D.

PAST PRESIDENT

Dennis D. Spencer, M.D.

BOARD MEMBERS

Amy Brooks-Kayal, M.D.

James C. Cloyd, Pharm.D.

John Huguenard, Ph.D.

Frances E. Jensen, M.D.

Eli M. Mizrahi, M.D.

Elson L. So, M.D.

EX-OFFICIO

Gregory K. Bergey, M.D.

Michael A. Rogawski, M.D., Ph.D.
(Epilepsy Currents)

Brandy Fureman, Ph.D. (NIH/NINDS)

Eric Hargis (Epilepsy Foundation)

Andres M. Kanner, M.D. (AAN Liaison)

David M. Labiner, M.D. (Director,
Council on Education)

Cesare T. Lombroso, M.D., Ph.D.

Page Pennell, M.D. (EF PAB Liaison)

Kevin J. Staley, M.D., Ph.D. (Research)

John Swann, Ph.D. (ILAE Liaison)

Richard Wennberg, M.D. (CLAE)



TABLE OF CONTENTS

Meeting Information	Poster Hall Map.....	4
	Posters & Platforms-at-a Glance.....	5
	AES Special Recognition.....	6
	Supporters.....	9
	Schedule-at-a-Glance.....	10
	Scientific Exhibits.....	31
	Exhibitors.....	65
	Poster Index by Authors.....	73
	General Information.....	94
	FRIDAY	National EpiFellows Foundation 17th Annual Scientific Forum.....
	Advances in the Management of Epilepsy and the Epilepsy Clinic.....	13
	Annual Fundamentals of Epilepsy.....	13
	Special Interest Group Meetings.....	14
	Hot Topics Symposium.....	15
	Spanish Symposium.....	15
SATURDAY	Hoyer Lecture.....	17
	Professionals in Epilepsy Care Symposium.....	17
	Special Interest Group Meetings.....	17
	Merritt-Putnam Symposium.....	18
	Special Interest Group Meetings.....	19
	Antiepileptic Therapy Symposium.....	19
	Investigators' Workshop.....	20
	Special Interest Group Meetings.....	20
SUNDAY	Annual Course.....	33
	Investigators' Workshop.....	34
	Thought Sessions.....	35
	Mentoring Session.....	35
	Reception in Support of Lennox and Lombroso Trust for Research & Training.....	36
	Investigators' Workshop Poster Session.....	36
	Epilepsy Monitoring Unit Symposium.....	36
	Special Interest Group Meetings.....	37
MONDAY	Presidential Symposium.....	47
	Lennox Lecture.....	47
	Investigators' Workshop.....	47
	Pediatric Epilepsy Highlights Session.....	47
	Pediatric State of the Art Symposium.....	48
	Platform Sessions.....	49
TUESDAY	Plenary II.....	61
	International League Against Epilepsy Symposium.....	61
	Special Interest Group Meetings.....	62
	Plenary III.....	62
	Special Interest Group Meetings.....	63

LOCATION KEY

Hynes = Hynes Convention Center
 Sheraton = Sheraton Boston Hotel

Watch for these 2010 dates!

Annual Meeting Call for Abstracts Available

Monday, March 1, 2010

AES Research Recognition and Distinguished Achievement Awards Nominations

Monday, August 9, 2010

AES 64th Annual Meeting

December 3-7, 2010
 San Antonio, TX



BANZEL® (rufinamide) 200, 400 mg Tablets

Brief Summary of full Prescribing Information: Please consult package insert for full Prescribing Information.

INDICATIONS AND USAGE BANZEL (rufinamide) is indicated for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome in children 4 years and older and adults. **CONTRAINDICATIONS** BANZEL is contraindicated in patients with Familial Short QT syndrome (see PRECAUTIONS, QT Shortening). **WARNINGS** Suicidal Behavior and Ideation Antiepileptic drugs increase the risk of suicidal thoughts or behavior in patients taking these drugs for any indication. Patients treated with any antiepileptic drug for any indication should be monitored for the emergence or worsening of depression, suicidal thoughts or behavior, or any unusual changes in mood or behavior. Pooled analyses of 199 placebo-controlled clinical trials (mono- and adjunctive therapy) of 11 different antiepileptic drugs showed that patients randomized to one of the antiepileptic drugs had approximately twice the risk (adjusted Relative Risk 1.8, 95% CI: 1.2, 2.7) of suicidal thinking or behavior compared to patients randomized to placebo. In these trials, which had a median treatment duration of 12 weeks, the estimated incidence rate of suicidal behavior or ideation among 27,863 antiepileptic drug-treated patients was 0.43%, compared to 0.24% among 16,029 placebo-treated patients, representing an increase of approximately one case of suicidal thinking or behavior for every 530 patients treated. There were four suicides in drug-treated patients in the trials and none in placebo-treated patients, but the number of events is too small to allow any conclusion about drug effect on suicide. The increased risk of suicidal thoughts or behavior was observed as early as one week after starting drug treatment and persisted for at least 24 weeks. Because most trials included in the analysis did not extend beyond 24 weeks, the risk of suicidal thoughts or behavior beyond 24 weeks could not be assessed. The risk of suicidal thoughts or behavior was generally consistent among drugs in the data analyzed. The finding of increased risk with antiepileptic drugs of varying mechanisms of action and across a range of indications suggests that the risk applies to all antiepileptic drugs used for any indication. The risk did not vary substantially by age in the clinical trials analyzed. The relative risk for suicidal thoughts or behavior was higher in clinical trials for epilepsy (3.5) than in clinical trials for psychiatric (1.5) or other conditions (1.9), but the absolute risk differences were similar (2.4, 2.9, and 0.9, respectively). Anyone considering prescribing BANZEL or any other antiepileptic drug must balance this risk with the risk of untreated illness. Epilepsy and many other illnesses for which antiepileptics are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior. Should suicidal thoughts and behavior emerge during treatment, the prescriber needs to consider whether the emergence of these symptoms in any given patient may be related to the illness being treated. Patients, their caregivers, and families should be informed that antiepileptic drugs increase the risk of suicidal thoughts and behavior and should be advised of the need to be alert for the emergence or worsening of the signs and symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts, behavior, or thoughts about self-harm. Behaviors of concern should be reported immediately to healthcare providers. **Central Nervous System Reactions:** Use of BANZEL has been associated with central nervous system-related adverse reactions. The most significant of these can be classified into two general categories: 1) somnolence or fatigue, and 2) coordination abnormalities, dizziness, gait disturbances, and ataxia (see ADVERSE REACTIONS). **PRECAUTIONS** **QT Shortening** Formal cardiac ECG studies demonstrated shortening of the QT interval (up to 20 msec) with BANZEL treatment. In a placebo-controlled study of the QT interval, a higher percentage of BANZEL-treated subjects (46% at 2400 mg, 46% at 3200 mg, and 65% at 4800 mg) had a QT shortening of greater than 20 msec at C_{max} compared to placebo (5–10%). Reductions of the QT interval below 300 msec were not observed in the formal QT studies with doses up to 7200 mg/day. Moreover, there was no signal for drug-induced sudden death or ventricular arrhythmias. The degree of QT shortening induced by BANZEL is without any known clinical risk. Familial Short QT syndrome is associated with an increased risk of sudden death and ventricular arrhythmias, particularly ventricular fibrillation. Such events in this syndrome are believed to occur primarily when the corrected QT interval falls below 300 msec. Nonclinical data also indicate that QT shortening is associated with ventricular fibrillation. Patients with Familial Short QT syndrome should not be treated with BANZEL (see CONTRAINDICATIONS). Caution should be used when administering BANZEL with other drugs that shorten the QT interval. **Multi-organ Hypersensitivity Reactions** Multi-organ hypersensitivity syndrome, a serious condition sometimes induced by antiepileptic drugs, has occurred in association with BANZEL therapy in clinical trials. One patient experienced rash, urticaria, facial edema, fever, elevated eosinophils, stuporous state, and severe hepatitis, beginning on day 29 of BANZEL therapy and extending over a course of 30 days of continued BANZEL therapy with resolution 11 days after discontinuation. Additional possible cases presented with rash and one or more of the following: fever, elevated liver function studies, hematuria, and lymphadenopathy. These cases occurred in children less than 12 years of age, within four weeks of treatment initiation, and were noted to resolve and/or improve upon BANZEL discontinuation. This syndrome has been reported with other anticonvulsants and typically, although not exclusively, presents with fever and rash associated with other organ system involvement. Because this disorder is variable in its expression, other organ system signs and symptoms not noted here may occur. If this reaction is suspected, BANZEL should be discontinued and alternative treatment started. All patients who develop a rash while taking BANZEL must be closely supervised. **Withdrawal of AEDs** As with all antiepileptic drugs, BANZEL should be withdrawn gradually to minimize the risk of precipitating seizures, seizure exacerbation, or status epilepticus. If abrupt discontinuation of the drug is medically necessary, the transition to another AED should be made under close medical supervision. In clinical trials, BANZEL discontinuation was achieved by reducing the dose by approximately 25% every two days. **Status Epilepticus** Estimates of the incidence of treatment emergent status epilepticus among patients treated with BANZEL are difficult because standard definitions were not employed. In a controlled Lennox-Gastaut syndrome trial, 3 of 74 (4.1%) BANZEL-treated patients had episodes that could be described as status epilepticus in the BANZEL-treated patients compared with none of the 64 patients in the placebo-treated patients. In all controlled trials that included patients with different epilepsies, 11 of 1240 (0.9%) BANZEL-treated patients had episodes that could be described as status epilepticus compared with none of 635 patients in the placebo-treated patients. **Information for Patients** Prescribers or other health professionals should inform patients, their families, and their caregivers about the benefits and risks associated with treatment with BANZEL and should counsel them in its appropriate use. A patient Medication Guide is available for BANZEL. The prescriber or healthcare professional should instruct patients, their families, and their caregivers to read the Medication Guide and should assist them in understanding its contents. Patients should be given the opportunity to discuss the contents of the Medication Guide and to obtain answers to any questions they may have. Patients should be advised of the following issues and asked to alert their prescriber if these occur while taking BANZEL: Suicidal Thinking and Behavior – Patients, their caregivers, and families should be informed that antiepileptic drugs increase the risk of suicidal thoughts and behavior and should be advised of the need to be alert for the emergence or worsening of the signs and symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts, behavior, or thoughts about self-harm. Behaviors of concern should be reported immediately to healthcare providers. Patients should be instructed to take BANZEL only as prescribed. BANZEL should be taken with food. As with all centrally acting medications, alcohol in combination with BANZEL may cause additive central nervous system effects. Patients should be advised about the potential for somnolence or dizziness and advised not to drive or operate machinery until they have gained sufficient experience on BANZEL to gauge whether it adversely affects their mental and/or motor performance. Female patients of childbearing age should be warned that the concurrent use of BANZEL with hormonal contraceptives may render this method of contraception less effective (see Drug Interactions). Additional non-hormonal forms of contraception are recommended when using BANZEL. Patients should be advised to notify their physician if they become pregnant or intend to become pregnant during therapy. Patients should be advised to notify their physician if they are breast-feeding or intend to breast-feed. Patients should be advised to notify their physician if they experience a rash associated with fever. **Laboratory Tests** Leucopenia (white cell count $< 3 \times 10^9/L$) was more commonly observed in BANZEL-treated patients (43 of 1171, 3.7%) than placebo-treated patients (7 of 579, 1.2%) in all controlled trials. **Drug Interactions** In vitro and in vivo studies have shown that BANZEL is unlikely to be involved in significant pharmacokinetic interactions. BANZEL can increase plasma concentrations of phenytoin by 21% or more due to non-linear pharmacokinetics. Valproate can increase BANZEL concentrations up to 70%. Patients stabilized on BANZEL before being prescribed valproate should begin valproate therapy at a low dose, and titrate to a clinically effective dose. Similarly, patients on valproate should begin at a BANZEL dose lower than 400 mg. Co-administration of BANZEL with ethinyl estradiol and norethindrone can decrease AUC_{0-24} of these hormonal contraceptives by 22% and 14% and C_{max} by 31% and 18%, respectively. Female patients of childbearing age should be warned that the concurrent use of BANZEL with hormonal contraceptives may render this method of contraception less effective. Additional non-hormonal forms of contraception are recommended when using BANZEL (see Information for Patients). **Drug/Laboratory Test Interactions** There are no known interactions of BANZEL with commonly used laboratory tests. **Antiepileptic Drugs Effects of BANZEL on other AEDs** Population pharmacokinetic analysis of average concentration at steady state of carbamazepine, lamotrigine, phenobarbital, phenytoin, topiramate, and valproate showed that typical rufinamide C_{max} levels had little effect on the pharmacokinetics of other AEDs. Any effects, when they occur, have been more marked in the pediatric population. Phenytoin: The decrease in clearance of phenytoin estimated at typical levels of rufinamide (C_{max} 15 µg/mL) is predicted to increase plasma levels of phenytoin by 7 to 21%. As phenytoin is known to have non-linear pharmacokinetics (clearance becomes saturated at higher doses), it is possible that exposure will be greater than the model prediction. **Effects of Other AEDs on BANZEL** Potent cytochrome P450 enzyme inducers, such as carbamazepine, phenytoin, primidone, and phenobarbital appear to increase the clearance of BANZEL. Given that the majority of clearance of BANZEL is via a non-CYP-dependent route, the observed decreases in blood levels seen with carbamazepine, phenytoin, primidone, and phenobarbital are unlikely to be entirely attributable to induction of a P450 enzyme. Other factors explaining this interaction are not understood. Any effects, when they occurred were likely to be more marked in the pediatric population. Valproate: Based on a population pharmacokinetic analysis, rufinamide clearance was decreased by valproate. In children, valproate administration may lead to elevated levels of rufinamide by up to 70%. Patients stabilized on BANZEL before being prescribed valproate should begin valproate therapy at a low dose, and titrate to a clinically effective dose. Similarly, patients on valproate should begin at a BANZEL dose lower than 400 mg. **Effects of BANZEL on other Medications** Hormonal contraceptives: Co-administration of BANZEL (800 mg BID for 14 days) and Ortho-Novum 1/35® resulted in a mean decrease in the ethinyl estradiol AUC_{0-24} of 22% and C_{max} by 18% and norethindrone AUC_{0-24} by 14% and C_{max} by 18%, respectively. The clinical significance of this decrease is unknown. Female patients of childbearing age should be warned that the concurrent use of BANZEL with hormonal contraceptives may render this method of contraception less effective. Additional non-hormonal forms of contraception are recommended when using BANZEL (see


Information for Patients). Triazolam: Co-administration and pre-treatment with BANZEL (400 mg bid) resulted in a 37% decrease in AUC and a 23% decrease in C_{max} of triazolam, a CYP 3A4 substrate. Olanzapine: Co-administration and pre-treatment with BANZEL (400mg bid) resulted in no change in AUC and C_{max} of olanzapine, a CYP 1A2 substrate. **Carcinogenicity, Mutagenicity, Impairment of Fertility** **Carcinogenicity:** Rufinamide was given in the diet to mice at 40, 120, and 400 mg/kg/day and to rats at 20, 60, and 200 mg/kg/day for two years. The doses in mice were associated with plasma AUCs 0.1 to 1 times the human plasma AUC at the maximum recommended human dose (MRHD, 3200 mg/day). Increased incidences of tumors (benign bone tumors (osteomas) and/or hepatocellular adenomas and carcinomas) were observed in mice at all doses. Increased incidences of thyroid follicular adenomas were observed in rats at all but the low dose; the low dose is < 0.1 times the MRHD on a mg/m² basis. **Mutagenicity:** Rufinamide was not mutagenic in the in vitro bacterial reverse mutation (Ames) assay or the in vitro mammalian cell point mutation assay. Rufinamide was not clastogenic in the in vitro mammalian cell chromosomal aberration assay or the in vivo rat bone marrow micronucleus assay. **Impairment of Fertility:** Oral administration of rufinamide (doses of 20, 60, 200, and 600 mg/kg/day) to male and female rats prior to mating and throughout mating, and continuing in females up to day 6 of gestation resulted in impairment of fertility (decreased conception rates and mating and fertility indices; decreased numbers of corpora lutea, implantations, and live embryos; increased preimplantation loss; decreased sperm count and motility) at all doses tested. Therefore, a no-effect dose was not established. The lowest dose tested was associated with a plasma AUC = 0.2 times the human plasma AUC at the MRHD. **PREGNANCY** **Pregnancy Category C** Rufinamide produced developmental toxicity when administered orally to pregnant animals at clinically relevant doses. Rufinamide was administered orally to rats at doses of 20, 100, and 300 mg/kg/day and to rabbits at doses of 30, 200, and 1000 mg/kg/day during the period of organogenesis (implantation to closure of the hard palate); the high doses are associated with plasma AUCs = 2 times the human plasma AUC at the maximum recommended human dose (MRHD, 3200 mg/day). Decreased fetal weights and increased incidences of fetal skeletal abnormalities were observed in rats at doses associated with maternal toxicity. In rabbits, embryo-fetal death, decreased fetal body weights, and increased incidences of fetal visceral and skeletal abnormalities occurred at all but the low dose. The highest dose tested in rabbits was associated with abortion. The no-effect doses for adverse effects on rat and rabbit embryo-fetal development (20 and 30 mg/kg/day, respectively) were associated with plasma AUCs = 0.2 times that in humans at the MRHD. In a rat pre- and post-natal development study (dosing from implantation through weaning) conducted at oral doses of 5, 30, and 150 mg/kg/day (associated with plasma AUCs up to =1.5 times that in humans at the MRHD), decreased offspring growth and survival were observed at all doses tested. A no-effect dose for adverse effects on pre- and post-natal development was not established. The lowest dose tested was associated with plasma AUC < 0.1 times that in humans at the MRHD. There are no adequate and well-controlled studies in pregnant women. BANZEL should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. **Labor and Delivery** The effect of BANZEL on labor and delivery in humans is not known. **Nursing Mothers** Rufinamide is likely to be excreted in breast milk. Because of the potential for serious adverse reactions in nursing infants from BANZEL, a decision should be made whether to discontinue nursing or discontinue the drug taking into account the importance of the drug to the mother. **Pediatric Use** The safety and effectiveness in patients with Lennox-Gastaut syndrome have not been established in children less than 4 years. **Geriatric Use** Clinical studies of BANZEL did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. A study evaluating the pharmacokinetics of rufinamide in elderly subjects showed that there were no significant differences in the plasma and urine pharmacokinetic parameters of rufinamide between the younger and elderly subjects under both single and multiple dose treatments. **ADVERSE REACTIONS** Placebo-controlled double-blind studies were performed in adults and in pediatric patients, down to age of 4, in other forms of epilepsy, in addition to the trial in Lennox-Gastaut syndrome. Data on CNS Reactions (see WARNINGS) from the Lennox-Gastaut study are presented first. Because there is no reason to suspect that adverse reactions would substantially differ between these patient populations, safety data from all of these controlled studies are then presented. Most of these adverse reactions were mild to moderate and transient in nature. **Common central nervous system reactions in the controlled trial of patients 4 years or older with Lennox-Gastaut syndrome treated with BANZEL as adjunctive therapy (see WARNINGS):** Somnolence was reported in 24.3% of BANZEL-treated patients compared to 12.5% of placebo patients and led to study discontinuation in 2.7% of treated patients compared to 0% of placebo patients. Fatigue was reported in 9.5% of BANZEL-treated patients compared to 7.8% of placebo patients. It led to study discontinuation in 1.4% of treated patients and 0% of placebo patients. Dizziness was reported in 2.7% of BANZEL-treated patients compared to 0% of placebo patients, and did not lead to study discontinuation. Ataxia and gait disturbance were reported in 5.4% and 1.4% of BANZEL-treated patients, respectively, and in no placebo patients. Balance disorder and abnormal coordination were each reported in 0% of BANZEL-treated patients and 1.6% of placebo patients. None of these reactions led to study discontinuation. **All Adverse Reactions for All Treated Patients with Epilepsy, Double-blind Adjunctive Therapy Studies:** The most commonly observed ($\geq 10\%$) adverse reactions in BANZEL-treated patients, when used as adjunctive therapy at all doses studied (200 to 3200 mg/day) with a higher frequency than in placebo were: headache, dizziness, fatigue, somnolence, and nausea. At the target dose of 45 mg/kg/day in children, the most commonly observed ($\geq 5\%$) adverse reactions in BANZEL-treated patients, given as adjunctive therapy, with a higher frequency than placebo were: somnolence, vomiting, headache, fatigue, dizziness, nausea, and convulsion. At doses up to 3200 mg/day in adults, the most commonly observed ($\geq 5\%$) adverse reactions in BANZEL-treated patients, given as adjunctive therapy, at all doses studied, with a higher frequency than placebo were: headache, dizziness, fatigue, nausea, somnolence, diplopia, nasopharyngitis, tremor, nystagmus, vision blurred and vomiting. Treatment-emergent adverse reactions in all pediatric double-blind adjunctive trials at the recommended dose of 45 mg/kg/day that occurred in at least 3% of BANZEL-treated patients (N=187) and occurred more frequently than in placebo patients (N=182) included somnolence, vomiting, headache, fatigue, dizziness, nausea, influenza, nasopharyngitis, decreased appetite, rash, ataxia, diplopia, bronchitis, sinusitis, psychomotor hyperactivity, abdominal pain upper, aggression, ear infection, disturbance in attention, and pruritus. Treatment-emergent adverse reactions in all adult double-blind adjunctive trials (up to 3200mg/day) that occurred in at least 3% of BANZEL-treated patients (N=823) and occurred more frequently than in placebo patients (N=376) included headache, dizziness, fatigue, nausea, somnolence, diplopia, tremor, nystagmus, vision blurred, vomiting, ataxia, abdominal pain upper, anxiety, constipation, dyspepsia, back pain, gait disturbance, and vertigo. In these studies, either BANZEL or placebo was added to current AED therapy. **Discontinuation in Controlled Clinical Studies** In controlled double-blind adjunctive clinical studies, 9.0% of patients receiving BANZEL as adjunctive therapy and 4.4% receiving placebo discontinued as a result of an adverse reaction. The adverse reactions most commonly leading to discontinuation of BANZEL ($> 1\%$) used as adjunctive therapy were generally similar in adults and children. In pediatric double-blind adjunctive clinical studies, 8.0% of patients receiving BANZEL as adjunctive therapy and 2.2% receiving placebo discontinued as a result of an adverse reaction. The adverse reactions most commonly leading to discontinuation of BANZEL ($> 1\%$) used as adjunctive therapy included convulsion, rash, fatigue, and vomiting. In adult double-blind adjunctive clinical studies (up to 3200 mg/day), 9.5% of patients receiving BANZEL as adjunctive therapy and 5.9% receiving placebo discontinued as a result of an adverse reaction. The adverse reactions most commonly leading to discontinuation of BANZEL ($> 1\%$) used as adjunctive therapy included dizziness, fatigue, headache, nausea, and ataxia. **Other Adverse Events Observed During Clinical Trials:** BANZEL has been administered to 1978 individuals during all epilepsy clinical trials (placebo-controlled and open-label). Adverse events occurring during these studies were recorded by the investigators using terminology of their own choosing. To provide a meaningful estimate of the proportion of patients having adverse events, these events were grouped into standardized categories using the MedDRA dictionary. Adverse events occurring at least three times and considered possibly related to treatment are included in the System Organ Class listings below. Terms not included in the listings are those already included above, those too general to be informative, those related to procedures, and terms describing events common in the population. Some events occurring fewer than 3 times are also included based on their medical significance. Because the reports include events observed in open label, uncontrolled observations, the role of BANZEL in their causation cannot be reliably determined. Events are classified by body system and listed in order of decreasing frequency as follows: **frequent adverse events**— those occurring in at least 1/100 patients; **infrequent adverse events**— those occurring in 1/100 to 1/1000 patients; **rare**— those occurring in fewer than 1/1000 patients. **Blood and Lymphatic System Disorders:** Frequent: anemia. Infrequent: lymphadenopathy, leukopenia, neutropenia, iron deficiency anemia, thrombocytopenia. **Cardiac Disorders:** Infrequent: bundle branch block right, atrioventricular block first degree. **Metabolic and Nutritional Disorders:** Frequent: decreased appetite, increased appetite. **Renal and Urinary Disorders:** Frequent: polyuria. Infrequent: urinary incontinence, dysuria, hematuria, nephrolithiasis, polyuria, enuresis, nocturia, incontinence. **DRUG ABUSE AND DEPENDENCE** The abuse and dependence potential of BANZEL has not been evaluated in human studies. **OVERDOSAGE** Because strategies for the management of overdose are continually evolving, it is advisable to contact a Certified Poison Control Center to determine the latest recommendations for the management of an overdose of any drug. One overdose of 7200 mg/day BANZEL was reported in an adult during the clinical trials. The overdose was associated with no major signs or symptoms, no medical intervention was required, and the patient continued in the study at the target dose. Treatment or Management of Overdose: There is no specific antidote for overdose with BANZEL. If clinically indicated, elimination of unabsorbed drug should be attempted by induction of emesis or gastric lavage. Usual precautions should be observed to maintain the airway. General supportive care of the patient is indicated including monitoring of vital signs and observation of the clinical status of the patient. Hemodialysis: Standard hemodialysis procedures may result in limited clearance of rufinamide. Although there is no experience to date in treating overdose with hemodialysis, the procedure may be considered when indicated by the patient's clinical state. For further product information, please visit www.BANZEL.com or call the Eisai Medical Services Department at 1-888-274-2378.

Rx Only BANZEL™ is a trademark of Novartis Pharma AG, used under license. Manufactured by Eisai Co., Ltd. Marketed by Eisai Inc., Woodcliff Lake, NJ 07677

©2008 Eisai Inc. Printed in U.S.A. Revised November 2008 RUF000089

For the adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients 4 years and older

Add Powerful Seizure Control To Patients' Lives



Visit Booth
401

Proven efficacy that may offer hope to patients with LGS

In patients inadequately controlled with 1–3 AEDs*:

- 42.5% reduction in tonic-atonic seizures with BANZEL® vs 1.4% increase with placebo ($P < 0.0001$)^{†1,2}
- 32.7% reduction in total seizures with BANZEL vs 11.7% reduction with placebo ($P < 0.002$)^{†1,2}
- Mostly mild to moderate and transient adverse events¹
- Titration can be as rapid as 1–2 weeks¹

Important Safety Information

- BANZEL is contraindicated in patients with Familial Short QT syndrome.
- AEDs increase the risk of suicidal thoughts or behavior in patients. Patients, their caregivers, and families should be informed of the risk and advised to monitor and report any emergence or worsening of depression, suicidal thoughts or behavior, or any unusual changes in mood or behavior, or thoughts of self-harm. If these symptoms occur, consider if it may be related to the AED or illness because epilepsy itself can increase these risks.
- Use of BANZEL has been associated with central nervous system-related adverse reactions, such as somnolence or fatigue, coordination abnormalities, dizziness, gait disturbances, and ataxia.
- Formal cardiac ECG studies demonstrated shortening of the QT interval (up to 20 msec) with BANZEL. Caution should be used when administering BANZEL with other drugs that shorten the QT interval.
- Multi-organ hypersensitivity syndrome has been reported in association with BANZEL therapy. In clinical trials, hypersensitivity reactions occurred in children less than 12 years of age and within 4 weeks of starting BANZEL therapy. If this reaction is suspected, BANZEL should be discontinued and alternative treatment started. All patients who develop a rash while taking BANZEL must be closely supervised.
- As with all AEDs, BANZEL should be gradually withdrawn to minimize the risk of increased seizure frequency.
- In all patients with epilepsy treated with BANZEL in double-blind, adjunctive therapy studies, the most commonly observed adverse reactions were headache, dizziness, fatigue, somnolence, and nausea.

Please see the brief summary of Prescribing Information on the following page.

*AEDs = antiepileptic drugs.

†Results of a 12-week, randomized, double-blind, multicenter, placebo-controlled, parallel-group trial to assess the effectiveness of BANZEL to reduce inadequately controlled seizures associated with LGS in patients (N = 138, intent to treat) being treated with 1–3 concomitant stable-dose AEDs.

References: 1. BANZEL® [package insert]. Woodcliff Lake, NJ: Eisai Inc; 2008. 2. Glauser T, Kluger G, Sachdeo R, Krauss G, Perdomo C, Arroyo S. Rufinamide for generalized seizures associated with Lennox-Gastaut syndrome. *Neurology*. 2008;70:1950-1958.


©2009 Eisai Inc. All rights reserved. BAN189 August 2009
BANZEL® is a registered trademark of Novartis Pharma AG, used under license.
Manufactured by Eisai Co., Ltd. Marketed by Eisai Inc., Woodcliff Lake, NJ 07677

 **BANZEL®**
(rufinamide) 200, 400 mg
TABLETS


Visit www.BANZEL.com

POSTER SESSIONS 1, 2, 3

Hynes - Hall D, Level 2



Questions? Please visit the poster information table in front of Hall D.



POSTERS AND PLATFORMS-AT-A-GLANCE

Saturday, December 5, 2009

Poster Session 1 – 1:00 p.m. - 8:00 p.m. – Hynes, Hall D (see pages 23-30)

Authors Present A: 1:00 p.m. - 2:00 p.m. (1.001 – 1.110)

Authors Present B: 2:00 p.m. - 3:00 p.m. (1.111 – 1.220)

Authors Present C: 5:00 p.m. - 6:00 p.m. (1.221 – 1.332)

Professionals in Epilepsy Care	1.001 – 1.012
Clinical Neurophysiology	1.013 – 1.069
Clinical Epilepsy	1.070 – 1.143
Human Imaging	1.144 – 1.187
Antiepileptic Drugs	1.188 – 1.252
Non AED/Non-Surgical Treatments	1.253 – 1.281
Surgery	1.282 – 1.310
Human Genetics	1.311 – 1.325
Practice Resources	1.326 – 1.332

Sunday, December 6, 2009

Poster Session 2 – 8:00 a.m. - 6:00 p.m. – Hynes, Hall D (see pages 38-45)

Authors Present D: Noon - 1:00 p.m. (2.001 – 2.112)

Authors Present E: 4:00 p.m. - 5:00 p.m. (2.113 – 2.224)

Authors Present F: 5:00 p.m. - 6:00 p.m. (2.225 – 2.338)

Clinical Neurophysiology	2.001 – 2.057
Clinical Epilepsy	2.058 – 2.130
Comorbidities	2.131 – 2.176
Antiepileptic Drugs	2.177 – 2.240
Neuropsychology/Language/Behavior	2.241 – 2.311
Human Genetics	2.312 – 2.326
Health Services	2.327 – 2.338

11:30 a.m. - 1:30 p.m. – Sheraton, Independence Ballroom, Level 2 (see pages 34-35)

Investigators' Workshop Lunch Poster Session	1.144, 3.001, 3.007, 3.008, 3.009, 3.012, 3.014, 3.028, 3.034, 3.036, 3.046, 3.048, 3.050, 3.078, 3.092, 3.095, 3.158, 3.330, 3.335, 3.341
--	---

5:30 p.m. - 7:00 p.m. – Sheraton, Independence Ballroom, Level 2 (see page 36)

Investigators' Workshop Poster Session	1.244, 3.015, 3.023, 3.026, 3.058, 3.059, 3.060, 3.062, 3.103, 3.126, 3.128, 3.129, 3.136, 3.137, 3.138, 3.142, 3.145, 3.149, 3.317, 3.353, 3.355
--	---

Monday, December 7, 2009

Poster Session 3 – 8:00 a.m. - 6:00 p.m. – Hynes, Hall D (see pages 50-58)

Authors Present G: 8:00 a.m. - 9:00 a.m. (3.001 – 3.120)

Authors Present H: 11:45 a.m. - 12:45 p.m. (3.121 – 3.240)

Authors Present I: 3:00 p.m. - 4:00 p.m. (3.241 – 3.361)

Translational Research	3.001 – 3.162
Clinical Epilepsy	3.163 – 3.235
Human Imaging	3.236 – 3.280
Surgery	3.281 – 3.308
Neuropathology of Epilepsy	3.309 – 3.361

Platform Sessions – 4:00 p.m. - 6:15 p.m. (see page 49)

Platform A: Translational Research	A.01 – A.08
Platform B: Surgery/Imaging	B.01 – B.09
Platform C: Clinical Epilepsy	C.01 – C.09

2009 Susan Spencer Fellowship/Early Career Physician-Scientist Award

Saturday, December 5 – 9:00 a.m. - 9:15 a.m., Hynes – Ballroom, Level 3
(immediately preceding the Hoyer Lecture)

Supported by the Milken Family Foundation

The Milken Family Foundation is proud to rename this program in honor of Dr. Susan Spencer. This program seeks to encourage the development of new therapies for epilepsy by providing research training for physicians early in their academic career. This award is primarily for investigators whose research interests will potentially affect epilepsy patients in the near term. Applications are reviewed on the basis of: the applicant's commitment to a research career, the training record of the mentor and epilepsy center and the quality and relevance of the research project for developing cures for epilepsy.

Yoshimi Sogawa, M.D.

Albert Einstein College of Medicine, Montefiore Medical Center

Mentor: Shlomo Shinnar, M.D., Ph.D.

Title: Computerized EEG Analysis Methods to Create the Algorithm to Detect Subtle Features on EEG

Epilepsy Research Recognition Awards

Monday, December 7 – 9:00 a.m. - 9:15 a.m., Hynes – Ballroom, Level 3
(immediately preceding the Presidential Symposium)

The American Epilepsy Society Epilepsy Research Recognition Awards are given annually to active scientists and clinicians working in all aspects of epilepsy research. They are designed to recognize professional excellence reflected in a distinguished history of research or important promise for the improved understanding, diagnosis and treatment of epilepsy. The awards of \$10,000 each are part of the AES grant and fellowship programs.



Award for Basic Science
Annamaria Vezzani, Ph.D.

Annamaria Vezzani obtained her Ph.D. degree in Neuropharmacology in Milano at the Mario Negri Institute for Pharmacological Research. She spent her first postdoctoral period in Baltimore at the Maryland Psychiatric Research Center, in the laboratory of Robert Schwarcz working on the mechanisms of epileptogenesis in experimental models.

She is a member of the Editorial Boards of *Epilepsy Currents*, *Epilepsy Research* and *Neuroscience* and Associate Editor for basic science of *Epilepsia*. She has been appointed the Chair of the Commission on Neurobiology of the International League Against Epilepsy (2005-2009) which is promoting initiatives for improving translational research in epilepsy.

Since 1999, she opened a new field of intensive studies in epilepsy research with the publication of seminal papers on the role of pro-inflammatory cytokines in seizures. The results showed that experimentally-induced seizures provoke extensive inflammation in the brain and that the activation of specific inflammatory processes in the brain contributes significantly to increase neuronal excitability, seizure susceptibility and neuronal damage.

She also contributed to pioneer studies published in 2002, to elucidate the role of P-glycoprotein, a drug efflux transporter, in the mechanisms of pharmacoresistance using experimental models of seizures. Her laboratory showed that seizure activity induces the brain expression of P-glycoprotein and that selective pharmacological blockade, or genetic inactivation of this protein, results in increased brain concentration, and efficacy, of antiepileptic drugs.

Her present research is focused on the preclinical characterization of novel targets for antiepileptic drug development and of gene therapy strategies.



Award for Clinical Science
Josemir W. Sander, M.D., Ph.D., FRCP

Ley Sander, M.D., Ph.D., FRCP is Professor of Neurology and Clinical Epilepsy at the UCL Institute of Neurology, London. He is Consultant Neurologist at the National Hospital for Neurology and Neurosurgery in Queen Square, London and at the Chalfont Centre for Epilepsy in Buckinghamshire. He is Head of the World Health Organisation Collaborative Centre for Research and Training in Neurosciences, London, UK and the Scientific Director of SEIN – Stichting Epilepsie Instellingen Nederland, Heemstede, the Netherlands.

He qualified in Medicine at the University of Parana in Brazil. After his initial medical training in Brazil, he moved to the UK where he completed his medical and neurological training. He obtained his Ph.D. at the Faculty of Medicine of the University of London in 1993. He is an elected Fellow of the Royal College of Physicians and a member of numerous organizations and professional societies including the Royal Society of Medicine, the American Academy of Neurology, the British Medical Association, the American Epilepsy Society and the British, Dutch, and Swiss chapters of the International League Against Epilepsy.

His main areas of research interest are the outcome of epilepsy (in terms of both remission and the risk of premature death and its causes), genetics aspects (particularly pharmacogenetics) and the management of epilepsy in resource-poor settings. He has an established track record of publications and grant support. Apart from his work in the United Kingdom and the Netherlands, he has been involved in epilepsy projects in China, Kenya, Senegal, Ecuador, Brazil and Bulgaria. He is a frequent speaker at international conferences, is a member of the Editorial Boards of *Epilepsia* and *The Lancet Neurology* and is actively involved in training young clinicians and researchers.



2009 William G. Lennox Award
Monday, December 7
Hynes – Ballroom, Level 3
9:00 a.m.
(Immediately preceding the Presidential Symposium)

Thomas P. Sutula, M.D., Ph.D.

Dr. Thomas Sutula is the Detling Professor and Chair of the Department of Neurology at the University of Wisconsin in Madison, where he is also the Director of the Center for Neuroscience. Dr. Sutula's research has focused on understanding how the capacity for activity-dependent plasticity in neural circuitry influences epilepsy and its consequences. He has devoted particular attention to kindling, a phenomenon of seizure-induced plasticity that models temporal lobe epilepsy. In 1988 he discovered that repeated brief seizures induced sprouting of the mossy fiber axons in the hippocampal dentate gyrus, and in 1989 demonstrated that sprouting is a feature of human temporal lobe epilepsy. Sprouting has subsequently been recognized in virtually all models of chronic focal epilepsy. His laboratory has provided extensive characterization of the anatomical features of the sprouted pathway, demonstrated that sprouting increases as a function of repeated seizures, and contributes to recurrent excitation in the dentate gyrus. In another series of studies, his laboratory has also demonstrated that repeated brief seizures evoked by kindling induce hippocampal neuronal loss in a pattern mimicking hippocampal sclerosis, with accompanying progressive memory deficits. His current work is addressing how early life seizures influence development of structural and functional organization of the hippocampus in adulthood, how activity-dependent alterations in the extracellular ionic environment progressively unmask recurrent excitation, and how genetic background influences susceptibility to posttraumatic epilepsy and stress disorders. His recent work with Wisconsin collaborators has revealed how metabolic regulation and glycolytic inhibition can be employed therapeutically to achieve beneficial anticonvulsant and disease-modifying effects in chronic epilepsy.



2009 AES Service Award
Saturday, December 5
Hynes – Ballroom, Level 3
9:00 a.m.
(Immediately preceding the Hoyer Lecture)

L. James Willmore, M.D.

L. James Willmore, M.D. is Professor of Neurology and of Pharmacology and Physiology and Associate Dean at Saint Louis University School of Medicine, the institution where he received his Doctor of Medicine degree. He trained in neurology at the University of Virginia where he completed a fellowship in Neurochemistry. He was the founding director of the Texas Comprehensive Epilepsy Program at the University of Texas School of Medicine in Houston where he trained numerous fellows. Dr. Willmore has spent his career blending clinical and basic science research regarding development of antiepileptic drugs, models of epilepsy, and the molecular mechanisms of epileptogenesis. His clinical studies have emphasized development of new drugs to treat epilepsy, and contributions to assessment of patients for epilepsy surgery. He is known for models of epilepsy in animals associated with hemorrhage or focal lipid peroxidation. His colleagues and he identified a molecular basis for chronic seizures in rodents, having found failure of glutamate transport as a fundamental change in these animals. Work in his laboratory has revealed molecular mechanisms for some antiepileptic drug actions. The NIH has supported his research as did the Veterans Administration. He received sabbatical training in Japan. He has served on several editorial boards, currently *Metabolic Brain Disease*, and has published widely in international journals, in chapters for books about epilepsy, and has contributed to and edited monographs concerning treatment of seizure disorders. He is a co-author of the book, *Advanced Therapy in Epilepsy*. He has received numerous awards for teaching, research and service, including the John Horsley Memorial Prize, the Hans Berger Distinguished Scholar Award and the Dean's Commendation for Teaching. He has contributed with service as a member of the Epilepsy Foundation's Professional Advisory Board, the House of Delegates, and the Client Advocacy Committee. He is a Fellow of the American Academy of Neurology and a member of the American Neurological Association.



2009 William G. Lennox Lecturer
Monday, December 7
Hynes – Ballroom, Level 3
2:15 p.m. - 3:00 p.m.

Michael A. Rogawski, M.D., Ph.D.

Dr. Michael A. Rogawski is Professor and Chair of the Department of Neurology at the University of California, Davis. Until 2006, he was senior investigator and chief of the Epilepsy Research Section at the National Institute of Neurological Disorders and Stroke in Bethesda, Maryland.

As a student, he studied biophysics at Amherst and medicine and pharmacology at Yale. He completed a postdoctoral fellowship in neurophysiology at NINDS and a residency in neurology at Johns Hopkins. Dr. Rogawski has conducted research on the physiology and pharmacology of ion channels and the cellular mechanisms of action of antiepileptic drugs. In addition, he has worked to develop new approaches to treat epilepsy, focusing on glutamate receptor antagonists and neuroactive steroids. Dr. Rogawski has served on the editorial boards of many journals in pharmacology, epilepsy research, and neurotherapeutics. He is one of the founders of *Epilepsy Currents* and currently serves as its co-editor-in-chief.

Among his other professional service activities, Dr. Rogawski has been a member of review panels for the NIH, the Epilepsy Foundation, CURE — Citizens United for Research in Epilepsy, the Office of Congressionally Directed Medical Research Programs, and the Peripheral and Central Nervous System Drugs Advisory Committee of FDA.

He has served as chair of the AES Program Committee, Technology Committee and Publications Committee and as a member of the AES Board of Directors. He was a co-organizer of several international epilepsy research conferences including Focus on Epilepsy, New Horizons in the Development of Antiepileptic Drugs, and Jasper's Basic Mechanisms of the Epilepsies. He received the Epilepsy Research Award from the American Society for Pharmacology and Experimental Therapeutics, and also the NINDS Merit Award, the NIH Director's Award, and a Certificate of Appreciation from AES.



2009 J. Kiffin Penry Excellence in Epilepsy Care Award
Saturday, December 5
Hynes – Ballroom, Level 3
5:30 p.m.
(Immediately preceding the AET Symposium)

Allan Krumholz, M.D.

Dr. Allan Krumholz is Professor of Neurology at the University of Maryland School of Medicine and Director of the University of Maryland Epilepsy Center and the Baltimore Veterans Administration Epilepsy Center of Excellence. He leads a multidisciplinary group devoted to the diagnosis and treatment of patients with seizure disorders that includes neurologists, neurosurgeons, psychiatrists, neuroradiologists, neurophysiologists, social workers, nurses and technologists. Currently he serves as the Coordinating Director of the Veterans Administration Northeast Epilepsy Center of Excellence. He has published over one hundred articles and chapters about epilepsy, emphasizing medical and surgical treatment, electroencephalographic diagnosis, status epilepticus, psychogenic seizures, and important social issues such as driving and employment.

Dr. Krumholz received his undergraduate degree from Queens College of the City University of New York, his M.D. from the Chicago Medical School, and completed a neurology residency followed by an EEG fellowship at the Johns Hopkins University School of Medicine. He is a fellow of the American Academy of Neurology (AAN) and a member of the American Neurological Association. Dr. Krumholz has long been active in the Epilepsy Foundation of the Chesapeake Region, previously serving as Chair of the Professional Advisory Board and as President of the Board of Directors. He served for many years on the Professional Advisory Board of the National Epilepsy Foundation (EF), which he chaired, and he also co-chaired the Foundation's Legal and Government Affairs Committee. In 1987, the Governor's Task Force on Employment of the Handicapped in Maryland named him Physician of the Year. He played a key role in the development of the joint AES, AAN, EF Consensus on Driving and Epilepsy, and has also served on the AES Annual Meeting and Scientific Program Committees.

YOUNG INVESTIGATOR & NURSE AWARDEES

Nurse Awardees

Contact Author	Abstract Title	Poster #
Susan Carlson, RN, M.S.N.	Evaluating Nurses' Knowledge Of Seizure Treatment In The Elderly Via An Online Educational Program	1.004
Victoria Driscoll, RN	Parents' Perspective On Quality Of Life Improvement In Patients With Intractable Epilepsy Receiving A Ketogenic Diet	1.281
Cora Flynn, M.Sc.	A Multi-Centred Audit Of Nurse-Led Epilepsy Telephone Advice Services	1.002
Karen Gilbert, M.S., ARNP, CNRN	Hypnotic Intervention For Anxiety, Pain And Nausea Management In Patients Having Intracranial Electrode Monitoring	1.267
Elizabeth Hamilton, BSN, M.S.N.	Folic Acid Supplementation In Women With Epilepsy	1.099
Karen Lapp, NP	Low Vitamin D Levels Are Not Correlated With Reduced Bone Mineral Density In A Rural Community-Based Epilepsy Population	1.211
Lucretia Long, RN, M.S., CNP	Educating Patients With Epilepsy: A Look At What Nurses Discuss	3.223
Madona Plueger, RN	Seizure Observation In The Epilepsy Monitoring Unit	1.003
Charlotte Swint, M.S.N., M.P.H.	How Do Parents Measure Efficacy And Tolerability Of Antiepileptic Drugs For The Treatment Of Childhood Epilepsy? Results Of A Preference Survey	2.181
Maria Zak, B.Sc.N., M.N.	Patterns Of Internet Utilization By Parents Of Children With Epilepsy For Information And Support	3.183

Young Investigator Awardees

Contact Author	Abstract Title	Poster/ Platform #
Tanja Brenner, Ph.D.	Serum Antibodies In Epilepsy	A.04
Rebecca L. Bromley, Ph.D.	IQ, Memory, Language And Attention In Children Exposed To Antiepileptic Drugs In Utero: Preliminary Outcomes At 6 Years Of Age	C.03
Robert E. Elliott, M.D.	Vagus Nerve Stimulation For Refractory Epilepsy: Single Surgeon Experience Of Over 700 Consecutive Operations	B.01
Mark Ferro, M.Sc., Ph.D.(c)	Predictors Of Depressive Symptoms In Mothers Of Children With New-Onset Epilepsy: A Longitudinal Examination	2.328
Jenny Hsieh, Ph.D.	Seizure-induced Hippocampal Neurogenesis Requires The bHLH Transcription Factor NeuroD	3.320
Janet Johnston, M.B.Ch.B.	A Novel GABRG2 Mutation In An Epilepsy Family	1.320
Stanislav Karsten, Ph.D.	Peripheral Blood Transcriptome Biomarkers For The Prediction Of Epilepsy During Early Latent Period	3.152
Carla LoPinto-Khoury, M.D.	FDG PET-Positive, MRI-Negative Patients With Temporal Lobe Epilepsy: Etiology And Outcomes Compared To Patients With Hippocampal Sclerosis	1.073
Saul Mullen, M.B.B.S.	Familial Glut1 Deficiency Syndrome Causes A Range Of Idiopathic Generalized Epilepsies	1.323
Michael S. Perry, M.D.	Predictors Of Outcome Following Incomplete Resection Of The Epileptogenic Zone For Intractable Childhood Epilepsy	B.04
Suresh Pujar, MBBS, M.D., MRCPCH	STEPSOUT – Prospective Population-Based Study Of Childhood Convulsive Status Epilepticus Outcomes	C.01
Aylin Reid, MD	Altered mRNA Expression Of GABA And Glutamate Receptor Subunits And Cation Chloride Co-Transporters Is Associated With Increased Seizure Susceptibility After Experimental Febrile Seizure	3.126
Anan Shtaya, M.D., Ph.D.	Seizure/Kainate Enhances The Proliferation Of Hippocampal Radial Glial Precursor Cells Via AMPA Receptors	A.02
Katia Vermoesen, Pharmacist	The Control Of Kainic Acid-Induced Status Epilepticus	3.324
Matthew Vestal, B.S.	Childhood Absence Epilepsy: Functional Neuroimaging Of Interictal Attention	C.08
Sorawit Viravan, M.D.	Brain MRI Characteristics Of Epileptogenic Tuber And Predictors Of Intractable Epilepsy In Tuberous Sclerosis Complex (TSC)	B.02
Michael Yoong, M.D.	Hippocampal Volume Is Reduced In Children With Other Forms Of Convulsive Status Epilepticus Compared To Children With Prolonged Febrile Seizures	2.096
Wei Zhang, D.D.S., Ph.D.	Surviving Hilar Somatostatin Interneurons Enlarge, Sprout Axons, And Form New Synapses With Granule Cells In A Mouse Model Of Temporal Lobe Epilepsy	3.323

Acknowledgment: Young Investigator Awards are supported by a grant from Medtronic, Inc.



AMERICAN EPILEPSY SOCIETY

is proud to recognize the following supporters
of the 2009 Annual Meeting.

Leadership Level

\$250,000 - \$499,999

Pfizer Inc.
UCB, Inc.

Sponsor Level

\$100,000 - \$249,999

GlaxoSmithKline

Supporter Level

\$50,000 - \$99,999

Sepracor Inc.
Lundbeck
Questcor Pharmaceuticals, Inc.
Eisai Inc.

Contributor Level

\$25,000 - \$49,999

Nihon Kohden America, Inc.
Medtronic, Inc.

Advocate Level

\$10,000 - \$24,999

Cyberonics, Inc.
PMT
Elekta
Ad Tech Medical Instrument Corp.
Care Fusion/Cardinal Health
Compumedics Limited
Grass Technologies
Natus Medical
Stellate, An Alpine Biomed Company

Patron Level

\$5,000 - \$9,999

Analyze Direct
Cadwell Laboratories
NeuroLogica Corporation
Ripple LLC
Health Learning Systems/LEAD
Blackrock Microsystems
Valeant Pharmaceuticals Inc.
Electrical Geodesics, Inc.
Epilepsy Foundation

SCHEDULE-AT-A-GLANCE

FRIDAY December 4

8:00 a.m. - 6:00 p.m.	Registration <i>Hynes - Hall A, Plaza Level</i>	1:30 p.m. - 3:00 p.m.	Special Interest Group Meetings <i>See page 14</i>
8:00 a.m. - 5:00 p.m.	National EpiFellows Foundation* 17th Annual Scientific Forum <i>Westin Copley Place</i>	3:30 p.m. - 5:00 p.m.	Special Interest Group Meetings <i>See page 14</i>
9:00 a.m. - 4:00 p.m.	Advances in the Management of Epilepsy and the Epilepsy Clinic* <i>Sheraton - Grand Ballroom, 2nd Floor</i>	3:30 p.m. - 5:00 p.m.	Fellows Reception <i>Sheraton - Fairfax A, 3rd Floor</i>
11:00 a.m. - Noon	Lunch - <i>On Your Own</i>	5:00 p.m. - 5:30 p.m.	Symposia Break <i>Sheraton - Back Bay Ballroom C/D, 2nd Floor</i>
11:00 a.m. - 12:30 p.m.	AES Press Briefing Session: <i>The Treatment Gap in Epilepsy - Researching the Possible</i> <i>Hynes - Room 107</i>	5:30 p.m. - 8:00 p.m.	Hot Topics Symposium: <i>Biomarkers in Epilepsy</i> <i>Sheraton - Republic Ballroom, 2nd Floor</i>
Noon - 2:30 p.m.	Annual Fundamentals of Epilepsy: <i>Neurophysiology 101</i> <i>Sheraton - Republic Ballroom, 2nd Floor</i>		Spanish Symposium: <i>Pitfalls in Diagnosis and Treatment of Epilepsy</i> <i>Sheraton - Back Bay Ballroom A, 2nd Floor</i>

*Separate registration required

SATURDAY December 5

7:00 a.m. - 6:00 p.m.	Registration <i>Hynes - Hall A, Plaza Level</i>	2:30 p.m. - 4:00 p.m.	Special Interest Group Meetings <i>See page 19</i>
8:00 a.m. - 9:00 a.m.	Breakfast - <i>On Your Own</i>	5:00 p.m. - 5:30 p.m.	Symposia Break <i>Hynes - Boylston Street Hall, Level 3</i>
9:00 a.m. - 11:00 a.m.	7th Judith Hoyer Lecture in Epilepsy: <i>Battling Epilepsy with Models and Molecules</i> <i>Hynes - Ballroom, Level 3</i>	5:30 p.m. - 7:30 p.m.	Antiepileptic Therapy Symposium: <i>Treatment Strategies for the Patient with Epilepsy</i> <i>Hynes - Ballroom, Level 3</i>
11:00 a.m. - 2:00 p.m.	Professionals in Epilepsy Care Symposium: <i>Predictors and Methodologies of Epilepsy Self-Management</i> <i>Hynes - Room 304, Level 3</i>	6:00 p.m. - 7:30 p.m.	Investigators' Workshop: <i>The Impact of Neuroinflammation on Neuronal Excitability and Excitotoxicity</i> <i>Sheraton - Constitution Ballroom, 2nd Floor</i>
11:00 a.m. - 11:45 a.m.	Light Lunch <i>Hynes - Boylston Hallway Level 2 & Level 3</i>	6:00 p.m. - 8:00 p.m.	Investigators' Workshop: <i>Mapping Cortical Function with Intracranial Electrodes: Pushing Beyond Penfield</i> <i>Sheraton - Grand Ballroom, 2nd Floor</i>
11:15 a.m. - 12:45 p.m.	Special Interest Group Meetings <i>See page 17</i>	6:00 p.m. - 7:30 p.m.	Special Interest Group Meetings <i>See page 20</i>
1:00 p.m. - 8:00 p.m.	Poster Session 1 - <i>See page 23</i> <i>Hynes - Hall D, Level 2</i>	8:00 p.m.	Concert to Benefit Dr. Susan Spencer Clinical Epilepsy Research Fund <i>See page 21</i>
2:00 p.m. - 5:00 p.m.	Merritt-Putnam Symposium: <i>Beyond Seizures: Mechanisms Underlying Epilepsy Spectrum Disorder</i> <i>Hynes - Ballroom, Level 3</i>		

SUNDAY December 6

7:00 a.m. - 6:00 p.m.	Registration <i>Hynes - Hall A, Plaza Level</i>	12:15 p.m. - 1:25 p.m.	Lunch - <i>On Your Own</i>
7:00 a.m. - 8:00 a.m.	Breakfast - <i>On Your Own</i>	2:00 p.m. - 5:00 p.m.	Scientific Exhibits <i>Sheraton - See page 31</i>
8:00 a.m. - 11:00 a.m.	Scientific Exhibits <i>Sheraton - See page 31</i>	5:00 p.m. - 7:00 p.m.	Exhibit Hall Reception in Support of Lennox and Lombroso Trust for Research & Training <i>Hynes - Exhibit Hall, Level 2</i>
8:00 a.m. - 4:30 p.m.	Annual Course: <i>Selecting Patients for Epilepsy Surgery</i> <i>Hynes - Ballroom, Level 3</i>	5:30 p.m. - 7:00 p.m.	Investigators' Workshop Poster Session <i>Sheraton - Independence Ballroom, 2nd Floor</i>
8:00 a.m. - 5:30 p.m.	Investigators' Workshop IW Posters: 11:30 a.m. - 1:00 p.m. Keynote Speakers: 1:15 p.m. - 1:45 p.m. <i>Sheraton - See page 34</i>	7:00 p.m. - 9:00 p.m.	Epilepsy Monitoring Unit Symposium: <i>Expert Consensus on Patient Safety</i> <i>Sheraton - Grand Ballroom, 2nd Floor</i>
8:00 a.m. - 6:00 p.m.	Poster Session 2 - <i>See page 38</i> <i>Hynes - Hall D, Level 2</i>	7:30 p.m. - 9:00 p.m.	Special Interest Group Meetings <i>See page 37</i>
Noon - 1:30 p.m.	Thought Sessions - <i>See page 35</i>		
12:15 p.m. - 1:15 p.m.	Mentoring Session* <i>Sheraton - Hampton, 3rd Floor</i>		

*Separate registration required

SCHEDULE-AT-A-GLANCE

MONDAY December 7

7:00 a.m. - 6:00 p.m.	Registration <i>Hynes – Hall A, Plaza Level</i>	2:15 p.m. - 3:00 p.m.	Lennox Lecture <i>Hynes – Ballroom, Level 3</i>
7:00 a.m. - 8:00 a.m.	Breakfast – <i>On Your Own</i>	3:15 p.m. - 4:45 p.m.	Investigators' Workshop: <i>Rodent Models of Febrile Seizures</i> <i>Sheraton – Constitution Ballroom, 2nd Floor</i>
8:00 a.m. - 11:00 a.m.	Scientific Exhibits <i>Sheraton – See page 31</i>	4:00 p.m. - 6:00 p.m.	Platforms: 3 Concurrent Sessions <i>See page 49</i>
8:00 a.m. - 6:00 p.m.	Poster Session 3 – <i>See page 50</i> <i>Hynes – Hall D, Level 2</i>	4:30 p.m. - 6:00 p.m.	Pediatric Epilepsy Highlights Session <i>Sheraton – Grand Ballroom, 2nd Floor</i>
9:00 a.m. - 11:30 a.m.	Presidential Symposium: <i>It Takes a Village: Solving the Treatment Gap</i> <i>Hynes – Ballroom, Level 3</i>	6:00 p.m. - 6:30 p.m.	Symposia Break <i>Sheraton – Foyer, Grand Ballroom, 2nd Floor</i>
9:00 a.m. - 4:00 p.m.	Exhibit Hall <i>Hynes – Exhibit Hall, Level 2</i>	6:30 p.m. - 8:30 p.m.	Pediatric State of the Art Symposium: <i>Treatable Metabolic Epilepsies</i> <i>Sheraton – Grand Ballroom, 2nd Floor</i>
11:30 a.m. - 1:00 p.m.	Lunch <i>Hynes – Exhibit Hall, Level 2</i>		
2:00 p.m. - 5:00 p.m.	Scientific Exhibits <i>Sheraton – See page 31</i>		

TUESDAY December 8

7:00 a.m. - 4:00 p.m.	Registration <i>Hynes – Hall A, Plaza Level</i>	11:00 a.m. - 12:30 p.m.	International League Against Epilepsy Symposium: <i>Redefining Treatment Resistant Epilepsy</i> <i>Sheraton – Grand Ballroom, 2nd Floor</i>
7:00 a.m. - 8:00 a.m.	Breakfast – <i>On Your Own</i>	12:30 p.m. - 1:30 p.m.	Light Lunch <i>Hynes – Exhibit Hall, Level 2</i>
8:00 a.m. - 1:30 p.m.	Exhibit Hall <i>Hynes – Exhibit Hall, Level 2</i>	12:45 p.m. - 2:15 p.m.	Special Interest Group Meetings <i>See page 62</i>
9:00 a.m. - 10:30 a.m.	Plenary II: <i>The Postictal and Interictal Periods: What Are We Missing?</i> <i>Sheraton – Grand Ballroom, 2nd Floor</i>	1:45 p.m. - 3:15 p.m.	Plenary III: <i>ICU Monitoring</i> <i>Sheraton – Grand Ballroom, 2nd Floor</i>
10:30 a.m. - 11:00 a.m.	Break <i>Hynes – Exhibit Hall, Level 2</i>	2:30 p.m. - 4:00 p.m.	Special Interest Group Meetings <i>See page 63</i>

Visit the Cyber Café

Registration Area

Hynes – Hall A, Plaza Level

Friday, December 4 8:00 a.m. - 6:00 p.m.

Saturday, December 5 7:00 a.m. - 6:00 p.m.

Sunday, December 6 7:00 a.m. - 11:30 a.m.

Supported by Questcor Pharmaceuticals, Inc.

Exhibit Hall

Hynes – Level 2

Sunday, December 6 5:00 p.m. - 7:00 p.m.

Monday, December 7 9:00 a.m. - 4:00 p.m.

Tuesday, December 8 8:00 a.m. - 1:30 p.m.

Supported by Lundbeck

LOCATION KEY

Hynes = Hynes Convention Center

Sheraton = Sheraton Boston Hotel

FRIDAY December 4, 2009

8:00 a.m. – 5:00 p.m.

National EpiFellows Foundation 17th Annual Scientific Forum

(separate registration required – see below for instructions)

Westin Copley Place

The National EpiFellows Foundation (NEF) will hold its 17th Annual Scientific Forum on Friday, December 4. The Forum, which convenes epilepsy fellows from the U.S., is held each year in conjunction with the Annual Meeting of the American Epilepsy Society. The Forum consists of a general session followed by case study workshops, the cases for which are submitted by attendees and selected by the NEF Advisory Board.

Directors of accredited epilepsy fellowship programs in the U.S. are encouraged to nominate an epilepsy fellow from their institution to attend the NEF Scientific Forum. Registration packets will be sent in June to directors. Registration is limited and nominees are selected on a first-come, first-served basis. The deadline for registration is Friday, September 25. For more information, please visit our Web site at www.epifellows.com or call 800.288.2074.

The NEF aims to foster the development of current trainees and recent graduates of epilepsy training programs. The Forum is one of several ways in which the foundation achieves this goal. In addition, each year the NEF awards research grants of up to \$20,000 each to qualified applicants.

The development of the NEF and its programs is supported by Pfizer Inc.

9:00 a.m. – 4:00 p.m.

Advances in the Management of Epilepsy and the Epilepsy Clinic

(separate registration required – see below for instructions)

Sheraton – Grand Ballroom, 2nd Floor

This intensive one-day conference is designed for those professionals who participate in the care of persons with epilepsy. The overall purpose is to improve services to individuals and families affected by epilepsy. The conference is presented by the Department of Neurology of Wake Forest University School of Medicine, Winston-Salem, North Carolina, through an unrestricted grant committed to the education of health professionals, in an effort to promote the comprehensive care of those with epilepsy and their families.

To register, contact Patricia Ann Gibson, ACSW, Department of Neurology, Wake Forest Health Sciences Center, Winston-Salem, NC 27157-1078, or call 800.642.0500. Registration fee is \$75 and includes lunch.

Noon – 2:30 p.m.

Annual Fundamentals of Epilepsy: Neurophysiology 101

(2.5 CME Credits)

Sheraton – Republic Ballroom, 2nd Floor

Overview

This symposium is designed to provide an understanding of both the basic neuronal foundation and the interpretation of the electroencephalogram (EEG). There will be an analysis of the neuronal circuitry involved in scalp EEG wave formation. Age-related EEG patterns may be difficult to interpret. Common paroxysmal patterns and their clinical significance will be discussed. Practice parameters for obtaining an EEG and the clinical utility of neurophysiologic testing will be outlined. Even with the advent of newer techniques, the EEG has arguably remained the gold standard for accessing neuronal function. The benefits and pitfalls of the newer diagnostic investigative techniques will be addressed.

Learner Outcomes

- ▶ Recognize the origin of EEG waveforms and the physiological properties of neurons and neuronal circuitry, resulting in improved interpretation of studies
- ▶ Differentiate between epileptiform and nonepileptiform paroxysmal electroencephalographic patterns
- ▶ Define clinical utility of the electroencephalogram in specific, at times contravercial, circumstances will be (after 1st seizure, 1st nonfebrile seizure, emergent EEG and prior to anti-epileptic agent discontinuation)
- ▶ Analyze the benefits and potential pitfalls of using newer diagnostic tools to enhance the yield of EEG.

Target Audience

Neurologists, child neurologists, pharmacists, neurodiagnostic technologists, neuroscientists interested in translational research and other professionals in epilepsy care

Program

Chair: Dave F. Clarke, M.B.B.S.

Opening Remarks

Dave F. Clarke, M.B.B.S.

Neuronal Circuitry to Scalp Electrodes

Miquel A. Cortez, M.D.

Paroxysmal Electroencephalographic Patterns

Ernst F. Niedermeyer, M.D.

Clinical Utility of the Electroencephalogram: When, Why and How Often?

Dave F. Clarke, M.B.B.S.

Newer Diagnostic Tools: Enhancing the Yield of EEG

James W. Wheless, M.D.

Credit Designation

The American Epilepsy Society designates this educational activity for a maximum of 2.5 *AMA PRA Category 1 Credits*[™]. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Pharmacy Credit

ACPE #073-999-09-117-L04-P; 0.25 CEUs

1:30 p.m. – 3:00 p.m.

Special Interest Group Meetings

Location listed under each session

Epidemiology

Hynes – Room 102, Plaza Level

Coordinator: Dale C. Hesdorffer, Ph.D.

Speakers: Shlomo Shinnar, M.D., Ph.D., Daniel H. Lowenstein, M.D.

Clinical definitions of prolonged seizures/status epilepticus have slowly moved from a duration of 30 minutes or more to one of at least five or ten minutes. The reasons for these changes in clinical practice are different from the processes that guide construction of meaningful epidemiological definitions. We will explore the impact of definitions of prolonged seizures on prognosis (e.g., mortality) and discuss characteristics of an epidemiologically meaningful definition.

Neuropharmacology

Hynes – Room 103, Plaza Level

Coordinators: Gail D. Anderson, Ph.D., Jacquelyn Bainbridge, Pharm.D., FCCP R. Eugene Ramsay, M.D.

Speakers: David M. Treiman, M.D., Brian K. Alldredge, Pharm.D., Michael Doherty, M.D.

At this year's meeting we will debate the role of new AEDs in the treatment of "Status Epilepticus." In this thought-provoking session there will be a debate regarding whether or not there is sufficient pre-clinical and/or clinical evidence to support the use of parenteral formulations of the new AEDs. Dr. David Treiman will discuss pre-clinical efficacy of the new AEDs in Status Epilepticus. Dr. Brian Alldredge will discuss the lack of evidence to support the use of the new AEDs and Dr. Michael Doherty will take the opposite stance.

Nursing Research

Hynes – Room 104, Plaza Level

Coordinators: Colleen Dilorio, Ph.D., RN, FAAN, Rebecca Schultz, RN, M.S.N., CPNP
Speakers: Colleen Dilorio, Ph.D., RN, FAAN, Janelle Wagner, Ph.D.

The Nursing Research SIG is designed to be a resource for nurses interested in research related to care of persons with epilepsy. The goal of the Nursing Research SIG is to facilitate the development of a network of nurses involved in epilepsy research. The SIG provides opportunities for presentations and discussions of current research of interest to nurses. This year the SIG will focus on research in epilepsy self-management. Nurses have an important role in promoting self-management among people with epilepsy, and nurses can make a significant contribution to research in this area. Nurses interested in presenting research on epilepsy self-management are asked to contact one of the coordinators.

Quality and Value Indicators in the Care of Patients with Epilepsy

Hynes – Room 101, Plaza Level

Coordinator: Joseph I. Sirven, M.D.

Speakers: Paul C. Van Ness, M.D., Nathan B. Fountain, M.D., Richard Zimmerman, M.D.

There are eight proposed Epilepsy Quality metrics which will need to be addressed in each and every visit with patients with epilepsy in order to assure quality care. Topics to be covered include: Which epilepsy care metrics will serve as the quality metrics for epilepsy care in the USA? What are the thoughts from government and other experts with experience in the measurement and reporting of quality metrics? What are the implications for not recording or meeting quality measurements? Potential future studies involving quality metrics will be reviewed.

Acknowledgment

This SIG is supported by Sepracor Inc.

3:30 p.m. – 5:00 p.m.

Special Interest Group Meetings

Location listed under each session

Clinical Nursing

Hynes – Room 101, Plaza Level

Coordinators: Irene Dustin, M.S.N., CRNP, Sarah Kiel, M.S.N., CPNP

Speakers: TBD

This year's clinical nursing SIG topic is managing the postictal patient. The emphasis will be on postictal psychosis. We will discuss the spectrum of behaviors encountered postictally and how to plan for the prevention and management of these problems. We will close with case discussions.

Military Epileptology

Hynes – Room 104, Plaza Level

Coordinators: Jose E. Cavazos, M.D., Ph.D., Jonathan Halford, M.D.

Speakers: Karen L. Parko, M.D., Claude G. Wasterlain, M.D., Paul A. Rutecki, M.D., Sunita Dergalust, Pharm.D., BCPS

Issues of concern to military epileptologists include: 1) access of care to video EEG monitoring and epileptologists within the VA, 2) implementation of VA Epilepsy Centers of Excellence, and 3) National VA Formulary and Generics.

Patient-Reported Outcomes

Hynes – Room 103, Plaza Level

Coordinators: Rosemarie Kobau, M.P.H., Erik K. St. Louis, M.D.

Speaker: Cindy Nowinski, M.D.

NIH Toolbox and Neuro-QOL are part of a multi-site effort supported by NIH to develop publicly available, health-related, quality of life (HRQOL) assessment tools (generic item banks, short forms and targeted scales) for adults and children with common neurological disorders including epilepsy. These tools are intended to be responsive to the needs of clinical researchers and will facilitate comparison of results across studies in different diseases.

Acknowledgment

This SIG is supported by Sepracor Inc.

Programming Neurostimulation Devices: The Nuts and the Volts

Sheraton – Republic Ballroom, 2nd Floor

Coordinators: Douglas R. Labar, M.D., Ph.D., James W. Wheless, M.D.

Speakers: Felice Sun, Ph.D., Paul Stypulkowski, Ph.D., Anthony Cowley

Neurostimulation therapy for epilepsy continues to grow with new devices entering the market. For this year's special interest group, we will have speakers discuss how to perform programming for the current neurostimulation devices that are either completing Phase III trials or approved. They will discuss the inherent features involved in programming neurostimulation devices, depending if they are stimulating a peripheral nerve, cortical structure or deep gray matter. They will also discuss how changes in the parameters affect each of these areas. Dr. Felice Sun, Senior Clinical Scientist at NeuroPace will discuss programming neurostimulation devices with cortical targets. She will discuss how the parameters were selected, and how changes in the parameters affect the charge density and the area of cortex stimulated. Dr. Paul Stypulkowski, Senior Engineer at Medtronic, will discuss how stimulation parameters are selected for deep brain stimulation. He will discuss how these parameters are unique, how they were chosen, and what potential parameters may lend themselves to clinical adjustment. Finally, Jason Begnaud, Clinical Engineer at Cyberonics, will discuss how parameters were selected for stimulation of a peripheral nerve. He will discuss how these parameters may change as function of age, how they differ from stimulation of the central nervous system, and how alterations in the parameters may affect efficacy or side effects. I think this will make a very interesting neurostimulation special interest group and look forward to seeing you there.

Acknowledgment

This SIG is supported by Cyberonics, Inc.

5:30 p.m. – 8:00 p.m.

**Hot Topics Symposium: Biomarkers in Epilepsy
(No CME Credits)**

Sheraton – Republic Ballroom, 2nd Floor

Overview

Outcomes in patients with epilepsy are highly unpredictable in respect to both the natural history of epilepsy and the effects of treatments. There is a need to more accurately counsel patients regarding outcomes and to optimize selection of individualized treatment. Epidemiologic data regarding the natural history of epilepsy will be presented and available outcome measures and their limitations will be reviewed. The clinical and EEG biomarkers that have been consistently identified in well-designed studies of epilepsy remission and intractability will be discussed. Various neuroimaging modalities, particularly MR, PET and SPECT, may provide biomarkers for the prognosis of both medical and surgical treatment. Pharmacogenomics may provide biomarkers that predict response to antiepileptic drug therapy and enable individualized treatment. Attempts to identify reliable pharmacogenomic biomarkers in epilepsy have so far been disappointing, but, advances in genomic technology and bioinformatics may eventually redress this. It is likely that multiple biomarkers will need to be considered for optimal outcome prediction in epilepsy. The epidemiological constraints on predictive pharmacogenetic testing will be explored.

Learner Outcomes

- ▶ Knowledge regarding epilepsy outcomes will enable more accurate counseling of patients and choice of treatments
- ▶ The limitations of currently available biomarkers in predicting epilepsy outcomes will be understood allowing appropriate use of diagnostic testing
- ▶ The potential utility of pharmacogenomics in predicting response to treatment will allow use of this technique by clinicians as improved predictability is achieved
- ▶ To review new findings in neurophysiology, imaging and genetics which assist in the diagnosis and treatment of epilepsy.

Target Audience

Neurologists, neurophysiologists, pharmacologists and pharmacists, epileptologists, neuroscientists interested in translational research

Program

Co-Chairs: Terence J. O'Brien, M.D., FRACP and R. Edward Hogan, M.D.

The Unpredictability of Epilepsy Outcomes

David M. Ficker, M.D.

Clinical and EEG Biomarkers

Elson L. So, M.D.

Imaging Biomarkers (MRI, PET, SPECT)

R. Edward Hogan, M.D.

Pharmacogenomic Biomarkers

Terence J. O'Brien, M.D., FRACP

Multivariate Predictive Models for Epilepsy Outcomes

Michael E. Johnson, M.D., Ph.D.

5:30 p.m. – 8:00 p.m.

**Spanish Symposium: Pitfalls in Diagnosis and Treatment of Epilepsy
(2.5 CME Credits)**

Sheraton – Back Bay Ballroom A, 2nd Floor

Overview

Accurate diagnosis in patients with epilepsy is imperative if appropriate intervention is to be initiated. Complete clinical history and examination are the initial steps but review of diagnostic studies is necessary to guarantee correct diagnostic formulation. Treatment options will be clearer, especially as regards appropriate medications for identified seizure type and epilepsy syndrome. Failure to control seizures may be due to poor patient adherence to treatment recommendations, to pharmacoresistance or to other factors. The patient with refractory epilepsy will need careful and complete review of history and diagnostic testing. Lectures and case histories will be used to address diagnostic and treatment strategies.

Learner Outcomes

- ▶ Develop diagnostic strategies that allow for more accurate diagnosis for newly-diagnosed patients and for patients with refractory epilepsy
- ▶ Define therapeutic options for newly-diagnosed patients and for patients with refractory epilepsy
- ▶ Incorporate patient education as a clinical tool in treatment and will provide opportunities for discussion with patients regarding diagnosis and treatment options.

Target Audience

Neurologists, nurses, social workers and other professionals in epilepsy care. The program will be presented in Spanish, thus facilitating comprehension and enhancing participation of attendants to the meeting from Spanish-speaking countries

Program

Co-Chairs: Manuel G. Campos, M.D. and Vicente J. Iragui, M.D., Ph.D.

Opening Remarks

Vicente J. Iragui, M.D., Ph.D.

Pitfalls in the Diagnosis of Patients with Epilepsy

Carlos DiGiano, M.D.

Pitfalls in the Treatment of Patients with Epilepsy

Jorge G. Burneo, M.D., M.S.P.H.

Counseling Children and Adult Patients with Epilepsy and Their Families

Álvaro Izquierdo, M.D.

Roundtable: Case Presentations and Discussion

Manuel G. Campos, M.D., Faculty and Participants

Credit Designation

The American Epilepsy Society designates this educational activity for a maximum of 2.5 *AMA PRA Category 1 Credits*™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Pharmacy Credit

ACPE #073-999-09-118-L01-P; 0.25 CEUs

Acknowledgment

This program is supported by an educational grant from UCB, Inc.

SATURDAY December 5, 2009

9:00 a.m. – 11:00 a.m.

7th Judith Hoyer Lecture in Epilepsy: Battling Epilepsy with Models and Molecules

Award Presentation: Susan Spencer Fellowship/Early Career Physician Scientist Award and AES Service Award

Hynes – Ballroom, Level 3

Lecturer: John W. Swann, Ph.D.

The 7th Judith Hoyer Lecture in Epilepsy, presented by invited Lecturer John W. Swann, Ph.D., is sponsored by the National Institute of Neurological Disorders and Stroke. Dr. Swann's presentation is the seventh in a series of lectures highlighting the promise of epilepsy research. This series is held in memory of Mrs. Judith Hoyer, an active member of the Board of Directors of the Epilepsy Foundation and the late wife of Representative Steny Hoyer (D-MD). Mrs. Hoyer spent her life both helping families to cope with epilepsy and promoting research into a cure and a better quality of life for those with the disorder. The purpose of the lecture is to raise awareness of epilepsy among researchers and the public and provide intellectual stimulation that will encourage continuing progress toward finding a cure for epilepsy.

11:00 a.m. – 2:00 p.m.

Professionals in Epilepsy Care Symposium: Predictors and Methodologies of Epilepsy Self-Management (2.5 CME Credits)

Hynes – Room 304, Level 3

Overview

This symposium will review the theory and use of self-management care in people with epilepsy and other chronic health disorders. There will be presentations of research regarding key components, outcomes, and predictors of effective self-management in epilepsy. Selected interventions that enhance knowledge and self-efficacy, change behavior, or increase coping and social support will be explored. Community and Web-based supports and programs will be discussed as innovative ways of enhancing self-management outside of clinical practice settings.

Learner Outcomes

- ▶ Apply the theory of self management in counseling and educating patients with epilepsy
- ▶ Identify three predictors of successful self management for individuals living with epilepsy
- ▶ Evaluate the psychosocial factors and behavioral interventions that can positively impact self management
- ▶ List resources and support networks that may improve patient competence.

Target Audience

Nurses, physicians, psychiatrists, psychologists, social workers, epilepsy educators and other professionals in epilepsy care

Program

Co-Chairs: Sandra M. Cushner Weinstein, PT, LCSW-C and Patricia O. Shafer, RN, M.N.

Opening Remarks: Patient Perspective vs. Medical Perspective

Sandra M. Cushner Weinstein, PT, LCSW-C

Theory of Self-Management

Colleen Dilorio, RN, Ph.D.

Epilepsy Self-Management in Clinical Practice: What We Do and Know
Patricia O. Shafer, RN, M.N.

Educational Methods: Role of Education and Self-Advocacy for People with Epilepsy

Janice M. Buelow, RN, Ph.D.

Programs to Support Self-Management

Colleen Dilorio, RN, Ph.D.

Psychosocial Methods: Resiliency and Adaptive Coping: The Role of Camps and Support Groups

Sandra M. Cushner Weinstein, PT, LCSW-C

Cognitive Behavior Therapy Targeting Seizure Triggers

Donna Andrews, Ph.D.

Cognitive Behavior Therapy for Nonepileptic Seizures

W. Curt LaFrance, Jr., M.D., M.P.H.

Credit Designation

The American Epilepsy Society designates this educational activity for a maximum of 2.5 *AMA PRA Category 1 Credits*[™]. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Submitted to the Association of Rehabilitation Nurses (ARN) for 2.5 contact hours. ARN is accredited as an approver of continuing nursing education by the American Nursing Credentialing Center's Commission on Accreditation.

Pharmacy Credit

ACPE #073-999-09-119-L01-P; 0.25 CEUs

Acknowledgment

This program is supported by an educational grant from GlaxoSmithKline.

11:15 a.m. – 12:45 p.m.

Special Interest Group Meetings

Location listed under each session

Basic Mechanisms

Sheraton – Constitution Ballroom, 2nd Floor

Coordinators: Claude G. Wasterlain, M.D., Raman Sankar, M.D., Ph.D.

Speakers: Annamaria Vezzani, Ph.D., Jerome Niquet, Ph.D., Stephane Auvin, M.D., Ph.D. or Raman Sankar, M.D., Ph.D., Quentin Pittman, Ph.D., Damir Janigro, Ph.D.

A radical reevaluation of the role of cell-mediated immunity and of the blood-brain-barrier (BBB) in epilepsy may be in order. Epileptic seizures cause a strong inflammatory reaction in the brain (Vezzani et al. 2005) and a breakdown of the blood-brain barrier (Janigro 2007). Surprisingly, recent studies show that preventing leukocytes from entering the brain (with antibodies to cell-adhesion molecules) blocks BBB leaks, stops acute pilocarpine seizures and blocks epileptogenesis (Fabene et al. 2008). How do these studies fit into the clinical context? Is immunosuppression indicated for status epilepticus? Is it the magic bullet for epileptogenesis? Bring two slides and your personal bias to the podium; we want to know all the answers.

EEG

Hynes – Room 210, Level 2

Coordinator: Jean Gotman, Ph.D.

Speakers: Richard Staba, Ph.D., Nathan Crone, M.D., Gregory A. Worrell, M.D., Ph.D., Hiroshi Otsubo, M.D., Jean Gotman, Ph.D., Katsuhiko Kobayashi, M.D.

Several studies have recently reported on high frequency activity (above 100Hz) in the intracerebral EEG of patients with epilepsy. We will review the technical issues involved in recording and displaying this activity accurately and the involvement of high frequencies in normal cognitive and memory function, as well as the potential that this activity is of clinical significance in the localization of epileptogenic regions.

Frontal Lobe

Hynes – Room 208, Level 2

Coordinator: Matthias J. Koepp, M.D., Ph.D.

Speakers: Christian Vollmar, M.D., Friedrich G. Woermann, M.D., Fernando Cendes, M.D., Ph.D.

We will discuss how seizure origin in or seizure spread to the frontal lobes affect cognitive functions that involve the frontal lobes. In this session, we will present neuropsychological, electrophysiological and imaging evidence for "frontal lobe" involvement and connectivity in TLE and compare these findings with data obtained from epilepsies arising in the frontal lobe themselves.

How to Obtain NIH Funding for Training and Career Development

Hynes – Room 206, Level 2

Coordinators: Randall Stewart, Ph.D. and Brandy E. Fureman, Ph.D.

Speaker: Stephen Korn, Ph.D.

The speaker will be Stephen Korn, Ph.D. of NINDS' Office of Training and Career Development. Steve will speak about various training and career development grant mechanisms and some recent changes to these mechanisms.

Sleep and Epilepsy

Hynes – Room 207, Level 2

Coordinators: Carl Bazil, M.D., Ph.D., Mark S. Quigg, M.D.

Speaker: Jeff Ellenbogen, M.D.

Memory loss and cognitive dysfunction are nearly universal concerns in people with epilepsy, however the potential causes are many. This year's SIG will focus on the role sleep plays in memory consolidation and cognitive processing — an exciting, rapidly changing field. Relevance of recent findings specifically to patients with epilepsy will also be discussed.

Surgery

Sheraton – Grand Ballroom, 2nd Floor

Coordinator: Michael M. Haglund, M.D., Ph.D.

Speakers: TBD

We will present cases from multiple institutions that resulted in interesting findings with regards to mapping preoperative function or epileptiform activity and surgical resections. This session has provided outstanding feedback from audience participation and great discussions. We look forward to having another exciting session. Please e-mail Michael Haglund at michael.haglund@duke.edu with cases before the meeting, so we can schedule the appropriate list. The earlier the better, as we have more cases than we can possibly present each year.

2:00 p.m. – 5:00 p.m.

Merritt-Putnam Symposium: Beyond Seizures: Mechanisms Underlying Epilepsy Spectrum Disorder (2.75 CME Credits)

Hynes – Ballroom, Level 3

Overview

Over the last several years, our field has become increasingly aware of the complex relationships between epilepsy and a host of cognitive, behavioral, psychiatric, and other neurological disorders, and even sudden death.

Clinical evidence supports the hypothesis that the underlying pathologies responsible for causing epilepsy may directly contribute to cognitive and other disorders associated with epilepsy. At the same time, increasing evidence points to a direct role for seizures themselves in contributing to the cognitive and behavioral disorders seen in epilepsy. Laboratory models are elucidating both sets of mechanisms. Recent evidence suggests that seizures and epilepsy may also be components of other cognitive disorders, such as autism and dementia. In addition, many anticonvulsant drugs are also used for neuropsychiatric indications, supporting at least partially shared mechanisms for the cognitive comorbidities of epilepsy and the ictal disorder itself.

Epilepsy is defined by the occurrence of seizures, but it is a disorder that exists within a wide spectrum of other disorders. While seizures often remain the focus of clinical care, the many other cognitive and behavioral disorders associated with epilepsy may be just as troubling, if not more so, to the patient and family. A comprehensive and effective approach to treating and managing epilepsy requires a sophisticated appreciation for the intricate relationships between epilepsy and these various other disorders.

This year's symposium will investigate our emerging clinical understanding and the basic neuroscience foundations of these associations.

Learner Outcomes

- ▶ Differentiate between the impact of epilepsy itself and associated cognitive and developmental comorbidities and direct appropriate intervention
- ▶ Assess the potential causes of comorbidities in patients with epilepsy and develop appropriate treatment strategies
- ▶ Evaluate psychiatric disorders which affect people with epilepsy and determine options for treatment
- ▶ Recognize the similar CNS mechanisms for epilepsy and other neuropsychiatric disorders when formulating plans for care.

Target Audience

Neurologists, neuropsychologists, psychiatrists, psychologists, social workers, pediatric neurologists, nurses and neuroscientists interested in translational research

Program

Chair: Frances E. Jensen, M.D.

Epilepsy, Cognition and Behavior: The Clinical Picture

Anne T. Berg, Ph.D.

Mechanisms Underlying Cognitive Impairment in Early-life Epilepsies

Amy Brooks-Kayal, M.D.

Epilepsy and Psychiatric Disorders: The Bidirectional Comorbidity

Andres M. Kanner, M.D.

Break 3:15 p.m. – 3:30 p.m.

The Serotonin Axis: Shared Mechanisms in Seizures, Depression and SUDEP

George B. Richerson, M.D., Ph.D.

Epilepsy and Dementia: Converging Mechanisms

Jeffrey L. Noebels, M.D., Ph.D.

Diagnosis and Management of the Non-ictal Components of Epilepsy: Implications From Novel Clinical and Basic Neuroscience

Frances E. Jensen, M.D.

Credit Designation

The American Epilepsy Society designates this educational activity for a maximum of 2.75 *AMA PRA Category 1 Credits*[™]. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Pharmacy Credit

ACPE #073-999-09-120-L04-P; 0.275 CEUs

Acknowledgment

This program is supported by an educational grant from GlaxoSmithKline.

2:30 p.m. – 4:00 p.m.

Special Interest Group Meetings

Location listed under each session

Engineering & Epilepsy

Hynes – Room 210, Level 2

Coordinators: Piotr J. Franaszczuk, Ph.D., Gregory K. Bergey, M.D.
Speakers: Marvin A. Rossi, M.D., Ph.D., Seyed M. Mirsattari, M.D., Ph.D., FRCP(C), Theodore H. Schwartz, M.D.

Traditional methods of focal epileptogenic changes include various electromagnetic field changes (e.g. EEG, MEG). Recently innovative techniques have been applied to both ictal and interictal activity to provide additional modalities to assess seizure activity. These methods can assist in seizure localization to either confirm more traditional methods or assist when routine methods do not provide definitive information. Ictal SPECT studies of focal changes in cerebral perfusion, fMRI assessment of interictal spikes, and optical imaging of hemodynamic changes associated with epileptogenic activity will be discussed. The potential benefits and pitfalls of these emerging technologies will be addressed.

MEG/MSI

Hynes – Room 208, Level 2

Coordinator: Jerry J. Shih, M.D.
Speakers: William Sutherling, M.D., Hiroshi Otsubo, M.D., Andrew C. Papanicolaou, Ph.D.

A panel of investigators in adult epilepsy, pediatric epilepsy, and cognitive neurosciences will select and present the most important scientific discoveries in the MEG field in the past five years and their impact on clinical practice. Presenters will be asked to hypothesize what MEG studies will show us in the five years. Audience participation is strongly encouraged in what should be a lively Q & A session.

Translational Research: Financing CNS Therapies in 2010 and Beyond

Hynes – Room 207, Level 2

Coordinators: Thomas P. Sutula, M.D., Ph.D. and Warren Lammert
Speakers: Stephen D. Collins, M.D., Ph.D., NeuroTherapeuticsPharma; Les Turski, Ph.D., Global Head of Research, Solvay Pharmaceuticals; Omar Amirana, M.D., Oxford Bioscience Partners

This SIG will discuss how the global financial downturn, escalating complexity of regulatory requirements, increasing development costs, and questions about the future of health care systems and markets have created uncertainties about prospects for return on investment that are significantly impacting every stage of the therapy development, potentially limiting innovation and introduction of new therapies. Speakers will include representatives from academia, small and big pharma, and institutional investors in biotech/pharma.

5:30 p.m. – 7:30 p.m.

AET Symposium: Treatment Strategies for the Patient with Epilepsy (1.75 CME Credits)

Award Presentation: J. Kiffin Penry Excellence in Epilepsy Care Award

Hynes – Ballroom, Level 3

Overview

Clinical consortia and basic science research can provide important information for the practicing clinician but only if the clinician is aware of the limits and strengths of these data. Gathering appropriate and complete clinical information in a comprehensive and efficient fashion allows for effective treatment recommendations and patient education. This symposium will focus on current sources of information regarding best practices as determined by both clinical consortia and focused basic research that examine utility and safety of treatment options for both newly-diagnosed and pharmacoresistant patients. Incorporating this information, i.e., translating research into practice, will allow the clinician to make informed recommendations to both pediatric and adult patients with epilepsy. Two lectures will address sources of treatment information as provided by clinical consortia and focused basic translational research. Two additional lectures will focus on the effective development of treatment strategies for the adult and pediatric patient population. The final lecture will discuss the safety and efficacy results from the first double-blinded controlled trial of responsive direct brain stimulation for the treatment of refractory partial seizures.

Learner Outcomes

- ▶ Improve treatment outcomes by participating in clinical consortia which provide “real life” experience with the full variety of treatment options
- ▶ Develop clinical strategies for assessing depression in patients in epilepsy, including suicide risk
- ▶ Incorporate into clinical decision-making an understanding of how translational research impacts patient care, including the utility of the current preclinical model systems that are employed for the development of new AEDs, structuring clinical trials, and assessing comorbidities
- ▶ Develop an efficient process to collect vital information regarding treatment efficacy and adverse events and assess the presence of existing comorbidities; utilize this information to synthesize a treatment plan and provide adequate education to the patient and his/her caregiver.

Target Audience

Neurologists, nurses, psychologists, social workers, pharmacists, and basic researchers conducting translational research

Program

Co-Chairs: H. Steve White, Ph.D. and Tracy A. Glauser, M.D.

Opening Remarks

H. Steve White, Ph.D.

There are Big Holes in Our Patient-Oriented Research: Could Consortium Trials Be the Plug?

Jacqueline A. French, M.D.

There Is More to Epilepsy Than Seizures: A User-Friendly Strategy to Assess Efficacy and Tolerability of Pharmacotherapy with AEDs and to Screen for Comorbidities in Adult Patients

Andres M. Kanner, M.D.

Strategies for Improving Clinic Efficacy in Pediatric Epilepsy Care

Tracy A. Glauser, M.D.

(continued on page 20)

Advances in Basic and Translational Research in Developing Antiepileptogenic and Neuroprotective Treatments for Epilepsy
Michael Wong, M.D., Ph.D.

Group Discussion
H. Steve White, Ph.D.

Credit Designation

The American Epilepsy Society designates this educational activity for a maximum of 1.75 *AMA PRA Category 1 Credits*™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Pharmacy Credit

ACPE #073-999-09-121-L01-P; 0.175 CEUs

Acknowledgment

This program is supported in part by educational grants from UCB, Inc., GlaxoSmithKline and Sepracor Inc.

6:00 p.m. – 7:30 p.m.

Investigators' Workshop

Sheraton – Constitution Ballroom, 2nd Floor

The Impact of Neuroinflammation on Neuronal Excitability and Excitotoxicity

Moderator: Annamaria Vezzani, Ph.D.
Speakers: Andrea Volterra, Michael S. Beattie, Ph.D., Mattia Maroso

6:00 p.m. – 8:00 p.m.

Translational Investigators' Workshop

Sheraton – Grand Ballroom, 2nd Floor

Mapping Cortical Function with Intracranial Electrodes: Pushing Beyond Penfield

Moderator: Daniel Yoshor, M.D.
Speakers: Michael S. Beauchamp, M.D., Robert T. Knight, M.D., Geoffrey Ghose, Itzhak Fried, M.D., Ph.D.

6:00 p.m. – 7:30 p.m.

Special Interest Group Meetings

Location listed under each session

Basic Neuroscience

Hynes – Room 302, Level 3

Coordinators: Karen S. Wilcox, Ph.D., Celine M. Dube, Ph.D.
Speakers: Celine M. Dube, Ph.D., Timothy A. Benke, M.D., Ph.D., Pierre-Pascal Lenck-Santini, Ph.D.

The SIG will focus on a discussion on the cognitive deficits after early-life seizures and their mechanisms. Dr. Céline M. Dubé will discuss the age and model dependent effects of seizures on cognition function. Dr. Timothy A. Benke will review the mechanisms underlying the cognitive impairments after early-life seizures. Pierre-Pascal Lenck-Santini will give an overview on the most suitable cognitive tests and their meanings.

Clinical Roundtable

Hynes – Room 207, Level 2

Coordinator: Kevin E. Chapman, M.D.
Speakers: Tallie Z. Baram, M.D., Ph.D., Eric Kossoff, M.D., O. Carter Snead III, M.D., FRCP

With the expectant approval of vigabatrin in the U.S., another weapon will be available for combating infantile spasms. Debate continues about which

treatment is "best," and where vigabatrin fits in the armamentarium of the pediatric epileptologist. The goal of this session is to debate the merits of different treatments, including vigabatrin, ACTH/Steroids, and ketogenic diet. Case discussions are encouraged from the audience.

Acknowledgment

This SIG is supported by Questcor Pharmaceuticals, Inc. and Lundbeck

Neuropsychology

Hynes – Room 206, Level 2

Coordinator: Marla Hamberger, Ph.D.
Speakers: Jeffrey Binder, M.D., David W. Loring, Ph.D., Fari Andelman, Ph.D.

Compared to an overabundance of discussions on WADA testing in the 1990s, the topic has received little attention during the past decade. Three speakers will each take one of the following positions: 1) retain the procedure, 2) modify the procedure with regard to patient selection and choice of anesthesia and 3) replace the WADA with noninvasive imaging techniques.

Acknowledgment

This SIG is supported by Pfizer Inc.

Non-epileptic Seizures

Hynes – Room 208, Level 2

Coordinators: Selim R. Benbadis, M.D., John J. Barry, M.D.
Speakers: Selim R. Benbadis, M.D., W. Curt LaFrance, Jr., M.D., M.P.H., Laura H. Goldstein, Ph.D., M.Phil.

Our group will be presenting a two-part presentation. The first is on Diagnostic Issues in NES by Dr. Benbadis. He will also discuss the tragedy of over-read EEGs, which is a major contributor to the misdiagnosis of epilepsy. The second will be on Treatment Issues and Dr. Goldstein will present data on a recent study using CBT treatment and Dr. LaFrance will present his study data on antidepressant treatment for people with NES.

Pregnancy Registry Outcomes

Hynes – Room 210, Level 2

Coordinators: Cynthia L. Harden, M.D., Georgia D. Montouris, M.D.
Speakers: Representatives from registries worldwide

The Pregnancy Outcomes SIG is designed to be a resource for information regarding pregnancy-related outcomes in women with epilepsy. It will provide presentations and discussion of the most up-to-date information from the major antiepileptic drug (AED) pregnancy registries and other data regarding pregnancy outcomes. The goal is to improve the ability to make evidence-based decisions in treating women of childbearing age who have epilepsy.

Tuberous Sclerosis Complex (TSC)

Hynes – Room 304/306, Level 3

Coordinators: Vicky H. Whittemore, Ph.D., Gregory L. Holmes, M.D.
Speakers: Orrin Devinsky, M.D., Howard L. Weiner, M.D., Joyce Wu, M.D., Gary W. Mathern, M.D.

Two groups will present different strategies for the pre-surgical workup and surgical approaches in epilepsy surgery for individuals with TSC.


Remember to Attend

Monday, December 7
1:15 p.m. – 2:00 p.m.

AES BUSINESS MEETING

Dessert and refreshments
Hynes – Room 210, Level 2

All AES members are encouraged to attend this yearly meeting.



and



Present

LONGWOOD SYMPHONY ORCHESTRA

To benefit:

Dr. Susan Spencer Clinical Epilepsy Research Fund

A fund in memory of Susan, coordinated by the American Epilepsy Society, to sponsor clinical epilepsy research fellowships.

Saturday, December 5, 2009 – 8:00 p.m.

New England Conservatory's Jordan Hall - 30 Gainsborough Street, Boston

Jonathan McPhee, Artistic Director and Conductor

Program:

Styx

Tapiola, Opus 112

Lord of the Rings

Giya Kancheli

Roger Tapping, viola

New World Chorale

Jean Sibelius

Howard Shore

A light reception will follow the concert. Shuttle buses will be available between 7:00 p.m. & 11:00 p.m. from the Hynes and the Sheraton Boston.

Hynes Convention Center: Boylston Street Entrance, one level down from the Plaza Level near Hall A

Sheraton Boston Hotel: Go to the Dalton Street door, adjacent to the hotel entrance

Concert tickets were pre-sold but check at **Registration** for **last minute availability**. **Donations** to the **Susan Spencer Clinical Research Fellowship Fund** can be made at any time on the **AES Web site**.

Back by Popular Demand...

The Dysrhythmics

to support

THE LENNOX AND LOMBROSO TRUST
FOR RESEARCH & TRAINING

A voluntary, tax deductible contribution of \$50, or whatever you can contribute will benefit the Lennox and Lombroso Trust for Research & Training. Please confirm your attendance at the Registration desk.

Sunday, December 6

Hynes Exhibit Hall – Level 2 5:00 p.m. – 7:00 p.m.

Authors Present Group A: 1:00 p.m. - 2:00 p.m.

Authors Present: 1.001 - 1.110

Authors Present Group B: 2:00 p.m. - 3:00 p.m.

Authors Present: 1.111 - 1.220

Authors Present Group C: 5:00 p.m. - 6:00 p.m.

Authors Present: 1.221 - 1.332

Professionals in Epilepsy Care

- 1.001** Bone Health Data In Veterans With Epilepsy/B. Hegermiller-Smith, P. Miller, A. Husain
- 1.002** A Multi-Centred Audit Of Nurse-Led Epilepsy Telephone Advice Services/C. Flynn, M. White, S. Murphy, E. Dempsey, S. Crowley, M. Fitzgerald, A. Connolly
- 1.003** Seizure Observation In The Epilepsy Monitoring Unit/M. Plueger, C. Bordson
- 1.004** Evaluating Nurses' Knowledge Of Seizure Treatment In The Elderly Via An Online Educational Program/S. Carlson
- 1.005** Factors Influencing Reproductive Decision-Making Among Individuals With Epilepsy/K. Helbig, B. Bernhardt, I. Helbig, M. Sperling
- 1.006** Linking Young Patients To Supports/A. Bezuyen, T. Conneely, C. Sweeney, L. Davis, D. Brace
- 1.007** Satisfaction With Creating Avenues For Parent Partnership: An Intervention For Parents Of Children With Epilepsy/J. Buelow, C. Johnson, D. Dunn, S. Perkins
- 1.008** Psychogenic Nonepileptic Seizures In Children: An Examination Of Individual And Family Stressors/J. Doss, F. Ritter
- 1.009** Employment Prognosis And Quality Of Life After Surgery In Mesial Temporal Lobe Epilepsy With Hippocampal Sclerosis In A Developing Country/N. Alonso, A. Azevedo, R. Centeno, L. Guilhoto, L. Caboclo, E. Yacubian
- 1.010** YouTube: A Gauge Of Public Perception And Awareness Surrounding Epilepsy/A. Lo, K. Gordon, M. Esser
- 1.011** Sleep Patterns Among Healthcare Providers At An Academic Epilepsy Center/W. Wu, A. Rodriguez
- 1.012** Epilepsy At School. Educative Action Of Associação Brasileira De Epilepsia With Elementary School Teachers In São Paulo City, Brazil/H. Martins, L. Guilhoto, M. Dourado, K. Lin, V. Alexandre, E. Almeida, S. Mesquita, C. Tavares, E. Yacubian

Clinical Neurophysiology

- 1.013** Long-Term Video-EEG In Canine Epilepsy/R. Poma, J. Ives
- 1.014** The Value Of Interictal Discharges In Patients With Normal MRI And Clear Ictal EEG Patterns/E. Aleissa, A. Bozorg, S. Benbadis
- 1.015** Outcome Prediction After Cardiac Arrest Treated With Hypothermia/A. Rossetti, M. Oddo, G. Logroscino, P. Kaplan

- 1.016** Effect Of Seizure Clustering On Onset Region In Patients With Multifocal Temporal Lobe Seizures/A. Sreenivasan, C. Jouny, P. Franaszczuk, G. Bergey
- 1.017** Hypermotor Seizures Occur More Often During Nightsleep In Frontal Than In Temporal Lobe Epilepsy/J. Rémi, A. Skadsem, S. Noachtar
- 1.018** Utility Of Color Density Spectral Array And Amplitude Integrated Electroencephalography For Seizure Identification In Critically Ill Children/C. Hahn, C. Stewart, H. Otsubo, A. Ochi, R. Sharma, V. Nenadovic, A. Guerguerian, J. Hutchison
- 1.019** Validation Study Of An Automated Seizure Detection Algorithm In Scalp EEG/J. Halford, D. Shiau, R. Kern, J. Chien, K. Kelly, J. Valeriano, P. Pardalos, J. Sackellares
- 1.020** Ping-Pong Seizure Patterns In Intracranial Electrodes/L. Lehnhoff, S. Chung
- 1.021** Characterization Of Long-Term Continuous Electrodermal Activity Lateralization In Pediatric Epilepsy Patients/M. Poh, T. Loddenkemper, N. Swenson, M. Sabtala, J. Madsen, R. Picard
- 1.022** Clinical Electroencephalography In Dementia Of Alzheimer's Type Revisited: EEG Findings In A Large Well-Characterized Cohort Of Patients With DAT and No History Of Seizures/A. Alexopoulos, B. Diehl, T. Wehner, S. Takeda, S. Ridge, K. Unnwongse, M. Peterson, I. Najm, R. Burgess
- 1.023** Mismatch Negativity (MMN) To Vowel-Speech Change In Patients With Temporal Lobe Epilepsy/K. Hara, M. Miyajima, H. Iino, A. Matsuda, Y. Emori, K. Ohta, T. Maehara, M. Inaji, E. Matsushima, M. Watanabe, Y. Watanabe, M. Hara, M. Matsuura
- 1.024** Advantages And Experience Using Centralized Data Center Facilities For Neurodiagnostic Data/M. Natola, B. Jobst, T. Darcey
- 1.025** Sudden Unexpected Death In A Patient With Nonepileptic Spells: A Cautionary Tale Of Patient Safety In The Epilepsy Monitoring Unit (EMU)/E. Tecoma, R. Compton, C. Wang, V. Iragui
- 1.026** Vowel-Speech Versus Pure-Tone Processing In Intractable Temporal Lobe Epilepsy/H. Iino, Y. Emori, A. Matsuda, M. Miyajima, K. Hara, K. Ohta, T. Maehara, M. Inaji, M. Hara, E. Matsushima, M. Matsuura

- 1.027** The Diagnostic Yield Of Long-Term Video-EEG In Patients With Frontal Seizures/R. Gandelman-Marton, S. Kipervasser, M. Neufeld
- 1.028** Value Of Overnight EEG Monitoring In The ICU/O. Khan, J. Montanye, C. Azevedo, J. Gonzalez, S. Arshad, M. Natola, S. Surgenor, R. Morse, R. Nordgren, K. Bujarski, G. Holmes, B. Jobst, V. Thadani
- 1.029** The Spectrum Of Ictal Oro-Alimentary Automatisms: A Video-Polygraphic-SEEG Analysis/E. Gardella, S. Francione, E. Zambrelli, L. Tassi, V. Chiesa, A. Piazzini, K. Turner, A. Vignoli, G. Lo Russo, M. Canevini
- 1.030** The New Trend Of Long-Term Video EEG Monitoring Using Dense-Array EEG For Patients With Medically Refractory Epilepsy/M. Yamazaki, A. Fujimoto, T. Yamamoto
- 1.031** SPECT Imaging In Four Patients With Stimulus-Induced Rhythmic, Periodic, Or Ictal Discharges (SIRPIDs)/M. Bensalem-Owen, V. Shelton, T. Fakhoury
- 1.032** A Comparative Assessment Of Electrical Status Epilepticus In Sleep And Focal Sleep Potentiated Spikes/Y. Eksioglu, E. Tas, M. Takeoka, D. Sarco, A. Rotenberg, S. Kothare, F. Duffy, B. Bourgeois, T. Loddenkemper
- 1.033** Induced EEG Burst Suppression In Patients With Refractory Status Epilepticus May Confer A Favorable Prognosis/M. Jimenez, J. Zapata, A. Franco, O. Hernandez, M. Massaro, L. Londoño, J. Ochoa
- 1.034** Relationships Between Ictal And Interictal High-Frequency Oscillations In Patients With Focal Epilepsy/M. Zijlmans, J. Jacobs, Y. Khan, R. Zemann, F. Dubeau, J. Gotman
- 1.035** Smaller Size Of Macrocontact Does Not Improve HFO Detection In Intracerebral EEG Recordings Of The Chronic Epileptic Rat/C. Chatillon, R. Zemann, A. Bortel, M. Avoli, F. Dubeau, J. Gotman
- 1.036** Quantitative Interictal Spike Component Analysis On Intracranial EEG In Patients With Refractory Non-Lesional Epilepsy Shows Better Correlation With Initial Phase Of The Spike In The Epileptogenic Zone/T. Mihaylova, D. Barkmeier, D. Fuerst, S. Mittal, M. Basha, J. Loeb, A. Shah
- 1.037** Variability Of Ictal EEG And Seizure Semiology In Patients With Severe Myoclonic Epilepsy Of Infancy/S. Kozlik, I. Mohamed, M. Blackman, C. Claassen, E. Wirrell, S. Wiebe

- 1.038** Continuous EEG Features And Electrographic Seizures Are Associated With Outcome In Adult Cardiac Arrest Patients Undergoing Therapeutic Hypothermia/R. Mani, S. Schmitt, D. Gaieski, B. Litt
- 1.039** Interictal Spike Morphology Correlate With Epileptogenic Zone Than Tumor Location In Patients With Primary Brain Tumors Undergoing Subdural Electrographic Recording For Epilepsy Surgery/M. Basha, D. Barkmeier, D. Fuerst, T. Mihaylova, S. Mittal, J. Loeb, A. Shah
- 1.040** Seizure Onset Timing And Localization: A Comparison Of Very Low Frequency (DC) And Very High-Frequency (HFO) Recording From Subdural Electrodes/M. Quach, E. Altay, A. Alexopoulos, T. O'Connor, R. Burgess
- 1.041** What Is The Diagnostic Value Of Repeating A Non-Diagnostic Video-EEG Study?/W. Cabaniss, S. Miller, R. Elgavish
- 1.042** Electrographic Spectral Mapping For The Cortical Organization Of Human Behavior/E. Chang, E. Edwards, A. Flinker, L. Secundo, H. Kirsch, N. Barbaro, R. Knight
- 1.043** Gamma-Oscillations Modulated By Listening And Overt Repetition Of Phonemes - Intracranial Recording In Patients With Epilepsy/M. Fukuda, R. Rothermel, C. Juhász, M. Nishida, S. Sood, E. Asano
- 1.044** Effects Of Drug Resistance On Orientation Of Current Dipole Sources Of Anterior Temporal Spikes/O. Kwon, S. Jung, S. Jung, K. Kang, H. Kang, K. Park, N. Choi, B. Lim
- 1.045** The Burst Suppression Pattern Of Secondary Generalized Seizures/A. Maheshwari, S. Cash
- 1.046** Cortical Gamma-Oscillations Modulated By Auditory-Motor Tasks - Intracranial Recording In Patients With Epilepsy/T. Nagasawa, R. Rothermel, C. Juhász, M. Fukuda, M. Nishida, T. Akiyama, S. Sood, E. Asano
- 1.047** Automatic Detection Of Epileptic Seizures In Scalp EEG-Recordings Based On Subspace Projections/T. Kluge, M. Hartmann, C. Baumgartner, H. Perko
- 1.048** An Electrophysiological Marker Of Neural Criticality And Epileptogenesis: The Curvature Of The LFP Square Amplitude Distribution/D. Hsu, H. Grabenstatter, M. Hsu, T. Sutula, J. Beggs, G. Worrell
- 1.049** Estimating Spike Field Coherence During Seizure Initiation/D. Grasse, K. Moxon
- 1.050** Comparison Of High-Frequency Oscillations And Conventional Frequency Activity At Seizure Onset/P. Modur, S. Zhang
- 1.051** High-Frequency EEG Activity Associated With Ictal Events In The TTX Model Of Infantile Spasms/J. Frost, C. Lee, R. Hrachovy, J. Swann
- 1.052** A New Method To Detect Interictal Spikes In Electrophysiological Data/O. Smart, J. Rolston, R. Gross
- 1.053** FFT Analysis On Kindling-Induced Afterdischarge In The Rabbit Hippocampus/S. Kogure, K. Tsuchiya, K. Kozuka
- 1.054** Epileptic Seizure Prediction By Scalp EEG Analysis/K. Kelly, D. Shiau, R. Kern, J. Chien, P. Pardalos, J. Valeriano, J. Halford, J. Sackellares
- 1.055** Analysis Of Pathological Functional Networks In Human Epilepsy/M. Kramer, U. Eden, E. Eskandar, E. Kolaczyk, S. Cash
- 1.056** Wireless Multichannel Miniaturized EEG In The Assessment Of Childhood Epilepsy/L. Lagae, B. Mijovic, K. Jansen, L. Brown, J. Vervisch, S. Vanhuffel, J. Penders
- 1.057** Using EEG Entropy To Identify Patients At Risk Of Future Seizures/P. Davis, T. Bond, P. Neskovic, E. Reyes, S. Garg, J. Gaitanis
- 1.058** Is There A Natural Division Between Ripples And Fast Ripples In Humans?/R. Zelmann, J. Jacobs, M. Zijlmans, C. Châtilion, F. Dubeau, J. Gotman
- 1.059** The Mu And The Missing Third: Evidence For Distinct And Focal Intracranial Alpha Band Fluctuations In Human Somatosensory And Auditory Cortex/J. Parvizi
- 1.060** Interictal High-Frequency Oscillations Indicate Seizure Onset Zone In Patients With Focal Cortical Dysplasia/M. Brazdil, J. Halamek, P. Jurak, P. Daniel, R. Kuba, J. Chrastina, Z. Novak, I. Rektor
- 1.061** Decomposition Of Instantaneous Frequencies Of Ictal Activity: Application Of Hilbert-Huang Transform In Evaluation Of Intracranial EEG Signals/Y. Hsin, T. Harnod, M. Lo
- 1.062** Microseizures And Ictogenesis In Focal Human Epilepsy/M. Stead, M. Bower, F. Meyer, R. Marsh, K. Lee, G. Worrell
- 1.063** Connectivity Analysis Of Ictal Activity From Electrographic Recording/C. Wilke, G. Worrell, B. He
- 1.064** Ictal Patterns Assessed By Measures Of Complexity: A Study Of 339 Partial Seizures/C. Jouny, P. Franaszczuk, G. Bergey
- 1.065** Source Localization Of Interictal Spikes In Patients With Temporal Lobe Epilepsy From A 76-Electrode Array/G. Wang, L. Yang, C. Wilke, G. Worrell, B. He
- 1.066** Bidirectional Propagation Of High-Frequency Interictal And Preictal Activity (70-170 Hz) As An Indicator Of Seizure Foci/A. Korzeniewska, C. Jouny, R. Kus, G. Bergey, N. Crone, P. Franaszczuk
- 1.067** Measurement Of Sleep Potentiated Spiking And Electrical Status Epilepticus In Sleep By Automated Wavelet-Based EEG Analysis/V. Chavakula, E. Park, S. Rakhade, A. Rotenberg, J. Madsen, T. Loddenkemper
- 1.068** Quantitative EEG Can Predict Clinical Changes In Individuals With Sturge-Weber Syndrome/J. Ewen, N. Crone, E. Kossoff, B. Lakshmanan, L. Ferenc, A. Comi
- 1.069** Interictal Source Localization Via Information Flow Analysis Of Scalp EEG/S. Sabesan, N. Wang, L. Iasemidis, D. Treiman
- Clinical Epilepsy**
- 1.070** Comparison Of ECG And Heart Rate Variability In Patients With Temporal Lobe Epilepsy Versus Psychogenic Nonepileptic Seizures/A. Abubakr, I. Iwuchukwu
- 1.071** Prospectively Determining Seizure-Related Injuries In Epilepsy: Results From The First 14 Months Of Systematic Assessment/D. Friedman
- 1.072** Neurocysticercosis With Calcified Lesions And Mesial Temporal Sclerosis: Fortuitous Association Or Possible Etiologic Role?/M. Oliveira, L. Castro, M. Martin
- 1.073** FDG PET-Positive, MRI-Negative Patients With Temporal Lobe Epilepsy: Etiology And Outcomes Compared To Patients With Hippocampal Sclerosis/C. LoPinto-Khoury, M. Sperling, C. Skidmore, M. Nei, A. Zangaladze, J. Evans, A. Sharan, S. Mintzer
- 1.074** Witness Description Of Ictal And Postictal Features In A Structured Interview Distinguishes Epileptic From Nonepileptic Convulsive Attacks/N. Azar, N. Vittal, N. Pitiyanuvath, L. Wang, Y. Shi, B. Abou-Khalil
- 1.075** Evaluating The Concerns Of Patients With Epilepsy/J. McAuley, S. Patankar, J. Elliott, L. Long, J. Moore, E. Klatte, S. Hart, J. Cios, B. Shneker
- 1.076** Benefits Of Outpatient Video-EEG Monitoring In Intellectually Disabled Patients/W. Milteer, R. Bhupalam, S. Zhang, P. Modur
- 1.077** Relationships Of Catamenial Epilepsy And Level Of Catameniality To Epilepsy Laterality And Focality/A. Herzog, K. Fowler, S. Smithson, L. Kalayjian, C. Heck, S. Oviedo, G. Corral-Leyva, The Progesterone Therapy Study Group
- 1.078** Health-Related Quality Of Life Among Patients Of Different Epileptogenic Foci/H. Yu, T. Hsu, C. Yiu, D. Yen, S. Kwan, Y. Lin, Y. Shih
- 1.079** Prevalence And Functional Burden Of Epilepsy In Nursing Home Elderly/L. Eberly, I. Leppik, S. Harms, D. Thurman, B. Virnig, P. Tuite, J. McCarten, L. Caplan, K. Svendsen, S. Li, J. Garrard
- 1.080** A Simple Scale To Differentiate Psychogenic Nonepileptic Attacks From Epileptic Seizures/A. Bozorg, S. Benbadis
- 1.081** Using Conversation Analysis To Distinguish Between Epilepsy And Non-Epileptic Seizures: A Prospective Multi-Rater Study/M. Reuber, C. Monzoni, B. Sharrack, L. Plug
- 1.082** What Is Wrong When There Are No Interictal Epileptiform Discharges On Scalp EEG? Intracranial Recordings In Patients With Pharmacologic-Resistant Epilepsy/K. Unnwonse, A. Alexopoulos
- 1.083** A Pre-Treatment Neurocognitive Questionnaire Provides Predictive Value For Seizure Recurrence In Newly Treated Epilepsy/S. Petrovski, C. Szoeko, N. Jones, M. Salzberg, R. Panelli, R. Huggins, T. O'Brien

- 1.084** Quality Of Life In A Cohort Of Peruvian Patients With Epilepsy: A Preliminary Report/J. Delgado, L. Mija, L. Portilla, W. Zapata, J. Cortez, J. Burneo
- 1.085** Epilepsy And Neurocysticercosis In Houston, Texas/D. Kung, J. Serpa-Alvarez, J. Kass, D. Friedman
- 1.086** Current Source Analysis Of Periodic Lateralized Epileptiform Discharges In Encephalitis: Anatomical Correlation With Diffusion MRI/K. Lee, O. Kwon, E. Joo, K. Kang, H. Kang, K. Park, N. Choi, B. Lim
- 1.087** Unexpected Adverse Effects Of Gamma Knife Radiosurgery For Mesial Temporal Lobe Epilepsy/T. Kawamura, H. Onishi, Y. Kohda, G. Hirose
- 1.088** Premonitory Features Predict Seizures In An Electronic Diary Study/ C. Hall, R. Lipton, T. Borkowski, S. Haut
- 1.089** Premenstrual Dysphoric Disorder In Women With Epilepsy: Relationships To Epileptic, Antiepileptic Drug And Reproductive Endocrine Features/ S. Smithson, B. Dworetzky, E. Bromfield, K. Gleason, E. Garcia, D. Sundstrom, K. Krishnamurthy, A. Herzog
- 1.090** Intra-operative Neuromolecular Imaging (NMI) In Neocortex Of Epilepsy Patients: Comparison With Resected Epileptogenic Tissue/P. Broderick, W. Doyle, S. Pacia, R. Kuzniecky, O. Devinsky, E. Kolodny
- 1.091** A Hypothesis Tested: The Analog Electroencephalographic Recording Is More Likely To Induce Clinical Non-Epileptic Events/F. Matsuo
- 1.092** Respiratory Events And Their Temporal Association With Interictal Discharges In Generalized Epilepsies/ P. Sithinamsuwan, W. Murphy, T. Churchward, M. Edmonds, K. Lawrence, L. Churilov, R. Pierce, S. Berkovic, J. Archer
- 1.093** Macro Sleep-Architecture And The Association Of Sleep Stage And Epileptiform Discharges In Adult Generalized Epilepsies/J. Archer, P. Sithinamsuwan, W. Murphy, T. Churchward, M. Edmonds, K. Lawrence, L. Churilov, R. Pierce, S. Berkovic
- 1.094** Cyclic Alternating Pattern In Primary And Secondary Generalized Epilepsies/W. Murphy, P. Sithinamsuwan, T. Churchward, M. Edmonds, K. Lawrence, L. Churilov, R. Pierce, S. Berkovic, J. Archer
- 1.095** Seizure Control In Unverricht-Lundborg Disease/R. Roivainen, M. Karvonen, T. Puumala
- 1.096** Early Identification Of Medically-Refractory Epilepsy In A Cohort Of Patients With Newly Diagnosed Epilepsy: Response To First Antiepileptic Medication/C. Cheung, J. Delgado, E. Sandison, J. Burneo
- 1.097** Treatment Of Early And Late Post-Stroke Seizures With Levetiracetam (LEV) In Monotherapy. A Safe And Effective Therapeutic Option In Preventing Recurrent Seizures/ M. Feleppa, S. Fucci, W. Di Iorio, G. Apice, M. D'Argenio
- 1.098** Non-Diagnostic Initial Long-Term Video-EEG Study, And Yield Of Repeat Studies/A. Robinson, N. Pitiyanuvath, B. Abou-Khalil, N. Azar
- 1.099** Folic Acid Supplementation In Women With Epilepsy/E. Hamilton, P. Graham, J. Edwards
- 1.100** No MRI Evidence Of Hippocampal Sclerosis In Healthy Subjects/S. Knake, K. Hattemer, J. Iwinska-Zelder, K. Shiratori, R. Jaeger, W. Oertel, H. Hamer, F. Rosenow
- 1.101** Correlation Between Ictal Onset Patterns And Responses To Electrical Cortical Stimulations: Cortico-Cortical Evoked Potential Study/R. Enatsu, Z. Piao, T. O'Connor, K. Horning, W. Bingaman, D. Nair
- 1.102** This poster has been changed to Platform B.09
- 1.103** Paternal Epilepsy Register: To Determine The Effects Of Paternal Epilepsy On Children — Initial Experience/B. Liggan, S. Tirupathi, N. Delanty
- 1.104** 'Position Of Convenience' In Epileptic And Nonepileptic Events/E. Martinez, B. Fisch, M. Grigg-Damberger
- 1.105** De Novo Auditory Aura After Temporal Lobe Surgery For Mesial Temporal Lobe Epilepsy/M. Hammoudi, B. Abou-Khalil
- 1.106** Fatigue In People With Epilepsy. The Validation Of The Fatigue Symptom Inventory, The Fatigue Assessment Instrument And The Fatigue Severity Scale/J. Tellez-Zenteno, L. Hernandez, F. Moien-Afshari, K. Knox, J. Britz
- 1.107** Risk Of Choking And Aspiration During Epileptic Seizures: A Retrospective Review From An Epilepsy Monitoring Unit/K. Noe, L. Tapsell, J. Sirven, J. Drazkowski
- 1.108** Seizure Semiology And Cardiovascular Risk Factors: The Changes With Ageing/D. Silveira, L. Jehi, J. Chapin, S. Krishnaiengar, E. Novak, I. Najm
- 1.109** Tacrolimus (FK506) Decreases The Threshold For Status Epilepticus/ F. Bannout, K. Graber, C. Anderson
- 1.110** Mutation Of The SCN1A Gene; Clinical And Genetic Aspects In Adult Patients/M. Veendrick, G. van Erp, S. Ebus
- 1.111** Remission And Relapse In An Adult Refractory Epilepsy Population/ B. Callaghan, M. Schlesinger, W. Rodemer, J. Pollard, D. Hesdorffer, W. Hauser, J. French
- 1.112** Heart Rate Changes During Epileptic Seizures/E. Olaru, J. Bergholte, E. Kutluay
- 1.113** Discontinuation Of Antiepileptic Drugs After Surgery In Low-Grade Brain Tumors/E. Artsy, R. Das, P. Black, E. Bromfield, J. Lee
- 1.114** Impact Of Evidence-Based Recommendations On Referral Pattern For Epilepsy Surgery/Z. Haneef, J. Stern, J. Engel, Jr.
- 1.115** SSRIs Prolong Seizure Duration In Patients With Focal Epilepsies/ E. Trinka, J. Dobsberger, J. Larch, G. Walsler, I. Unterberger, G. Kuchukhidze, A. Ristic
- 1.116** Voxel-Based Morphometry (VBM) Reveals Progression Of Gray Matter Atrophy In Patients With Refractory Frontal Lobe Epilepsy/C. Yasuda, M. Morita, A. Costa, A. Costa, T. Cardoso, L. Betting, C. Guerreiro, H. Tedeschi, E. Oliveira, M. Guerreiro, F. Cendes
- 1.117** Are Seizures In The Setting Of Sleep Deprivation Provoked?/S. Lieblich, J. Lee, N. Lawn, J. Dunne
- 1.118** Patients Can Self-Predict Seizures In An Electronic Diary Study/ S. Haut, C. Hall, T. Borkowski, R. Lipton
- 1.119** Intractable Epilepsy In An Urban Hispanic Population: A Review Of The First 100+ Cases Referred To An Epilepsy Monitoring Unit/D. Millett, J. Smith, C. Heck, L. Kalayjian, D. Ko, A. Partikian, A. Gonzalez, C. Liu, N. Jimenez
- 1.120** The Differential Diagnosis Of Facial Movements: Seizures Or Not?/ J. Pizarro-Otero, P. Hernandez-Frau, A. Bozorg, I. Eissa, S. Benbadis
- 1.121** Factors Associated With Time To Discontinuation Of Antiepileptic Drug (AED) Treatment In A Commercially-Insured Population Of Patients With Epilepsy Receiving 2 or 3 AEDs/ J. Forlenza, S. Johnston, E. Durden, G. Lenhart, S. Ascher, D. Biondi, L. Costa, G. Wan
- 1.122** Evaluation Of Emergency Care In Clinical Trial Participants: Is There Communication Between Research Staff And Treating Physicians During A Medical Emergency?/S. Marsh, S. Chung
- 1.123** Social Support And Quality Of Life Among Persons With Epilepsy/ C. Charyton, J. Elliott, B. Lu, J. Moore
- 1.124** Nonconvulsive Status Epilepticus (NCSE) In Cancer Patients/M. Spindler, L. Jacks, X. Chen, K. Panageas, L. DeAngelis, Edward Avila
- 1.125** Specialty Epilepsy Clinic Impact On Seizure Frequency And Medication Cost In An Institutionalized, Multiply Handicapped, Refractory Epilepsy Population/R. Wechsler, C. Stute, R. Lott, A. Travis, A. Havey
- 1.126** STEP ONE: Study On The Treatment Of Elderly Patients With Older And Newer Antiepileptic Drugs – Interim Report On Recruitment And Drop-Out Rates/G. Kraemer, E. Trinka, K. Werhahn
- 1.127** An Open-Label Extension Of Two Placebo-Controlled Studies Of Carisbamate As Adjunctive Treatment Of Partial Onset Seizures In Adults: 18-Month Update/J. Halford, R. Kälviäinen, E. Ben-Menachem, J. Schmitt, F. Wiegand, G. Novak
- 1.128** Risk Factors For Drug-Resistant IGE – A Clinical And Electrophysiological Study/P. Kinirons, S. Cash, A. Cole
- 1.129** Essential Features In Elderly Epilepsy Treatment Strategies/E. Baeta
- 1.130** Attitudes Toward Driving Motor Vehicles In People With Epilepsy: Comparing A Reporting Vs. Non-Reporting State/J. Drazkowski, E. Neiman, J. Sirven, K. Noe
- 1.131** Use Of Ketamin In Treating Refractory Status Epilepticus: A Case Series/D. Singh, K. Kelly, S. Rana, J. Valeriano

1.132 Musical Auras In 15 Patients With Focal Epilepsy/R. O'Dwyer, I. Tuxhorn

1.133 Clinical Features Associated With Electrographic Seizures In Patients Placed On Continuous EEG Monitoring In The ICU/S. Schmitt, R. Mani

1.134 Carisbamate As Adjunctive Treatment Of Partial Onset Seizures In Adults: Results At 18 Months From An Ongoing Open-Label Extension Of A Double-Blind, Randomized, Dose-Ranging Study/S. Lippmann, W. Rosenfeld, F. Wiegand, J. Schmitt, G. Novak

1.135 Return To Driving Rates Following Epilepsy Surgery When Comparing Temporal Resections Vs. Frontal Resections/T. Constantino, P. House

1.136 Tolerability Of Carisbamate As Adjunctive Treatment Of Partial Onset Seizures In Adults In Three Double-Blind, Randomized, Placebo-Controlled Studies/M. Sperling, E. Fought, J. Schmitt, F. Wiegand, G. Novak

1.137 Prediction, Triggers, And Termination Of Partial Seizures/W. Tatum, J. Dionisio

1.138 22-24-Year Mortality Data From The National General Practice Study Of Epilepsy (NGPSE)/A. Neligan, G. Bell, A. Johnson, S. Shorvon, J. Sander

1.139 Idiopathic Generalized Epilepsy In Adult Characterized By Typical Absence Seizures - Video-EEG Studies/A. Valle, N. Rodrigues, M. Lima, M. Chamma, M. Jorge, A. Neto, D. Silva, F. Fregni

1.140 The Nature And Extent Of Cerebellar Atrophy In Chronic Temporal Lobe Epilepsy/T. Oyegbile, K. Dabbs, J. Jones, P. Rutecki, R. Pierson, M. Seidenberg, B. Hermann

1.141 Periodic Patterns And Their Association To Seizures And Outcome In Continuous EEG Monitoring In The ICU/D. Taylor, K. Folami, J. Wu, S. LaRoche

1.142 Psychiatric Assessment Of Pre-Surgical Epilepsy Patients/G.E. Tesar

1.143 Musicogenic Epilepsy With Independent Bilateral Temporal Seizures/F. Andermann, D. Amrom, E. Andermann, B. Zifkin, F. Dubeau, M. Doherty

Human Imaging

1.144 Regional Inhibition Of P-gp Activity At The Human Blood-Brain Barrier As Measured By PET Imaging/S. Eyal, M. Muzi, A. Ke, J. Link, D. Mankoff, A. Collier, J. Unadkat

1.145 fMRI Memory Assessment In Healthy Subjects: A New Approach To View Lateralization Data On An Individual Level/M. Strandberg, C. Elfgrén, I. Rorsman, K. Källén

1.146 Evaluation Of Dopamine Receptors And Transporter In The Human Neocortex Of Patients With Temporal Lobe Epilepsy: An Autoradiography Study/L. Rocha, M. Mujica, S. Orozco-Suarez, M. Alonso-Vanegas, J. Villeda-Hernandez, E. Calixto

1.147 Intra-Subject Reproducibility Of EEG-fMRI For Interictal Epileptic Events: A Comparison Between 1.5T And 3.0T Scanners/T. Gholipour, F. Moeller, F. Dubeau, J. Gotman

1.148 Reversible Splenic Lesion Of The Corpus Callosum In Chronic Epilepsy Patients/J. Scott, J. Fagnou, P. Federico

1.149 Voxel-Based Relaxometry Assists In Localizing Focal Epilepsy Of Unknown Origin/P. Federico, R. Kosior, R. Sharkey, M. Lauzon, R. Frane

1.150 Implementation Of Video-EEG-fMRI To Investigate Epileptic Activity/U. Chaudhary, V. Kokkinos, R. Rodionov, D. Carmichael, S. Vulliamoz, R. Thornton, D. Gasston, B. Diehl, J. Duncan, L. Lemieux

1.151 Localization And Identification Of Status Epilepticus By MR Pulsed Arterial Spin Labeling/A. Evans, C. O'Donovan, J. Burdette

1.152 White Matter Changes After The Selective Removal Of An Epileptogenic Lesion In The Human Brain/S. Takaya, N. Mikuni, R. Matsumoto, T. Mitsueda, H. Imamura, S. Urayama, N. Sawamoto, A. Ikeda, H. Fukuyama

1.153 Diffusion Tensor Imaging Of Parahippocampal Gyrus As A Lateralizing Tool In Intractable Temporal Lobe Epilepsy/A. Ray, A. Akhondi-Asl, K. Elisevich, H. Soltanian-Zadeh

1.154 Alteration Of Dopamine D2/3 Receptor Binding In Patients With Juvenile Myoclonic Epilepsy/K. Werhahn, C. Landvogt, H. Buchholz, V. Bernedo, M. Schreckenberger

1.155 Anti-Correlation Between The Default-Mode Network And The Mesial Temporal Lobe In TLE/V. Morgan, B. Abou-Khalil

1.156 Relationships Between Fiber Tract Compromise And Regional Cortical Thinning In Patients With Mesial Temporal Lobe Epilepsy (MTLE)/C. McDonald, H. Girard, L. Gharapetian, D. Hagler Jr, J. Kuperman, V. Iragui, E. Tecoma, A. Dale, E. Halgren

1.157 3 Tesla Imaging Of The Brain In Temporal Lobe Epilepsy: The Potential For Clinical Application/P. Iyer, J. Meaney, C. Doherty

1.158 Acute Crossed Cerebellar Diaschisis (CCD) As A Network Phenomenon In Status Epilepticus Demonstrated By DWI/S. Ruegg, N. Rastalsky, S. Wetzel, A. Gass

1.159 Distance-Based Analysis Of DTI Tractography: Evidence For Focal Pathology In Temporal Lobe Epilepsy/L. Concha, H. Kim, B. Bernhardt, N. Bernasconi

1.160 Frontal Lobe Functional Correlates Of Diffusion Tensor Imaging In Temporal Lobe Epilepsy/M. Dulay, A. Verma, C. Karmonik, M. Kawai, Z. Xue, A. Strutt, M. York, R. Grossman

1.161 Simultaneous EEG And fMRI Of Vertex Sharp Transients/M. Caporrio, Z. Haneef, S. Yeh, C. Buttinelli, J. Stern

1.162 Functional Neuroimaging In Ring Chromosome 20 Syndrome/D. Campos, E. Marín, S. Herrero, E. Cortijo, A. Calleja, M. Ruiz-Gómez, M. Alonso, R. Fenández-Herranz, M. Toledano

1.163 BOLD Signal Changes Preceding Negative Responses In EEG-fMRI In Patients With Focal Epilepsy/J. Gotman, R. Rathakrishnan, F. Moeller, P. LeVan, F. Dubeau

1.164 Thalamofrontal Circuitry Abnormalities And Frontal Executive Dysfunction In Juvenile Myoclonic Epilepsy: Diffusion Tensor MRI And Neuropsychological Studies/J. Kim, J. Kim, S. Suh, H. Seol, K. Jung, S. Koh

1.165 Visualization Of Epileptic Networks: A MEG Guided Diffusion Tensor Tractography Approach/D. Madhavan, S. Podariu, M. White

1.166 Simultaneous EEG And Functional MRI Employing Novel Noise Reduction/F. McGlone, R. Duseath, J. Stern

1.167 How Common Is Brain Atrophy In Patients With Medial Temporal Lobe Epilepsy?/L. Bonilha, J. Edwards, P. Morgan, J. Halford

1.168 In Vivo/In Vitro Evidence For Altered Metabotropic Glutamate Receptor Type 5 (mGluR5): A Biomarker For Epileptogenicity In Mesial Temporal Lobe Epilepsy (MTLE)/E. Kobayashi, J. Hall, L. Minuzzi, F. Dubeau, F. Andermann, J. Rowley, M. Guiot, T. Johnson, J. Antel, G. Massarweh, J. Soucy, M. Diksic, P. Rosa-Neto

1.169 Presurgical Language fMRI And Postsurgical Verbal Memory Decline In Left-Sided Temporal Lobe Epilepsy/F. Woermann, K. Labudda, M. Mertens, J. Aengenendt, A. Ebner

1.170 99mTc-HMPAO-SPECT Of Hypermotor Seizures Analyzed By Statistical Parametric Mapping (SPM)/A. Bleasel, C. Wong, G. Larcos, R. McCredie, E. Somerville

1.171 Presurgical Memory fMRI In Patients With Left-Sided Temporal Lobe Epilepsy With And Without Postsurgical Memory Decline/K. Labudda, M. Mertens, J. Aengenendt, A. Ebner, F. Woermann

1.172 Using Fuzzy C-Means Index Matrix To Valid The Cortical Micro-Disorganization That Corresponded To Focal Epileptogenesis/T. Shen, Y. Hsin

1.173 Connectivity Of The Supplementary Motor Cortex In Frontal Lobe Epilepsies: An fMRI-Based Tractography Study/S. Vulliamoz, C. Vollmar, M. Yogarajah, P. Thompson, J. Stretton, M. Koepp, M. Symms, J. Duncan

1.174 Cortical Analysis In Idiopathic Generalized Epilepsies/L. Betting, C. Yasuda, L. Li, C. Guerreiro, F. Cendes

1.175 Functional Connectivity Of Medial Thalamus Is Altered In Patients With Idiopathic Generalized Epilepsy Compared To Healthy Controls/C. Grova, F. Moeller, E. Kobayashi, T. Gholipour, F. Pittau, P. Bellec, F. Dubeau, J. Gotman

1.176 Epileptic Activity Anticorrelated With Activity In Default Mode Network Using ICA/X. Liang, B. Abou-Khalil, V. Morgan

1.177 A New MRI Sequence For Seizures: FLAIR With Contrast/I. Melguizo, R. Shatzmiller, D. Ko, P. Kim

- 1.178** Reduced Serotonin Transport In Temporal Lobe Epilepsy/W. Theodore, A. Finegersh, D. Cannon, J. Musachio, P. Herscovitch
- 1.179** Independent Component Analysis (ICA) Of Generalized Spike Wave Discharges In fMRI: Comparison With General Linear Model-Based EEG-fMRI/F. Moeller, P. LeVan, J. Gotman
- 1.180** Cognitive fMRI Shows Increased Coactivation Of Motor Cortex In Juvenile Myoclonic Epilepsy/C. Vollmar, J. O'Muircheartaigh, V. Kumari, P. Thompson, M. Symms, G. Barker, R. Duncan, M. Richardson, M. Koepp
- 1.181** Exploring Haemodynamic Changes Linked To Focal Seizures Using Simultaneous EEG-fMRI/R. Thornton, R. Rodionov, H. Laufs, S. Vulliemoz, D. Carmichael, A. McEvoy, S. Lhatoo, R. Elwes, P. Chauvel, F. Bartolomei, M. Walker, M. Guye, J. Duncan, L. Lemieux
- 1.182** Mapping Thalamic Nuclear Pathology In Temporal Lobe Epilepsy/ B. Bernhardt, H. Kim, J. Natsume, A. Bernasconi
- 1.183** Extension Of Structural Lesions Beyond Hippocampus And Natural History Of Temporal Lobe Epilepsy Due To Mesial Temporal Sclerosis – A VBM Study/M. Santana, L. Caboclo, R. Centeno, H. Carrete, Jr., A. Jackowski, E. Yacubian
- 1.184** Diffusion Tensor Imaging (DTI) Of The Cingulum And Its Correlations With Neuropsychological Findings In Refractory Temporal Lobe Epilepsy (TLE)/E. Altay Erbayat, R. Busch, J. Chapin, B. Diehl
- 1.185** Collateral Sulcus Volume Changes In Temporal Lobe Epilepsy/T. Stoub
- 1.186** Normalization Of Contralateral Hippocampus Quantitative Percent Pathology Map Results Only Two Months Following Temporal Lobectomy/R. Elgavish, A. Elkhetali, T. Elgavish, R. Knowlton, K. Riley, G. Elgavish
- 1.187** Resting Functional Connectivity In Patients With Typical Childhood Absence Seizures/X. Bai, M. Vestal, J. Guo, R. Berman, M. Negishi, E. Novotny, T. Constable, H. Blumenfeld
- Antiepileptic Drugs**
- 1.188** Generic Substitution Of Levetiracetam Resulting In Increased Incidence Of Breakthrough Seizures/ C. Fitzgerald, M. Jacobson
- 1.189** Effects Of Vehicle And Dose Routes On The Distribution Of Carbamazepine And 10, 11-Epoxy Metabolite To CSF And Brain/M. Walzer, D. Tolbert, S. Reid, I. Bekersky, D. Wesche, M. Beconi
- 1.190** Acute Hyperammonemic Encephalopathy Associated With Topiramate And Valproate Combination Therapy/S. Abbas, S. Nicholas-Bublick, I. Ali
- 1.191** Identification Of Potentially Effective Antiepileptic Drug Combinations In Patients With Epilepsy/T. Welty, R. Elgavish, E. Faught, B. Barnes
- 1.192** Adverse Outcomes Of Generic Substitution Of Antiepileptic Drugs In A Tertiary Epilepsy Center/I. Karakis, G. Montouris
- 1.193** Efficacy And Tolerability Of Intravenous Levetiracetam As Treatment Of Nonconvulsive Status Epilepticus In The Elderly/N. Paciello, M. Chiumminto, M. Paciello
- 1.194** Managing Refractory Epilepsy: A Study Of Pharmacoresistance In Epilepsy (SOPHIE) In Brazil/W. Alexandre, A. Sakamoto, E. Monteiro, R. Souza, P. Freitas-Lima, E. Perucca
- 1.195** Bone Mineral Density And Quality In Older Men With Epilepsy Treated With Non-enzyme Inducing Antiepileptic Drugs/A. Pack, R. Pelgrift, A. Randall, D. McMahon, E. Shane
- 1.196** An Investigation Of The Effects Of Eslicarbazepine Acetate On Hyponatremia: A Pooled Analysis Of Three Double-Blind Phase III Clinical Studies/M. Vesavel, E. Ben-Menachem, K. Tripp, C. Elger, L. Almeida, P. Soares-da-Silva
- 1.197** Results From An International Observational Study Of Pregnancy Outcomes Following Exposure To Lamotrigine: Interim Sixteen-Year Results/J. Messenheimer, J. Weil, M. Cunningham
- 1.198** NRXN1 Variants Are Associated With Behavioral Difficulty In Response To Levetiracetam/T. Urban, N. Walley, P. Nicoletti, E. Heinzen, D. Ge, K. Shianna, R. Radtke, D. Goldstein
- 1.199** Pharmacokinetics Of Perampanel, A Highly Selective Ampa-Type Glutamate Receptor Antagonist/D. Templeton
- 1.200** Screening Assay For The Induction Of Human CYP3A4, p-glycoprotein And Rat CYP3A1 By AEDs In Vitro: Insights Into Potential Pharmacokinetic Resistance/J. Lamb, J. Raucy, M. Franklin, H. White
- 1.201** Do Anti-Dementia Drugs Modify The Course Of Senile Myoclonic Epilepsy (SME)? Observations From Down Syndrome (DS) & Implications For The General Population/W. Mathurin, S. Brown, R. Shankar, C. Murton
- 1.202** A Double-Blind, Randomized, Placebo-Controlled Study To Evaluate The Safety, Tolerability, And Efficacy Of Ganaxolone As Add-On Therapy In Adults With Uncontrolled Partial Onset Seizures/J. Tsai, P. Pennell, E. Garofalo
- 1.203** A Prospective, Two-Cohort Study To Assess The Effect Of Lamotrigine Or Phenytoin On The Pharmacokinetics Of Atorvastatin/J. Miller, J. Bullman, A. Nicholls, A. Vuong, J. Messenheimer
- 1.204** A Drug-Drug Interaction Study Of Carisbamate And The Oral Contraceptive, Ortho Tri-Cyclen Lo[®], In Healthy Women/K. Moore, P. Zannikos, B. Solanki, A. Dibernardo, G. Romano, H. Brashear
- 1.205** KONQUEST: Keppra Versus Older AEDs And Neuropsychiatric, Neurocognitive And Quality Of Life Outcomes In Treatment Of Epilepsy As Substitution MonoTherapy (KONQUEST): Analysis Of Baseline To Three-Month Data/T. O'Brien, M. Todaro, T. Bright, A. Roten, D. Germaine, S. Petrovski, L. MacGregor, H. Gasko, Z. Matkovic, R. Yerra
- 1.206** Effectiveness And Tolerability Of Lacosamide In Adult Patients With Refractory Partial Epilepsy/F. Schneider, M. Bleiss-Ahrens, J. Geithner, F. Bisping, C. Kessler, U. Runge
- 1.207** First Experiences With Lacosamide In Pharmacoresistant Epilepsies/K. Bohlmann, B. Greshake, H. Straub
- 1.208** Is Antiepileptic Drug Use Associated With Suicidality In Patients With Epilepsy?/S. Wen, K. Meador, D. Loring, S. Eisenschenk, B. Hartzema
- 1.209** Six Months Postmarketing Experience With Lacosamide In Patients With Pharmacoresistant Focal Epilepsy At A Tertiary Epilepsy Center In Germany/T. Wehner, S. Bauer, H. Hamer, K. Hattemer, I. Immisch, S. Knake, M. Nowak, P. Reif, A. Strzelczyk, F. Rosenow
- 1.210** Experience With A Single Patient IND Program With Lacosamide (Vimpat) As Adjunctive Therapy For Intractable Partial-Onset Seizures/H. Henninger
- 1.211** Low Vitamin D Levels Are Not Correlated With Reduced Bone Mineral Density In A Rural Community-Based Epilepsy Population/K. Lapp, A. Stojic, E. Sandok, F. McKiernan
- 1.212** Intravenous Lacosamide For Treatment Of Status Epilepticus After Failing First-Line Therapy/C. Kellinghaus, S. Berning, I. Immisch, S. Knake, F. Rosenow, A. Rossetti
- 1.213** Bone Mineral Density In Patients On Enzyme Inducing Versus Non-Inducing Anti-Epileptic Drugs/K. Sivaraaman, M. Jacobson
- 1.214** A Retrospective Analysis Of Switching To Lamotrigine From Other Antiepileptic Drugs/A. Antony, D. Madhavan
- 1.215** Levetiracetam In Patients With Post-Traumatic Epilepsy: Observations In A Case Series/R. Meo, L. Bilo, M. de Leva
- 1.216** Brivaracetam As Adjunctive Treatment Of Refractory Partial-Onset Seizures In Adults: Results From Two Randomized, Double-Blind, Placebo-Controlled Trials/V. Biton, K. Werhahn, M. Johnson, U. Falter, K. Climo, I. Schelstraete, A. Brodsky, P. von Rosenstiel
- 1.217** Brivaracetam Modulates Na⁺ Currents Expressed In A Neuroblastoma Cell Line: Comparison With Carbamazepine/I. Niespodziany, N. Leclère, A. Matagne, C. Wolff
- 1.218** Effect Of Topiramate On Human Sperm Motility And Cervical Mucus Penetration/M. Boxer, I. Blatt, G. Band

- 1.219** Safety And Tolerability Of Brivaracetam As Adjunctive Treatment In Adults With Refractory Epilepsy: Randomized, Double-Blind, Placebo-Controlled Trial/P. Kwan, M. Johnson, U. Falter, V. Pietteur, A. Brodsky, P. von Rosenstiel
- 1.220** Initial Post-Marketing Experience Using Rufinamide In Non Lennox-Gastaut Adult Epilepsy Patients/A. Cohn, C. Harden, E. Ramsay
- 1.221** Detecting Efficacy Of AEDs In The Photosensitivity Model Likely Requires Both Appropriate Dosing And Effect Over Time for AEDs Not Optimally Active Within 12 Hours After A Single Dose/D. Kasteleijn-Nolst Trenité, R. Reed, W. Rosenfeld, M. Osborn, P. Schaefer, B. Hosmane, B. Abou-Khalil
- 1.222** Suicidality And New AED Exposure In Older Patients: Is The FDA Warning Appropriate For All Drugs In All Populations?/M. Pugh, L. Copeland, A. Van Cott, E. Mortensen, J. Zeber, C. Wang, J. Cramer
- 1.223** An Investigation Of The Effect Of Eslicarbazepine Acetate On Cardiac Repolarization: A Pooled Analysis Of Over-Read Electrocardiograms From Three Double-Blind Phase III Clinical Studies/K. Tripp, M. Versavel, L. Almeida, P. Soares-da-Silva
- 1.224** Pharmacokinetic Variations And Impact On Seizures After Brand To Generic Substitution Of Oxcarbazepine In Adults With Epilepsy/A. Cook, M. Bensalem-Owen, T. Owens-Acey, H. McKee, K. Sinclair, T. Fakhoury
- 1.225** Pregabalin Used Adjunctively With Levetiracetam In The Treatment Of Partial-Onset Refractory Epilepsy: Efficacy And Safety As A Function Of Additional Concomitant AEDs/B. Uthman, M. Almas, T. Leon-Columbo, T. Hedberg, S. Giordano
- 1.226** Intra-Operative Determination And In Vitro Modeling Of P450 Activity By The Human Blood-Brain Barrier/N. Marchi, C. Ghosh, J. Martines Gonzales, M. Hossain, V. Fazio, D. Janigro
- 1.227** Trends in Antiepileptic Drug Prescribing For Older Patients With New-Onset Epilepsy: 2004-2006/A. Van Cott, M.J. Pugh
- 1.228** A Single Ascending Dose Study Of ICA-105665 In Healthy Volunteers/M. Risner, G. Rigdon, E. Moore, M. Allison, W. Wargin, S. Hetherington
- 1.229** AED Generic Substitution – The Effects On The Dependent Variable In Epilepsy Clinical Trials/B. Smith, W. Zachry III
- 1.230** Blood Lipid Parameters In Patients Taking Levetiracetam, Carbamazepine Or Lamotrigine/S. Svalheim, E. Taubøll, G. Luef, M. Rauchenzauner, A. Lossius, L. Gjerstad
- 1.231** An Evaluation Of The Effect Of Eslicarbazepine Acetate On Metabolic Parameters: A Pooled Analysis Of Three Double-Blind Phase III Clinical Studies/M. Friedman, M. Versavel, J. French, L. Almeida, E. Ben-Menachem, K. Tripp, C. Elger, P. Soares-da-Silva
- 1.232** Adherence To Antiepileptic Drugs And Beliefs About Medication Among Patients With Epilepsy/L. Nakhutina, J. Gonzalez, N. Prus, A. Grant
- 1.233** ICA-105665-02: Multiple, Ascending Dose Study: Healthy Volunteers/G. Rigdon, S. Hetherington, E. Moore, M. Allison, W. Wargin
- 1.234** A Multiple, Ascending-Dose Study Of ICA-105665 In Patients With Epilepsy/S. Hetherington, V. Biton, G. Rigdon, E. Moore, W. Wargin
- 1.235** Seizure-Free Rates In Adults With Refractory Partial Onset Seizures Taking Retigabine/D. Burdette, C. Elger, H. Mansbach, P. Shin, S. Hall
- 1.236** The Impact Of Pregabalin On Sleep Architecture And Timing In Partial Epilepsy/S. Giordano, T. Hedberg, E. Whalen, R. Cheung
- 1.237** Absolute Bioavailability Of Divalproex Sodium Extended-Release In Elderly Patients With Epilepsy By A Stable Isotope Technique/R. Rimmel, S. Marino, R. Reed, J. Conway, J. Rarick, A. Birnbaum, I. Leppik, M. Llorente, R. Preston, R. Segura, R. Ramsay
- 1.238** Long-Term Maintenance Of Efficacy With Retigabine In Adult Epilepsy Patients: Extension Study Of RESTORE 2/H. Lerche, H. Mansbach, P. Shin, S. Hall
- 1.239** A Longer Duration Of Antiepileptic (AED) Monotherapy Is Associated With Adverse Bone Health Effects/T. O'Brien, M. Sakellarides, T. Bright, M. Todaro, A. Roten, L. Day, S. Petty, J. Wark
- 1.240** Lacosamide For The Treatment Of Focal Epilepsies: Post-Marketing Experience In 40 Patients/S. Arnold, A. Beige
- 1.241** An Investigation Of The Effect Of Eslicarbazepine Acetate On The Pharmacokinetics Of Carbamazepine: A Pooled Analysis Of Three Placebo-Controlled Phase III Clinical Studies/J. Maia, M. Versavel, T. Nunes, A. Falcao, L. Almeida, P. Soares-da-Silva
- 1.242** The Effects Of The Cannabinoid-Receptor Antagonist, SR141716A, On The Development Of Spontaneous Recurrent Seizures After Kainate-Induced Status Epilepticus/W. Pouliot, K. Staley, F. Dudek
- 1.243** Bioavailability Of Lamictal XR Vs. Lamictal In Elderly Patients: Use Of Stable Isotope Labelled Lamotrigine/R. Ramsay, A. Polepally, A. Birnbaum, I. Leppik, J. Rarick, R. Rimmel
- 1.244** Effect Of P-gp Inhibition In Drug-Resistant TLE Using A Single-Dose Of Tariquidar/M. Feldmann, S. Sisodiya, M. Asselin, J. Duncan, M. Koepp
- 1.245** An Evaluation Of Depressive Symptoms Following Treatment With Eslicarbazepine Acetate: A Pooled Analysis In The Open-Label Extensions Of Three Phase III Studies In Subjects With Partial-Onset Seizures/L. Almeida, T. Nunes, M. Versavel, J. Maia, P. Soares-da-Silva
- 1.246** Incidence Of Rash In The Pooled Population Of Three Placebo-Controlled Phase III Clinical Trials With Eslicarbazepine Acetate/T. Nunes, M. Versavel, L. Almeida, J. Maia, P. Soares-da-Silva
- 1.247** Examination Of Increasing Placebo Response Over The Duration Of Treatment In Controlled, Randomized, Double Blind Studies/E. Whalen, J. French, S. Giordano, B. Emir
- 1.248** Long-Term Maintenance Of Efficacy With Retigabine In Adult Epilepsy Patients: Extension Study Of RESTORE 1/H. Mansbach, W. Rosenfeld, P. Shin, S. Hall
- 1.249** An Investigation Of Therapeutic Effect Of Eslicarbazepine Acetate Combined With Carbamazepine: Pooled Analysis Of Three Placebo-Controlled Phase III Clinical Studies/P. Soares-da-Silva, M. Versavel, T. Nunes, J. Maia, L. Almeida
- 1.250** Pregabalin Use In Epilepsy: Results Of The Post-Marketing Antiepileptic Drug/Device Survey (PADS)/G. Morris, B. Swartz, W. Tatum, R. Burgerman, N. Fountain, G. Montouris, J. French, R. Faight, Jr., C. Harden, L. Brown, B. Bourgeois, A. Kanner, J. Kroll
- 1.251** Effectiveness Of Levetiracetam In The Treatment Of Epilepsia Partialis Continua/P. Pritchard, Z. Li
- 1.252** Levetiracetam: A Potential Alternative To Phenytoin As First Line Prophylactic Anti-Epileptic Therapy In Aneurysmal Subarachnoid Hemorrhage/S. Lewis, S. Schmitt
- Non-AED/Non-Surgical Treatments (Hormonal, Ketogenic, Alternative, Etc.)**
- 1.253** Efficacy, Tolerability And Long Term Adherence Of A Modified Ketogenic Diet (Atkins) In The Management Of Pharmacoresistant Epilepsy/M. Smith, N. Politzer, M. McAndrews, D. MacGarvie, M. del Campo
- 1.254** Effect Of Estradiol On Seizure Frequency In A Man With Epilepsy Undergoing Gender Transformation/C. Harden, A. Cohn, E. Ramsay, E. Marcus
- 1.255** Gender Differences In Antiseizure Sensitivity Of Neurosteroids In The Pilocarpine Model of Status Epilepticus/D. Reddy
- 1.256** Antiepileptogenic Activity Of Progesterone In Wild-Type And Progesterone Receptor Knockout Mice/M. Saraf, S. Briyal, D. Reddy
- 1.257** Transient Sinus Dysfunction During ACTH Therapy In West Syndrome/H. Yoshikawa, S. Watanabe
- 1.258** Long-Term Health And Seizure Outcomes Of Children Treated With The Ketogenic Diet/E. Kossoff, A. Patel, P. Pyzik, J. Rubenstein, Z. Turner
- 1.259** Reduced Seizures In Children With Refractory Epilepsy Using The Ketogenic Diet: Benefits From Increased Experience And Gradual Diet Modification/B. Bjurulf

- 1.260** Comparison Of Atkins And Low Glycemic Index Diets In Children With Intractable Epilepsy/S. Koh, D. Daniels, M. Stevenson, J. Smith, K. Knupp, J. Parsons, B. Miller, P. Levisohn
- 1.261** Evaluation Of Prognosis After A Short-Term And Long-Term Trial Of The Ketogenic Diet In Infantile Spasms: A Randomized, Controlled Comparison/H. Kang, Y. Lee, J. Lee, E. Lee, S. Eom, S. You, H. Kim
- 1.262** Efficacy And Safety Of The Ketogenic Diet For Intractable Epilepsy In Infancy/K. Choi, H. Kang, Y. Lee, J. Lee, H. Kim
- 1.263** Anticonvulsant Effects Of The Ghrelin Receptor Agonist Capromorelin Against Pilocarpine-Induced Limbic Seizures/J. Portelli, N. Aourz, L. Ver Donck, Y. Michotte, I. Smolders
- 1.264** Functional Interactions Occur Between sst2 and sst3 Receptor Subtypes/l. Smolders, N. Aourz, D. De Bundel, J. Portelli, Y. Michotte
- 1.265** An Unbiased Stereological Comparison Of Anticonvulsant And Diet-Induced Neuroprotection In Hippocampus Of Epileptic Kcna1-Null Mice/J. Wilke, H. Milligan, J. Rho
- 1.266** Minocycline Rescues Rats From Weight Loss And Cerebral Lesions After Pilocarpine-Induced Status Epilepticus/G. Arisi, A. Montañez, M. Foresti, K. Katki, J. Heida, R. Sanchez, L. Shapiro
- 1.267** Hypnotic Intervention For Anxiety, Pain And Nausea Management In Patients Having Intracranial Electrode Monitoring/K. Gilbert, D. Hu, L. Thomson, A. Achilles, K. Richardson, D. Roberts, B. Jobst, V. Thadani
- 1.268** Prediction Of VNS Therapy Outcome By EEG Changes After Transcranial Direct Current Stimulation (tDCS)/J. Sperner, I. Orosz, P. Russ
- 1.269** The 6 Hz Test In Metabolism-Based Epilepsy Therapy: Statistical Considerations/A. Hartman, J. Hardwick
- 1.270** Antiepileptic Effects Of An Anaplerotic Diet In Two Chronic Mouse Epilepsy Models/K. Borges, S. Willis, L. Sweetman, J. Stoll
- 1.271** An Integrated Management Of Intractable Epilepsy Through Reflexology And AEDs/K. Dalal, H. Kumar, K. Sharma, M. Tripathi, D. Elanchezhian
- 1.272** Modified Atkins Diet For Medically Intractable Epilepsy In Children: A European Study/M. Miranda, M. Mortensen, J. Povlsen, H. Nielsen, S. Beniczkyk
- 1.273** CSF Levels Of Dopamine, Serotonin But Not Norepinephrine Metabolites Are Influenced By The Ketogenic Diet In Children With Intractable Epilepsy/M. Dahlin, J. Månsson, P. Åmark
- 1.274** An Estimate Of Repetitive Transcranial Magnetic Stimulation Placebo Effect/E. Bae, W. Theodore, F. Fregni, R. Cantello, A. Pascual-Leone, A. Rotenberg
- 1.275** Ketogenic Diet In The Treatment Of Intractable Infantile Spasms/S. Gedela, D. Holder, S. Williams
- 1.276** Successful ECT Treatment For Medically Refractory Nonconvulsive Status Epilepticus In Pediatric Patient/H. Shin, C. O'Donovan, A. Greffe, W. McCall, J. Boggs, A. Harper, W. Bell, P. Rosenquist
- 1.277** Interictal EEG Changes In Children Treated With The Ketogenic Diet/O. Bennett-Back, A. Ochi, T. Akiyama, T. Go, E. Donner, Y. Liu, M. Zak, H. Otsubo
- 1.278** Effect Of A High-Fat Formula-Only Ketogenic Diet On Plasma Levels Of Lipids And Lipoproteins In Children/R. Schultz, A. Wilfong
- 1.279** The First 50: The Ketogenic Diet Experience At A Newly Established Ketogenic Diet Program/R. Said, M. Spears, S. Arnold
- 1.280** Ketogenic Diet Efficacy In Children With Pharmacologically Intractable Epilepsy Of Different Types/A. Abdelmoity, V. Driscoll, L. Thomson, J. Le Pichon
- 1.281** Parents' Perspective On Quality Of Life Improvement In Patients With Intractable Epilepsy Receiving A Ketogenic Diet/V. Driscoll, J. Le Pichon, L. Vaughn, L. Thomson, G. Womelduff, A. Abdelmoity
- Surgery**
- 1.282** Invasive Investigation For Insular Epilepsy: Opened Micro-Dissection Of The Sylvian Fissure (Type 1) Vs. Combined Yale-Grenoble Stereotactic Implantation (Type 2)/A. Bouthillier, W. Surbeck, A. Weil, R. Malak, P. Cossette, L. Carmant, A. Lortie, D. Nguyen
- 1.283** Safety And Utility Of Stereotactic Depth Electrode Implantation Into The Insula In The Evaluation Of Medically Intractable Epilepsy/A. Desai, B. Jobst, V. Thadani, D. Roberts
- 1.284** Structural Changes In Mesial Temporal Sclerosis With Magnetic Resonance Diffusion Tensor Imaging/A. Gutiérrez, V. Villanueva, V. Belloch, A. Beltran, J. Martínez, R. Conde, M. Peris, J. Alvarez-Garijo
- 1.285** Extraoperative Electrical Stimulation Studies: A Useful Tool In Localizing Epileptogenic Foci In Nonlesional, Medically-Refractory Epilepsy Cases/K. Fountas, E. Kapsalaki, J. Smith
- 1.286** Screening Of Epilepsy Patients For Temporal Lobectomy/S. Knight, M. Jacobson, P. Pomerants
- 1.287** Impact Of Epilepsy Surgery In Adults With Medically Intractable Partial Epilepsy: Propensity Score Method For Bias Reduction In The Comparison Of Epilepsy Surgery To A Non-Randomized Control Group/M. Picot, J. Loubersac, P. Kahane, A. Crespel, P. Gelisse, E. Hirsch, P. Derambure, S. Dupont, E. Landré, F. Chassoux, L. Valton, J. Vignal, C. Marchal, A. Rougier, C. Lamy, F. Semah, A. Biraben, A. Arzimanoglou, J. Petit, P. Thomas, A. Jauss
- 1.288** Correlation Of Scalp Ictal Patterns And Interictal Epileptiform Discharges To Effectiveness Of Intracranial EEG Monitoring In Bitemporal Epileptogenicity/V. Wasade, S. Bhatt, J. Constantinou, N. Gohokar, M. Spanaki-Varelas, L. Schultz, B. Smith, K. Elisevich
- 1.289** Vagus Nerve Stimulator Battery Replacement: When Is The Right Time?/J. Lee, N. Sanossian, C. Heck, L. Kalayjian
- 1.290** Seizure Outcome And Complications After Resective Epilepsy Surgery In Patients Over 50 Years At Operation: Data From The Swedish National Epilepsy Surgery Register 1990-2004/B. Rydenhag, R. Flink, K. Malmgren
- 1.291** Surgical Outcome In Patients Undergoing Reoperation For Pharmacologically Intractable Temporal Lobe Epilepsy/R. Jung, S. Aull-Watschinger, E. Assem-Hilger, K. Novak, T. Czech, C. Baumgartner, E. Pataraja
- 1.292** Effect Of Chronic Vagal Nerve Stimulation On Interictal Epileptiform Discharges/R. Kuba, D. Nesvadba, M. Brázdil, I. Rektor
- 1.293** Surgery In Lesional Mesial Temporal Lobe Epilepsy By Ambulatory Magnetoencephalography/A. Russi, B. Oliver, T. Tarancón, M. Santiuste, R. Nowak
- 1.294** Our Experience With The Effect Of Intraoperative Thermal Inactivation On Memory Impairment After Anterior Temporal Lobectomy/l. Tyrlikova, Z. Novak, M. Brazdil, R. Kubikova, R. Kuba, J. Chrasina, S. Megova, I. Rektor
- 1.295** Presurgical Evaluation Of Nonlesional Epilepsy With Foramen Ovale Electrodes/D. Prasad, E. Tecoma, V. Iragui
- 1.296** Analysis Of Peri-Ictal Slow Activity On Subdural Electrode Recording/A. Fujimoto, W. Hader, N. Pillay, H. Dhaliwal, W. Murphy, Y. Starreveld, S. Wiebe
- 1.297** Comparison Of Intracerebral Depth EEG And Magnetic Source Imaging Findings In The Evaluation For Resective Epilepsy Surgery/K. Upchurch, J. Stern, N. Salamon, E. Behnke, S. Dewar, D. Eliashiv
- 1.298** Coexistence Of Mesial Temporal Sclerosis And Neurofibromatosis In A Case Of Surgically Treated Refractory Epilepsy/P. Ferguson, M. Baker, T. Ellis, C. O'Donovan
- 1.299** Cognitive And Surgical Outcomes In Refractory Temporal Lobe Epilepsy With Discordant Neuropsychological Profiles/A. Gargaro, E. Coimbra, C. Galdi, S. Escorsi-Rosset, T. Velasco, A. Pinheiro Martins, V. Alexandre Jr, D. Araujo, C. Carlotti, Jr., J. Assirati, Jr., M. Bianchin, A. Sakamoto

- 1.300** Successful Utilization Of Diffusion Tensor Imaging Of The Geniculo-Calcarine Radiation In Pre-Surgical Planning For Patients Undergoing Anterior Temporal Lobectomy/M. DiSano, T. Ellmore, S. Dreyer, G. Kalamangalam, J. Slater, N. Tandon
- 1.301** Outcomes From Hemispherectomies: A Retrospective Study At Children's Hospital, Denver/L. Zawadzki, S. Koh, P. Laoprasert, K. Knupp, M. Handler
- 1.302** Surgical Treatment For Paediatric Extra-Temporal Epilepsy/L. D'Argenzio, M. Colonnelli, W. Harkness, S. Harrison, J. Cross
- 1.303** Hemispherotomy For Epileptic Encephalopathy Associated With Congenital Hemiplegia/R. Morse, G. Holmes, B. Jobst, V. Thadani, K. Bujarski, D. Gardner, A. Duhaime
- 1.304** Corpus Callosotomy And Subsequent Surgery For Children With Drug-Resistant Epilepsy/T. Ono, H. Baba, K. Toda, K. Ono
- 1.305** Safety And Utility Of The Orthogonally Placed Supplemental Depth Electrodes For Localizing The Ictal Onset Zone In Pediatric Neocortical Epilepsy/H. Kim, C. Lee, R. Knowlton, C. Rozzelle, J. Blount
- 1.306** Pediatric Epilepsy Surgery In Epileptic Encephalopathy/Y. Jin Lee, H. Kang, J. Lee, J. Kim, D. Kim, K. Shim, Y. Lee, H. Kim
- 1.307** Psychiatric Disorders In Extra-Temporal Epilepsy/M. Colonnelli, J. Cross, L. D'Argenzio, S. Hannan, W. Harkness, I. Heyman
- 1.308** Seizure Semiology And Surgical Outcome In Children With Refractory Epilepsy, Generalized EEG Findings, And A Congenital Or Early Acquired Brain Lesion/A. Moosa, T. Loddenkemper, H. Kim, D. Lachhwani, A. Gupta, G. Cosmo, P. Kotagal, W. Bingaman, E. Wyllie
- 1.309** Surgery For Intractable Epilepsy Due To Unilateral Cortical Disease: Comparison Between Anatomical And Functional Hemispherectomy/A. Pinto, M. Takeoka, A. Bergin, B. Bourgeois, F. Duffy, D. Sarco, P. Black, A. Poduri
- 1.310** Defining The Spectrum Of Practice In Pediatric Epilepsy Surgery: The Comparison Of A Single Institutional Experience To The ILAE International Practice Survey/V. Micic, A. Wilfong, A. Malphrus, R. Schultz, D. Yoshon, L. Chapieski, C. Akman, J. Riviello
- Human Genetics**
- 1.311** A Large Family With Autosomal Dominant Neurocardiogenic Syncope/K. Klein, M. Bahlo, C. O'Callaghan, J. McMahon, K. Lawrence, L. Dibbens, I. Scheffer, S. Berkovic
- 1.312** Seizure Semeiology In r(20) Syndrome: A Clinical-Video EEG Study/M. Canevini, A. Vignoli, M. Mastrangelo, I. Flocchi, V. Chiesa, S. Bova, F. La Briola, E. Zambrelli

- 1.313** Mutant GABA_A Receptor Alpha1(A322D) Subunits Linked To Juvenile Myoclonic Epilepsy Associate With Wild Type Subunits But Do Not Inhibit Their Trafficking Or Function/M. Gallagher, L. Ding, H. Feng, E. Botzolakis, R. Macdonald
- 1.314** Genetic Analyses In Different Breeds Identifies A Novel Mutation And Several New Loci In Canine Focal Idiopathic Epilepsies/H. Lohi, E. Seppälä, T. Jokinen, K. Kyöstilä, O. Forman, C. Mellersh, A. But, P. Jokinen, I. Baranowska, M. Berendt, C. Gullov, M. Fredholm, C. Sizinaskas, R. Viitmaa, A. Short, W. Ollier, C. Hitte, A. Grall, C. Andre, B. Minassian, K. Ekenstedt, E. Patterson, C. Drögemüller, T. Leeb, K. Lindblad-Toh, G. Johnson
- 1.315** Gene Expression Profile Suggests A Different Molecular Mechanism For Familial And Sporadic Forms Of Mesial Temporal Lobe Epilepsy/C. Maurer-Morelli, C. Rocha, R. Domingues, C. Yasuda, H. Tedeschi, E. de Oliveira, F. Cendes, I. Lopes-Cendes
- 1.316** Neonatal Seizures And Microcephaly Due To A Novel Mutation In TUBA1A/A. Jansen, Y. De Vlaeminck, S. Seneca, W. Lissens, L. De Meirleir
- 1.317** Familial And Sporadic 15q13.3 Microdeletions In Idiopathic Generalized Epilepsy: A Model For Disorders With Complex Inheritance/J. Mulley, L. Dibbens, S. Mullen, I. Helbig, H. Mefford, M. Bayly, S. Bellows, C. Leu, H. Trucks, T. Obermeier, M. Wittig, A. Franke, H. Caglayan, Z. Yapica, E. EPICURE Consortium, T. Sander, E. Eichler, I. Scheffer, S. Berkovic
- 1.318** The GAT3 Gene Is Associated With Epileptogenesis/Y. Ok Kim, M. Kim, S. Jang, Y. Cho, Y. Kim
- 1.319** Clinical And Neurophysiological Characterization Of A New Large Family With Familial Adult Myoclonic Epilepsy (FAME)/I. Scheffer, D. Crompton, L. Sadleir, M. Bahlo, C. Bromhead, S. Bellows, R. Badawy, T. Arsov, R. Harty, K. Lawrence, J. Dunne, S. Berkovic
- 1.320** A Novel GABRG2 Mutation In An Epilepsy Family/J. Johnston, R. Thomas, C. Hammond, H. Morris, P. Smith, M. Rees
- 1.321** Association Of Epilepsy With Voltage Gated Sodium Channel Gene Polymorphisms In Han Chinese/L. Baum, C. Zhang, V. Wong, P. Ng, C. Lui, N. Sin, B. Tomlinson, K. Wong, P. Kwan
- 1.322** Fine Mapping Of Seizure Susceptibility Loci On Mouse Chromosome 11/J. Kearney, N. Hawkins
- 1.323** Familial Glut1 Deficiency Syndrome Causes A Range Of Idiopathic Generalized Epilepsies/S. Mullen, A. Suls, Y. Weber, H. Lerche, P. De Jonghe, S. Berkovic, I. Scheffer
- 1.323** Familial Glut1 Deficiency Syndrome Causes A Range Of Idiopathic Generalized Epilepsies/S. Mullen, A. Suls, Y. Weber, H. Lerche, P. De Jonghe, S. Berkovic, I. Scheffer

- 1.324** A Complete Single Copy Loss Of TSC2 Is Associated With A Severe Tuberous Sclerosis Phenotype/D. Amrom, F. Andermann, J. Hall, B. Zifkin, E. Andermann
- 1.325** Characterization Of Interstitial 6q Deletions In Two Adult Patients With Mental Retardation And Seizures/E. Andermann, D. Amrom, J. Lavoie, M. Veilleux, F. Andermann

Practice Resources

- 1.326** An Ictal Assessment Tool For The Epilepsy Monitoring Unit/C. Bordson, M. Plueger, L. Ortiz
- 1.327** Epilepsy Surgery Phase Evaluation Manager/John Gilmore, E. Oberst, D. Holder
- 1.328** Development Of An Antiepileptic Drug Response Database In A Multi-Disciplinary Epilepsy Clinic/V. Nguyen, S. Dergalust
- 1.329** Improving Neurologist-Patient Communication To Promote More Effective Assessment Of Side Effects And Comorbidities In Epilepsy: Results Of A Phase II Communication Study/J. Stern, D. Labiner, F. Gilliam, P. Penovich, M. Onofrey, C. Eagan, E. Mathis, G. Holmes
- 1.330** Parents Guide: Ketogenic Diet [English & Spanish Versions]/B. Zupec-Kania
- 1.331** Seize Your Strengths: A Workshop To Promote Positive Functioning In People With Epilepsy/R. Kobau, A. Keane, N. Eatough
- 1.332** National Institute Of Neurological Disorders And Stroke (NINDS), National Institutes Of Health (NIH), Common Data Element (CDE) Project: Epilepsy CDE Update/S. Trollinger, C. Frazier, S. Kunitz, K. Miller, A. Stout, B. Fureman, M. Jacobs, J. Odenkirchen

2009 SCIENTIFIC EXHIBITS
Sheraton Boston Hotel

Scientific exhibits will again be on display at this year's Annual Meeting and will be located in the Sheraton Boston Hotel on the Second Level, Back Bay Ballrooms B and C. These exhibits will provide meeting attendees an opportunity to update themselves on the latest research. Authors will be present throughout the exhibit.

Sunday, December 6 • 8:00 a.m. - 11:00 a.m.

UCB, Inc. (1 of 2)

Lacosamide: A New Direction in the Treatment of Epilepsy

*Back Bay
Ballroom B*

Lundbeck

Novel Anticonvulsants for Patients With Epilepsy: Vigabatrin, Clobazam, and IV Carbamazepine

*Back Bay
Ballroom C*

Sunday, December 6 • 2:00 p.m. - 5:00 p.m.

Medtronic, Inc.

Medtronic Deep Brain Stimulation Research and Technology Update

*Back Bay
Ballroom B*

Monday, December 7 • 8:00 a.m. - 11:00 a.m.

UCB, Inc. (2 of 2)

The Evolution of UCB's SV2A Epilepsy Platform: Keppra XR and Brivaracetam

*Back Bay
Ballroom B*

Monday, December 7 • 8:00 a.m. - 5:00 p.m.

Sepracor Inc.

Eslicarbazepine Acetate: Developing a New Antiepileptic Treatment

*Back Bay
Ballroom C*

SUNDAY December 6, 2009

8:00 a.m. – 4:30 p.m.

Annual Course: Selecting Patients for Epilepsy Surgery (6.5 CME Credits)

Hynes – Ballroom, Level 3

Overview

The AES Annual Course this year is devoted to epilepsy surgery. The course will emphasize selection criteria for surgery, reviewing the clinical and laboratory features employed to determine candidacy for surgery. Speakers will review the characteristics that favor surgical treatment and those that militate against surgery. The program includes lectures, debates about surgical controversies, and case studies, and has an internationally renowned faculty.

Target Audience

Practicing physicians, fellows, residents, nurses, pharmacists, neuropsychologists and research scientists

Learner Outcomes

- ▶ Identify the historical features that suggest that an individual patient is a good candidate for epilepsy surgery evaluation
- ▶ Use diagnostic testing including EEG, MRI, MEG, Wada test, PET scan and other diagnostic tests in selecting candidates for surgery and improving patient outcomes
- ▶ When defining surgical margins utilize the factors which maximize surgical benefit and minimize complication rates
- ▶ Improve management of epilepsy surgery patients by utilizing available technology to map cortical function
- ▶ Apply data obtained during the preoperative evaluation process to decisions regarding surgical treatment
- ▶ Recognize indications for re-operation after unsuccessful epilepsy surgery.

Program

Chair: Michael R. Sperling, M.D.

- 8:00 - 8:10 a.m. Introduction and Case Presentations
Michael R. Sperling, M.D.
- Case of uncontrolled CPS with dominant temporal lobe structural lesion
 - Case of uncontrolled CPS and secondarily generalized partial seizures of extratemporal origin
 - Case of uncontrolled drop attacks in patient with Lennox-Gastaut syndrome
- 8:10 - 8:40 a.m. Who Should Consider Surgery? Recognizing a Surgical Candidate at an Office Interview
Frank G. Gilliam, M.D., M.P.H.
- 8:40 - 9:10 a.m. Localizing and Lateralizing Features of Auras and Seizures
Nancy R. Foldvary-Schaefer, D.O.
- 9:10 - 9:30 a.m. The Interictal EEG
Barbara Dworetzky, M.D.

- 9:30 - 10:05 a.m. Debate: MEG Adds Value to the Surgical Evaluation Process
Hermann Stefan, M.D. and Robert C. Knowlton, M.D.
- 10:05 - 10:25 a.m. Break
- 10:25 - 10:45 a.m. Identifying a Structural Lesion
Graeme D. Jackson, M.D., FRACP
- 10:45 - 11:20 a.m. Debate: Surgery Should Generally Not Be Performed in the Absence of a Well-defined Structural Lesion
Gregory D. Cascino, M.D. and Itzhak Fried, M.D., Ph.D.
- 11:20 - 11:40 a.m. Interictal Cortical Dysfunction
Thomas R. Henry, M.D.
- 11:40 - 12:15 p.m. Debate: The WADA Test Is Obsolete
John T. Langfitt, Ph.D. and Ashwini Sharan, M.D.
- 12:15 - 1:25 p.m. Lunch Break – On Your Own
- 1:25 - 2:00 p.m. Debate: Is It Necessary to Define the Ictal Onset Zone with EEG Prior to Performing Resective Epilepsy Surgery?
John W. Miller, M.D., Ph.D. and Andrew J. Cole, M.D., FRCP(C)
- 2:00 - 2:20 p.m. Assessment of Safety of Resection/Functional Capacity
Ronald P. Lesser, M.D.
- 2:20 - 2:50 p.m. fMRI as a Tool to Map Cortical Function: Is It Ready for Prime Time?
Jeffrey R. Binder, M.D.
- 2:50 - 3:05 p.m. Break
- 3:05 - 3:40 p.m. Debate: Planning Extent of Resection: The Benefits of Small-Targeted Resections vs. Large, Extensive Resections
Jeffrey P. Blount, M.D. and Robert E. Gross, M.D., Ph.D.
- 3:40 - 4:05 p.m. Synthesis of Data
John S. Duncan, FRCP
- 4:05 - 4:20 p.m. Reoperation: If Primary Surgery Fails, When Should Reoperation Be Considered?
Robert R. Goodman, M.D., Ph.D.
- 4:20 - 4:30 pm. Outcome of the Cases Discussed and Conclusion
Michael R. Sperling, M.D.

Credit Designation

The American Epilepsy Society designates this educational activity for a maximum of 6.5 *AMA PRA Category 1 Credits*[™]. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Pharmacy Credit

ACPE #073-999-09-122-L04-P; 0.65 CEUs

8:00 a.m. – 5:30 p.m.

Investigators' Workshop

Sheraton – Room names under each session

Overview

These workshops, conducted informally and designed to encourage interaction, will address several important areas of rapidly emerging knowledge in clinical management and research in epilepsy. The workshops are designed to identify challenges in current research, propose methods to overcome those challenges, and identify areas for future investigations.

The four Clinical Investigators' Workshops provide a series of working seminars in areas of active clinical investigation and controversy. In addition, Clinical Investigators' Workshops cover basic research approaches germane to each clinical topic in addition to relevant and recent human studies. Speakers present results from their ongoing research and place their findings in the context of current understanding. This year's topics have a focus on advanced imaging techniques ('Magnetic Resonance Imaging Changes After Prolonged Febrile Seizures and Temporal Lobe Epilepsy' and 'Imaging Drug-Resistance') as well as on advanced electrophysiological and neurochemical recording techniques applicable to the human brain ('Sensing the Brain in Epilepsy'). These topics exemplify the value of epilepsy research as a window into the functioning of the human brain. Accordingly, one of these workshops has been selected in a translational category for a longer presentation of two hours in order to accommodate a particularly broad scope from basic to clinical research ('Mapping Cortical Function with Intracranial Electrodes: Pushing Beyond Penfield').

The 11 Basic Science Workshops will highlight a number of research areas which have been developing rapidly over the last year. These include the relationship between epilepsy and depression ('Epilepsy and Depression: The Two Faces of BDNF/Jak Dependent Neurogenesis'), the role of nonneuronal cells in epilepsy ('The Impact of Neuroinflammation on Neuronal Excitability and Excitotoxicity' and 'Neuron-glia Signaling and Epilepsy'), seizures in the immature brain ('Rodent Models of Febrile Seizures' and 'Do Neonatal Seizures per se Cause Brain Damage? New Insights from Mutations of Potassium Channels'), novel therapeutic approaches ('Stem Cells and Epilepsy' and 'Curing the Disease by Replacing the Defective Gene: Is It So Straightforward?'). Two further workshops focus on 'Possible Mechanisms of SUDEP: Towards Prediction and Prevention' and the neurobiology and treatment of tuberous sclerosis ('Rapamycin: From Tuberous Sclerosis and Beyond'). Workshops on emerging imaging modalities in basic research include 'Optical Imaging of Epilepsy — Hemodynamic and Light Scattering Changes in the Brain' and 'Imaging Synchrony with Activity-dependent Dyes: The Nuts and Bolts'.

The Basic Science Workshops are scheduled on three days of the Meeting. Most of the workshops will run as concurrent sessions on Sunday, while two concurrent workshops including the longer translational workshop are scheduled for Saturday evening and one single workshop on Monday afternoon.

This year we will feature one of the Epilepsy Research Recognition Award recipients in a keynote address on Sunday.

Target Audience

Basic scientists, neurologists, neuroscientists, pharmacologists, neuropsychologists and neurosurgeons who are investigators performing studies in epilepsy

Program

Investigators' Workshop: Heinz Beck, M.D., Chair,
Nicholas P. Poolos, M.D., Ph.D., Vice Chair
Clinical Investigators' Workshop: Matthias J. Koepp, M.D., Ph.D., Chair

Morning Session I – 8:00 a.m. - 9:30 a.m.

1. Magnetic Resonance Imaging Changes After Prolonged Febrile Seizures and Temporal Lobe Epilepsy: What Basic Science Can Learn from Clinical Studies and Vice Versa
Sheraton – Constitution Ballroom A, 2nd Floor
Moderator: Celine Dube, Ph.D.
Speakers: Darrell V. Lewis, Jr., M.D., Celine Dube, Ph.D., Olli Gröhn, Ph.D.

2. Imaging Synchrony with Activity-dependent Dyes: The Nuts and Bolts
Sheraton – Constitution Ballroom B, 2nd Floor
Moderator: Kevin J. Staley, M.D.
Speakers: Rosa Cossart, Andrew Trevelyan, M.D., Kevin J. Staley, M.D., John White, Ph.D.

3. Stem Cells and Epilepsy
Sheraton – Grand Ballroom, 2nd Floor
Moderators: Jack M. Parent, M.D. and Scott C. Baraban, Ph.D.
Speakers: Hongjun Song, Ph.D., Scott C. Baraban, Ph.D., Jack M. Parent, M.D., Lori L. Isom, Ph.D.

Break: 9:30 a.m. - 10:00 a.m.

Morning Session II – 10:00 a.m. - 11:30 a.m.

4. Imaging Drug Resistance
Sheraton – Grand Ballroom, 2nd Floor
Moderator: Matthias J. Koepp, M.D., Ph.D.
Speakers: Oliver Langer, M.D., Sanjay M. Sisodiya, M.D., Philippe Ryvlin, M.D., Ph.D., Matthias J. Koepp, Ph.D.

5. Rapamycin: From Tuberous Sclerosis and Beyond
Sheraton – Constitution Ballroom A, 2nd Floor
Moderator: Aristeia Galanopoulou, M.D., Ph.D.
Speakers: Peter B. Crino, M.D., Ph.D., Michael Wong, M.D., Ph.D., Paul S. Buckmaster, D.V.M., Ph.D., Emmanuel Raffo, M.D., Ph.D.

6. Epilepsy and Depression: The Two Faces of BDNF/Jak Dependent Neurogenesis
Sheraton – Constitution Ballroom B, 2nd Floor
Moderator: Andre Lagrange, M.D., Ph.D.
Speakers: Linda Overstreet-Wadiche, Ph.D., Shelley Russek, Ph.D., Francis Lee, M.D., Ph.D.

11:30 a.m. - 1:00 p.m. Poster Session (Boxed Lunch)

Sheraton – Independence Ballroom, 2nd Floor

1.144 Regional Inhibition Of P-gp Activity At The Human Blood-Brain Barrier As Measured By PET Imaging, *S. Eyal, M. Muzi, A. Ke, J. M. Link, D. A. Mankoff, A. Collier, J. D. Unadkat*

3.001 Manipulating Reelin Signaling Through Disabled-1 Alters Adult Neurogenesis In The Intact And Epileptic Hippocampus, *M. M. Kron, H. Zhang, D. C. Lagace, A. J. Eisch, B. W. Howell, J. M. Parent*

3.007 Expression Of Calcium Permeable AMPA Receptors During Status Epilepticus, *K. Rajasekaran, J. Kapur*

3.008 Calcium Channel Abnormalities In Inhibitory Presynaptic Terminals Of Epileptogenic Neocortex, *L. Faria, D. A. Prince*

3.009 Initial Loss But Later Excess Of GABAergic Synapses With Dentate Granule Cells In A Rat Model Of Temporal Lobe Epilepsy, *P. Buckmaster, K. Thind, R. Yamawaki, I. Phanwar, G. Zhang, X. Wen*

3.012 An Imbalance Of Excitation And Inhibition Revealed In The Visual-Evoked Responses Of Idiopathic Generalized Epilepsy Patients, *J. J. Tsai, A. Norcia, A. Wade*

- 3.014** Downregulation Of HCN Channels In Epilepsy Is Associated With Decreased Phosphorylation Via p38 MAPK Pathway, *S. Jung, J. B. Bullis, N. P. Poolos*
- 3.028** In Vivo Multiphoton Imaging Detects Acute Dendritic Injury Caused By Brief Seizures, *D. Guo, S. Arnsperger, M. Wong*
- 3.034** Lipopolysaccharide (LPS) Potentiates KA-Induced Seizures And Peripheral Leukocyte Infiltration, *S. Koh, L. Mlsna, A. Chang, M. Kim*
- 3.036** Early-Life Seizures Alter Dendritic Spine Development In Primary But Not Oblique Apical Dendrites Of Rat Pyramidal CA1 Neurons, *J. J. Lippman Bell, P. M. Klein, F. E. Jensen*
- 3.046** Persistent Chloride Accumulation And Anticonvulsant Resistance In Neonatal Seizures, *V. I. Dzhalal, J. J. Glykys, G. Feng, T. Kuner, G. J. Augustine, B. J. Bacskai, K. J. Staley*
- 3.048** Post-Depolarization Potentiation Of GABA_A Receptors: A Novel Mechanism Regulating Tonic Inhibition In Hippocampal Neurons, *C. B. Ransom, G. B. Richerson, Y. Wu*
- 3.050** The Propagation Of Epileptiform Events Across The Corpus Callosum: Results From An In Vitro Preparation, *G. Aaron, J. Walker, S. Leung*
- 3.078** Comorbidity Between Temporal Lobe Epilepsy And Depression: The Role Of Hippocampal Interleukin-1-Beta, *A. Mazarati, D. Shin, E. Pineda, R. Sankar*
- 3.092** Depletion Of STRAD-Alpha Results In Nuclear Accumulation Of LKB1 And Leads To Aberrant mTOR Activation And Lamination During Corticogenesis, *K. Orlova, W. Parker, G. G. Heuer, J. Yoon, M. Baybis, R. S. Fenning, K. S. Strauss, P. B. Crino*
- 3.095** Modulation Of Astrocyte Glutamate Transporters Decreases Seizures In A Mouse Model Of Tuberous Sclerosis Complex, *L. H. Zeng, A. W. Bero, D. M. Holtzman, M. Wong*
- 3.158** Reduced Power Spectrum Of Pentylentetrazole-Induced Seizure Electrographic Activity From Transcutaneous Electrical Stimulation Via Concentric Ring Electrodes, *W. G. Besio, X. Liu, K. Gale, A. Medvedev, S. Kay*
- 3.330** The Effects Of Hippocampus CA1 Single Neuron Firing Properties On Interictal Spike Patterns During Seizure Onset In A Rat Model Of Temporal Lobe Epilepsy, *J. Zhou, S. S. Talathi, A. Cadotte, Z. Liu, G. L. Holmes, P. R. Carney*
- 3.335** Spontaneous Epilepsy And Neuronal Hyperexcitability In Kv12.2 -/- Mice, *F. Bertaso, X. Zhang, J. Yoo, C. Schmedt, S. Clancy, J. L. Noebels, T. Jegla*
- 3.341** Distinct CB1R-Mediated Control Of GABA Release From Somatic And Dendritic CCK+ Interneurons In The Hippocampus, *S. H. Lee, C. Földy, I. Soltesz*

1:15 p.m. - 1:45 p.m. Keynote Speakers

Research Recognition Award Recipient (Basic Science)
Annamaria Vezzani, Ph.D.
Sheraton – Constitution Ballroom A, 2nd Floor

Research Recognition Award Recipient (Clinical Science)
Josemir W. Sander, M.D., Ph.D., FRCP
Sheraton – Constitution Ballroom B, 2nd Floor

Afternoon Session I – 2:00 p.m. - 3:30 p.m.

- 7. Possible Mechanisms of SUDEP: Towards Prediction and Prevention**
Sheraton – Grand Ballroom, 2nd Floor
 Moderator: Josemir W. Sander, M.D., Ph.D., FRCP
 Speakers: Josemir W. Sander, M.D., Ph.D., FRCP, Stilyian Kalitzin, Ph.D., Brian Murray, M.D., FRCP, Peter L. Carlen, M.D.

- 8. Do Neonatal Seizures per se Cause Brain Damage? New Insights from Mutations of Potassium Channels**
Sheraton – Constitution Ballroom B, 2nd Floor
 Moderator: Maria R. Cilio, M.D., Ph.D.
 Speakers: Timothy Benke, M.D., Ph.D., Maria R. Cilio, M.D., Ph.D., Maurizio Tagliatela, M.D., Ph.D., Nanda A. Singh, Ph.D.

- 9. Optical Imaging of Epilepsy: Hemodynamic and Light Scattering Changes in the Brain**
Sheraton – Constitution Ballroom A, 2nd Floor
 Moderator: Theodore H. Schwartz, M.D., FACS
 Speakers: Michael M. Haglund, M.D., Ph.D., Theodore H. Schwartz, M.D., FACS, Sydney S. Cash, M.D., Ph.D., Devin K. Binder, M.D., Ph.D.

Break: 3:30 p.m. - 4:00 p.m.

Afternoon Session II – 4:00 p.m. - 5:30 p.m.

- 10. Sensing the Brain in Epilepsy**
Sheraton – Constitution Ballroom B, 2nd Floor
 Moderators: Hitten P. Zaveri, Ph.D. and Dennis D. Spencer, M.D.
 Speakers: Bruce Lanning, Ph.D., Daryl Kipke, Ph.D., Tore Eid, M.D., Ph.D.

- 11. Curing the Disease by Replacing the Defective Gene: Is It So Straightforward?**
Sheraton – Constitution Ballroom A, 2nd Floor
 Moderator: Russell M. Sanchez, Ph.D.
 Speakers: Beverly Davidson, Ph.D., Francesco Noe, Thomas J. McCown, Ph.D.

- 12. Neuron-glia Signaling and Epilepsy**
Sheraton – Grand Ballroom, 2nd Floor
 Moderator: Christian Steinhäuser, Ph.D.
 Speakers: Giorgio Carmignoto, Ph.D., Annamaria Vezzani, Ph.D., Christian Steinhäuser, Ph.D.

Noon – 1:30 p.m. Thought Sessions

Indo-American Epilepsy Education
Sheraton – Jefferson, 3rd Floor
 This Thought Session is to promote understanding and collaborative interaction between professionals involved in epilepsy care in the United States of America and India to improve care and treatment for patients with epilepsy.

Ring Chromosome 20 Syndrome
Sheraton – Back Bay Ballroom D, 2nd Floor
 In this Thought Session, a discussion will be held about Ring Chromosome 20 syndrome and the latest updates on research and clinical information available to patients affected with this disorder.

12:15 p.m. – 1:15 p.m. Mentoring Session for Junior Investigators Pre-application is required
Sheraton – Hampton, 3rd Floor

This program is targeted to fellows, postdoctoral researchers, instructors, and assistant professor level junior faculty. Epilepsy professionals at the Associate Professor or Professor level will volunteer to serve as mentors. Accepted applicants will meet with their assigned mentors during this time.

5:00 p.m. – 7:00 p.m.

Reception in Support of Lennox and Lombroso Trust for Research & Training

Hynes – Exhibit Hall, Level 2

Share the dream to cure epilepsy! Come mingle with your colleagues and show your support at the Annual Reception. A voluntary, tax deductible contribution of \$50, or whatever you can contribute, will benefit the Lennox and Lombroso Trust for Research & Training. To assist in planning, advanced registration is required.

5:30 p.m. – 7:00 p.m.

Investigators' Workshop Poster Session

Sheraton – Independence Ballroom, 2nd Floor

1.244 Effect Of P-gp Inhibition In Drug-Resistant TLE Using A Single-Dose Of Tariquidar, *M. Feldmann, S. Sisodiya, M. C. Asselin, J. S. Duncan, M. J. Koepf*

3.015 A Role For Toll-like Receptor 4 Activation By The High Mobility Group Box 1 (HMGB1) Protein In Ictogenesis, *M. Maroso, S. Balosso, T. Ravizza, I. Vanzulli, E. Aronica, M. Molteni, C. Rossetti, J. Liu, M. E. Bianchi, A. Vezzani*

3.023 Mapping Of Glutamate Reuptake Capacity And Afferent Input To Cortical Microgyri Reveals Functional Components Of An 'Epileptic Zone', *C. G. Dulla, H. Tani, J. A. Brill, R. J. Reimer, J. R. Huguenard*

3.026 Evidence For A Rapid Presynaptic Modification Of GABA Release During Status Epilepticus In The Young Animal, *S. Joshi, H. P. Goodkin*

3.058 Pathologies Common In Epilepsy Produce And Differentiate Ripples And Fast Ripples: Predictions From A Physiological Hippocampal Computer Model, *W. Stacey, B. Litt*

3.059 Calcium Imaging Of Distinct Onset Patterns Of Ictal And Interictal-Like Activity In An In Vitro Model Of Chronic Epilepsy, *H. R. Sabolek, W. Swiercz, K. Staley*

3.060 Short-Term Synaptic Plasticity Of Low-Threshold Spiking (LTS) Inhibitory Neurons And Their Role In Preventing Seizure Activity In Cortex, *K. A. Richardson, E. E. Fanselow, D. Golomb, B. W. Connors*

3.062 Transgenic Knock-In Mice With Phosphorylation Deficits At GluR1 Ser831 And Ser845 Reveal Reduced Susceptibility To Excitability And Seizures In The Neonatal Period, *S. Rakhade, E. Fitzgerald, C. Zhou, K. Takamiya, R. L. Huganir, F. E. Jensen*

3.103 Multiple Seizures Produce Arrhythmogenic Electrical Activity In The Heart And Increase Susceptibility To Experimentally-Induced Arrhythmias In Kindled Rats, *S. Bealer, J. G. Little*

3.126 Altered mRNA Expression Of GABA And Glutamate Receptor Subunits And Cation Chloride Co-Transporters Is Associated With Increased Seizure Susceptibility After Experimental Febrile Seizure, *A. Y. Reid, G. C. Teskey, Q. J. Pittman*

3.128 Neuropsychiatric Comorbidities In The Plaur-/- Mouse Model Of Frontal Lobe Epilepsy, *G. B. Bissonette, M. H. Bae, D. A. Depireux, E. M. Powell*

3.129 Rapamycin Rescues Epilepsy And Mossy Fiber Sprouting In A NS-PTEN Knock-Out Model Of Cortical Dysplasia, *C. Sunnen, M. C. Ljungberg, D. Parghi, J. N. Lugo, G. D'Arcangelo, A. E. Anderson*

3.136 Multicellular Calcium Imaging Demonstrates The Hyperexcitability Of Dentate Granule Cells During Epileptogenesis In The Pilocarpine-Induced Model Of Epilepsy, *C. Cho, H. Takano, F. Hsu, D. Coulter*

3.137 Hippocampal Depth Recordings From Long Evans Rats Subjected To Neonatal Seizures Reveal Development Of Spontaneous Limbic Seizures, *P. M. Klein, S. Rakhade, F. E. Jensen*

3.138 Normal Development Of Place Cells: A Baseline For Understanding Cognitive Effects Of Early Life Seizures, *R. Scott, G. L. Holmes, P. P. Lenck-Santini*

3.142 Altered Excitatory Neurotransmission In The Reticular Thalamus Of The GluR4 Knock-Out Mouse Model Of Absence Epilepsy, *C. J. Lacey, J. T. Paz, A. S. Bryant, J. R. Huguenard*

3.145 Deficits In Striatal-Enriched Tyrosine Phosphatase (STEP) Decrease Incidence Of Audiogenic Seizures In A Mouse Model Of Fragile-X, *J. R. Naegele, D. V. Hall, S. M. Goebel-Goody, M. Baum, J. Park, L. Ding, Y. Zhang, P. J. Lombroso*

3.149 Electrocorticography In A Brain-Computer Interface (BCI) Paradigm, *J. J. Shih, D. J. Krusienski*

3.317 Heterogeneous Impact Of Status Epilepticus On The Apical Dendritic Structure Of Adult-Generated Granule Cells, *S. C. Danzer, B. L. Murphy, A. W. Loepke, R. Y. Pun*

3.353 A Novel Signaling Pathway Governing The Control Of Parvalbumin-Expressing Basket Cells By CCK In The Rat Hippocampus, *S. Yeun Lee, C. Foldy, J. Szabadics, L. Hilgenberg, M. Smith, I. Soltesz*

3.355 Differential Regulation Of Synaptic Plasticity In Epilepsy, *S. S. Iyengar, D. D. Mott*

7:00 p.m. – 9:00 p.m.

Epilepsy Monitoring Unit Symposium: Expert Consensus on Patient Safety (2.0 CME Credits)

Sheraton – Grand Ballroom, 2nd Floor

Overview

Patient safety in epilepsy monitoring units (EMU) is a common concern but data defining appropriate practice to promote patient safety in EMUs is lacking. A recent survey identified a wide variation in clinical practice and a lack of consensus regarding patient management in EMUs. This program will build on the findings of the AES EMU Patient Safety workgroups that were presented last year. Findings from a study using a Delphi Technique will be presented to establish expert consensus on patient safety recommendations. Methods for applying recommendations and evaluating outcomes will be discussed.

Learner Outcomes

- ▶ Evaluate presented consensus regarding patient care (environments, activities, seizure provocation, treatment of emergent seizures, and seizure observation) within the EMU in order to examine current practice in their EMUs
- ▶ Strategize methods to apply recommendations to build a safer EMU
- ▶ Identify mechanisms to evaluate patient outcomes regarding patient safety in the EMU
- ▶ Implement patient safety efforts within the EMU.

Target Audience

Neurologists, nurses and other mid-level practitioners, neurodiagnostic technologists, hospital administrators

Program

Co-Chairs: Janice M. Buelow, RN, Ph.D. and Gregory L. Barkley, M.D.

Introduction and Overview of Patient Safety
Janice M. Buelow, RN, Ph.D.

Review of Methodology and Use of the Delphi Techniques
Mary Jo Pugh, RN, Ph.D.

Review and Assess the Delphi Study Findings as the Expert Consensus for Patient Safety

Paul M. Levisohn, M.D. and Christine O'Dell, RN, M.S.N.

Clinical Relevance and Applications of Findings

Patricia O. Shafer, M.N., RN and Gregory L. Barkley, M.D.

Panel Discussion

All faculty

Credit Designation

The American Epilepsy Society designates this education activity for a maximum of 2.0 *AMA PRA Category 1 Credits*[™]. Physicians should only claim credit commensurate with the extent of their participation in the activity.

This activity will be submitted to the Association of Rehabilitation Nurses (ARN) for 2.0 contact hours. ARN is accredited as an approver of continuing nursing education by the American Nursing Credentialing Center's Commission on Accreditation.

Pharmacy Credit

ACPE #073-999-09-123-L05-P; 0.2 CEUs

Acknowledgment

This program is supported by an educational grant from UCB, Inc.

7:30 p.m. – 9:00 p.m.

Special Interest Group Meetings

Location listed under each session

Botanicals and Alternative Treatments for Epilepsy

Hynes – Room 207, Level 2

Coordinators: Siegwald M. Elsas, M.D., Steven C. Schachter, M.D.
Speakers: M. Barry Sterman, Ph.D., Boris Kotchoubey, Ph.D., Jonathan E. Walker, M.D.

EEG Biofeedback is attracting interest as an option for self-treatment of epileptic seizures. In this session, we will discuss the development of different methods of biofeedback for epilepsy, and the possible role of EEG biofeedback as an aid to improve seizure control in epilepsy patients. We will consider the published research and practical experience of several centers which use widely differing methods to accomplish similar goals.

Children's Hour

Hynes – Room 304/306, Level 3

Coordinators: Marcio A. Sotero de Menezes, M.D., Lionel Carmant, M.D.
Speakers: J. Helen Cross, M.D., Ph.D., Mohamad Mikati, M.D., Ph.D., Graziella di Cristo, M.D., Janet Soul, M.D.

During the Children's Hour we will discuss the therapeutic approach to neonatal seizures. Dr. Helen Cross will discuss previous and ongoing cohort studies on the outcome of neonatal seizures. Dr. Mohamad Mikati will discuss experimental evidence showing that using conventional therapeutic targets might be deleterious to the developing brain. Dr. Graziella di Cristo will discuss the mechanisms by which GABAergic drugs can indeed lead to abnormal development of neuronal networks and Dr. Janet Soul will discuss new therapeutic options specific to the newborn with a focus on the bumetanide trial.

Junior Investigator Workshop

Hynes – Room 206, Level 2

Coordinators: Audrey S. Yee, M.D., Brandy E. Fureman, Ph.D.
Speakers: Robert L. Macdonald, M.D., Ph.D., Tim Benke, M.D., Ph.D., Brenda E. Porter, M.D., Ph.D.

Starting a new lab and new academic position can be daunting processes. We will discuss "nuts and bolts" of starting a lab, techniques for finding advocates/mentors/go-to people who have charted similar courses. We will also discuss furnishing your lab and techniques for finding individuals to staff your lab. This interactive session provides a forum for asking questions of experts in the field and networking with peers.

Neuroendocrinology

Hynes – Room 208, Level 2

Coordinators: Jana Veliskova, M.D., Ph.D., Doodipala S. Reddy, Ph.D., R.Ph.
Speakers: Istvan Mody, Ph.D., Jaideep Kapur, M.D., Ph.D., Doodipala S. Reddy, Ph.D.

The delta-subunit containing GABAA receptors, located perisynaptically/extrasynaptically, mediate "tonic" current activated by ambient GABA levels, thus "setting" the baseline excitability of neurons. Neurosteroids potentiate most GABAA receptor isoforms, but the delta-subunit containing receptors are more sensitive to neurosteroids making them the prime targets. The delta-subunit undergoes dynamic plasticity in epilepsy and during ovarian cycle. This SIG will focus on delta-subunit as a novel target for seizure disorders.

Neuropathology

Hynes – Room 210, Level 2

Coordinator: Harvey B. Sarnat, M.D., FRCPC
Speakers: TBD

This year's Neuropathology SIG will focus on two issues, to be presented by Dr. Harvey B. Sarnat: 1) the spectrum of histopathological alterations that are included under the rubric "focal cortical dysplasia" and the correlation of these disorders of architecture of the neocortical plate to epileptogenesis. Acquired as well as genetic causes of the focal dysplasias will be discussed and classified; 2) synaptogenesis in the fetal and infant hippocampus and neocortical plate, as demonstrated by a synaptic vesicle wall protein, synaptophysin. Immunoreactive antibodies to this protein may be applied to formalin-fixed, paraffin embedded sections of brain both in postmortem examination and also in surgical resections of brain tissue in the treatment of epilepsy. Synaptophysin can be correlated with other histopathological markers of neuronal maturation. In the fetus of the late 2nd and 3rd trimesters, correlation of the timing of cortical synaptogenesis can be made clinically with EEG maturation in preterm neonates of corresponding conceptual ages and with clinical neurological development. Abnormal cortical synaptogenesis in some malformations will be shown and correlated with epilepsy. The fetal cortex does not yet possess sufficient intrinsic synaptic circuitry to generate epileptic activity before about 26 weeks' gestation. Immature synaptic circuitry may account for differences between the infantile epilepsies and seizure disorders in older children and adults. Time will be provided in the last 30 minutes of the session for participants to show neuropathological cases of epileptic cortex of general interest or that pose diagnostic challenges.

Temporal Lobe Club

Hynes – Room 302, Level 3

Coordinators: Robert J. Gumnit, M.D. and Jerome Engel, Jr., M.D., Ph.D.
Speakers: Robert J. Gumnit, M.D., Andrew N. Wilner, M.D., FACP, FAAN, John M. Stern, M.D., Nathalie Jette, M.D., FRCPC

Recent data indicate that the number of hospitalizations for epilepsy has increased significantly since these reports were published; however, there is no evidence to show a comparable increase in surgical procedures performed for epilepsy during this time. Epilepsy hospitalizations, as well as data for epilepsy surgery from the NAEC will be presented, and the underutilization of surgical therapy for epilepsy will be discussed.

Authors Present Group D: Noon – 1:00 p.m.

Authors Present: 2.001 – 2.112

Authors Present Group E: 4:00 p.m. – 5:00 p.m.

Authors Present: 2.113 – 2.224

Authors Present Group F: 5:00 p.m. – 6:00 p.m.

Authors Present: 2.225 – 2.338

Clinical Neurophysiology

2.001 Phase Space Plots Of Seizures In A Cohort Of Children With Childhood Absence Epilepsy/M. Schwabe, K. Hecox
2.002 Patient-Specific Epileptic Seizure Detection Using EEG Wavelet Packet Analysis/A. Shahidi Zandi, G. Dumont, M. Javidan
2.003 Parameter-Free Extraction Of The Functional Network Topology From Intracranial EEG Recordings: A Time-Resolved Study Of Graph Properties In Focal Onset Seizures/ F. Amor, C. Rummel, H. Gast, K. Schindler
2.004 Detection Of Seizure-Associated High-Frequency Oscillations Above 500 Hz/K. Kobayashi, T. Agari, M. Oka, H. Yoshinaga, I. Date, Y. Ohtsuka, J. Gotman
2.005 Abnormal Cortical Excitability And Photosensitive Epilepsy/S. Seri, D. Brazzo, P. Bill, G. Di Lorenzo, P. Veggioni
2.006 Long-Term Changes In Interictal, High Density, Scalp EEG Phase Synchronization And Power In Different Spectral Bands Assist In Localizing Sites Of Seizure Onsets/M. Holmes, C. Ramon
2.007 Computerized Source Analysis Of EEG Seizure Onset In Nocturnal Frontal Lobe Epilepsy/M. Tracy, F. Duffy, M. Takeoka
2.008 EEG Digital Trend Analysis For Rapid Seizure Detection In Children: Comparison Of Techniques/ J. Riviello, V. Micic, A. Thompson, C. Akman
2.009 Electric Source Imaging — Increasing The Number Of Recording Electrodes To 256 Improves Source Localization Precision Of Interictal Epileptiform Activity/G. Lantz, V. Brodbeck, M. Seeck, D. Tucker, C. Michel
2.010 Stereotrode Effect In Microwire Recordings In Humans/A. Brandt, I. Eble, S. Hefft, A. Schulze-Bonhage
2.011 Markov Chain Analysis Of Pediatric Ictal EEGs/K. Vincent, S. Merrill, C. Struble, K. Hecox
2.012 Determining The Firing Rate Of Interictal Population Spikes Leading To Seizures/S. Myers, S. Talathi, P. Carney
2.013 Role Of Subdural Electroocortigraphy In Prediction Of Long-Term Seizure Outcome In Epilepsy Surgery/E. Asano, C. Juhasz, A. Shah, S. Sood, H. Chugani
2.014 Clinical Implications Of Fronto-Temporal EEG Spikes In Patients With Temporal Lobe Epilepsy/I. Yung, S. Rose, S. Qian, S. Hawes-Ebersole, J. Ebersole, J. Tao

2.015 The Relationship Of Interictal Epileptiform Discharges To Clinical Epilepsy Severity: A Study Of Routine EEGs/M. Selvitelli, L. Walker, D. Schomer, B. Chang
2.016 Scalp Permeating High-Frequency EEG Recording On Seizure Onset: Utilization In Non-Invasive EEG Study/ H. Hasegawa
2.017 EEG Findings In A Cohort Of Patients With New-Onset Seizures/ E. Sandison, J. Burneo
2.018 Co-Registration Of Cyst-Like Tubers And Epileptiform Activity In Tuberos Sclerosis Complex/ C. Chu-Shore, A. Gallagher, D. Costello, M. Montenegro, P. Major, E. Thiele
2.019 Patterns Of Intracranial Seizure Propagation In Temporal Lobe Epilepsy/ J. Tao, I. Yung, S. Qian, S. Rose, R. Penn, S. Ebersole, J. Ebersole
2.020 High-Frequency Changes During Interictal Spikes Detected By Time-Frequency Analysis/J. Jacobs, K. Kobayashi, J. Gotman
2.021 Treatment Of Non-Anoxic PLEDS With Antiepileptic Medications: A Prospective Observational Study/ J. Louie, J. Narayanan
2.022 Seizure Incidence, EEG Characteristics, And Short-Term Outcome In The Pediatric Stroke Population/R. Singh, N. Zecavati, S. Weinstein, J. Carpenter
2.023 Using Continuous EEG (CEEG) Monitoring To Predict And Monitor Anterior Region Vasospasm In Patients With Subarachnoid Hemorrhage (SAH)/R. Rathakrishnan, J. Gotman, F. Dubeau, M. Angle
2.024 EEG Abnormalities In Children With New Onset Epilepsy After An Initial Normal EEG/J. Goraya, I. Valencia, K. Carvalho, D. Khurana, J. Melvin, A. Legido
2.025 2C QTc In The EEG You Should Not/M. Wise, N. Madan, K. Carvalho, D. Khurana, J. Melvin, A. Legido, I. Valencia
2.026 Periodic EEG Pattern Associated With Pentobarbital Withdrawal/ A. Popescu, E. Pina-Garza, B. Abou-Khalil
2.027 How Useful Is The Routine EEG Study In Differentiating Seizure From Other Non-Specific Diagnoses?/C. Ulloa, N. Sethi, G. Solomon
2.028 Use And Misuse Of EEG In The Emergency Department Of An Academic Hospital: A Single Center Pilot Study/ B. Legros, A. Higueta

2.029 Seizure Onset Detection In The Electroocortogram By A Frequency Analysis Algorithm Versus Human Observers/K. de Gooijer-van de Groep, Z. Agirre-Arrizubieta, G. Huiskamp, C. Ferrier, A. van Huffelen, F. Leijten
2.030 Knowledge Of The Emergency Department Clinicians On Emergent EEG Indications: A Single Center Survey/ A. Higueta, B. Legros
2.031 Isolated Thin Curvilinear Heterotopia In The Periventricular White Matter Of The Frontal Horns: Clinical-Electrophysiological Correlations/ R. Serafini, K. Elisevich, M. Spanaki, S. Gaddam, B. Smith
2.032 The Added Value Of Intracerebral SEEG Recordings In The Pre-Surgical Evaluation Of Refractory Focal Epilepsy Cases/F. Babbain, A. Olivier, J. Hall, F. Andermann, J. Gotman, F. Dubeau
2.033 Is There A Difference In Outcome In Patients With Periodic Lateralized Epileptiform Discharges (PLEDs) With Clinical Seizures Versus Without/ A. Taavoni, J. Valeriano
2.034 Beyond The Dipole: Estimation Of Spatial Epileptic Source Dynamics And Propagation Models From Scalp EEG Recordings/C. Stamoulis, B. Chang
2.035 Receptive Language Mapping With Magnetic Source Imaging (MSI) And Electrical Cortical Stimulation (ECS)/W. Zhang, G. Risse, J. Landsteiner, B. Owens, L. Petersen, M. Dunn, F. Ritter, M. Frost, J. Doescher, P. Penovich, R. Doss, E. Mouderrres, D. Dickens
2.036 Localization Of Epileptic Foci In Children With Intractable Epilepsy Secondary To Multiple Cortical Tubers Using Synthetic Aperture Magnetometry Kurtosis/I. Sugiyama, K. Imai, A. Ochi, C. Go, T. Akiyama, O. Snead, E. Widjaja, S. Chuang, H. Otsubo
2.037 Noninvasive Detection And Localization Of Pathologic High-Frequency Oscillation In Tuberos Sclerosis Complex With Wavelet-Based Beamformer/J. Xiang, Y. Chen, Y. Wang, Y. Liu, H. Fujiwara, N. Hemasilpin, K. Lee, F. Mangano, J. Leach, D. Franz, K. Holland, D. Rose
2.038 Diagnostic Tool Of Magnetoencephalography For Atypical Benign Partial Epilepsy: Rolandic-Sylvian Spike Sources/H. Shiraishi, K. Haginoya, N. Nakasato, Y. Kakisaka, E. Nakagawa, K. Sugai, D. Chan, H. Otsubo

- 2.039** MEG Source Localization With Multiple Algorithms In Pediatric Epilepsy Surgery Candidates With Tuberosus Sclerosis Complex/H. Fujiwara, D. Rose, N. Hemasilpin, K. Lee, F. Mangano, J. Seo, D. Franz
- 2.040** MEG Source Localization Of Interictal Epileptiform Discharges In Patients Where EEG Localization Is Difficult Or Impossible: A Report Of 4 Cases With Massive Asymmetric Brain Abnormalities/K. Jin, A. Alexopoulos, J. Mosher, R. Burgess
- 2.041** Recording Temporal Epileptic Activity With MEG Using A Light Weight Magnetic Shield/X. De Tiège, E. Carrette, M. Op De beeck, M. Bourguignon, P. Boon, K. Vonck, B. Legros, S. Goldman, P. Van Bogaert
- 2.042** Concordance Between Distributed MEG Source Localization/ Dynamic, And Simultaneous IEEG Study Of Epileptic Spikes/B. Godet, F. Gombert, L. Garnero, M. Baulac, S. Baillet, C. Adam
- 2.043** Recording Epileptiform Activity With Magnetoencephalography In Patients With Refractory Epilepsy Implanted With A Vagus Nerve Stimulator Is Feasible And Presents Added Value In The Presurgical Evaluation/E. Carrette, X. De Tiège, P. Boon, M. Op De Beeck, V. De Herdt, A. Meurs, B. Legros, R. Raedt, M. Bourguignon, S. Goldman, P. Van Bogaert, K. Vonck
- 2.044** Pre-Surgical Functional Neuroimaging Using fMRI And MEG In Sedated Children/D. Clarke, M. McManis, F. Perkins, Z. Patay, F. Boop, L. Birg, A. McGregor, J. Wheless, R. Ogg
- 2.045** Real-Time Artifact Suppression In Magnetoencephalography Recordings/ J. Mosher, K. Jin, A. Alexopoulos, R. Burgess
- 2.046** Evidence Of Impaired Auditory Information Processing In Children With Intractable Epilepsy: MEG Study/ M. Korostenskaja, M. Pardos, T. Kujala, P. Horn, H. Fujiwara, D. Brown, P. Alku, Y. Wang, D. Rose, J. Xiang, A. Byars, T. Degrauw, R. Naatanen, K. Lee
- 2.047** Concordance Between Magnetoencephalography (MEG) And Intracranial Electroencephalogram Findings (ICEEG)/J. Bulacio, K. Jin, A. Alexopoulos, D. Nair, T. O'Connor, J. Gonzalez-Martinez, W. Bingaman, R. Burgess, J. Mosher, I. Najm
- 2.048** Using Magnetoencephalography To Localize Language In Preschool Children Prior To Epilepsy Surgery/ M. McManis, F. Perkins, J. Wheless, F. Boop
- 2.049** MEG Source Localization Algorithms For Interictal Discharges: Strengths, Limitations, And Cautions For Interpretation/D. Rose, H. Fujiwara, N. Hemasilpin, K. Lee, F. Mangano, K. Holland, T. Arthur, D. Morita, J. Seo, K. Stannard
- 2.050** Can An Epileptic Spike Peak Earlier In The EEG Than The MEG?/ P. Afra, M. Funke, F. Matsuo
- 2.051** Gamma Oscillations Modulated By Word Association Tasks - Intracranial Recording-/L. Thampratankul, T. Nagasawa, R. Rothermel, C. Juhasz, E. Asano
- 2.052** Abnormalities Of Diffusion Tensor Imaging In Epileptic Areas In Childhood Epilepsy/L. Meng, J. Xiang, W. Yuan, Y. Wang, Y. Chen, X. Wang, H. Fujiwara, N. Hemasilpin, K. Lee, F. Mangano, J. Leach, K. Holland-Bouley, D. Rose
- 2.053** Speech Localization In The Left Mesial Frontal Lobe/B. Feddersen, J. Rémi, S. Noachtar
- 2.054** In Vivo Connectivity Between Dorsal Hippocampal Commissure And Bilateral Mesial Temporal Structures/ M. Koubeissi, D. Durand, S. Rashid, T. Syed, R. Maciunas, H. Lüders
- 2.055** Peri-Ictal Alteration Of Cortico-Cortical Excitability In Focal Cortical Dysplasia In Humans: A Cortico-Cortical Evoked Potential Study/R. Matsumoto, M. Kinoshita, T. Kikuchi, M. Inouchi, M. Matsushashi, N. Mikuni, H. Fukuyama, R. Takahashi, A. Ikeda
- 2.056** Functional Neuroanatomy Of The Insular Cortex/C. Stephani, G. Fernandez-Baca-Vaca, R. Maciunas, M. Koubeissi, H. Lüders
- 2.057** A Comparison Of Responsive Neural Stimulation Protocols For Seizure Suppression/P. Rajdev, P. Irazoqui
- Clinical Epilepsy**
- 2.058** Prevalence Of Status Epilepticus In The Critical Care Patient Population/ G. Venkatraman, D. Shmerkovich, M. Andriola, I. Zilberman, R. Spiegel
- 2.059** Idiopathic Photosensitive Occipital Lobe Epilepsy: A Case Study Of Monozygotic Twins/M. Maguire, S. Taggart
- 2.060** Do Subclinical Electrographic Seizure Patterns Affect Heart Rate And Its Variability?/P. Adjei, R. Surges, C. Scott, C. Kallis, M. Walker, S. Shorvon
- 2.061** Convulsive Status Epilepticus In Honduran Adults/H. Skinner, A. Thompson, S. Dubon, M. Medina, J. Nicholas, J. Edwards, K. Holden
- 2.062** Demographic, Clinical And Comorbid Conditions As Predictors Of Psychogenic Nonepileptic Spells/ J. Elliott, B. Shneker
- 2.063** The Informative Value Of Hypersalivation And Postictal Coughing For Seizure Origin In Temporal Lobe Epilepsy/J. Hoffmann, C. Elger, A. Kleffuss-Lie
- 2.064** Expression Of Slit2 In Brain Tissues Of Patients With Intractable Epilepsy And Rats Following Lithium-Pilocarpine Induced Status Epilepticus/W. Xuefeng
- 2.065** Increased Expression Of SCRAPPER In Brain Tissues Of Patients With Temporal Lobe Epilepsy/W. Xuefeng
- 2.066** Netrin-G2 In The Brain Tissue Of Patients With Intractable Epilepsy And Rat Models/W. Xuefeng
- 2.067** The Study Of Protein Level Expression Of Phosphorylation Myosin Light Chain And Myosin Light Chain And Myosin Light Chain Kinase In Refractory Temporal Epilepsy/W. Xuefeng
- 2.068** Etiology Of Triphasic Waves On EEG/L. Cook, L. Selwa
- 2.069** Taking Care Of Women With Epilepsy: Are The Guidelines Being Followed?/P. Penovich, J. Hanna
- 2.070** Misdiagnosis Of Recurrent Frontal Nonconvulsive Status Epilepticus As Schizophrenia: A Case Report/C. Liu, Y. Hsin
- 2.071** Fertility Trends In Women With Epilepsy: Observations From The Kerala Registry Of Epilepsy And Pregnancy/ S. Thomas, C. Sapna
- 2.072** Rating Scale For Psychogenic Nonepileptic Seizures: Scale Development And Clinimetric Testing/ U. Aguglia, V. Cianci, F. Condino, H. Somma-Mauvais, M. Latella, G. Farnarier, A. Labate, A. Gambardella, A. Quattrone
- 2.073** Longitudinal Outcomes In Patients With Confirmed Nonepileptic Seizures/J. Bisping, R. Doss, P. Penovich
- 2.074** Knowledge And Beliefs Survey On An Ethnically Diverse Adult Epilepsy Population Treated At The University Of Minnesota/M. Fiol, G. Vazquez, D. Groth, K. Allison
- 2.075** Absence Of REM Sleep Behavior Disorder In Epileptic Patients With Bilateral Mesial Temporal Sclerosis Not Due To Autoimmune Encephalitis/ A. Iranzo, M. Carreño
- 2.076** Epilepsy Patients' Attitudes Towards Ambulatory Seizure Prediction Devices/A. Schulze-Bonhage, K. Wagner, A. Carius, A. Schelle, M. Ihle
- 2.077** MEG/EEG In Eating Epilepsy Associated With Right Mesial Temporal Lobe Tumor: Review Of Olfactory Processing/J. Nicholas, A. Bagic, G. Ghearing
- 2.078** Optimism, Pessimism, And Health: Implications For Individuals With Seizure Disorders/B. Schefft, G. Kent, S. Howe, G. Matthews, R. Krikorian, J. Szaflarski
- 2.079** Psychogenic Nonepileptic Seizures At A Veterans Administration Medical Center/M. Salinsky
- 2.080** Levetiracetam And Acute Repetitive Seizures In The Emergency Department Setting/T. Ting, K. Pargeon
- 2.081** Psychological Profile And Abuse History Of Non-Diagnostic Female Patients In The Epilepsy Monitoring Unit/ L. Uber-Zak, J. Drazkowski, A. Strutt, L. Baxter, J. Park, M. Ropacki, D. Cacciopo
- 2.082** Suspect Effort, Mood, Locus Of Control And Quality Of Life In A Sample Of Female Psychogenic And Temporal Lobe Epilepsy Patients/A. Strutt, S. Hill, M. York, L. Uber-Zak, T. Fogel
- 2.083** The Different Faces Of Dual Epilepsy/J. Dineen, O. Tuohy, S. Tirupathi, N. Delanty

- 2.084** Utility Of Routine EEG Study In Identifying Seizure As The Etiology Of The Index Event In Patients Referred With A Diagnosis Of Migraine And Other Non-Specific Headache Disorders/ N. Sethi, C. Ulloa, G. Solomon
- 2.085** Response To Driving Restrictions In Epilepsy/A. Worley, M. Selenica, W. Tatum
- 2.086** Patterns Of Relapse And Remission In Chronic Epilepsy/ M. Amarouche, A. Neligan, J. Sander, S. Shorvon
- 2.087** Use Of Intravenous Levetiracetam In Infants And Toddlers With Prolonged Or Serial Seizures/ C. Joshi, E. Wirrell
- 2.088** Is Levetiracetam Effective In Treatment Of The Electrical Status Epilepticus During Slow Wave Sleep (ESES)?/B.I Sitwat, S. Gedela, D. Holder, I. Vaisleib
- 2.089** Health And Socioeconomic Outcomes In Adulthood Of Childhood Onset Epilepsy: National Cohort Study/R. Chin, S. Pujar, P. Cumberland, E. Ross, C. Peckham, R. Scott
- 2.090** Predictors Of Improved Outcome Following Reoperation For Intractable Childhood Epilepsy/C. Nguyen, S. Perry, M. Duchowny, T. Resnick, P. Jayakar
- 2.091** Treatment Of Epileptogenic Activity On EEG Prevents Epilepsy And Psychomotor Delay In Children With Tuberos Sclerosis/S. Jozwiak, K. Kotulska, D. Domanska-Pakiela, D. Chmielewski, D. Dunin-Wasowicz, J. Borkowska, D. Kuczynski, B. Lojszczyk, M. Respondek-Liberska, J. Dangel
- 2.092** Is Venous Angioma An Epileptogenic Lesion In Children?/ S. Nam, K. Park
- 2.093** SCN1A Mutations And SUDEP In Families/D. Sirsi, S. Arnold
- 2.094** Parental Report Of Behavioral And Cognitive Diagnoses In Childhood-Onset Epilepsy: A Case – Sibling-Controlled Analysis/E. Benn, D. Hesdorffer, F. Dimario, S. Levy, F. Testa, A. Berg
- 2.095** How Common Is Ictal Hypoxemia And Bradycardia In Children With Partial Complex And Generalized Convulsive Seizures?/B. Moseley, K. Nickels, J. Britton, E. Wirrell
- 2.096** Hippocampal Volume Is Reduced In Children With Other Forms Of Convulsive Status Epilepticus Compared To Children With Prolonged Febrile Seizures/M. Yoong, M. Martinos, C. Clark, R. Chin, R. Scott
- 2.097** Vitamin D Status In Children With Intractable Epilepsy Treated With The Classic Or Medium-Chain Triglyceride (MCT) Ketogenic Diet/ Y. Mei Liu, M. Zak, V. Chan, E. Donner
- 2.098** Insulin-Like Growth Factor-1 Is Associated With Cognitive Outcome In Infantile Spasms/R. Riikonen, U. Turpeinen, J. Jääskeläinen
- 2.099** Neurodevelopmental And Epilepsy Outcomes In A North American Cohort Of Infantile Spasms Patients/ A. Partikian, W. Mitchell
- 2.100** Perceived Stigma In Children With New-Onset Epilepsy And Its Impact On Health-Related Quality Of Life/J. Koumoutsos, E. Painter, T. Glauser, A. Modi
- 2.101** Electrode Safety In Pediatric Prolonged EEG Recordings/R. Jarrar, M. McKay, C. Luketich, K. Williams, J. Buchhalter
- 2.102** Neuroimaging Practice And Yield In A Population-Based Cohort Of Children With Newly Diagnosed Epilepsy Under The Age Of Two Years/C. Eltze, W. Chong, T. Cox, A. Whitney, R. Scott, J. Cross
- 2.103** Changing Prevalence Of Psychiatric Symptoms In Children And Youth With Epilepsy. A Population Based Study – The Akershus Health Profile Study/K. Alfstad, J. Clench-Aas, B. van Roy, L. Gjerstad, M. Lossius
- 2.104** Neurodevelopmental Impact Of Early Seizure Onset In Executive Function Of Children And Adolescents With Temporal Lobe Epilepsy/P. Rzezak, D. Fuentes, S. Thome-Souza, T. Pradines, K. Valente
- 2.105** Atypical Language Organization Is Common In Prenatal And Early-Acquired Temporal Lobe Lesions/ B. Korman, G. Rey, P. Jayakar, T. Resnick, M. Duchowny
- 2.106** Childhood-Onset Idiopathic Generalized Epilepsy, Not Otherwise Specified (IGE NOS) Is Medically Benign But Socially Depressing: A Population-Based Cohort With >20-Year Follow Up/C. Camfield, P. Camfield
- 2.107** Surgical Treatment Of Epileptic Spasms/H. Hwang, K. Lee, J. Seo, D. Rose, K. Holland-Bouley, F. Mangano
- 2.108** Vitamin D Insufficiency: Prevalence And Risk Factors Among Children With Epilepsy/R. Shellhaas, A. Barks, S. Joshi
- 2.109** Early Onset Childhood Absence Epilepsy: Is It A Different Entity?/ P. Farooque, J. Goraya, I. Valencia, K. Carvalho, H. Hardison, A. Legido, D. Khurana
- 2.110** Metabolic Testing In Children With Epilepsy And Developmental Delay/G. Jeong, S. Kim, J. Lee, Y. Hwang
- 2.111** Is Jeavons Syndrome (Eyelid Myoclonia With Absences) Generalized Or Localization-Related Epilepsy?/C. Go, S. Viravan, A. Ochi, O. Snead III, H. Otsubo
- 2.112** Validation Of The Pediatric Epilepsy Self-Management Questionnaire: Assessing Disease Management In Children With Epilepsy/ A. Modi, S. Monahan, D. Daniels, T. Glauser
- 2.113** Analysis Of Cytokine Levels In The Febrile Seizure Patients/J. Choi, J. Chae, K. Kim, Y. Hwang
- 2.114** Seizure Exacerbation After Initiation Of Levetiracetam In Children/ D. Marafie, R. Das, A. Datta, J. Lipton, K. Maski, M. Takeoka
- 2.115** Functional Magnetic Resonance Imaging Group Decision-Making Based On Brain Asymmetry/M. Guillen, M. Adjouadi, B. Bernal, X. You, A. Barreto, N. Rishe, P. Jayakar, W. Gaillard
- 2.116** Utility Of Ictal PET/CT In The Management Of Non-Convulsive Focal Status Epilepticus/M. Blackman, I. Mohamed, S. Kozlik, C. Molnar, S. Wiebe
- 2.117** Integrating Nonlinear Decision Functions With Principal Component Analysis In fMRI Language Activation Patterns Classification/M. Adjouadi, X. You, M. Guillen, M. Ayala, M. Cabrerizo, P. Jayakar, A. Barreto, N. Rishe, J. Sullivan, D. Dlugos, M. Berl, J. Vanmeter, D. Morris, E. Donner, B. Bjornson, M. Smith, B. Bernal, W. Gaillard
- 2.118** Health-Related Quality Of Life In Children With New Onset Epilepsy: A Longitudinal Assessment Of The First 2 Years Post-Diagnosis/K. Speechley, C. Camfield, S. Levin, M. Smith, S. Wiebe, G. Zou
- 2.119** Incidence And Outcome Of Seizures In Long-Term Survivors Of Pediatric Brain Tumors/N. Ullrich, S. Pomeroy, T. Luddenkemper
- 2.120** Peri-ictal Depression In Children With Temporal Lobe Epilepsy/A. Pereira, F. Lee, T. Pradines, S. Thome-Souza, K. Valente
- 2.121** Effects Of Hemispherectomy On Quality Of Life–Preliminary Study/ D. Muthugovindan, J. Hartman, A. Hartman, E. Kossoff, P. Pyzik, C. Smith, E. Vining
- 2.122** Treatment Of Landau-Kleffner Syndrome With Pulse Dose Prednisone: Behavioral And Language Outcomes/ A. Hempel, F. Ritter, M. Frost
- 2.123** Cardiovascular Autonomic Changes In Partial Seizures In Children/M. Goyal
- 2.124** Timing Of Seizure Onset From Diverse Brain Locations In Respect To The Sleep-Wake Cycle/J. Kaleyias, T. Luddenkemper, R. Das, A. Alexopoulos, S. Kothare
- 2.125** A Generator Mechanism Of Epileptic Spasms And Generalized Spikes In A Patient With A Focal Cortical Lesion: An EEG-fMRI Study/ M. Inouchi, T. Kato, M. Shibata, R. Matsumoto, N. Sawamoto, T. Hanakawa, T. Mima, S. Urayama, K. Anami, R. Takahashi, A. Ikeda, H. Fukuyama
- 2.126** Negative Motor Area Seizures And Medical Treatment/K. Sugai, E. Nakagawa, H. Komaki, M. Sasaki
- 2.127** Predictors And Comparison Of Antiepileptic Drug Related Psychiatric Side Effects In Children With Epilepsy/ E. Segal, H. Arif, L. Hirsch
- 2.128** Mesial Temporal Sclerosis In Children/B. Gemici, A. Datta, A. Poduri, M. Takeoka
- 2.129** Sleep Disturbances In Pediatric Migraine And Epilepsy/N. Ashok, G. Sun, A. Venkatasubramanian
- 2.130** Infantile Spasms: Etiology And Predictors Of Outcome/D. Jacobsen, J. Conry

Cormorbidity (Somatic And Psychiatric)

- 2.131** Perceived Epilepsy Stigma And Quality Of Life In Epilepsy/N. Prus, L. Nakhutina, A. Grant
- 2.132** Bone Turnover Markers And Serum Homocysteine In Young Adult Women On Antiepileptic Drug Monotherapy/C. Shore, M. Peacock, A. Friedman, D. Sabau, J. Wu, J. Buelow
- 2.133** Code Blue: Seizures/M. Hoerth, J. Larson, M. Anderson, J. Draskowski, K. Noe, J. Sirven
- 2.134** Epilepsy And Psychiatric Disorders: Evidence For A Bidirectional Relationship/D. Hesdorffer, L. Ishihara-Paul, L. Mynepal, D. Webb, J. Weil, W. Hauser
- 2.135** A Randomised Controlled Trial Of CBT And Standard Medical Care In Patients With Dissociative (Non-Epileptic) Seizures/L. Goldstein, T. Chalder, C. Chigwedere, J. Moriarty, B. Toone, J. Mellers
- 2.136** Treatment Outcome Of Depressive Symptoms In Patients With Epilepsy/M. Ito, M. Okazaki, N. Adachi, M. Kato, T. Onuma
- 2.137** Video-EEG Can Prevent Unnecessary Vagus Nerve Stimulator Implantation In Patients With Psychogenic Nonepileptic Spells (PNES)/A. Arain, Y. Song, N. Azar, N. Bangalore-Vittal
- 2.138** Psychiatric And Cognitive Profiles Of Patients With Epilepsy And Psychogenic Nonepileptic Seizures/V. Turner, A. Piazzini, V. Barbieri, V. Chiesa, A. Vignoli, E. Gardella, G. Tisi, S. Scarone, R. Canger, M. Canevini, O. Gambini
- 2.139** Frequency Of Anxiety And Depression In Epilepsy Monitoring Unit/K. Siddiqui, S. Wahaas, S. Sinha
- 2.140** Refractory Epilepsy Is Highly Associated To Severe Dento-Alveolar And Maxillofacial Injuries/A. Costa, C. Yasuda, M. Franca, M. Morita, F. Cendes
- 2.141** Increased Risk Of SUDEP Among Epileptic Patients Receiving Placebo In Randomised Controlled Trials/P. Ryvlin, S. Rheims
- 2.142** There Is An Epilepsy Belt Corresponding To The Stroke Belt/R. Faught, J. Richman, Y. Kim, P. Kratt, R. Martin, K. Clements, R. Foushee, M. Pisu
- 2.143** Quality Of Life, Depression, Anxiety And Multidimensional Perceived Social Support In Patients Of A Developing Country With Epilepsy/A. Akcali, A. Altindag, S. Gobel, N. Cansel
- 2.144** Use Of Sleep Medications Prior To Presentation To Sleep Clinic In Patients With Epilepsy And Insomnia: A Retrospective Study/M. Khaund, A. Rodriguez
- 2.145** Health Status Burden In Individuals With Self-Reported Epilepsy From The National Survey Of Epilepsy, Comorbidities And Health Outcomes/J. Cramer, R. Ottman, R. Lipton, A. Ettinger, M. Yang, M. Reed, G. Wan
- 2.146** Quality Of Life Of Caregivers With Respect To Their Relation To Patients With Epilepsy/A. Verma, M. Kawai, L. Rogers, M. Dulay
- 2.147** Chronic Depression In Patients With Mesial Temporal Lobe Epilepsy (MTLE) Is Associated With More Widespread Gray Matter Atrophy. A Voxel Based Morphometry (VBM) Study/P. Salgado, C. Yasuda, F. Pereira, F. Cendes
- 2.148** Psychiatric Outcome Of Epilepsy Surgery: The Role Of Somatoform Disorders/A. Velez, K. McCoy, C. Szabo
- 2.149** Prevalence Of Co-Morbid Epilepsy In Patients With Primary Psychiatric Disorders: Data From The Atlantic Behavioral Health Program, A Community-Based Facility/J. Politsky, L. Rizutto, F. Tahil, S. Brophy
- 2.150** Neurotrophic Factors In Temporal Lobe Epilepsy Patients With And Without Psychiatric Comorbidities/L. Kandratavicius, J. Hallak, R. Scanduzzi, J. Assirati, Jr., C. Carlotti, Jr., J. Leite
- 2.151** Depression In Epilepsy Patients Using The NDDI-E/D. Ficker, J. Szaflarski, M. Privitera, J. Cavitt, S. Malik, M. Turner
- 2.152** Screening For Suicidality Risk In Patients With Epilepsy Made Ridiculously Easy/A. Kanner, E. Sanchez, H. Kanner
- 2.153** Psychogenic Or Epileptic? Pay Attention To Review-Of-Symptoms D. Gulati, V. Rajasekaran, M. Koubeissi, R. Taye, T. Syed
- 2.154** Prevalence Of Obesity In Patients With Epilepsy/J. Janousek, A. Barber, P. Klein
- 2.155** Repeated Restraint Stress Accelerates Electrical Amygdala Kindling In Rats/N. Jones, H. Lee, G. Kumar, M. Morris, S. Rees, T. O'Brien, M. Salzberg
- 2.156** Epigenetic Regulation Of The NR2B Gene In Hippocampus Following Kainate-Induced Status Epilepticus/R. Parrish, F. Lubin
- 2.157** Effect Of Temporal Lobe Epilepsy On Auditory Frequency And Amplitude Discrimination/V. Arnedo, K. Donnelly, N. Prus, R. Mahmoud, K. Lee, A. Grant
- 2.158** Objective, Subjective, And Affective Predictors Of Patient Health Satisfaction Following Anterior Temporal Lobectomy For Medically Refractory Epilepsy/D. Koby, M. Trenerry, T. Ferman, G. Cascino, E. So
- 2.159** Perceived Emotional Distress As A Predictor Of Lifetime Seizure Load In Adults With Intractable Temporal Lobe Epilepsy/K. Donnelly, B. Schefft, S. Howe, J. Szaflarski
- 2.160** How Well Do We Communicate The Diagnosis Of Psychogenic Nonepileptic Spells?/F. Chaudhry, S. Gill, N. Bangalore-Vittal, P. Singh, Y. Song, N. Azar, A. Arain
- 2.161** Amygdala Volumes In Childhood Absence Epilepsy/A. Schreiberman Cohen, M. Daley, P. Siddarth, I. Loesch, J. Levitt, S. Gurbani, R. Caplan
- 2.162** Depressive Symptoms In Adolescents With Epilepsy Attending The Epilepsy Clinic Of The University Pediatric Hospital In Puerto Rico/M. Salcedo, M. Rios
- 2.163** Long-Term Alterations In Social Behavior And The Motor Pathway Following Early-Life Seizures/J. Lugo, A. Brewster, A. Anderson
- 2.164** Examination Of A Cognitive-Behavioral Intervention "Coping With Epilepsy" (COPE): A Program For Youth And Families/J. Wagner, G. Smith, P. Ferguson, S. Risko
- 2.165** Depression And Anxiety In Parents Of Children With Epilepsy/S. Sinha, S. Samman, N. Elbakry, S. Wahaas, M. Marwa, K. Siddiqui, A. Mahmoud
- 2.166** Suicidality And Brain Volumes In Pediatric Epilepsy/R. Caplan, P. Siddarth, J. Levitt, S. Gurbani
- 2.167** Parent And Self-Reported Prevalence Of Anxiety And Depression In Cognitively Normal Children With Established Epilepsy/M. Aboian, S. Davis, K. Nickels, B. Casella, T. Brown, E. Wirrell
- 2.168** Externalizing Behaviors In Cognitively Normal Children With Established Epilepsy By Parental Report/S. Davis, M. Aboian, K. Nickels, B. Casella, T. Brown, E. Wirrell
- 2.169** Psychiatric Comorbidities In Children And Adolescents Undergoing Epilepsy Surgery/T. Falcone, P. Klaas, P. Kotagal
- 2.170** Comorbidities In Children With Benign Focal Epilepsy Of Childhood/S. Indulkar, N. Le, R. Sarkis, R. Burgess, T. Loddenkemper
- 2.171** Surgical Resection Of Hypothalamic Hamartomas For Severe Behavioral Symptoms/E. Hastriter, J. Kerrigan, H. ReKate, Y. Ng
- 2.172** Elevated ADHD Rates In Mothers Of Children With Comorbid ADHD And Epilepsy/J. Gonzalez-Heydrich, L. Luna, S. Rao, J. McClendon, P. Rotella, D. Waber, K. Boyer, J. Whitney, S. Faraone, D. Guild, H. Hamoda, J. Biederman
- 2.173** Demyelinating Lesions Involving The Subthalamic Nucleus May Be An Important Factor In The Development Of Epilepsy In Multiple Sclerosis Patients: An Evoked Potential Study/E. Papathanasiou, M. Pantzaris, P. Myrianthopoulou, E. Kkolou, S. Papacostas
- 2.174** Responsiveness In Epilepsy Scale (RES): A New Tool For Measuring Impaired Consciousness During Seizures/L. Yang, P. Kurashvili, A. Sreenivasan, P. Manza, J. Anaya, H. Hamid, K. Detyniecki, M. Naidu, C. Ransom, M. Desalvo, J. Giacino, H. Blumenfeld
- 2.175** Comorbidity Of Migraine Without Aura And Unprovoked Seizure In The General Population/R. Gill, R. Lipton, R. Ottman

2.176 Psychiatric Outcomes After Epilepsy Surgery: A Systematic Review/S. Macrodimitris, E. Sherman, J. Tellez-Zenteno, S. Wiebe, A. Metcalf, L. Hernandez-Ronquillo, N. Jetté

Antiepileptic Drugs

2.177 Pregabalin: Preliminary Experience In Intractable Childhood Epilepsy/M. Jan, S. Zuberi, B. Alsaihati
2.178 Valproate-Resistant Seizures In A Child With Angelman Syndrome Successfully Treated With Levetiracetam Monotherapy: A Case Report And Review Of The Literature/ M. Cleanthous, P. Nicolaidis, S. Hadjiloizou
2.179 Cognitive Functions At 6 Years Of Age After Fetal Exposure To Antiepileptic Drugs Used In Mothers With Juvenile Myoclonic Epilepsy/N. Jovic
2.180 Dose Effects On Verbal And Nonverbal Cognitive Functions At Age 3 In Children Exposed In Utero To Antiepileptic Drug/K. Meador, M. Cohen, N. Browning, G. Baker, J. Clayton-Smith, P. Pennell, L. Kalayjian, J. Liporace, M. Privitera, A. Kanner, D. Combs-Cantrell, D. Loring
2.181 How Do Parents Measure Efficacy And Tolerability Of Antiepileptic Drugs For The Treatment Of Childhood Epilepsy? Results Of A Preference Survey/C. Swint, S. Blake, S. Kohler, J. Hawley, K. Rask, M. Perry
2.182 Absolute Body Fat Content With Valproate, Carbamazepine And Lamotrigine Monotherapy/R. Sheth
2.183 Long-Term Effectiveness And Tolerability Of The Orphan Drug Rufinamide In Childhood-Onset Refractory Epilepsy: First European Experience/G. Kluger, A. Mueller, G. Kurlemann, E. Haberlandt, J. Ernst, U. Runge, F. Schneider, C. Makowski, R. Boor, T. Bast
2.184 Conversion To Levetiracetam Monotherapy In Children With Symptomatic And Cryptogenic Focal Epilepsy – First Results/E. Korn-Merker, A. Hofmann-Peters, R. Boor, G. Kurlemann, T. May
2.185 Does Valproic Acid Have A Specific Benefit In The Treatment Of Infantile Spasms In Patients With Down Syndrome?/C. Patterson, T. Resnick, D. Holder, I. Vaisleib
2.186 Effects Of Levetiracetam And Valproic Acid Monotherapy On Sex-Steroid Hormones In Prepubertal Children/G. Luef, M. Rauchenzauner, G. Bitsche, E. Haberlandt, S. Svalheim, E. Tauboll, L. Wildt, K. Rostasy
2.187 Management Of Pediatric Epilepsy Following Treatment Of Acute Lymphocytic Leukemia/S. O'Connor, M. Chico, K. Eggner, M. Zupanc
2.188 Behavioral And Mood Side Effects Improve In Pediatric Epilepsy Patients When Switched From Immediate-Release To Extended-Release Levetiracetam/ K. Rathke
2.189 Treatment Of Complex Partial Epilepsy With Pregabalin: Cognitive Side Effects?/J. Titus, L. Thio

2.190 A Multi-Center Comparative Trial Of Low And High Dose Zonisamide In Children With Newly Diagnosed Epilepsy As Monotherapy/S. Eun, H. Kim, I. Lee, H. Chung, B. Eun, J. Lee, J. Kim, H. Kang, E. Suh, D. Kim, S. Eom, H. Moon
2.191 Early-Life Exposure To Antiepileptic Drugs Results In Behavioral And Neuropsychiatric Abnormalities In Adult Rats/P. Forcellini, R. Kozlowski, C. Snyder, K. Gale, A. Kondratyev
2.192 Efficacy And Security Results Of Levetiracetam Treatment In Febrile Seizures/P. Smeyers, F. Mulas
2.193 UCB Antiepileptic Drug Pregnancy Registry/S. Alekar, I. Leppik, G. Montouris, C. Harden
2.194 The Pharmacokinetics Of Commonly Used Antiepileptic Drugs In Immature CD1 Mice/G. Markowitz, S. Kadam, D. Boothe, N. Irving, A. Comi
2.195 Levetiracetam-Induced Optic Neuropathy/P. Maertens, D. Dees
2.196 Vitamin D Status In Pediatric Patients With Epilepsy: Effect Of Antiepileptic Drugs/R. Wehbeh, B. Weinstock-Guttman, B. Teter, A. Weinstock
2.197 Neurodevelopmental Outcome In Children Exposed To Antiepileptic Drugs In Utero/N. Dzhabarova, T. Bindra, M. Andriola, R. Spiegel
2.198 Iron Overload In An Epileptic Child With Hemochromatosis/D. Dees, P. Maertens
2.199 Seizure Exacerbation In Children On Oxcarbazepine/C. Harini, S. Adhami
2.200 Efficacy And Tolerability Of Keppra XR/G. Jones, E. Crisp, B. Kirmani
2.201 Transport Of Antiepileptic Drugs By P-Glycoprotein In Cell Monolayer Models/C. Zhang, L. Baum, Z. Zuo, P. Kwan
2.202 An Open-Label Trial Of Lacosamide As Add-On Therapy For Refractory Partial-Onset Seizures/ T. Mayer, M. Lutz
2.203 Effect Of The New Anticonvulsant Drug Lacosamide On Persistent Na⁺-Current And Firing Behavior Of Hippocampal Pyramidal Cells/ M. Uebachs, T. Opitz, T. Stoehr, I. Niespodziany, C. Wolff, H. Beck
2.204 Clinical Experience With Lacosamide In Difficult To Treat, Drug Resistant Patients/H. Meencke, C. Dehnicke, S. Bartels
2.205 Low-Dose Monotherapy With Lamotrigine Extended-Release For Treatment Of Partial Seizures: Conversion Monotherapy Using Historic Control Data/J. French, N. Temkin, P. Caldwell, A. Hammer, J. Messenheimer
2.206 Pharmacokinetics And Safety Of Intravenous Topiramate In Adult Patients/A. Clark, J. Cloyd, I. Leppik, J. White, R. Brundage, R. Kriel
2.207 [³H]Levetiracetam Binds To AMPA Glutamate Receptors At A Site That Modulates The AMPA Receptor Desensitization/J. Bidlack, I. Rasheed

2.208 The Effect Of Valproate And Levetiracetam On Steroidogenesis In Forskolin-Stimulated H295R Cells/ K. von Krogh, H. Harjen, C. Almås, K. Zimmer, E. Dahl, I. Olsaker, E. Taubøll, E. Ropstad, S. Verhaegen
2.209 Lymphocyte Toxicity Assay For The Laboratory Assessment Of Antiepileptic Drug Hypersensitivity: An Evaluation Of Clinical Experience In An Adverse Drug Reaction Clinic And Laboratory/A. Prasad, A. Elzagallai, N. Shear, G. Koren, M. Rieder
2.210 Association Between HLA-B*1502 Allele And Cutaneous Reactions Induced By Carbamazepine Or Lamotrigine In Han Chinese/W. Liao, Y. Shi, S. Cheng, M. Ng, P. Kwan
2.211 Clinical Experience With Rufinamide In An Academic Medical Center/J. Miller-Horn, R. Spiegel, L. Bello, M. Andriola
2.212 Rapid Anticonvulsant Action Of A Propofol Prodrug Administered By The Intrapulmonary Route In Rats/A. Dhir, D. Zolkowska, B. del Cid, C. Lossin, R. Murphy, M. Rogawski
2.213 The Impact Of The Last Observation Carried Forward On The Indirect Comparisons Of Placebo-Controlled Trials In Drug-Resistant Partial Epilepsy/S. Rheims, M. Cucherat, P. Ryvlin
2.214 Benzodiazepine Efficacy In A Mouse Model Of Absence Epilepsy Based On A Human Mutation In The Gamma2 GABA-A Subunit/C. Reid, N. Taylor, S. Berkovic, S. Petrou
2.215 Phenytoin Preferentially Affects Slow Inactivation In Heterologously Expressed Voltage Gated Sodium Channels (Nav1.2)/C. French
2.216 Comparison Of Lamotrigine Conversion Monotherapy Studies: LAM30055 And 105-30/31/P. Caldwell, A. Hammer, A. Vuong, J. Messenheimer
2.217 Effect Of Blockade Of Endogenous Neuraminidase On Synaptogenesis And Network Excitability In Rat Hippocampus/D. Isaev, I. Lushnikova, E. Isaeva, A. Savrasova, G. Skibo, G. Holmes
2.218 Effect Of Levetiracetam On Hippocampal Protein Expression And Cell Proliferation In Rats/R. Raedt, L. Paulson, K. Vonck, A. Persson, A. Van Dycke, G. Kuhn, P. Boon, E. Ben-Menachem
2.219 Targeting Synaptic Kainate Receptor Function With Novel Marine-Derived Anticonvulsant Compounds/ S. Frausto, M. Gill, M. Ikoma, M. Sasaki, M. Oikawa, R. Sakai, G. Swanson
2.220 Exacerbation Of Seizures After Addition Of Rufinamide/G. Ghacibeh, E. Fertig, R. Kulikova
2.221 P450 Cytochromes Are Functionally Expressed At The Epileptic Human Blood-Brain Barrier/C. Ghosh, J. Martines Gonzales, M. Hossain, V. Fazio, L. Cucullo, D. Janigro, N. Marchi

- 2.222** A Multicenter, Open-Label Trial To Assess The Safety And Tolerability Of A Single Intravenous Loading Dose Of Lacosamide Followed By Oral Maintenance As Adjunctive Therapy In Subjects With Partial-Onset Seizures: An Interim Report/N. Fountain, G. Krauss, J. Isojarvi, D. Dilley, P. Doty
- 2.223** Pharmacokinetic Evaluation Of Intravenous Lacosamide As Short-Term Replacement For Oral Lacosamide In Partial-Onset Seizures/W. Cawello, G. Krauss, M. Brock, A. Eggert
- 2.224** Minimally Important Change In QOLIE-31 Scores: Estimates From Three Placebo-Controlled Lacosamide Trials In Patients With Partial Onset Seizures/C. de La Loge, S. Borghs, K. Mueller, J. Cramer
- 2.225** Safety And Tolerability Of Adjunctive Rufinamide In Treatment Of Epilepsy: 2 Years Of Spontaneous Adverse Event Reporting Data And Analysis/A. Arzimanoglou, T. Glauser, M. Narurkar, A. Mann, A. LoPresti-Solis
- 2.226** Adverse Events Associated With Anticonvulsant Drug Formulation Substitution In Pediatric And Adult Epilepsy Patients/J. Paolini, C. Chu-Shore, C. Macdonald, P. Bruno, R. Thibert, E. Thiele
- 2.227** Long-Term Efficacy Of Lacosamide For Partial-Onset Seizures: An Interim Evaluation Of Completer Cohorts Exposed To Lacosamide For Up To 36 Months/E. Ben-Menachem, J. French, J. Isojarvi, D. Hebert, P. Doty
- 2.228** Preliminary Evaluation Of The Risk Of Cognitive Adverse Events In Lacosamide Clinical Trials For Adjunctive Treatment Of Partial Onset Seizures/ D. Hebert, C. Helmstaedter, A. Kanner, J. Isojarvi, A. Eggert, P. Doty
- 2.229** Early And Sustained Response To Rufinamide As Adjunctive Therapy For Seizures Associated With Lennox-Gastaut Syndrome/T. Glauser, B. Santana, W. Wang, M. Narurkar
- 2.230** Bioavailability Of Clobazam When Administered With Aplesauce/ D. Tolbert, S. Reid, M. Walzer, A. Johnson, M. Beconi, I. Bekersky, S. Harris, M. Weinberg
- 2.231** Long-Term Safety And Tolerability Of Lacosamide For Partial-Onset Seizures: An Interim Evaluation Of Patients Exposed To Lacosamide In Double-Blind And Open-Label Trials/ W. Rosenfeld, F. Rosenow, J. Isojarvi, D. Hebert, P. Doty
- 2.232** The Transient Effect Of Antiepileptic Drugs On Seizure Control – “Honeymoon Phenomenon”/B. Shneker, J. Elliott, J. McAuley
- 2.233** Efficacy Of Adjunctive Lacosamide In Patients With Partial-Onset Seizures And Prior Surgical Interventions For Epilepsy/S. Benbadis, C. Elger, D. Hebert, J. Isojarvi
- 2.234** The Influence Of Insurance On Antiepileptic Drug Selection/E. Fertig, G. Ghacibeh, K. Perrine
- 2.235** Outcome Of Infants With Prenatal Exposure To Lacosamide During The Clinical Development Program/ J. Isojarvi, C. Williams, P. Doty
- 2.236** Systemically Active Neuropeptide-Y And Neurotensin Analogs For The Treatment Of Refractory Epilepsy/B. Klein, E. Adkins-Scholl, T. Pruess, B. Green, G. Bulaj, H. White
- 2.237** Generic Switchback Rate Of Antiepileptic Medications In Persons With Epilepsy/L. Malsin, E. Sandok, A. Stojic
- 2.238** Clinical Features And Treatment Of In-Hospital Seizures At An Academic Medical Center/M. Fields, J. French, D. Labovitz, R. Radwani, A. Joshi
- 2.239** Levetiracetam And Leupeptin Prevent Post-Traumatic Epileptogenesis In An *In Vitro* Model Of Neocortical Injury/D. Ling, L. Yang, S. Afroz, H. Michelson, J. Goodman, H. Valsamis, L. Kesner, A. Stracher
- 2.240** Relative Bioavailability And Tolerability Of Intranasal Diazepam Compared To Rectal Diazepam In Healthy Adult Volunteers/V. Ivaturi, R. Kriel, H. Mansbach, J. Cloyd
- Neuropsychology/Language/Behavior**
- 2.241** Transient News Events Test: Feasibility In Assessment Of Post-Temporal Lobectomy Remote Memory Deficits/B. Leeman, E. Macklin, D. Schomer, M. O'Connor
- 2.242** Measuring Perceived Stigma In Adults With Epilepsy: Where Does Resilience Fit?/J. McGlone, J. Gillespie, K. Lee, B. Pohlmann-Eden, R. Sadler
- 2.243** Visual Naming Performance After ATL Resection: Impact Of Atypical Language Dominance/S. Kovac, G. Moeddel, J. Reinholz, A. Alexopoulos, T. Syed, S. Schuele, T. Lineweaver, R. Busch, T. Loddenkemper
- 2.244** The Role Of Dichotic Listening And Functional MRI In The Assessment Of Language Lateralisation In Adults With Epilepsy/F. Oltmanns, H. Meencke, H. Haettig
- 2.245** The Localizing Value Of Right Side Recall Of The Rey Complex Figure In Left Temporal Lobe Epilepsy Patients/ R. Gillen, A. Ritaccio, T. Lynch
- 2.246** Pseudoseizure Characteristics Among Veterans With Post-traumatic Stress Disorder (PTSD)/S. Izadyar, D. Chen
- 2.247** Differential Effects Of Standard Anteromedial Temporal Lobe Resection On Visual And Auditory Naming/ M. Hamberger, W. Seidel, G. McKhann, R. Goodman
- 2.248** Comparison Of The PAI And MMPI-2 For Identifying PNES In An EMU Population/K. Kirlin, D. Locke, D. Osborne, D. Hurst, K. Noe, J. Drazkowski, J. Sirven
- 2.249** The Effects Of Art Intervention In Depression And Anxiety In Patients Undergoing Long-Term Video-EEG Monitoring/A. Tanner, C. Walters, C. Roets, C. Kryger
- 2.250** Increased Paranoia Following Standard Temporal Lobectomy Vs. Selective Amygdalohippocampectomy For Refractory Epilepsy/K. Bujarski, L. Flashman, B. McDonald, B. Jobst, V. Thadani
- 2.251** Comparison Of The MMPI-2 And The MMPI-2-RF In An EMU Population/ D. Locke, K. Kirlin, D. Hurst, D. Osborne, J. Drazkowski, J. Sirven, K. Noe
- 2.252** The Effects Of Stress On Memory Functioning In Patients With Temporal Lobe Epilepsy/C. Baker, B. Schefft, J. Szafarski, S. Howe, M. Privitera
- 2.253** Cross-Modal Registration Enabling Language Mapping With fMRI, Electrocortical Stimulation, And Intracranial ECoG In Individual Patients/G. Klein, A. Ettinger, K. Perrine, S. Hwang, S. Schaffer, S. Jain, M. Ackerman, A. Mehta
- 2.254** Hippocampal Volume And Performance On Matched Tests Of Verbal And Nonverbal Memory/ N. Sanford, J. Djordjevic, M. Jonesgotman, N. Bernasconi, V. Sziklas
- 2.255** Auditory Naming Performance Is Related To Degree Of Left Temporal Lobe Abnormality In Epilepsy Patients/ R. Doss, G. Risse
- 2.256** Survey Of Internet And Computer Use In Veterans With Epilepsy/ A. Van Cott, M. Pramuka
- 2.257** Concerns Of Living In Korean Epilepsy Patients/E. Choi, J. Kang, K. Jo, S. Yim, Y. No, J. Kwon, D. Shin, S. Lee
- 2.258** The Role Of The Hippocampus In Accelerated Forgetting Of Spatial Tasks In Humans With Hippocampal Resections And Animals With Kainate-Induced Temporal Lobe Epilepsy/ L. Barkas, D. Hamilton, E. Redhead, W. Gray
- 2.259** Activation Of The Mesial Temporal Lobe Using Magnetic Source Imaging(MSI): Possible Relationship To Mesial Temporal Sclerosis And WADA Memory Performance/G. Risse, R. Doss, D. Dickens, W. Zhang
- 2.260** Organization Of Language-Specific Cortex Distribution In Drug Resistant Temporal Lobe Epilepsy Patients: An EEG Study/E. Patariaia, S. Aull-Watschinger, R. Jung, E. Stögmann, E. Hilger, G. Lindinger
- 2.261** Relationships Between Depression, Epilepsy Self-Efficacy, And Stigma In Hispanics/J. Chong, P. Atkinson, J. Nguyen, E. Ouellette, D. Labiner
- 2.262** The Impact Of Unsatisfactory Seizure Control In Executive And Attentional Processes In Patients With Juvenile Myoclonic Epilepsy/ S. Moschetta, D. Fuentes, C. Mello, L. Fiore, K. Valente
- 2.263** Juvenile Myoclonic Epilepsy: Two Distinct Phenotypes When Considering Clinical And Personality Traits/K. Valente, S. Moschetta, C. Mello, J. Gois, L. Fiore, D. Fuentes

- 2.264** Abnormal Mismatch Negativity For Pure-Tone Sounds In Temporal Lobe Epilepsy/M. Miyajima, A. Matsuda, Y. Emori, H. Iino, K. Hara, K. Ohta, T. Maehara, M. Inaji, M. Matsuura, E. Matsushima
- 2.265** Decision-Making For Epilepsy Surgery In The Urban Underinsured: A Patient's Perspective/L. Kalayjian, P. Shilian, A. Lizama, V. Hawkins, D. Ko, D. Millett, C. Liu, C. Heck
- 2.266** Patients' Response On Viewing Their Own Seizures After Long-Term Video-EEG Monitoring and Its Impact On Neuropsychological Outcome/A. Bansal, N. Baheti, A. Radhakrishnan, A. Alexander, K. Radhakrishnan
- 2.267** Best Predictors Of Pre-Operative Side Of Epilepsy Surgery And Predicting Post-Surgical Memory Outcome Following Temporal Lobe Epilepsy/M. Schoenberg, M. Werz, R. Maciunas
- 2.268** Impact Of Neuropsychological Functions And Clinical Variables In The Social Adjustment In Patients With Temporal Lobe Epilepsy With Hippocampal Atrophy/J. Gois, K. Valente, S. Vicentiis, L. Fiori, S. Moschetta, D. Fuentes
- 2.269** Depression As Measured By The GDS-5 In Elderly Nursing Home Residents Taking Antiepileptic Medications/A. Birnbaum, L. Eberly, J. Rarick, M. Gramling-Aden, T. Pettus, T. McCarthy, T. Lackner, I. Leppik
- 2.270** Social Adjustment in Epilepsy: The Relationship With Perceived Stigma And Illness Severity/P. Crawford, N. Webster, F. Thomas
- 2.271** Verbal And Figural Fluency In Anglophones And Francophones/M. Jones-Gotman, V. Sziklas, J. Djordjevic, E. Sheppard
- 2.272** Category-Related Naming And Recognition Deficits In Epilepsy Surgery Patients Reflect Disconnection Syndromes/D. Drane, J. Ojemann, E. Aylward, V. Phatak, A. Hebb, D. Tranel, J. Miller, G. Ojemann
- 2.273** Social Cognitive Dysfunction Revealed By Iowa Gambling Test In Patients With Mesial Temporal Lobe Epilepsy/N. Akamatsu, M. Yamano, S. Tsuji, S. Kobayakawa, M. Kawamura
- 2.274** Post-Operative Verbal Memory Change At 4 Months Predicts Seizure Control Years After Left Temporal Lobectomy/M. Trenerry, T. Ferman, E. So, G. Cascino
- 2.275** Assessment Of Material-Specific Memory Function In The Medial Temporal Lobes/S. Banks, V. Sziklas, L. Rudy, M. Jones-Gotman
- 2.276** Connectivity Of Wernicke's Area/C. Conner, M. DiSano, S. Dreyer, T. Ellmore, N. Tandon
- 2.277** Spatial Probability Map Of Essential Language Sites: Cortical Stimulation Current Density Maps Of A Population/S. Dreyer, M. DiSano, T. Ellmore, J. Breier, G. Kalamangalam, J. Slater, N. Tandon
- 2.278** Attention And Material-Specific Memory In Children With Lateralized Epilepsy/M. Smith, J. Engle
- 2.279** Characterization Of Memory Impairment In Pediatric Localization Related Epilepsy/K. Blackstone, J. Mayo, E. Moore, C. Vaidya, W. Gaillard, M. Berl
- 2.280** Child And Adolescent Perceptions Of Social Function Two Years After Epilepsy Surgery/K. Hum, I. Elliott, M. Smith
- 2.281** Developmental Outcome In Children After Epilepsy Surgery/A. Datta, K. Boyer, M. Vendrame, A. Poduri, T. Loddenkemper
- 2.282** A Comprehensive Assessment Of Children With Epilepsy And Suicidality/J. Jones, P. Siddarth, S. Gurbani, R. Caplan
- 2.283** Academic Problems In Children With Seizures: Relationships Over Time With Neuropsychological Functioning And Family Variables/D. Dunn, C. Johnson, A. Byars, T. deGrauw, P. Fastenau, S. Perkins, J. Austin
- 2.284** Language And Brain Volumes In Children With Epilepsy/P. Siddarth, J. Levitt, S. Gurbani, R. Caplan
- 2.285** ADHD Symptoms In Childhood Absence Epilepsy/L. Vega, P. Commissariat, M. Chung, M. Vestal, M. DeSalvo, H. Blumenfeld, M. Spann
- 2.286** Everyday Verbal Memory And Pediatric Epilepsy/L. Chapieski, K. Evankovich, M. Hiscock, R. Collins
- 2.287** The Consequences Of Childhood Epilepsy In ADHD, Cognitive And Academic Performance: A Different Transcultural View: The Latin American Experience/E. Barragán, M. Hernandez, R. Duron, M. Guerreiro, E. Espinosa
- 2.288** Developmental Abilities Of Children Exposed To Levetiracetam In Utero: Preliminary Findings/R. Shallcross, R. Bromley, B. Irwin, J. Morrow, G. Baker
- 2.289** The Developmental Profiles Of Children Following CSE/M. Martinos, M. Yoong, R. Scott, M. de Haan
- 2.290** The Role Of Perception On Nonverbal Executive Functions In Childhood Epilepsies/M. Spann, M. Roth, P. Commissariat, S. Strube, C. Vega
- 2.291** Do Neuropsychological Measures Lateralize In Pediatric Temporal Lobe Epilepsy?/K. Evankovich, R. Schultz, A. Wilfong, A. Malphrus, C. Akman, M. Chapieski
- 2.292** Reliable Language Lateralization By Functional Transcranial Doppler Sonography In Children With Atypical Language Representation/T. Polster, H. Lohmann, J. Aengenendt, S. Knecht, F. Woermann
- 2.293** Pattern Of Attention Difficulties In Children With Localization-Related Epilepsy/J. Walkowiak, K. Blackstone, E. Duke, J. Salpekar, W. Gaillard, M. Berl
- 2.294** Benign Focal Epilepsy Of Adolescence: Mild Neuropsychological Dysfunction In Patients From Community/L. Guilhoto, R. Fernandes, S. Pacheco, D. Ballester, A. Gilio
- 2.295** Cognitive Deficits In Children With Benign Rolandic Epilepsy/R. Trobliger, M. Fiorito-Grafman, K. Perrine, M. Lancman
- 2.296** Self-Efficacy And Depression Assessment/G. Smith, P. Ferguson, J. Wagner, B. Wannamaker
- 2.297** Emotional And Behavioral Problems In Children With Drug Resistant Focal Epilepsy/C. Akman, W. Angus, V. Micic, A. Mapherus, K. Evancovich, R. Schultz, J. Riviello, M. Chiapeski
- 2.298** Memory Impairment Is Selectively Associated With ¹⁸F-FDG-PET Hypometabolism Of The Temporal Lobe In Occipital Lobe Epilepsy/A. Knopman, C. Wong, A. Bleasel, R. Stevenson, J. Homewood, A. Mohamed, E. Somerville, S. Eberl, L. Wen, M. Fulham
- 2.299** Language Mapping In Bilingual Patients With Electrocortical Stimulation And ECoG Spectral Mapping/M. Cervenka, P. Franaszczuk, N. Crone
- 2.300** ECoG Recordings During Word Repetition And Verbal Memory Tasks: Gamma Activation In Frontal Executive Language Areas/V. Towle, J. McKeen, B. Parris, M. Kohrmann, J. Ebersole, S. Hawes-Ebersole, J. Tao, R. Penn, D. Frim
- 2.301** Patterns Of Non-Left Language Dominance In WADA Testing/K. Perrine, G. Klein, J. Krellman, A. Ettinger, S. Schneider, A. Mehta, C. Harden, D. Labar, T. Schwartz, A. Fried, M. Lancman
- 2.302** A First Epidemiological Study Of Psychogenic Nonepileptic Seizures (PNES) In Cyprus/C. Michaelides, M. Neophytou, M. Karekla, S. Papacostas
- 2.303** The Relationship Of WADA Test And Hippocampal Resection Extent To Postoperative Outcomes Of Cognition And Memory In Mesial Temporal Lobe Epilepsy/J. Woo Kang, J. Lee, H. Park, M. Lee, E. Joo, D. Seo, S.B. Hong, S.C. Hong
- 2.304** Seizure Disorders May Imply Separable Mechanisms Of Orientation and Conscious Attention/D. Tucker, M. Holmes
- 2.305** Hippocampal Interictal Spikes Transiently Disrupt Specific Memory Processing Operations, And Are Suppressed By Endogenous Theta Rhythm/J. Kleen, G. Holmes, R. Scott, P. Lenck-Santini
- 2.306** Neuropsychological Outcomes After Epilepsy Surgery: A Systematic Review/E. Sherman, T. Fay, J. Tellez-Zenteno, S. Wiebe, N. Jette
- 2.307** Sylvian Fissure (SF) Asymmetry And Magnetic Source Imaging (MSI) Determination Of Language Dominance/E. Adams, W. Zhang, G. Risse, F. Ritter, K. Buhrke
- 2.308** The Impact Of Environmental Enrichment In A Developmental Rat Model Of Cortical Dysplasia/M. Lucas, P. Lenck-Santini, G. Richard, Q. Zhao, R. Scott, J. Kleen, G. Holmes
- 2.309** Impact Of Temporal Lobe Spikes On Hippocampal Replay During An Alternation Task/G. Richard, P. Santini, J. Kleen, G. Holmes

2.310 Neuropsychological Assessment Of Patients With Epilepsy: An International Survey/J. Djordjevic, P. Scheffler, L. Rudy, M. Jones-Gotman
2.311 Functional Mapping Of Language Cortex With Cortico-Cortical Evoked Potentials/S. Shaw, A. Korzeniewska, P. Franaszczuk, N. Crone

Human Genetics

2.312 Val66Met BDNF Gene Polymorphism And Temporal Lobe Epilepsy/J. Bragatti, L. Schenkel, C. Torres, G. Manfro, C. Blaya, A. de Souza, D. de Souza, L. Jardim, S. Segal, M. Bianchin
2.313 New Biomarkers In Diagnosing And Treatment Of Epilepsy: Genotoxicology And The Polymorphisms Of Steroid Production Pathways/S. Miskov, A. Fucic, D. Zeljezic, J. Katic, R. Gjergja, M. Gamulin, V. Demarin
2.314 A Novel Allele In A Familial Case Of Idiopathic Epilepsy In A Small Island State/J. Mifsud, M. Cassar
2.315 Candidate Genes From Genomic Structural Variation In Epilepsy/A. Luat, F. Serajee, A. Huq
2.316 Familial Temporal Lobe Epilepsy: A Benign Epilepsy Syndrome Without Hippocampal Sclerosis, Showing Complex Inheritance/D. Crompton, I. Scheffer, A. McIntosh, M. Cook, I. Taylor, P. McKelvie, D. Vears, K. Lawrence, J. McMahon, B. Grinton, S. Berkovic
2.317 Mitochondrial DNA Deletions In The Epileptic Focus Of Patients With Hippocampal Sclerosis/W. Kunz, G. Zsurka, A. Kudin, C. Elger
2.318 Severe Epilepsy As The Major Symptom Of A New Mutation In The Mitochondrial tRNA-Phe Gene/G. Zsurka, K. Hampel, A. Kudin, R. Sassen, C. Kornblum, W. Kunz
2.319 Recurrent Microdeletions Predispose To The Idiopathic Generalised Epilepsies/I. Helbig, C. de Kovel, H. Trucks, H. Mefford, C. Baker, C. Leu, C. Kluck, H. Muhle, S. von Spiczak, P. Ostertag, T. Obermeier, A. Kleefuss-Lie, K. Hallmann, M. Steffens, V. Gaus, B. Schmitz, K. Klein, H. Hamer, F. Rosenow, E. Brilstra, D. Kasteleijn-No
2.320 SCN1A Mutation Screening In Adult Patients With Lennox-Gastaut Syndrome Features/K. Selmer, C. Lund, K. Brandal, D. Undlien, E. Brodtkorb
2.321 Vaccine Encephalopathies And Dravet Syndrome: Preliminary Data From The VACENC Study/S. von Spiczak, I. Helbig, U. Drechsel-Baeuerle, H. Muhle, A. van Baalen, M. van Kempen, D. Lindhout, I. Scheffer, S. Berkovic, B. Keller-Stanislawski, U. Stephani

2.322 Expression And Immunohistochemical Analysis Of Aquaporin Genes In Mesial Temporal Sclerosis Expression And Immunohistochemical Analysis Of Aquaporin Genes In Mesial Temporal Sclerosis/N. Bebek, O. Ozdemir, M. Sayitoglu, B. Baykal, U. Ozbek, A. Karasu, E. Tüzün, I. Izin, C. Gürses, S. Akat, A. Sencer, N. Cine, M. Imer, G. Pulur, A. Canbolat, A. Gökyigit
2.323 Characterization Of Epilepsy In Prader-Willi Syndrome/K. Maski, M. Vendrame, W. Tan, S. Kothare
2.324 Evidence Of MicroRNA Regulation In Mesial Temporal Sclerosis/D. Dogini, T. Pereira, C. Rocha, C. Yasuda, H. Tedeschi, E. de Oliveira, C. Maurer-Morelli, F. Cendes, I. Lopes-Cendes
2.325 Global Analysis Of Gene Expression In Refractory Epilepsy Associated With Mesial Temporal Sclerosis/L. Castro, P. Ramos, B. Corradini, H. Wen, E. Amaro, Jr., E. Tampelini, A. Vallota Silva, W. Jacob-Filho, L. Barreta, C. Moreira
2.326 Effects Of UPP On PSD95/NR2B Expression In Rats With Pilocarpine-Induced Epilepsy/Y. Chen, J. Zhang, Z. Zhang

Health Services

2.327 Health Resource Utilization In Patients With Active Epilepsy/A. Walker, B. Edelman Lewis, T. Kurth
2.328 Predictors Of Depressive Symptoms In Mothers Of Children With New-Onset Epilepsy: A Longitudinal Examination/M. Ferro, K. Speechley, W. Avison, M. Campbell
2.329 The Experiences Of People With Epilepsy As They Journey Through The Pathways Of Epilepsy Care In Ireland: A Qualitative Phenomenological Study/J. Varley, N. Delanty, C. Normand, M. Fitzsimons
2.330 Epilepsy-Related Deaths In Queensland, A Population-Based Study/D. Clark, K. Riney
2.331 Carer Burden And Its Predictors In Epilepsy, A Study Using BoSS (Burden Of Seizure Scale) – A Novel Epilepsy Specific Carer Burden Questionnaire/S. Yerra, J. Purnama, D. Velakoulis, T. O'Brien
2.332 A Step Toward Routine EEG Recording In The Emergency Department/A. Fenton, S. Baki, M. Bordoley, G. Chari, R. Cracco, D. Dvorak, M. Shah, S. Zehtabchi, A. Omurtag
2.333 A 10-Step-Algorithm For Transitioning Pediatric Epilepsy Patients To An Adult Service/B. Pohlmann-Eden, P. Camfield, C. Camfield, A. Doucette, S. Rahey

2.334 Improving Processes And Refocusing Resources: The Role Of The Epilepsy Electronic Patient Record/P. O'Byrne, N. Delanty, J. Grimson, C. Normand, J. Varley, M. Dunne, B. Dunleavy, M. Fitzsimons
2.335 Disparities Of Epilepsy Care In The Emergency Department/R. Zepeda, K. Gleason, E. Bublick, D. Pallin, B. Dworetzky
2.336 Epilepsy Educational Program For Spanish-Speaking Epilepsy Patients/D. Brace, L. Myers
2.337 Prevalence Of Depression In Epilepsy Based On CES-D And NDDI-E/A. Ettinger, R. Manjunath, M. Good, R. Sheth, P. Buzinec, E. Faught
2.338 Health Outcomes In Patients With Epilepsy And Comorbid Depression/R. Manjunath, M. Good, A. Ettinger, R. Sheth, P. Buzinec, E. Faught

MONDAY December 7, 2009

9:00 a.m. – 11:30 a.m.

Presidential Symposium: It Takes a Village: Solving the Treatment Gap (2.0 CME Credits)

Award Presentations: Research Recognition Awards, Lennox Award, NINDS Update by Story Landis, Ph.D. and ILAE Update by Solomon L. Moshé, M.D.

Hynes – Ballroom, Level 3

Overview

The successful pharmacological, surgical and psychosocial management of patients with epilepsy generally requires sustained access to competent and knowledgeable physicians and, often, allied healthcare providers, as well as suitable therapies that are continually available, affordable and culturally acceptable. Patients who lack access to appropriate care providers or therapies, or both, are affected by the treatment gap, and represent the large majority of patients with epilepsy worldwide, with devastating consequences. This symposium explores the underlying reasons for the treatment gap in developed and developing countries, and explores potential solutions and their relevance to the care of all patients with epilepsy.

Learner Outcomes

- ▶ Define the extent of the treatment gap in developing and developed countries and the consequences for patient care
- ▶ Identify underlying reasons for the treatment gap and describe the Out of the Shadows global campaign
- ▶ State the impact of educational efforts and demonstration projects on the treatment gap and apply that knowledge in meeting treatment gaps in provision of clinical care
- ▶ Compare and contrast models for closing treatment gaps in therapeutic areas other than epilepsy and apply lessons from these models to treatment of patients with epilepsy
- ▶ Categorize the ongoing research and list the unanswered questions that may lead to solutions for the treatment gap
- ▶ Evaluate the potential impact of global efforts to close the treatment gap on the care of all patients with epilepsy.

Target Audience

Neurologists, nurses and midlevel providers, pharmacists, social scientists, and other professionals in epilepsy care

Program

Chair: Steven C. Schachter, M.D.

It Takes a Village: Overview

Jerome Engel, Jr., M.D., Ph.D.

The Epilepsy Treatment Gap: Where and Why

Samuel Wiebe, M.D.

Approaches to Narrowing the Treatment Gap in Epilepsy

Gretchen Birbeck, M.D., M.P.H.

Models for Closing Treatment Gaps Outside of Epilepsy

John Howe, M.D.

Calling All Villagers: Where Do We Go From Here?

Steven C. Schachter, M.D.

Credit Designation

The American Epilepsy Society designates this educational activity for a maximum of 2.0 *AMA PRA Category 1 Credits*™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Pharmacy Credit

ACPE #073-999-09-124-L01-P; 0.2 CEUs

Acknowledgment

This program is supported by educational grants from UCB, Inc. and Pfizer Inc.

2:15 p.m. – 3:00 p.m.

Lennox Lecture

Hynes – Ballroom, Level 3

The Future of Epilepsy Therapy

Lecturer: Michael A. Rogawski, M.D., Ph.D.

3:15 p.m. – 4:45 p.m.

Investigators' Workshop

Sheraton – Constitution Ballroom, 2nd Floor

Rodent Models of Febrile Seizures

Moderator: Steven Petrou, Ph.D.

Speakers: Sebastian Schuchman, M.D., John C. Oakley, M.D., Tallie Z. Baram, M.D., Ph.D.

4:00 p.m. – 6:00 p.m.

Platform Sessions: 3 Concurrent

Hynes – See page 49

There will be three concurrent sessions consisting of selected key scientific abstracts submitted to the Annual Meeting.

4:30 p.m. – 6:00 p.m.

Pediatric Epilepsy Highlights Session

Sheraton – Grand Ballroom, 2nd Floor

This session will provide a concise and focused overview of this year's key scientific abstracts in diverse areas of pediatric epilepsy.

1.187 Resting Functional Connectivity In Patients With Typical Childhood Absence Seizures, *X. Bai, M. Vestal, J. Guo, R. Berman, M. Negishi, E. Novotny, T. Constable, H. Blumenfeld*

1.258 Long-Term Health And Seizure Outcomes Of Children Treated With The Ketogenic Diet, *E. H. Kossoff, A. Patel, P. L. Pyzik, J. E. Rubenstein, Z. Turner*

1.323 Familial Glut1 Deficiency Syndrome Causes A Range Of Idiopathic Generalized Epilepsies, *S. Mullen, A. Suls, Y. G. Weber, H. Lerche, P. De Jonghe, S. F. Berkovic, I. E. Scheffer*

2.022 Seizure Incidence, EEG Characteristics, And Short-Term Outcome In The Pediatric Stroke Population, *R. Singh, N. Zecavati, S. Weinstein, J. Carpenter*

2.096 Hippocampal Volume Is Reduced In Children With Other Forms Of Convulsive Status Epilepticus Compared To Children With Prolonged Febrile Seizures, *M. Yoong, M. Martinos, C. A. Clark, R. F. Chin, R. C. Scott*

(continued on page 48)

2.118 Health-Related Quality Of Life In Children With New Onset Epilepsy: A Longitudinal Assessment Of The First 2 Years Post-Diagnosis, *K. N. Speechley, C. Camfield, S. Levin, M. L. Smith, S. Wiebe, G. Y. Zou*

2.161 Amygdala Volumes In Childhood Absence Epilepsy, *A. Schreibman Cohen, M. Daley, P. Siddarth, I. K. Loesch, J. Levitt, S. Gurbani, R. Caplan*

2.180 Dose Effects On Verbal And Nonverbal Cognitive Functions At Age 3 In Children Exposed In Utero To Antiepileptic Drug, *K. J. Meador, M. Cohen, N. Browning, G. Baker, J. Clayton-Smith, P. Pennell, L. Kalayjian, J. Liporace, M. Privitera, A. Kanner, D. Combs-Cantrell, D. Loring*

2.282 A Comprehensive Assessment Of Children With Epilepsy And Suicidality, *J. Jones, P. Siddarth, S. Gurbani, R. Caplan*

2.328 Predictors Of Depressive Symptoms In Mothers Of Children With New-Onset Epilepsy: A Longitudinal Examination, *M. A. Ferro, K. N. Speechley, W. R. Avison, M. K. Campbell*

3.025 KCNQ Channel Opener Therapy For Neonatal Hypoxia-Induced Seizures, *Y. H. Raol, D. Shmueli, A. R. Brooks-Kayal*

3.287 Seizure Recurrence Risk And Early Identification Of Refractoriness After A First Seizure Following Epilepsy Surgery, *L. Jehi, R. Sarkis, W. Bingaman, P. Kotagal, I. Najm*

3.340 Accelerated Limbic Epileptogenesis Following Early Life Stress Is Associated With Enhanced Corticosterone Response, Hippocampal Cell Loss And Neurogenesis, *G. Kumar, N. C. Jones, S. M. Rees, M. J. Morris, T. J. O'Brien, M. J. Salzman*

3.342 Stem Cell Protein Expression And mTOR Pathway Activation Distinguishes Type I From Type II Focal Cortical Dysplasias, *V. Tsai, K. A. Orlova, M. Baybis, G. G. Heuer, S. Sisodiya, M. Thom, K. A. Strauss, E. Aronica, P. B. Storm, P. B. Crino*

6:30 p.m. – 8:30 p.m.
Pediatric State of the Art Symposium:
Treatable Metabolic Epilepsies
(2.0 CME Credits)

Sheraton – Grand Ballroom, 2nd Floor

Overview

This symposium will review epilepsies due to inherited disorders that are treatable, yet catastrophic if unrecognized. An overview of treatable metabolic epilepsies (presenting as neonatal seizures, infantile spasms and medication-resistant seizures) will provide background and examples of conditions which require rapid identification. Three specific disorders [vitamin dependent epilepsies, glucose transporter deficiency and DEND (developmental delay, epilepsy, and neonatal diabetes)] will be discussed in depth, including diagnostic testing and treatment.

Learner Outcomes

- ▶ Diagnose treatable inherited metabolic epileptic encephalopathies using appropriate laboratory investigations
- ▶ Use pyridoxine, folic acid, and pyridoxal phosphate as required therapeutic interventions when treating neonatal epilepsy
- ▶ Assess the need for a lumbar puncture for diagnosis of glucose transporter deficiency and communicate necessity of testing when consulting with PCP regarding infants with epilepsy
- ▶ Use oral hypoglycemic agents rather than insulin for treatment of a neonate with epilepsy and diabetes.

Target Audience

Pediatric neurologists, epileptologists, neuroscientists, pediatricians and neurology nurse specialists

Program

Chair: Phillip L. Pearl, M.D.

The Top Ten Diagnoses You Can't Afford to Miss

Phillip L. Pearl, M.D.

Pyridoxine Dependent Seizures in All Its Forms

Sidney M. Gospe, Jr., M.D., Ph.D.

Update on Glucose Transporter Deficiency and Use of the Ketogenic Diet

Darryl C. De Vivo, M.D.

Putting an End to DEND: A New and Eminently Treatable Metabolic Epilepsy

Edward C. Cooper, M.D., Ph.D.

Credit Designation

The American Epilepsy Society designates this educational activity for a maximum of 2.0 *AMA PRA Category 1 Credits*™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Pharmacy Credit

ACPE #073-999-09-125-L01-P; 0.2 CEUs

Acknowledgment

This program is supported in part by educational grants from GlaxoSmithKline and Questcor Pharmaceuticals, Inc.

Log on to the AES Web site

Here are a few of the highlights:

- Membership** – Join online and you may also visit the AES membership area at the registration desk at the Annual Meeting
- Professional Development** – Epilepsy education programs and archived AES symposia
- Annual Meeting Information**
- Abstracts** – Searchable database
- Research** – Information regarding awards and grants
- Publications** – Featuring Epilepsy Currents, Epilepsia, AES News and AES Annual Reports
- Press Room** – Press release archives, fact sheets and position statements

www.AESNET.org

<p>A. Translational Research Hynes – Room 306, Level 3 Moderators: Peter B. Crino, M.D., Ph.D. Richard P. Morse, M.D.</p>	<p>B. Surgery/Imaging Hynes – Room 304, Level 3 Moderators: Thomas R. Henry, M.D. Devin K. Binder, M.D., Ph.D.</p>	<p>C. Clinical Epilepsy Hynes – Room 302, Level 3 Moderators: Sanjay P. Singh, M.D. Lauren Frey, M.D.</p>
<p>A.01 Interplay Between Basket, OLM And Pyramidal Cells During Seizure-Like Events In Vitro/R. Parekh, J. Cressman, S. J. Schiff, J. Ziburkus 4:00 p.m.</p>	<p>B.01 Vagus Nerve Stimulation For Refractory Epilepsy: Single Surgeon Experience Of Over 700 Consecutive Operations/R. E. Elliott, A. Morsi, S. Kalhorn, J. Marcus, J. Sellin, M. Kang, A. Silverberg, C. Carlson, E. B. Geller, O. Devinsky, W. Doyle</p>	<p>C.01 STEPSOUT – Prospective Population-Based Study Of Childhood Convulsive Status Epilepticus Outcomes/S. Pujar, B. Neville, R. Scott, R. Chin</p>
<p>A.02 Seizure/Kainate Enhances The Proliferation Of Hippocampal Radial Glial Precursor Cells Via AMPA Receptors/A. Shtaya, W. P. Gray 4:15 p.m.</p>	<p>B.02 Brain MRI Characteristics Of Epileptogenic Tuber And Predictors Of Intractable Epilepsy In Tuberous Sclerosis Complex (TSC)/S. Viravan, K. Velayudam, P. Kotagal, D. K. Lachhwani, E. Wyllie, I. Tuxhorn, W. E. Bingaman, A. Gupta</p>	<p>C.02 MEG Localization Of The Epileptogenic Focus And fMRI Language Patterns In Children With Epilepsy/O. Bar-Yosef, H. Otsubo, S. Chuang, D. Morris, W. Logan, E. J. Donner</p>
<p>A.03 Mitochondrial Oxidative Stress And DNA Damage During Lithium-Pilocarpine-Induced Epileptogenesis/S. Waldbaum, L. P. Liang, M. Patel 4:30 p.m.</p>	<p>B.03 Racial Disparities In The Surgical Management Of Intractable Temporal Lobe Epilepsy In The United States: A Population-Based Analysis/ S. McClelland III, H. Guo, K. S. Okuyemi</p>	<p>C.03 IQ, Memory, Language And Attention In Children Exposed To Antiepileptic Drugs In Utero: Preliminary Outcomes At 6 Years Of Age/ R. L. Bromley, A. Gummerly, R. Shallcross, M. Briggs, G. Mawer, J. Clayton-Smith, G. A. Baker</p>
<p>A.04 Serum Antibodies In Epilepsy/T. Brenner, Y. Hart, S. J. Howell, J. Palace, G. J. Sills, M. J. Brodie, R. Liguori, A. Vincent, B. Lang 4:45 p.m.</p>	<p>B.04 Predictors Of Outcome Following Incomplete Resection Of The Epileptogenic Zone For Intractable Childhood Epilepsy/M. S. Perry, C. Dunoyer, P. Dean, S. Bhatia, J. Ragheb, I. Miller, T. J. Resnick, P. Jayakar, M. S. Duchowny</p>	<p>C.04 Does The Nature Of A SCN1A Mutation Influence The Temporal Evolution Of Seizure Types In Dravet Syndrome?/A. Brunklaus, R. Birch, J. Duncan, S. Stenhouse, S. Zuberi</p>
<p>A.05 KCNJ10 Gene Variation And Epilepsy/ R. J. Buono, F. W. Lohoff, H. K. Basehore, M. R. Sperling, D. J. Dlugos, M. D. Privitera, J. French, W. Lo, S. C. Schachter, P. Cossette, W. H. Berrettini, T. N. Ferraro 5:00 p.m.</p>	<p>B.05 Refractory Frontal Lobe Epilepsy: Clinical Aspects And The Importance Of Earlier Surgical Treatment/A. P. Pinheiro-Martins, M. M. Bianchin, T. R. Velasco, V. C. Terra, D. Araújo Jr, V. Alexandre Jr, H. R. Machado, J. A. Assirati, Jr., C. G. Carlotti Jr, A. C. Sakamoto</p>	<p>C.05 CNS-Related Comorbidities In Individuals With Self-Reported Epilepsy From The National Survey Of Epilepsy, Comorbidities And Health Outcomes/R. Ottman, R. B. Lipton, A. B. Ettinger, J. A. Cramer, M. L. Reed, G. J. Wan</p>
<p>A.06 Focal Cooling Prevents Post-Traumatic Epilepsy Induced By Fluid Percussion Injury In The Rat In A Blind And Randomized Study/ R. D'Ambrosio, M. Smyth, J. S. Fender, J. W. Miller, S. M. Rothman, D. R. Verley 5:15 p.m.</p>	<p>B.06 Responsive Neurostimulation Modulates Cortical Rhythms In Patients With Epilepsy/ V. S. Sohal, F. T. Sun</p>	<p>C.06 Modern Monotherapies In Newly Diagnosed Epilepsy: Comparative Retention And Efficacy/ G. J. Sills, J. P. Leach, E. A. Wilson, P. Parker, K. Kelly, I. Hamill, J. Greene, R. Duncan, M. J. Brodie</p>
<p>A.07 Localized Recurrent Excitation In The Dentate Gyrus Of A Cortical Contusion Model Of Post-Traumatic Epilepsy/R. F. Hunt, S. W. Scheff, B. N. Smith 5:30 p.m.</p>	<p>B.07 Patterns Of Disconnection Associated With Memory Dysfunction In Temporal Lobe Epilepsy/ M. Yogarajah, N. Focke, S. Bonelli, P. Thompson, M. Symms, M. J. Koeppe, J. Duncan</p>	<p>C.07 Discontinuation Of Zonisamide Due To Psychiatric And Cognitive Adverse Events: A Case-Control Study/J. R. White, T. S. Walczak, S. E. Marino, A. K. Birnbaum, T. E. Beniak, I. E. Leppik</p>
<p>A.08 Progressive Changes In GABAergic Inhibition During Development Of Temporal Lobe Epilepsy After Status Epilepticus In Rat/W. S. Mueller, D. E. Bragin, J. L. Sanderson, S. Peterson, J. A. Connor 5:45 p.m.</p>	<p>B.08 EEG Seizure-Onset Patterns And Surgical Outcome In Non-Lesional Extratemporal Epilepsy/ T. Zakaria, E. So, K. Noe, G. Cascino, F. B. Meyer, W. Marsh, E. Wirrell, G. Worrell</p>	<p>C.08 Childhood Absence Epilepsy: Functional Neuroimaging Of Interictal Attention/M. Vestal, X. Bai, M. Negishi, R. Berman, C. Vega, M. Spann, M. DeSalvo, C. L. McAuliffe, E. J. Novotny, R. T. Constable, H. Blumenfeld</p>
<p>No platform presentation 6:00 p.m.</p>	<p>B.09 Results of a Multicenter Double-Blinded Randomized Controlled Pivotal Investigation Of The RNS™ System For Treatment Of Intractable Partial Epilepsy In Adults/M. Morrell and the RNS System Pivotal Investigators</p>	<p>C.09 Who Should Be Referred For An Epilepsy Surgery Evaluation? Development Of An Appropriateness And Necessity Rating Tool/ N. Jette, J. Tellez-Zenteno, W. Hader, S. Macrodimitris, L. Hamiwka, E. Wirrell, H. Guan, E. Sherman, J. Burneo, A. Metcalfe, L. Hernandez-Ronquillo, C. Kwon, F. Andermann, P. Camfield, L. Carmant, J. Davenport, J. Farmer, D. Gross, R. Huntsman, M. Sadler, O. Snead III, D. Steven, M. Wheatley, S. Wiebe</p>

Authors Present Group G: 8:00 a.m. – 9:00 a.m.

Authors Present: 3.001 – 3.120

Authors Present Group H: 11:45 a.m. – 12:45 p.m.

Authors Present: 3.121 – 3.240

Authors Present Group I: 3:00 p.m. – 4:00 p.m.

Authors Present: 3.241 – 3.361

Translational Research**3.001** Manipulating Reelin Signaling

Through Disabled-1 Alters Adult Neurogenesis In The Intact And Epileptic Hippocampus/M. Kron, H. Zhang, D. Lagace, A. Eisch, B. Howell, J. Parent

3.002 The Effect Of Chemical Absence Model On The Progression Of Kindling In Wistar Rats/F. Onat, M. Sahiner, E. Sakalli, K. Tezcan, R. Aker, C. Ozkara, O. Snead, E. Eskazan**3.003** Differential Molecular Regulation Of Glutamate In Kindling Resistant Rats/T. Doi, Y. Ueda, M. Takaki, Y. Chihara, J. Willmore**3.004** 8-iso-PGF_{2α} Production Is Increased Following Status Epilepticus/A. Kelso, M. Korecka, L. Shaw, H. Cock**3.005** Inhibition Of Poly(ADP-Ribose) Polymerase-1 Preserves Mitochondrial Function And CA1 Hippocampal Neurons Following Kainate-Induced Status Epilepticus/Y. Lai, S. Baker, W. Craigen, A. Anderson**3.006** Interneuron Progenitor Transplants Attenuate The Propagation Of Acute Focal Seizures In Mouse Neocortex/M. Zhao, E. De la Cruz, L. Guo, H. Ma, T. Schwartz, S. Anderson**3.007** Expression Of Calcium Permeable AMPA Receptors During Status Epilepticus/K. Rajasekaran, J. Kapur**3.008** Calcium Channel Abnormalities In Inhibitory Presynaptic Terminals Of Epileptogenic Neocortex/L. Faria, D. Prince**3.009** Initial Loss But Later Excess Of GABAergic Synapses With Dentate Granule Cells In A Rat Model Of Temporal Lobe Epilepsy/P. Buckmaster, K. Thind, R. Yamawaki, I. Phanwar, G. Zhang, X. Wen**3.010** Reduced Excitability Of Neuronal Circuits In The Hippocampus Of Scn8a Mutant Mice/B. Tanaka, A. Goldin**3.011** Molecular And Morphological Mechanisms Underlying Early-Life Seizure-Induced Protection/L. Friedman, J. Mancuso, G. La Torre, A. Sagyhan, D. Iacobas, S. Iacobas, D. Spray**3.012** An Imbalance Of Excitation And Inhibition Revealed In The Visual-Evoked Responses Of Idiopathic Generalized Epilepsy Patients/J. Tsai, A. Norcia, A. Wade**3.013** Comparative Neuroanatomical And Temporal Characterization Of Fluorjade-Positive Neurodegeneration After Status Epilepticus Induced By Systemic And Intrahippocampal Pilocarpine In Wistar Rats/O. Castro, M. Furtado, A. Fernandes, C. Tilelli, N. Garcia-Cairasco**3.014** Downregulation Of HCN Channels In Epilepsy Is Associated With Decreased Phosphorylation Via p38 MAPK Pathway/S. Jung, J. Bullis, N. Poolos**3.015** A Role For Toll-Like Receptor 4 Activation By The High Mobility Group Box 1 (HMGB1) Protein In Ictogenesis/M. Maroso, S. Balosso, T. Ravizza, I. Vanzulli, E. Aronica, M. Molteni, C. Rossetti, J. Liu, M. Bianchi, A. Vezzani**3.016** Use Of Induced Pluripotent Stem Cells To Study Channel Gene Mutations Causing Human Epilepsy/Y. Liu, L. Lopez-Santiago, M. Natowicz, A. Gupta, L. Isom, M. Meisler, J. Parent**3.017** Wistar Audiogenic Rats: Phenotypic Characterization And Hypothalamic-Pituitary-Adrenal (HPA) Axis Evaluation/E. Umeoka, J. Oliveira, C. Gati, J. Antunes-Rodrigues, L. Elias, N. Garcia-Cairasco**3.018** GABA(A) Receptor Subunits And Spontaneous Activity In Neuronal Cultures/L. Eisenman, H. Shu, C. Zorumski, S. Menerick**3.019** Differential Latency Between Glutamate And GABA Release With Seizures Induced By NMDA/Y. Chihara, Y. Ueda, T. Doi, J. Willmore**3.020** Effects Of Valproate On Diurnal Rhythmicity Of Spontaneous Limbic Seizures In Chronic Epileptic Rats/W. Hofstra, E. Van Vliet, W. Wadman, A. De Weerd, J. Gorter**3.021** Febrile Temperatures Increase Intrinsic Excitability And Spontaneous Synaptic Activity Of Hippocampal CA3 Pyramidal Cells And Interneurons/J. Kim, J. Kauer, B. Connors**3.022** On The Role Of P-Glycoprotein Function In The Blood-Brain Barrier In Pharmacoresistance: A PET Study In Epileptic Rats/R. Voskuyl, S. Syvänen, G. Luurtsema, C. Molthoff, A. Windhorst, M. Huisman, A. Lammertsma, E. de Lange**3.023** Mapping Of Glutamate Reuptake Capacity And Afferent Input To Cortical Microgyri Reveals Functional Components Of An 'Epileptic Zone'/C. Dulla, H. Tani, J. Brill, R. Reimer, J. Huguenard**3.024** Oxytocin-Induced Hypergrooming In The Wistar Audiogenic Rat (WAR) Strain: Modeling Compulsion And Epilepsy Comorbidities/S. Marroni,

J. Santos, F. Nakano, N. Garcia-Cairasco

3.025 KCNQ Channel Opener Therapy For Neonatal Hypoxia-Induced Seizures/Y. Raol, D. Shmueli, A. Brooks-Kayal**3.026** Evidence For A Rapid Presynaptic Modification Of GABA Release During Status Epilepticus In The Young Animal/S. Joshi, H. Goodkin**3.027** MicroRNA Regulation Of Translation Following Status Epilepticus/R. Risbud, C. Lee, B. Porter**3.028** In Vivo Multiphoton Imaging Detects Acute Dendritic Injury Caused By Brief Seizures/D. Guo, S. Arnsperger, M. Wong**3.029** Neuronal Activation And Degeneration In Different Behavioral Profiles In The Amygdala Electrical Stimulation Status Epilepticus Model/V. Santos, C. Tilelli, O. Castro, A. Fernandes, N. Garcia-Cairasco**3.030** Neonatal Hypoxic-Ischemic Injury Results In Sensitivity To Seizures And Down-Regulation Of Antioxidant Ability In Matured Rats/Y. Ueda, T. Doi, Y. Chihara, A. Nakajima, J. Willmore**3.031** Chronic Injury Reduces The Production Of New Neurons From Endogenous Stem Cells In The Adult Human Epileptic Hippocampus – A Microenvironment Effect/M. Zaben, W. Gray**3.032** Pathological High-Frequency Oscillations Occur After Lateral Fluid Percussion Injury In Rats With Post-Traumatic Epilepsy/R. Staba, A. Bragin, J. Almajano, P. Lepe, V. Mahadev, Y. Cai, C. Giza, J. Engel**3.033** Postnatal Expression Pattern Of HCN Channel Isoforms In Thalamic Neurons: Relationship To Maturation Of Thalamocortical Oscillations/M. Pawlowski, T. Kanyshkova, P. Meuth, C. Dubé, R. Bender, A. Brewster, A. Baumann, T. Baram, H. Pape, T. Budde**3.034** Lipopolysaccharide (LPS) Potentiates KA-Induced Seizures And Peripheral Leukocyte Infiltration/S. Koh, L. Mlsna, A. Chang, M. Kim**3.035** Evidence That Busetanide Suppresses Epileptiform Activity In Adult Primate Cortex Independent Of Effects On GABA-A Signaling/D. Hochman, M. Haglund**3.036** Early-Life Seizures Alter Dendritic Spine Development In Primary But Not Oblique Apical Dendrites Of Rat Pyramidal CA1 Neurons/J. Lippman Bell, P. Klein, F. Jensen

- 3.037** Brain Extracellular Glutamate, Glutamine, And GABA Levels In Refractory Epilepsy Patients. Microdialysis Data From 84 Patients/ J. Romanyshyn, T. Eid, I. Cavus, S. Spencer, K. Vives, D. Spencer
- 3.038** Effects Of Cooling On Synchronous Epileptiform Discharges In Mice Hippocampus And Cortex Recorded Through A Multi-Electrode Array (MEA)/G. Motamedi, A. Gonzalez-Sulser, D. Press, R. Dzakupas, S. Vicini
- 3.039** Computational Model Of The Contribution Of Axonal Conduction Failure To Sustained CA3 Synchrony/ W. Swiercz, K. Staley, Y. Berdichevsky
- 3.040** Effects Of Epilepsy Chronicity On Cortical Excitability/R. Badawy, R. Macdonell, S. Berkovic, G. Jackson
- 3.041** Status Epilepticus Induces Aberrant Activation Of mTOR Signaling In The Rat Hippocampus/A. Brewster, F. Vanegas, A. Anderson
- 3.042** In Vivo Measurements Of Vagus Nerve Compound Action Potentials In Experimental Rats/R. El Tahry, R. Raedt, V. De Herdt, A. Van Dycke, T. Wyckhuys, A. Meurs, J. Delbeke, K. Vonck, W. Wadman, P. Boon
- 3.043** Differential Vulnerability And Anti-Oxidant Response In Hippocampal Subfields After Pilocarpine-Induced Status Epilepticus In Mice/Y. Cho, B. Lee, K. Heo, H. Kim, K. Cho, G. Kim
- 3.044** Interictal Immunological Changes In Patients With Refractory Epilepsy/ M. Nowak, S. Bauer, S. Cepok, A. Todorova-Rudolph, G. Li, B. Tackenberg, F. Rosenow, B. Hemmer, H. Hamer
- 3.045** Frameshift Mutations In The Terminal Exon Of ARX Cause Ohtahara Syndrome/M. Kato, N. Koyama, M. Ohta, K. Miura, K. Hayasaka
- 3.046** Persistent Chloride Accumulation And Anticonvulsant Resistance In Neonatal Seizures/V. Dzhalal, J. Glykys, G. Feng, T. Kuner, G. Augustine, B. Bacskai, K. Staley
- 3.047** Interictal Spikes Appear During The Latent Period In A Model Of Epileptogenesis Based On Organotypic Hippocampal Slice Cultures/ J. Dyhrfeld-Johnsen, W. Swiercz, H. Sabolek, Y. Berdichevsky, K. Staley
- 3.048** Post-Depolarization Potentiation Of GABA_A Receptors: A Novel Mechanism Regulating Tonic Inhibition In Hippocampal Neurons/C. Ransom, G. Richerson, Y. Wu
- 3.049** Spatiotemporal Dynamics Of Epileptiform Activity In Vitro/A. Hazra, A. Barua, N. Nguyen, T. Wadade, B. Bodmann, K. Josic, J. Ziburkus
- 3.050** The Propagation Of Epileptiform Events Across The Corpus Callosum: Results From An In Vitro Preparation/ G. Aaron, J. Walker, S. Leung
- 3.051** The Omega-3 Fatty Acid Derived Mediator Neuroprotectin D1 (NPD1) Downregulates Epileptogenesis/ N. Bazam, T. Quebedeaux, A. Musto
- 3.052** Decreased Inhibition In Chronically Epileptogenic Neocortex Due To Abnormalities In Presynaptic Terminals Of Fast-Spiking Interneurons/ Y. Ma, D. Prince
- 3.053** Measurement Of Paired-Pulse Suppression In Relation To GABAergic Inhibition In The Dentate Gyrus Of Rat Hippocampal Slices/L. Shao, F. Dudek
- 3.054** Does Gabapentin Prevent Post-Traumatic Epileptogenesis?/H. Li, K. Graber, D. Prince
- 3.055** A Role For The Midline Thalamus In Limbic Seizures: Part Of A Divergent-Convergent Circuit Amplification Circuit/D. Sloan, D. Zhang, E. Bertram
- 3.056** Increase In mGluR5 Expression And Interneuron Activation In Malformed Cortex/K. Jacobs, A. George, A. Pomier
- 3.057** Restoration Of The SE-Induced Changes In CaN Activity Precedes Recurrent Seizure Activity In The Pilocarpine Rat Model/S. Churn, B. Low, J. Campbell, S. Patel, J. Kurz, D. Register
- 3.058** Pathologies Common In Epilepsy Produce And Differentiate Ripples And Fast Ripples: Predictions From A Physiological Hippocampal Computer Model/W. Stacey, B. Litt
- 3.059** Calcium Imaging Of Distinct Onset Patterns Of Ictal And Interictal-Like Activity In An In Vitro Model Of Chronic Epilepsy/H. Sabolek, W. Swiercz, K. Staley
- 3.060** Short-Term Synaptic Plasticity Of Low-Threshold Spiking (LTS) Inhibitory Neurons And Their Role In Preventing Seizure Activity In Cortex/K. Richardson, E. Fanselow, D. Golomb, B. Connors
- 3.061** Characterization Of A Novel Mutant Mouse With A Low Seizure Threshold And Sporadic Spontaneous Seizures: Akt3-Nmf350/S. Tokuda, C. Mahaffey, W. Frankel
- 3.062** Transgenic Knock-In Mice With Phosphorylation Deficits At GluR1 Ser831 And Ser845 Reveal Reduced Susceptibility To Excitability And Seizures In The Neonatal Period/ S. Rakhade, E. Fitzgerald, C. Zhou, K. Takamiya, R. Huganir, F. Jensen
- 3.063** Markers Of Long-Term Potentiation After Traumatic Brain Injury/A. Iglesias, Y. Wang, P. Muller, S. Rakhade, F. Jensen, A. Rotenberg
- 3.064** Tonic GABAergic Inhibition Controls The NMDA Receptor-Mediated Activation Of Hippocampal Interneurons And The Frequency Of Network Synchronization/E. Mann, I. Mody
- 3.065** Simulations Of Epileptiform Activity In Neural Network Models Of Focal Cortical Pathology/P. Kudela, W. Anderson, G. Bergey, P. Franaszczuk
- 3.066** Increased Hippocampal Extracellular Noradrenalin Concentration Contributes To The Anticonvulsant Effect Of VNS In The Focal Pilocarpine Rat Model For Limbic Seizures/A. Meurs, L. Mollet, R. Clinckers, R. Raedt, R. El Tahry, V. Deherdt, K. Vonck, I. Smolders, Y. Michotte, P. Boon
- 3.067** Analysis Of Hippocampal Interdependencies For Early Seizure Detection/A. Cadotte, S. Talathi, J. Zhou, S. Myers, D. Hwang, W. Ditto, P. Carney
- 3.068** Partial Voltage-Gated Sodium Channel Inactivation Results In Seizures In Organotypic Culture Model Of Epilepsy/Y. Berdichevsky, W. Swiercz, M. Yarmush, K. Staley
- 3.069** Over-Exposed: Ligand Excess Biases Synaptic GABA_A Receptors Towards Desensitized States With Seizure Potentiation/D. Naylor
- 3.070** Gene Expression Analysis Of TSC-Cortical Tubers Reveals Higher Expression Levels For Cell Adhesion And Inflammatory Factors/K. Boer, P. Crino, J. Gorter, M. Nellist, F. Jansen, W. Splet, P. van Rijen, F. Wittink, T. Breit, D. Troost, W. Wadman, E. Aronica
- 3.071** Levitiracetam Has Apoptotic Effects In Human Ovarian Follicular Cells/E. Taubøll, E. Gregoraszcuk, A. Wojtowicz, T. Milewicz
- 3.072** Sclerotic Astrocytes In Human Tuberous Sclerosis And Hippocampal Sclerosis/X. Wu, A. Sosunov, C. Mikell, R. Goodman, P. Crino, H. Weiner, G. McKhann II
- 3.073** Alteration Of Cortical GABA_A Receptor Subunit Expression And Pharmacology In Angelman Syndrome/ L. Jansen, W. Roden, L. Peugh
- 3.074** Altered Glutamate And GABA Receptor Expression In Cortical Tissue Resected From Pediatric Patients With Status Epilepticus/T. Loddenkemper, A. Alexopoulos, A. Joseph, R. O'Dwyer, D. Talos, I. Najm, F. Jensen
- 3.075** Functional Rundown Of GABA_A Receptors In Human Hypothalamic Hamartoma/J. Wu, G. Li, J. Kerrigan
- 3.076** Role Of Microglial Activation On Synaptic Plasticity In A Rat Model Of Epileptogenesis And In Human Epileptic Brain/M. Vendrame, D. Talos, F. Jensen
- 3.077** Distinct Metabolic Profiles Are Seen In Human Epileptogenic Tissue Studied In Vitro: Cortical Dysplasias Versus Temporal Lobe Sclerosis/ A. Williamson, O. Petroff, D. Spencer, T. Eid
- 3.078** Comorbidity Between Temporal Lobe Epilepsy And Depression: The Role Of Hippocampal Interleukin-1-Beta/ A. Mazarati, D. Shin, E. Pineda, R. Sankar
- 3.079** Prenatal Freeze Lesioning Produces Epileptogenic Focal Cortical Dysplasia/K. Takase, H. Shigetou, S. Suzuki, H. Kikuchi, Y. Ohyagi, J. Kira
- 3.080** Post-Stroke Integration Of New Neurons Into Functional Hippocampal Networks Using Spatial Exploration-Induced Arc Protein Expression In A Mouse Model Of Neonatal Stroke/ S. Kadam, C. Hicks-Smith, D. Smith, P. Worley, A. Comi
- 3.081** Mapping Mouse Limbic Seizure Susceptibility Loci On Chromosomes 10 And 18/S. Seal, A. Phillips, A. Palmer, M. Winawer

- 3.082** Interictal Resting Functional Connectivity In WAG/Rij Rats: A Possible Biomarker Of Epilepsy/A. Mishra, X. Bai, M. Purcaro, J. Motelow, M. DeSalvo, F. Hyder, H. Blumenfeld
- 3.083** A QTL On Mouse Chromosome 1 Contributes To Pilocarpine-Induced Seizure Susceptibility/M. Winawer, A. Phillips, R. Buono, T. Ferraro
- 3.084** Astroglial Loss And Edema Formation In The Rat Piriform Cortex And Hippocampus Following Pilocarpine-Induced Status Epilepticus/H. Song, W. Choi, T. Kang
- 3.085** Involvement Of The Lateral Septum In Cortical Deactivation During Limbic Seizures In Rats/D. Englot, B. Modi, A. Mishra, M. DeSalvo, F. Hyder, H. Blumenfeld
- 3.086** Environmental Enrichment Delays The Onset Of Limbic Epilepsy And Improves Anxiety-Like And Neurocognitive Behaviours/M. Yang, M. Salzberg, S. Rees, T. O'Brien, N. Jones
- 3.087** DBA/1 Mice Are A Useful Model Of SUDEP For Evaluating Chronic Prevention Treatments/C. Faingold, M. Randall, S. Tupal
- 3.088** CREB Deficiency Suppresses The Development Of Epilepsy/B. Porter, J. Blendy, X. Zhu
- 3.089** Comparison Of Multiple Automated Methods Of Spike Detection With Expert Review In A Neonatal Hypoxia Model/A. White, D. Shmueli, Y. Raol
- 3.090** Effect Of WIN 55,212-2 Mesylate – A Highly Potent Cannabinoid CB1 And CB2 Receptor Agonist On The Protective Action Of Carbamazepine, Phenytoin, Phenobarbital And Valproate In The Mouse Maximal Electroshock-Induced Seizure Model/J. Luszczki, S. Czuczwar
- 3.091** Effect Of ACEA – A Highly Selective Cannabinoid CB1 Receptor Agonist On The Protective Action Of Clonazepam, Ethosuximide, Phenobarbital And Valproate In The Mouse Pentylenetetrazole-Induced Clonic Seizure Model/S. Czuczwar, J. Luszczki
- 3.092** Depletion Of STRAD-Alpha Results In Nuclear Accumulation Of LKB1 And Leads To Aberrant mTOR Activation And Lamination During Corticogenesis/K. Orlova, W. Parker, G. Heuer, J. Yoon, M. Baybis, R. Fenning, K. Strauss, P. Crino
- 3.093** Effects Of Repeated Administration Of Valproic Acid After Seizures Induced By Organophosphorous Compounds In Sprague-Dawley Rats/M. Furtado, L. Lumley, M. Moffett, T. Pak, M. Addis, B. Robertson, S. Lichtenstein, J. Schwartz, M. Schultz, F. Rossetti, D. Yourick
- 3.094** Using An Etiologically Realistic Post-Traumatic Epilepsy Model And ECoG For Antiepileptic Drug Testing/C. Eastman, J. Fender, D. Verley, R. D'Ambrosio
- 3.095** Modulation Of Astrocyte Glutamate Transporters Decreases Seizures In A Mouse Model Of Tuberos Sclerosis Complex/L. Zeng, A. Bero, D. Holtzman, M. Wong
- 3.096** The Balance Of Inhibitory And Excitatory Synaptic Activity Is Altered In Fast-Spiking Interneurons In Experimental Cortical Dysplasia/F. Zhou, H. Chen, S. Roper
- 3.097** Anterior Nucleus Deep Brain Stimulation In A Large Animal Epilepsy Model/J. Giftakis, T. Billstrom, J. Allen, W. Schindeldecker, N. Barka, L. Lentz, D. Carlson, R. Jensen, N. Graves, P. Stypulkowski
- 3.098** Hippocampal Cytokine Expression After Neonatal Hypoxia-Induced Seizures/J. Heida, K. Katki, G. Arisi, K. Zhang, L. Shapiro, R. Sanchez
- 3.099** Dietary Treatments For Modulating Post-Traumatic Brain Hyperexcitability/A. DeLance, K. Van, C. Poon, B. Lyeth, H. Wenzel, P. Schwartzkroin
- 3.100** Timing And Localization Of BOLD fMRI Signal Changes In A Bicuculline Induced Tonic-Clonic Seizure Model/M. DeSalvo, U. Schridde, A. Mishra, J. Motelow, M. Purcaro, F. Hyder, H. Blumenfeld
- 3.101** Frontal Neocortex Is More Epileptogenic Than Parietal And Parietal-Occipital Neocortices After Fluid Percussion Injury In The Rat/G. Curia, J. Fender, R. D'Ambrosio
- 3.102** Increased Seizure Susceptibility And Postictal Respiratory Suppression In Mice With Genetic Deletion Of 5-HT Neurons/G. Buchanan, G. Richerson
- 3.103** Multiple Seizures Produce Arrhythmogenic Electrical Activity In The Heart And Increase Susceptibility To Experimentally-Induced Arrhythmias In Kindled Rats/S. Bealer, J. Little
- 3.104** Spontaneous Seizures In The Repeated Flurothyl Model: A New Model Of Epileptogenesis/R. Ferland, D. Papandrea
- 3.105** Seizure Analysis Of BXD Recombinant Inbred Mice In The Repeated Flurothyl Model/D. Papandrea, B. Herron, R. Ferland
- 3.106** The EL Mouse: A Natural Model Of Autism And Epilepsy/J. Mantis, J. Meidenbauer, T. Seyfried
- 3.107** Status Epilepticus Produces Arrhythmogenic Cardiac Electrical Activity/J. Little, S. Bealer
- 3.108** Is There A Valuable Biomarker When Inflammation Invalidates The Neuroprotective Effect Of Diazepam In A Status Epilepticus Model?/S. Auvin, C. Lecointe, S. Dubucquoi, L. Vallee, R. Bordet
- 3.109** Long QT Mouse Model Links The Dual Phenotype Of Cardiac Arrhythmias And Epilepsy With Sudden Unexplained Death In Epilepsy/A. Goldman, E. Glasscock, J. Yoo, T. Chen, T. Klassen, J. Noebels
- 3.110** Phenobarbital Infusion In The Mediodorsal Thalamus Suppresses Limbic Seizures/G. Martz, K. Heutinck, J. Williamson, E. Bertram
- 3.111** Pharmacological Blockade Of Cys-Leukotriene Biosynthesis Ameliorates Post-Injury Oxidative Stress In A Rat Model Of Post-Traumatic Epilepsy/L. Frey, L. Liang, A. Lepkin, C. Unkart, M. Patel
- 3.112** The GAERS Ca_v3.2 T-type Calcium Channel Mutation (GCM) Affects Relative Expression Of The Channel Splice Variants/C. Ng, J. Tyson, K. Powell, S. Cain, C. Reid, T. Snutch, T. O'Brien
- 3.113** Anticonvulsant Effects Of ACTH In Animal Model Of Infantile Spasms: A Possible Mechanism Through MC4 Receptors/M. Yum, L. Velisek, T. Chachua, J. Veliskova
- 3.114** Normal Adult Female Sprague-Dawley Rats Exhibit Spike Wave Discharges/P. Pearce, D. Friedman, J. LaFrancois, H. Scharfman
- 3.115** Perfusion MRI Changes During Status Epilepticus In The Rat Pilocarpine Model/M. Choy, M. Lythgoe, J. Wells, E. Proctor, D. Thomas, D. Gadian, R. Scott
- 3.116** Specific Anticonvulsant Action Of GABA-B Receptor Positive Modulator CGP7930 In Immature Rats/P. Mareš
- 3.117** Adult Human Neural Progenitor Cells Survive, Migrate, And Differentiate Into Multiple Neuronal Phenotypes In Experimental Cortical Dysplasia/S. Roper, H. Chen, D. Akakin, H. Martinez, D. Steindler, F. Siebzehnrubl
- 3.118** Early Status Epilepticus In 12-Day-Old Rats Leads To Functional And Morphological Impairment/H. Kubova, K. Faberova, P. Mares
- 3.119** Early Neuronal Degeneration Induced By Status Epilepticus In Cortical And Subcortical Structures/R. Druga, P. Mareš, H. Kubova
- 3.120** Knock-In Mouse Strain Confirms Effect Of Kcnj10 Genetic Variation On Seizure Susceptibility/T. Ferraro, M. Eaton, G. Smith, C. Schwebel, G. Doyle, F. Lohoff, W. Berrettini, Y. Kucheryavykh, M. Inyushin, L. Kucheryavykh, S. Skatchkov, R. Buono
- 3.121** Covariance Analyses Of Occipital Lobe CBF In The Photosensitive Baboon: Hemispheric Asymmetry Of ILS Processing?/C. Szabo, S. Narayana, C. Franklin, K. Knape, M. Leland, J. Williams, P. Fox
- 3.122** Developmental Expression Of Parvalbumin And Somatostatin In GABAergic Interneurons In Normal Rodent Cortex And Experimental Cortical Dysplasia/D. Akakin, H. Chen, S. Roper
- 3.123** Control Of Seizure With Low Frequency Stimulation/S. Rashid, G. Pho, M. Werz, D. Durand
- 3.124** Prenatal Targeting Of Vasculogenesis Affects Specific Blood-Brain Barrier Genes And Proteins/Q. Fan, N. Marchi, V. Fazio, M. Hossain, P. Faber, D. Janigro
- 3.125** White Blood Cell Brain Extravasation Is Not Required To Generate Acute Seizures/M. Nguyen, Q. Teng, Q. Fan, C. Ghosh, D. Janigro, N. Marchi

- 3.126** Altered mRNA Expression Of GABA And Glutamate Receptor Subunits And Cation Chloride Co-Transporters Is Associated With Increased Seizure Susceptibility After Experimental Febrile Seizure/A. Reid, G. Teskey, Q. Pittman
- 3.127** A Modeling And Simulation Approach To Characterize The Effects Of Cardiopulmonary Bypass And Deep Hypothermic Circulatory Arrest On Intravenous Topiramate Pharmacokinetics/J. Mondick, A. Zuppa, A. Pirzadeh, P. Pastuszko, A. Pastuszko, R. Faught, J. Cloyd, A. Clark, M. Gastonguay, R. Clancy
- 3.128** Neuropsychiatric Comorbidities In The Plaur-/- Mouse Model Of Frontal Lobe Epilepsy/G. Bissonette, M. Bae, D. Depireux, E. Powell
- 3.129** Rapamycin Rescues Epilepsy And Mossy Fiber Sprouting In A NS-PTEN Knock-Out Model Of Cortical Dysplasia/C. Sunnen, M. Ljungberg, D. Parghi, J. Lugo, G. D'Arcangelo, A. Anderson
- 3.130** Post-Traumatic Epileptogenesis Is Associated With Injury Severity After Cortical Contusion In Mice/B. Smith, R. Hunt, L. Haselhorst, E. Bach, J. Rios-Pilier, K. Schoch, S. Scheff, K. Saatman
- 3.131** Alteration Of Blood Brain Barrier Permeability And Brain Damage In Developing Rats With Kainic Acid-Induced Seizures/D. Adstamongkonkul, Q. Zhao, G. Holmes
- 3.132** T-Cell Extravasation Is Not Required For The Development Of Acute Seizures In Response To Blood-Brain Barrier Disruption In A Pig Model/Q. Teng, N. Marchi, L. Franic, M. Nguyen, T. Masaryk, P. Rasmussen, D. Janigro
- 3.133** Effects Of Interictal Spikes On The Developing Brain/Q. Zhao, O. Khan, G. Holmes
- 3.134** Comparison Of Seizure Secondary Generalization Insights From Rat Kindling/M. Kendirli, J. Williamson, E. Bertram
- 3.135** Altered Glutamatergic Synaptic Signaling In A TSC Mouse Model/D. Talos, A. Joseph, B. Lee, L. Meikle, D. Kwiatkowski, F. Jensen
- 3.136** Multicellular Calcium Imaging Demonstrates The Hyperexcitability Of Dentate Granule Cells During Epileptogenesis In The Pilocarpine-Induced Model Of Epilepsy/C. Cho, H. Takano, F. Hsu, D. Coulter
- 3.137** Hippocampal Depth Recordings From Long Evans Rats Subjected To Neonatal Seizures Reveal Development Of Spontaneous Limbic Seizures/P. Klein, S. Rakhade, F. Jensen
- 3.138** Normal Development Of Place Cells: A Baseline For Understanding Cognitive Effects Of Early Life Seizures/R. Scott, G. Holmes, P. Lenck-Santini
- 3.139** Further Validation Of An Animal Model Of Infantile Spasms By Different Treatments/T. Chachua, M. Yum, J. Velišková, L. Velišek
- 3.140** Acute Seizures In A Rat Model Of Perinatal Hypoxia-Ischemia/A. Zayachkivsky, M. Lehmkuhle, F. Dudek
- 3.141** Features Of Epilepsy In A Schizophrenia-Related Animal Model/H. Lee, D. Dvorak, A. Fenton
- 3.142** Altered Excitatory Neurotransmission In The Reticular Thalamus Of The GluR4 Knock-Out Mouse Model Of Absence Epilepsy/C. Lacey, J. Paz, A. Bryant, J. Huguenard
- 3.143** Altered Intrathalamic GABAergic Neurotransmission In The GluR4 Knock-Out Mouse Model Of Absence Epilepsy/J. Paz, C. Lacey, A. Bryant, J. Huguenard
- 3.144** VNS-Induced Reduction Of Seizures And Changes In Gene Expression In A Rat Model Of Chronic Epilepsy/L. Treiman, S. Marsh, S. Sabesan, R. Ferguson, D. Treiman
- 3.145** Deficits In Striatal-Enriched Tyrosine Phosphatase (STEP) Decrease Incidence Of Audiogenic Seizures In A Mouse Model Of Fragile-X/J. Naegele, D. Hall, S. Goebel-Goody, M. Baum, J. Park, L. Ding, Y. Zhang, P. Lombroso
- 3.146** LGI1-Null Mice: A New Model For Epilepsy?/S. Baulac, E. Chabrol, V. Navarro, I. Cohen, G. Provenzano, R. Miles, M. Baulac, E. Leguern
- 3.147** A Brain-Computer Interface Using Event-Related Potentials (ERPs) And Electrographic Signals (ECog) In Humans/P. Brunner, A. Ritaccio, J. Emrich, H. Bischof, G. Schalk
- 3.148** Epileptic Seizures From Abnormal Neural Networks: Impact On The Existence Of A Preictal Period And Seizure Predictability/F. Azhar, P. Kudela, P. Franaszczuk, W. Anderson
- 3.149** Electrographic In A Brain-Computer Interface (BCI) Paradigm/J. Shih, D. Krusienski
- 3.150** Cellular Electrophysiological Effects Of Seizure-Preventing Concentrations Of Transmeningeal Muscimol In The Rat Neocortex/N. Ludvig, H. Tang, S. Baptiste, G. Medveczky, N. Artan, H. Chao, P. Mirowski, O. Devinsky, J. French, R. Kuzniecky
- 3.151** Detecting Abnormally Large-Amplitude Multi-Neuron Bursts Before Focal Neocortical EEG Seizure Onset In Freely Behaving Rats/N. Artan, P. Mirowski, H. Tang, G. Medveczky, S. Baptiste, H. Chao, O. Devinsky, R. Kuzniecky, N. Ludvig
- 3.152** Peripheral Blood Transcriptome Biomarkers For The Prediction Of Epilepsy During Early Latent Period/S. Karsten, N. Vi, A. Bragin, A. Mazarati, L. Kudo
- 3.153** Support Vector Machine Algorithms For Early Seizure Detection In An Animal Model Of Temporal Lobe Epilepsy/S. Talathi, M. Nandan, W. Ditto, P. Khargonekar, P. Carney
- 3.154** Anticonvulsant Effect Of Photoreleased GABA Using A Visible Light Emitting Diode And A Novel Caged Compound In Rat Brain Slices/X. Yang, D. Peterka, R. Yuste, S. Rothman
- 3.155** Subtracted Activated SPECT (SAS) Validates Propagation Of Direct Neurostimulation Therapy In Double Band Heterotopia White Matter/M. Rossi, O. Graf, T. Hoepfner, G. Stebbins, R. Byrne, T. Stoub, M. Stein, D. Bergen, A. Balabanov, A. Kanner, M. Smith
- 3.156** Novel High-Frequency Surface Mounted Optical Recording System For Chronic Intracranial Optical Imaging/H. Ma, M. Cox, M. Bahlke, J. Beck, M. Zhao, I. Kymissis, T. Schwartz
- 3.157** Reducing Thalamo-Cortical System Susceptibility To Large-Scale Paroxysmal Oscillations Through Customized Central Thalamic Electrical Stimulation In A Rodent Model Of Generalized Seizures/S. Nagel, A. Alexopoulos, R. O'Dwyer, T. Chen, I. Najm
- 3.158** Reduced Power Spectrum Of Pentylentetrazole-Induced Seizure Electrographic Activity From Transcutaneous Electrical Stimulation Via Concentric Ring Electrodes/W. Besio, X. Liu, K. Gale, A. Medvedev, S. Kay
- 3.159** Theta Rhythm Induction Through Deep Brain Stimulation Suppresses Interictal Epileptic Discharges/P. Pascal Lenck-Santini, M. McCue, G. Richard, J. Kleen, G. Holmes
- 3.160** Assimilating And Controlling Seizure Dynamics/G. Ullah, S. Schiff
- 3.161** Propagation Direction Of Interictal Spikes Recorded In Human Neocortex On A Fixed-Geometry Micro-Electrode Array/K. Thomson, C. Schevon, R. Emerson, P. House, R. Goodman, G. Mckhann Jr, F. Dudek, B. Greger
- 3.162** Co-Design Of Hardware And Software To Optimize Seizure Detection Algorithms Towards A Closed-Loop Epilepsy Prosthesis/S. Raghunathan, S. Gupta, H. Markandeya, K. Roy, P. Irazoqui

Clinical Epilepsy

- 3.163** Use Of Vagal Nerve Stimulator In Refractory Status Epilepticus/D. Thielemann
- 3.164** Signs Of Dysautonomia In Children With Dravet Syndrome/B. Wical, D. Leighty, M. Tervo, J. Maytum, R. Tervo
- 3.165** Seizures During Acute Lymphoblastic Leukemia Treatment In Children/I. Lee, Y. Kim, S. Chung
- 3.166** Evolution Of Benign Focal Epileptiform Discharges In Childhood/N. Le, R. Sarkis, R. Burgess, T. Loddenkemper
- 3.167** "Simple Febrile Seizures Plus (SFS+)": It Is Okay To Have More Than One Seizure Within A 24-Hour Period/Y. Ng, M. Grill
- 3.168** A Long-Term Follow-Up Study Of Dravet Syndrome Up To Adulthood/M. Akiyama, K. Kobayashi, Y. Ohtsuka
- 3.169** How Many Of My Patients Will Die? Mortality In Pediatric Epilepsy In Olmsted County, Minnesota/K. Nickels, E. Wirrell

- 3.170** Panayiotopoulos Syndrome: Clinical Features And Sequential EEG Changes/B. Lim, H. Hwang, J. Chae, K. Kim, Y. Hwang
- 3.171** Diagnostic Utility Of Microarray Analysis In Children With Epilepsy, Mental Retardation (MR) Or Neurodevelopmental Disorders (ND): One Center's Experience/H. Ezugha, H. Marks, C. Anderson, D. Khurana, A. Legido, I. Valencia
- 3.172** Epilepsy Mimicries: A One-Year Study/H. El Shakankiry
- 3.173** Electro-Clinical Correlation Of Midline Spikes: Redefining A New Syndrome/S. Kothare, M. Tracy, R. Das, F. Duffy, Y. Eksioğlu, M. Vendrame
- 3.174** Seizures In Individuals With Chromosome 15q Duplications/R. Thibert, E. Thiele
- 3.175** Provocation Of Seizures Caused By Vaccination In Children With SCN1A-Mutation/B. Tro-Baumann, A. Mueller, J. Lotte, S. Von Spiczak, I. Helbig, G. Kluger
- 3.176** Serial Electroencephalographic Findings Of Children With Epilepsy Associated With Tuberous Sclerosis/E. Lee, M. Jeong, M. Yum, T. Ko
- 3.177** Quality Of Life In Childhood Epilepsy: What Factors Explain Youth And Their Parents' Rating?/G. Ronen, D. Streiner, L. Verhey, L. Lach, M. Boyle, C. Cunningham, P. Rosenbaum
- 3.178** Screening For Bone Health In Pediatric Epilepsy Patients/A. Venkatasubramanian, D. Dlugos
- 3.179** The Risk Factors For Post-Traumatic Seizure In Children/B. Ho Cha, K. Whang, S. Jeong
- 3.180** Treatable Autonomic Paroxysms Presenting As Nonepileptic Seizures In Neurodevelopmental Disorders/V. Murugan, P. Haywood, V. Shrubbs, N. Thomas
- 3.181** Different Patterns Of Cortical Glucose Metabolism And Etiologies In Patients With Infantile Spasms/J. Byun, Y. Lee, S. Lee, H. Kim, J. Lee
- 3.182** Estimated Rate For Achieved And Maintained Seizure Freedom With Lamotrigine Monotherapy For Newly-Diagnosed Absence Epilepsy Using Results From Two Similar Trials/S. Kerls, J. Messenheimer, M. Frank, G. Holmes, A. Hammer
- 3.183** Patterns Of Internet Utilization By Parents Of Children With Epilepsy For Information And Support/M. Zak, J. Mulligan, A. Kuo, S. Weiss
- 3.184** Quality Life In Pediatric Patients With Epilepsy In Mexico/V. Lopez, E. Barragan, M. Hernandez
- 3.185** Sunlight, Strobe, Eye Closure And Eyes-Closed State In Generalized Epilepsy With Eyelid Myoclonia: More Than Meets The Eye?/J. Peters, M. Takeoka
- 3.186** EEG Confirmed Seizures In Infants With Neonatal Encephalopathy Treated With Whole-Body Hypothermia/T. Tsuchida, S. Weinstein, J. Placette, T. Chang
- 3.187** Propofol Infusion Syndrome – The Devil You Don't Know/T. Powell, A. Gregg, M. Geraghty
- 3.188** Bone Health And Age Of Onset Of Epilepsy And Antiepileptic Medication: An AED-Discordant Twin And Sibling Pair Study/S. Petty, K. Hill, M. Sakellarides, K. Lawrence, S. Berkovic, T. Fedorova, P. Sambrook, T. O'Brien, J. Wark
- 3.189** Can Intracranially Recorded Interictal Spikes Predict Seizure Onset?/Z. Agirre-Arrizubieta, K. de Gooijer, G. Huiskamp, C. Ferrier, A. van Huffelen, F. Leijten
- 3.190** Prevalence Of Epilepsy In Korea: Nationwide Study From The National Health Insurance Statistics/S. Lee, K. Jung, I. Lee, S. Lee, D. Kim, M. Kim, J. Kim, S. Lee, Y. Kim
- 3.191** Survey Of EEG Monitoring And Non-Convulsive Seizure Management In Critically Ill Patients/N. Abend, D. Dlugos, C. Hahn, L. Hirsch, S. Herman
- 3.192** Optical Coherence Tomography In Patients Taking Vigabatrin: Exploring A Structure-Function Relationship/L. Clayton, J. Duncan, S. Sisodiya, J. Acheson
- 3.193** Prevalence Of Temporal Lobe Epilepsy And Mesial Temporal Sclerosis In A Tertiary Care Hospital In Pakistan/A. Zafar, S. Quadri, F. Siddiqui, M. Sheerani, S. Enam, W. Boling, S. Ahmed
- 3.194** Where There Are No Neurologists: Decreasing The Epilepsy Treatment Gap In The Amazon/P. Espinosa, A. Berkowitz, N. Falcone, D. Dvorquez, K. Principe, W. Principe, M. Murphy, C. Shanahan, A. Kao, D. Fee, K. Swartz, S. Cash, B. Vasquez
- 3.195** Ictal Hypoventilation Contributes To Cardiac Arrhythmia And SUDEP: Report On Two Deaths And Four Potentially Life-Threatening Events In Video-EEG Monitored Patients/L. Bateman, M. Spitz, M. Seyal
- 3.196** Seizure Prognosis In Patients With Low-Grade Brain Tumors/B. Jobst, C. Kahlenberg, D. Roberts, E. Demidenko, V. Thadani, K. Bujarski, C. Fadul
- 3.197** Ictal And Postictal Respiratory Changes In Localization-Related Epilepsy/M. Seyal, L. Bateman
- 3.198** Prevalence Of Epilepsy-Related Death In An Epilepsy Clinic/J. von Gaudecker, N. Fountain
- 3.199** Improved Outcomes In Newly Diagnosed Epilepsy/M. Brodie, G. Bagnagous, P. Kwan
- 3.200** Clinical Characteristics, EEG And MRI Findings Of Partial Epilepsy In Tertiary Epilepsy Center/H. Park, J. Kang, S. Choi, E. Joo, D. Seo, S. Hong
- 3.201** Epilepsy And Neurocysticercosis In Northwest Cameroon: A Serological Study/C. Snead, J. Akenack, I. Takougang, A. Niamnshi, V. Tsang, J. Noh, P. Wilkins, M. Fongwa, J. Keystone, L. Cockburn, D. Stephens, S. Angwafor, S. Weiss, M. Smith, I. Elliott
- 3.202** Long-Term Safety Data With Lamotrigine Extended-Release: A Meta-Analysis Of 3 Controlled Clinical Trials/A. Vuong, A. Hammer, S. Kerls, P. Caldwell, J. Messenheimer
- 3.203** Pragmatic Intent-To-Treat Analysis For Lamotrigine Extended-Release From 3 Epilepsy Clinical Trials/A. Hammer, A. Vuong, S. Kerls, P. Caldwell, J. Messenheimer
- 3.204** Drug Resistance Of Mesial Temporal Lobe Epilepsy Depends On Etiology And Is Less Frequent With Cavernomas As Compared To Hippocampal Sclerosis/K. Hattamer, P. Thiel, A. Haag, X. Chen, L. Benes, H. Hamer, S. Knake, U. Sure, F. Rosenow
- 3.205** Epidemiological, Clinical And Electrophysiological Features Of Dacrystic Seizures/J. Blumberg, B. Oehl, W. Tatum, S. Schuele, A. Alexopoulos, C. Kellinghaus, A. Schulze-Bonhage, T. Loddenkemper
- 3.206** The Effect Of Intravenous Levetiracetam On Spike-Wave Activity In Patients With Idiopathic Generalized Epilepsy/T. Fakhoury, H. McKee, A. Chumley, M. Bensalem-Owen
- 3.207** Utilization Of Video In Routine EEG/J. DeWolfe
- 3.208** Factors Affecting The Provision Of Epilepsy-Related Surgical Procedures: Results From A National Inpatient Survey/T. Smith, L. Shi, M. Khan, X. Xiong, C. Bazil
- 3.209** Under Counting Epilepsy: Finding The Undiagnosed Along The Arizona – Mexico Border/D. Labiner, J. Chong
- 3.210** Do We Need Video-EEG For The Presurgical Evaluation Of Patients With Temporal Lobe Epilepsy Due To Mesial Temporal Sclerosis?/D. Yam, D. Steven, R. McLachlan, J. Burneo
- 3.211** Differential Diagnosis And Video-EEG Features Of Nocturnal Wandering/R. Silvestri, I. Arico', R. Conurso
- 3.212** Epidemiology Of Medically Refractory Epilepsy Patients Evaluated For Surgery In A Tertiary Referral Centre In Canada/R. Seetharam, D. Steven, R. McLachlan, W. Blume, J. Girvin, J. Burneo
- 3.213** An Anterior Temporal Lobectomy And Radical Amygdalohippocampectomy (ATLRA) For Mesial Temporal Sclerosis: Preoperative Risk Factors For Long-Term Seizure Control In A Highly Selected Population/R. Bollo, R. Elliott, J. Berliner, A. Silverberg, E. Geller, O. Devinsky, W. Doyle
- 3.214** Corpus Callosotomy Outcomes: To Define The Criteria For Selection Of Patient Preoperatively For Either Partial Or Complete Corpus Callosotomy/S. Kalirao, J. Hanna
- 3.215** Parasagittal And Mesial Hemispheric Intractable Epilepsy/S. Kumar, W. Blume
- 3.216** Errors In EEG Interpretations What Is Mis-Interpreted Other Than Temporal Sharp Transients?/P. Hernandez-Frau, A. Bozorg, J. Pizarro-Otero, I. Eissa, S. Benbadis

- 3.217** Fatal Status Epilepticus: A Clinico-Pathological Analysis Among 100 Patients From A Resource Poor Setting/S. Sinha, P. Satishchandra, A. Mahadevan, B. Bhimani, J. Kovur, S. Shankar
- 3.218** Towards An Easier And Safer Ketogenic Diet/J. Nathan
- 3.219** Bilateral MTL-ES: Is It A Distinct Electro-Clinical Entity?/R. Iyer, R. Ashalatha, K. Radhakrishnan
- 3.220** The Prevalence And Distribution Of The Idiopathic Generalised Epilepsies And Their Seizures In Tasmania, Australia/W. D'Souza, H. Roberts, T. O'Brien, N. Pearce, M. Cook
- 3.221** Incidence And Decision-Making For WADA Testing Over The Last Decade/R. Das, A. Alexopoulos, T. Loddenkemper
- 3.222** Does Solitary Cysticercal Granuloma (SCG) Cause Intractable Epilepsy In Developing Countries?: An Experience From A Tertiary Epilepsy Center From South India/R. Shiva Kumar, K. Radhakrishnan
- 3.223** Educating Patients With Epilepsy: A Look At What Nurses Discuss/L. Long
- 3.224** Epidemiology Of Epilepsy In The Russian Federation/A. Guekht, W. Hauser, L. Milchakova, Y. Churillin, A. Shpak, E. Gusev
- 3.225** Clinical Experience With Rufinamide (Banzel) In Patients With Intractable Epilepsy/P. Bruno, P. Venna, J. Hirshberg, J. Paolini, R. Thibert, E. Thiele
- 3.226** Sirolimus Treatment And Its Effect On Seizures In TSC: A Case Series/S. Camposano, S. Dabora, J. Paolini, E. Thiele
- 3.227** Factors Predicting Seizure Control In Patients With Idiopathic Generalized Epilepsies/J. Szaflarski, C. Lindsell, C. Banks, M. Privitera
- 3.228** Eveningness Predominates In Idiopathic Generalized Epilepsy Syndromes With Seizures On Awakening, But Not In Those With Random Circadian Distribution Of Seizures/J. Asconape, J. McGee
- 3.229** Depth Of EEG Suppression Does Not Predict Outcome Of Refractory Status Epilepticus/A. Crepeau, S. Sabesan, N. Wang, D. Treiman
- 3.230** Prevalence Of Psychogenic Nonepileptic Seizures In New Mexico/H. Saria, B. Fisch
- 3.231** Mortality In Epilepsy – Results From A Large Danish Cohort/J. Christensen, C. Pedersen, J. Olsen, P. Sidenius, M. Vestergaard
- 3.232** Predictors Of Survival In Prolonged Refractory Status Epilepticus (PRSE)/R. Kilbride, D. Costello
- 3.233** A Three-Year Therapeutic Response Follow-Up Of Patients With Juvenile Myoclonic Epilepsy And Different Reflex Traits/M. Guaranha, P. Sousa, G. de Araújo Filho, K. Lin, L. Guilloto, L. Caboclo, E. Yacubian
- 3.234** Duration Of Epilepsy And Occurrence Of Status Epilepticus/J. Langer, M. Liu, A. Tholpady, N. Fountain
- 3.235** Subclinical Seizures In Critically Ill Patients/D. Eliashiv, I. Tsimerinov, A. Pirrozi, T. Lin, C. Miller, D. Palestrant, J. Chung
- Human Imaging**
- 3.236** Quantitative Brain Surface Mapping Of Cortical Hypometabolism In Neocortical Epilepsy/B. Alkonyi, C. Juhasz, O. Muzik, E. Asano, A. Saporta, A. Shah, H. Chugani
- 3.237** Diffusion Tensor Imaging And FDG-PET Findings In Cryptogenic West Syndrome/T. Fukasawa, J. Natsume, T. Nakata, M. Naiki, Y. Azuma, H. Fukatsu, T. Ikuta, A. Okumura, T. Negoro, K. Watanabe
- 3.238** Thalamic Involvement In Patients With Prolonged Febrile Seizures: A Voxel-Based Morphometric Study/J. Natsume, A. Sofue, K. Maruyama, T. Fukasawa, T. Nakata, T. Negoro, K. Watanabe, N. Bernasconi, A. Bernasconi
- 3.239** Voxel-Based Analysis Of FDG PET Images For The Presurgical Lateralization And Localization Of Epileptic Foci In Children With Intractable Epilepsy/A. Kumar, C. Juhasz, E. Asano, O. Muzik, H. Chugani
- 3.240** Role Of The Cerebellum In Language Dominance And Processing/M. Berl, E. Duke, J. Mayo, L. Rosenberger, K. Blackstone, N. Ratner, J. VanMeter, C. Vaidya, W. Gaillard
- 3.241** Transient Focal Increase Of Interictal Glucose Metabolism In Sturge-Weber Syndrome: Implications For Epileptogenesis/C. Juhasz, H. Chugani
- 3.242** Event-Related BOLD Time Course Reflects Cortical And Sub-Cortical Interactions In Children With Typical Absence Seizures/P. Carney, R. Masterton, A. Harvey, I. Scheffer, S. Berkovic, G. Jackson
- 3.243** The Syndrome Of Bilateral Perisylvian Polymicrogyria And Arthrogyria Multiplex Congenita/A. Poduri, V. Chitsazzadeh, S. D'Arrigo, C. Pantaleoni, D. Riva, C. Busse, H. Kuester, A. Duplessis, J. Gaitanis, M. Sahin, C. Garganta, M. Topcu, K. Dies, B. Barry, J. Partlow, A. Barkovich, C. Walsh, B. Chang
- 3.244** Intellectual Abilities And Neuroanatomical Alterations In Children And Adolescents With Epilepsy/J. Hwa Lee, S. Kim, H. Lee
- 3.245** EEG-Triggered fMRI And EEG Source Analyses To Evaluate Anatomical And Functional Networks In Landau-Kleffner Syndrome/D. Brazzo, J. NThai, P. Bill, T. Pisano, S. Seri
- 3.246** Ictal SPECT In Children With Focal Cortical Dysplasia: Prognostic Value For Outcome In Epilepsy Surgery/P. Krsek, M. Kudr, B. Maton, S. Malone, A. Jahodova, P. Jayakar, C. Dunoyer, G. Morrison, J. Ragheb, T. Resnick, M. Duchowny
- 3.247** Utilization Of DTI Fiber Tractography In Corpus Callosotomy/J. Flamini, S. Palasis, L. Hayes, R. Jones
- 3.248** White Matter Abnormalities In GLUT1 Deficiency Syndrome: A Diffusion Tensor Image Study With SPM/T. Nakata, J. Natsume, T. Fukasawa, Y. Azuma, T. Negoro, K. Yanagihara, H. Fukatsu, K. Watanabe
- 3.249** Cortical Morphometry In Childhood Absence Epilepsy/D. Tosun, P. Siddarth, S. Gurbani, B. Hermann, R. Caplan
- 3.250** Post-Surgical White Matter Changes Identified Using Diffusion Tensor Imaging In Children Following Hemispherectomy/R. Munian Govindan, H. Chugani, D. Altinok, S. Sood
- 3.251** Pre- And Post-Anticonvulsive Treatment Changes In Interictal Cerebral Oxygenation And Neuronal Activity In Infants With Infantile Spasms/A. Gallagher, C. Chu-Shore, N. Roche-Labarbe, A. Surova, M. Franceschini, R. Thibert, S. Cash, E. Thiele, P. Grant
- 3.252** Clinical And Histopathological Correlates Of ¹¹C-alpha-methyl-L-tryptophan (AMT) PET Abnormalities In Children With Intractable Epilepsy/H. Chugani, A. Kumar, W. Kupsky, E. Asano, S. Sood
- 3.253** Functional MRI Language Paradigms For Presurgical Mapping In Children With Epilepsy/A. Chan, O. Bar-Yosef, D. Morris, I. Lax, W. Gaillard, W. Logan, E. Donner
- 3.254** Pediatric Functional Imaging Consortium: Sub-patterns Of Language Dominance In Pediatric Localization Related Epilepsy Identified By Data-Driven Separation Analysis/W. Gaillard, X. You, B. Bernal, M. Guillen, M. Ayala, P. Jayakar, A. Barreto, N. Rische, J. Sullivan, D. Blugos, M. Berl, J. VanMeter, D. Morris, E. Donner, B. Bjornson, M. Smith, M. Adjouadi
- 3.255** Noninvasive Cortical Imaging Of Epileptiform Activity From Interictal Spikes In Pediatric Patients/B. He, Y. Lai, X. Zhang, W. van Drongelen, M. Kohrman
- 3.256** MEG Findings And Its Concordance With Video EEG And Subdural EEG And Surgical Outcomes In Children/D. Frances Depositario-Cabacar, R. Fasano, A. Yaun, P. Pearl, J. Conry, T. Tsuchida, C. Heath, S. Sato, W. Gaillard
- 3.257** fMRI Predicts Post-Operative Language Deficit Following Epilepsy Surgery Involving Supplementary Motor Area/K. Lee, F. Mangano, J. Seo, J. Leach, C. Stevenson
- 3.258** Diffusion Tensor Imaging Following Hemispherotomy In Children/N. Specchio, D. Longo, C. Quattrocchi, V. Cannata, E. Genovese, F. Randisi, M. Cilio, M. Balestri, F. Vigeveno, L. Fusco, G. Fariello
- 3.259** Brain Development In Children With New/Recent Onset Epilepsy: A Prospective (2-Year) Controlled Cohort Investigation/B. Hermann, D. Tosun, R. Caplan, P. Siddarth, R. Sheth, A. Toga, M. Seidenberg

- 3.260** Functional Integrity Of Malformations Of Cortical Development: An fMRI Study/G. Kuchukhidze, F. Koppelstaetter, I. Unterberger, J. Dobesberger, G. Walser, J. Larch, M. Delazer, T. Gotwald, S. Felber, A. Ischebeck, E. Trinka
- 3.261** Single-Subject Voxel-Based Relaxometry For Clinical Assessment Of Temporal Lobe Epilepsy/R. Kosior, M. Lauzon, R. Sharkey, R. Frayne, P. Federico
- 3.262** Language Reorganization In Patients With Brain Lesions And Short Duration Epilepsy/E. Duke, M. Berl, L. Rosenberger, J. Conry, P. Pearl, T. Tsuchida, D. Depositaro-Cabacar, C. Heath, L. Vezina, S. Sato, W. Theodore, W. Gaillard
- 3.263** BOLD Responses To Epileptic Seizures: Variability Of Onset And Duration Detected By Non-Linear Regression/P. LeVan, L. Tyvaert, J. Gotman
- 3.264** Three-Dimensional Surface Mapping Shows Hippocampal Atrophy Contralateral And Ipsilateral To Seizure Foci In Temporal Lobe Epilepsy Patients With Depression, Or A History Of Febrile Seizures/A. Finegersh, C. Avedissian, P. Thompson, I. Dustin, W. Theodore
- 3.265** Quantitative Magnetic Resonance Imaging Findings In Idiopathic Generalized Epilepsy/C. Carlson, J. DuBois, L. Marcuse, R. Kuzniecky, O. Devinsky, C. Boo, M. Mikhly, M. Blumberg, T. Thesen
- 3.266** Sensitivity And Specificity Of EEG Source Imaging For Focus Localization In The Presurgical Evaluation/L. Spinelli, V. Brodbeck, G. Lantz, C. Pollo, K. Schaller, M. Vargas, M. Wismmeyer, C. Michel, M. Seeck
- 3.267** The Brain Subcortical Network Of Secondary Generalized Seizures: A SISCOM Study/S. Strickland, Y. Park, P. Culbertson-Brown, K. Lee, B. Choi, A. Murro, R. Kaminski, K. Drake
- 3.268** 7T Spectroscopic Imaging For Neocortical Epilepsy/J. Pan, N. Avdievich, D. Spencer, H. Hetherington, S. Spencer
- 3.269** Is Hippocampal Volume Relevant To Surgical Outcome In Mesial Temporal Lobe Epilepsy?/A. Pereira, C. Yasuda, E. Belfiore, L. Conz, J. Moraes, H. Tedeschi, E. Oliveira, F. Cendes
- 3.270** Optical Imaging Of Hemodynamic Responses To Neuronal Activity In The Human Cortex/M. Haglund, D. Hochman
- 3.271** The Topography Of FDG-PET Hypometabolism In Neocortical Epilepsy Predicts Surgical Outcome/C. Wong, A. Bleasel, L. Wen, S. Eberl, K. Byth, M. Fulham, E. Somerville, A. Mohamed
- 3.272** Usefulness Of Repeated Ictal SPECTs For Localizing Seizure Focus/J. Lee, H. Park, J. Kang, E. Joo, D. Seo, S. Hong
- 3.273** Religious Beliefs About Epilepsy Among Saudi Population: Community-Based Study/F. Bamogaddam, M. El Mubarak
- 3.274** Interactive Interictal Spike Detection Software For Simultaneous EEG-fMRI Data Using Multiway Partial Least Squares/M. Negishi, E. Novotny, D. Spencer, R. Constable
- 3.275** The Role Of Pet In MRI Negative Epilepsies/C. Özkara, S. Gokdemir, Ö. Ertürk, C. Yalcinkaya, M. Uzan, M. Hallaç, S. Albayram, B. Öz
- 3.276** White Matter Abnormality In Idiopathic Generalized Epilepsy Demonstrated With Diffusion Tractography/M. Liu, C. Lebel, C. Beaulieu, D. Gross
- 3.277** Detection Of Hemodynamic Responses To Epileptic Activity Using EEG/NIRS Simultaneous Acquisitions/A. Machado, F. Lesage, J. Lina, C. Grova
- 3.278** Structural Generalized Epilepsies In Postictal Psychosis/J. DuBois, C. Carlson, R. Kuzniecky, O. Devinsky, K. Alper, M. Blumberg, M. Mikhly, K. Starner, T. Thesen
- 3.279** Multitmodal Image Co-Registration Techniques In The Localization And Treatment Of Focal Epilepsy/T. Darcey, D. Roberts, V. Thadani, B. Jobst, K. Bujarski
- 3.280** Multimodality Imaging In Patients With Epilepsy And Malformations Of Cortical Development (MCD): fMRI, MRS And DTI/J. Burneo, R. Bartha, C. Jones
- Surgery**
- 3.281** Concordance Between Distribution Of Interictal Fast Ripples And Resection Area May Contribute To Seizure Freedom For Epilepsy Surgery/T. Akiyama, C. Go, A. Ochi, I. Sugiyama, E. Donner, S. Weiss, O. Snead III, J. Rutka, J. Drake, I. Elliott, H. Otsubo
- 3.282** Usefulness Of SISCOM (Subtraction Ictal SPECT Coregistered To MRI) In Pediatric Epilepsy Surgery/A. Takahashi, K. Kaido, Y. Kaneko, T. Otsuki, E. Nakagawa, K. Sugai, M. Sasaki, N. Sato
- 3.283** VNS In Children With Refractory Generalized Epilepsy Or Focal Epilepsy Due To Diffuse Cortical Abnormalities Or Damage/A. Cukiert, C. Cukiert, J. Burattini, P. Mariani, C. Baise, M. Argentoni-Balochi, V. Mello, C. Forster
- 3.284** Role Of Noninvasive Functional Imaging In The Treatment Of Intractable Nonlesional Epilepsy In Childhood/J. Seo, K. Holland-Bouley, D. Rose, L. Rozkhov, H. Fujiwara, J. Leach, M. Gelfand, F. Mangano, K. Lee
- 3.285** Focal Cortical Dysplasia Type IIB: Post-Operative Outcome In Relation To MRI Morphology/J. Wagner, H. Urbach, P. Niehusmann, C. Elger, J. Wellmer
- 3.286** Temporal Lobe Pleomorphic Xanthoastrocytoma And Chronic Epilepsy: Long-Term Surgical Outcome/D. Wallace, R. Byrne, D. Ruban, E. Cochran, D. Roh
- 3.287** Seizure Recurrence Risk And Early Identification Of Refractoriness After A First Seizure Following Epilepsy Surgery/L. Jehi, R. Sarkis, W. Bingaman, P. Kotagal, I. Najm
- 3.288** Corpus Callosotomy Is An Effective Treatment For Lennox-Gastaut Syndrome (LGS) In Iso-Dicentric Chromosome 15 Syndrome/C. Anderson, G. Baltuch, S. Schmitt, P. Crino
- 3.289** Surgical Outcome Following Resection Of Rolandic Focal Cortical Dysplasia/R. Sarkis, L. Jehi, W. Bingaman, I. Najm
- 3.290** This poster has been changed to Platform C.09
- 3.291** Good Practice Guidelines For Choosing The Most Appropriate Generator Site For Vagus Nerve Stimulation/S. Brown, H. Sullivan
- 3.292** Prospective Longitudinal 5- And 10-Year Seizure Outcome Of Resective Epilepsy Surgery In Sweden/K. Malmgren, I. Olsson, R. Flink, B. Rydenhag
- 3.293** Epilepsy Surgery For Pharmacoresistant Temporal Lobe Epilepsy At Hôpital Notre-Dame/W. Surbeck, A. Weil, A. Bouthillier, I. Rouleau, P. Cossette, J. Saint-Hilaire, N. Giard, D. Nguyen
- 3.294** Early Surgical Intervention Of Cavernous Malformation Improves Seizure Outcome/S. Chung, K. Smith, J. Zabramski, R. Spetzler
- 3.295** Temporal Lobe Surgery: A Comparison In Outcome Between Populations Based On MRI Findings/F. Vale, S. Benbadis
- 3.296** Quality Of Life Outcome After Temporal Or Extra-Temporal Epilepsy Surgery: A Systematic Review/H. Dhaliwal, S. Macrodimitris, S. Wiebe, J. Tellez-Zenteno, A. Metcalfe, L. Hernandez-Ronquillo, N. Jette
- 3.297** Early Somatosensory Symptoms In Refractory Temporal Epilepsy/A. Weil, W. Surbeck, A. Bouthillier, P. Cossette, L. Carmant, A. Lortie, D. Nguyen
- 3.298** Vagus Nerve Stimulation In Patients With Tuberosus Sclerosis Complex: Efficacy Of New Implantations And Association Of Device Inefficacy With Subsequent Outcome Of Intracranial Epilepsy Surgery/S. Kalthorn, R. Elliott, C. Carlson, Y. Moshel, H. Weiner, O. Devinsky, W. Doyle
- 3.299** Are We Running Out Of Temporal Lobe Epilepsy Patients With Hippocampal Sclerosis? A Mono-Centric, 22-Year Retrospective Of 1,280 Patients With Temporal Lobe Epilepsy/C. Helmstaedter, M. von Lehe, H. Clusmann, C. Elger, J. Schramm
- 3.300** Seizure Outcome After Selective Amygdalo-Hippocampectomy In Bilateral Compared To Unilateral Ammon's Horn Sclerosis/M. Malter, H. Tschampa, H. Urbach, M. Von Lehe, H. Clusmann, C. Elger, C. Bien
- 3.301** Complications After Temporal Or Extra-Temporal Epilepsy Surgery – A Systematic Review/W. Hader, S. Wiebe, J. Tellez-Zenteno, C. Kwon, N. Jette
- 3.302** A Novel Method For SEEG Implantation/J. Gonzalez-Martinez, M. von Roden, J. Bulacio, I. Najm, W. Bingaman

- 3.303** The Tuberous Sclerosis Complex Natural History Database Project/ J. Nakagawa, V. Whittemore, M. Cinkosky, S. Sparagana, E. Thiele, C. Brown, M. Frost, W. McClintock, E. Bebin, M. Kohrman, H. Northrup, J. Wu, P. Levisohn, S. Koh, A. Gupta, S. Ashwal, M. Duchowny, I. Miller, J. LaJoie, A. Jansen
- 3.304** Social Outcomes After Temporal Or Extra-Temporal Epilepsy Surgery: A Systematic Review/C. Kwon, L. Hamiwka, L. Macrodimitris, J. Tellez-Zenteno, S. Wiebe, A. Metcalfe, L. Hernandez-Ronquillo, N. Jette
- 3.305** Utility Of Functional Imaging Localization Tests On Epilepsy Surgery Decision-Making/R. Knowlton, N. Limdi, R. Elgavish, A. Paige, H. Kim, K. Riley, J. Blount, M. Kilgore
- 3.306** Cortical Ependymoma: An Unusual Epileptogenic Lesion/ J. Van Gompel, F. Meyer, K. Koeller, W. Marsh, G. Cascino, G. Worrell, C. Giannini
- 3.307** Amygdala Dysplasia In Temporal Lobe Epilepsy/M. Iwasaki, N. Nakasato, H. Suzuki, T. Tominaga
- 3.308** Outcomes After Epilepsy Surgery For Malformations Of Cortical Development/N. Barbaro, E. Chang, D. Wang, A. Barkovich, T. Tihan, J. Sullivan, P. Garcia

Neuropathology of Epilepsy

- 3.309** Understanding The Supports Of The Limbic Acute T2 Hypersignal Following Status Epilepticus Induced By Pilocarpine In Rats/E. Azabou, P. Sanchez, F. Navarro, A. Montavont, S. Bouvard, P. Ryvlin, L. Bezin
- 3.310** Urokinase-Type Plasminogen Activator Regulates Post-Injury Neurodegeneration And Neurogenesis But NOT Vascular Changes In The Mouse Hippocampus/X. Ndeke Ekane, L. Lahtinen, F. Barinka, Y. Akamine, J. Rantala, A. Pitkänen
- 3.311** Downregulation Of Potassium Channel Subunits KCNQ2 And KCNQ3 Following Pilocarpine Induced Seizures/ E. Pineda, D. Shin, A. Mazarati, R. Sankar
- 3.312** Spatio-Temporal Characterization Of Very Fast Oscillations In Hippocampus/I. Naggar, R. Orman
- 3.313** Time Course Of The Inflammatory Cell Response Following Status Epilepticus In The Developing Brain/ J. Niquet, M. Lopez-Meraz, C. Wasterlain
- 3.314** Does Perinatal Cortical Photothrombic Ischemic Stroke Induce Epileptogenesis In Rat?/J. Otahal, T. Jason, A. Hráčová, C. Brozickova, V. Feštrová, N. Mikulecká, H. Kubová
- 3.315** A Comparison Of Surgical Pathologies Between Epileptic Spasms And Partial Seizures In Children/Y. Inage, W. Halliday, H. Otsubo
- 3.316** Brain Inflammation In A Rat Model Of Post-Traumatic Epilepsy (PTE): Focus On The IL-1 β System/A. Vezzani, T. Ravizza, J. Nissinen, I. Kharatishvili, I. Vanzulli, A. Pitkänen
- 3.317** Heterogeneous Impact Of Status Epilepticus On The Apical Dendritic Structure Of Adult-Generated Granule Cells/S. Danzer, B. Murphy, A. Loepke, R. Pun
- 3.318** Anticonvulsive Effects Of Insulin-Regulated Aminopeptidase Deletion In A Pentylene-tetrazol Mouse Seizure Model Are Not Mediated By The Accumulation Of Somatostatin-14/E. Loyens, A. Schallier, D. De Bundel, H. Demaegdt, S. Chai, A. Albiston, G. Vauquelin, P. Vanderheyden, Y. Michotte, I. Smolders
- 3.319** Reorganization Of The Supramammillo-Hippocampal Pathway In The Pilocarpine Model Of Temporal Lobe Epilepsy/R. Soussi, J. Boulland, L. Ferhat, M. Esclapez
- 3.320** Seizure-Induced Hippocampal Neurogenesis Requires The bHLH Transcription Factor NeuroD/J. Hsieh, K. Ure
- 3.321** Role Of Periventricular Nodular Heterotopia In The Propagation Of Epileptiform Discharges In Brain Slices From MAM Rats/N. Tschuluun, P. Schwartzkroin, H. Wenzel
- 3.322** PAF Antagonism During Epileptogenesis/A. Musto, N. Bazan
- 3.323** Surviving Hilar Somatostatin Interneurons Enlarge, Sprout Axons, And Form New Synapses With Granule Cells In A Mouse Model Of Temporal Lobe Epilepsy/W. Zhang, R. Yamawaki, X. Wen, J. Uhl, J. Diaz, D. Prince, P. Buckmaster
- 3.324** The Control Of Kainic Acid-Induced Status Epilepticus/ K. Vermoesen, I. Smolders, A. Massie, Y. Michotte, R. Clinckers
- 3.325** Decreased Expression Of vGLUT1 Increases Vulnerability To Seizures/ A. Schallier, A. Massie, E. Loyens, D. Moechars, Y. Michotte, I. Smolders
- 3.326** Pharmacological And Neurochemical Characterisation Of The Involvement Of Hippocampal Adrenoreceptor Subtypes In The Modulation Of Acute Limbic Seizures/ R. Clinckers, I. Smolders, T. Zgavc, K. Vermoesen, Y. Michotte
- 3.327** The Effects Of Paradoxical Sleep Deprivation On Pilocarpine-Induced Temporal Lobe Epilepsy: A Possible Protective Effect?/G. Matos, E. Kinjo, R. Pestana, E. Vicente, A. Santos, K. Sameshima, G. Xavier, L. Britto, A. Valle
- 3.328** Therapeutic Failure Of Ablative Cyclophosphamide Treatment In Rasmussen's Encephalitis/ V. Ramaswamy, D. Sinclair, L. Resch, F. Giuliani, T. Snyder, A. Woods, B. Wheatley, E. Johnson, C. Power, D. Gross
- 3.329** Cellular Density Of Human Hypothalamic Hamartomas/A. Strobel, K. Simeone, S. Coons, J. Kerrigan
- 3.330** The Effects Of Hippocampus CA1 Single Neuron Firing Properties On Interictal Spike Patterns During Seizure Onset In A Rat Model Of Temporal Lobe Epilepsy/J. Zhou, S. Talathi, A. Cadotte, Z. Liu, G. Holmes, P. Carney

- 3.331** Increased PLA2 Activity In The Hippocampus Of Patients With Mesial Temporal Sclerosis And Psychosis/ L. Talib, K. Valente, N. Barbosa, S. Vincentiis, W. Gattaz
- 3.332** Impaired Inhibition Of CA1 Pyramidal Cells In Aged Rodent Hippocampus/D. Mott, E. Stanley, J. Fadel
- 3.333** Morphological Characteristics In Patients With Temporal Lobe Epilepsy/ J. Villeda, M. Alonso-Vanegas, L.L. Rocha, S. Orozco-Suarez, L. Osorio-Rico
- 3.334** Reactive Oxygen Species And Neuronal Death In The Rat Model Of Temporal Lobe Epilepsy Induced By Pilocarpine/E. Kinjo, R. Pestana, M. Hernandez, L. Britto
- 3.335** Spontaneous Epilepsy And Neuronal Hyperexcitability In Kv12.2 -/- Mice/F. Bertaso, X. Zhang, J. Yoo, C. Schmedt, S. Clancy, J. Noebels, T. Jegla
- 3.336** Modifications In The RNAm Expression Of GABA_A Receptor Subunits, gat-1 And gat-3 Transporters In Tissue Of Patients With Temporal Lobe Epilepsy Resistant To Pharmacology Treatment/ S. Orozco-Suarez, D. Escalante-Santiago, I. Fera-Romero, L. Rocha, M. Alonso-Vanegas, J. Villeda, H. Nicolini-Sánchez, A. Velasco
- 3.337** In Vivo Study Of The Impact Of Amygdala Kindling On The Firing Pattern Of Single Neurons In The Thalamus In A Genetic Absence Epilepsy Rat Model/ N. Carcak, F. Onat, D. Pinault, T. O'Brien
- 3.338** Age-Dependent Induction Of IL-1 β In The Frontoparietal Cortex Of Genetic Absence Epilepsy Rats From Strasbourg (GAERS): Implications For Spike-And-Wave Development/D. Akin, I. Vanzulli, R. Aker, A. Vezzani, T. Ravizza, F. Onat
- 3.339** TNFR1 Expression In The Developing Rat Brain After Status Epilepticus/M. Lopez-Meraz, D. Alvarez-Croda, J. Manzo
- 3.340** Accelerated Limbic Epileptogenesis Following Early Life Stress Is Associated With Enhanced Corticosterone Response, Hippocampal Cell Loss And Neurogenesis/G. Kumar, N. Jones, S. Rees, M. Morris, T. O'Brien, M. Salzberg
- 3.341** Distinct CB1R-Mediated Control Of GABA Release From Somatic And Dendritic CCK+ Interneurons In The Hippocampus/S. Hun Lee, C. Földy, I. Soltesz
- 3.342** Stem Cell Protein Expression And mTOR Pathway Activation Distinguishes Type I From Type II Focal Cortical Dysplasias/V. Tsai, K. Orlova, M. Baybis, G. Heuer, S. Sisodiya, M. Thom, K. Strauss, E. Aronica, P. Storm, P. Crino
- 3.343** Effect Of Neonatal Seizures On Spontaneous And Miniature Inhibitory Post-Synaptic Currents In Rat Somatosensory Cortex/E. Isaeva, D. Isaev, G. Holmes

- 3.344** CCR2 Expression Is Up-Regulated In The Hippocampus After Pilocarpine-Induced Seizures/M. Foresti, G. Arisi, A. Montañez, L. Shapiro
- 3.345** Molecular Characterization Of A New Spontaneous Genetic Rat Model Of Generalized Epilepsy With Absence Seizures/A. Valle, C. Maurer-Morelli, C. Rocha, M. Chamma, S. Botte, I. Lopes-Cendes
- 3.346** The Effects Of Paradoxical Sleep Deprivation On Absence Seizures In Rats/E. Vicente, G. Matos, K. Sameshima, A. Valle
- 3.347** A Central Role For The mTOR Cascade In Reactive Astrogliosis/C. Mikell, R. McGovern, Z. Wright, A. Sosunov, X. Wu, A. Ducruet, E. Connolly, G. McKhann
- 3.348** Probing States Of Vigilance To Predict Epileptic Seizures/S. Sunderam, N. Chernyy, J. Mason, S. Weinstein, S. Schiff, B. Gluckman
- 3.349** Auto-Immune Basis Of Rasmussen Encephalitis: Development Of A New Animal Model/L. Carmant, M. Ouardouz, F. Fontaine, D. Hebert, M. Connolly, D. Nguyen, Y. Robitaille, E. Haddad
- 3.350** Dravet Syndrome: Clinical, Genetic, And Neuropathological Characterization In A Series Of Patients/C. Catarino, J. Liu, I. Liagkouras, R. Birch, S. Zuberi, M. Koepp, L. Martinian, M. Thom, S. Sisodiya
- 3.351** Abnormal Proliferation And Migration After Recurrent Early-Life Seizures: A Role For Metabotropic Glutamate Receptors/G. La Torre, D. Simsovits, M. Corcia, L. Friedman
- 3.352** Similar Activation Of GIN Inhibitory Cells Yields Different Downstream Effects On Excitatory Cells/E. Faselow, A. Kinnischtzke
- 3.353** A Novel Signaling Pathway Governing The Control Of Parvalbumin-Expressing Basket Cells By CCK In The Rat Hippocampus/S. Yeun Lee, C. Foldy, J. Szabadics, L. Hilgenberg, M. Smith, I. Soltesz
- 3.354** Thalamic Lesions Increase The Frequency Of Spiking During Sleep/E. Tas, M. Takeoka, J. Molino, M. Gregas, Y. Eksioğlu, A. Rotenberg, S. Kothare, T. Loddenkemper
- 3.355** Differential Regulation Of Synaptic Plasticity In Epilepsy/S. Iyengar, D. Mott
- 3.356** Glutamine Potentiates Glutamate Release During High-Frequency Stimulation Of Isolated Layer 1 Axons/R. Reimer, H. Tani, C. Dula, J. Huguenard
- 3.357** Origin And Characteristic Of Scar Astrocytes/A. Sosunov, X. Wu, C. Mikell, R. McGovern, Z. Wright, P. Derosa, A. Ducruet, E. Connolly, R. Goodman, G. McKhann
- 3.358** Non-Response To Antiepileptic Drug Therapy With Valproate Is Associated To CYP2C9 *2 AND *3 Genotype In Young Patients With Epilepsy/E. Ojopi, W. Gattaz, S. Thome-Souza, K. Valente
- 3.359** Differences Between Epileptogenic Tubers In Tuberous Sclerosis Complex (TSC) 1 And 2/C. Batista, D. Chugani, A. Luat, R. Govindan, X. Lu, C. Juhasz, O. Muzik, H. Chugani
- 3.360** The Location Of The Cortical Focus In The GAERS Model Of Absence Epilepsy Is In The S2 Region Of The Somatosensory Cortex/T. Zheng, T. O'Brien, M. Morris, L. van Raay, V. Jovanovska, A. Gandrathi, D. Pinault
- 3.361** Selective VEGF Inhibition Using PTK787 Decreases Spontaneous Seizure Expression In The Epileptic Rat Brain/K. Jenrow, C. Liccardello, K. Lapanowski, D. Evans, K. Elisevich

AMERICAN
EPILEPSY
SOCIETY

EPILEPSY CURRENTS

The Journal of the American Epilepsy Society

Receive ***Epilepsy Currents*** with your AES Membership

Epilepsy Currents is a bi-monthly current-awareness journal providing reviews, commentaries and abstracts from the world's literature on the research and treatment of epilepsy. Each issue is divided into two main sections; Basic Sciences and Clinical Sciences. An outstanding Editorial Board reviews the literature and assigns topics and articles to world experts for comment.

The Epilepsy Currents editors are looking for topics you would like to see covered in the journal. Please forward any suggestions you have to ctubby@aesnet.org.

b

Blackwell
Science



*Pamela and Charles L. Shor Foundation
for Epilepsy Research*

A Special Thanks to the Pamela and Charles L. Shor Foundation for Epilepsy Research for Providing the Annual Meeting Tote

Up to two-thirds of people with epilepsy report that stress may trigger seizures. The Pamela and Charles L. Shor Foundation for Epilepsy Research was established to understand and prevent the effects of stress on people with epilepsy. The Foundation aims to fund research and educate clinicians, investigators and patients about the latest advances in the field. A yearly workshop held in Cincinnati has gathered investigators from around the United States, and a consortium capable of performing multicenter studies is now being organized. A Web site providing access to information for investigators, clinicians and patients is under development. Further information on the Foundation can be obtained by contacting Michael Privitera, M.D., Medical Director of the Pamela and Charles L. Shor Foundation for Epilepsy Research. E-mail: michael.privitera@uc.edu

TUESDAY December 8, 2009

9:00 a.m. – 10:30 a.m.

Plenary II: The Postictal and Interictal Periods: What Are We Missing? (1.5 CME Credits)

Sheraton – Grand Ballroom, 2nd Floor

Overview

Clinical epilepsy has traditionally focused on “the seizure” as the measure of morbidity. Yet even for patients with refractory epilepsy, seizures occupy a tiny fraction of their lives. This course will address the cognitive (e.g., memory, attention), behavioral (e.g., depression, psychosis), physical (e.g., headache) and electrophysiological features of the postictal and interictal states in children and adults. Lessons from animal models of epilepsy help to understand the pathophysiology of these changes. The clinical spectrum as well as the frequency and severity of symptoms outside the ictal period will be reviewed. Diagnostic, preventive, and therapeutic strategies will be discussed.

Learner Outcomes

- ▶ Improved ability to recognize and assess interictal cognitive and behavior complications in patients with epilepsy so that they are evaluated and treated appropriately
- ▶ Increase the detection of postictal cognitive and behavioral complications in patients with epilepsy so that they are addressed in planning treatment
- ▶ Using increased understanding pathophysiology of interictal and postictal cognitive and behavior problems in animal models, apply this understanding of underlying mechanisms to patients and plan appropriate interventions.

Target Audience

Neurologists, nurses, neurophysiologists, behavioral scientists and neuroscientists

Program

Co-Chairs: Orrin Devinsky, M.D. and Bruce P. Hermann, Ph.D.

Opening Remarks

Orrin Devinsky, M.D.

The Role of Interictal Activity on Cognitive and Behavioral Function

Robert S. Fisher, M.D., Ph.D.

What Can Animals Teach Us About Postictal and Interictal Behavior?

Gregory L. Holmes, M.D.

Does Postictal Behavior Predict Interictal Behavior?

Orrin Devinsky, M.D.

Postictal Symptoms: Diagnosis and Treatment

Siddhu Nadkarni, M.D.

Credit Designation

The American Epilepsy Society designates this educational activity for a maximum of 1.5 *AMA PRA Category 1 Credits*™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Pharmacy Credit

ACPE #073-999-09-126-L01-P; 0.15 CEUs

Acknowledgment

This program is supported by an educational grant from Pfizer Inc.

11:00 a.m. – 12:30 p.m.

ILAE Symposium: Redefining Treatment Resistant Epilepsy (1.5 CME Credits)

Sheraton – Grand Ballroom, 2nd Floor

Overview

Although the concept of refractory epilepsy may appear to be self-explanatory and intuitive at first glance, a precise definition has remained elusive. This has resulted in diverse criteria being used by different clinicians and researchers, making it difficult to compare results across studies and to make recommendation for clinical practice. It is hoped that a consensus definition proposed by the ILAE will have global impact in improving patient care and facilitating clinical research. This session will discuss the difficulty in deriving the definition, will explain the new ILAE definition, and will outline future plans to use the definition.

Learner Outcomes

- ▶ Assess response to therapy and assign a category of response to AED therapy (response, failure, inadequate trial)
- ▶ Determine timing for referral of patients for non-medical therapies in refractory patients
- ▶ Apply understanding of the new ILAE definition for treatment resistant epilepsy
- ▶ Define medical intractability in children using the new ILAE definition applies to children with epilepsy.

Target Audience

Neurologists epileptologists, advanced practice nurses and neuropsychologists

Program

Co-Chairs: Jacqueline A. French, M.D. and Samuel Wiebe, M.D.

Opening Remarks

Samuel Wiebe, M.D.

Complexities in Defining Treatment Resistance

Patrick Kwan, M.D., Ph.D.

ILAE Definition of Refractory Epilepsy

Anne T. Berg, Ph.D.

Consideration of Special Populations

Alexis A. Arzimanoglou, M.D.

The Future: Where Do We Go From Here?

Jacqueline A. French, M.D.

Wrap-up

Credit Designation

The American Epilepsy Society designates this educational activity for a maximum of 1.5 *AMA PRA Category 1 Credits*™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Pharmacy Credit

ACPE #073-999-09-127-L01-P; 0.15 CEUs

Acknowledgment

This program is supported by an educational grant from Lundbeck.

ILAE would like to recognize Dr. Susan Spencer for her contributions to global education and the Global Campaign as well as her efforts in drafting the North American Declaration and founding *Epilepsy Currents*.

12:45 p.m. – 2:15 p.m.
Special Interest Group Meetings

Location listed under each session

Controversies in Epilepsy

Hynes – Room 302, Level 3

Coordinator: Hans O. Luders, M.D., Ph.D.

Speakers: Philippe Kahane, M.D., Mohamad Koubeissi, M.D., Felix Rosenow, M.D.

Videotapes of epileptic seizures will be presented by the moderator (Hans O. Luders). The moderator will then ask the audience and the assigned discussants (Drs. Kahane, Koubeissi and Rosenow) to analyze the ictal symptomatology of the seizures and to try to deduce the seizure onset zone and the symptomatogenic zone. After the discussion of each case, the moderator will show 2 - 3 slides (interictal EEG, ictal EEG, MRI, etc.) documenting the correct answers and quoting pertinent literature. Attempts will be made to show typical cases that illustrate the value of ictal semiology.

Acknowledgment

This SIG is supported by Pfizer Inc.

Genetics

Hynes – Room 207, Level 2

Coordinators: Andrew P. Escayg, Ph.D., Jennifer Kearney, Ph.D.

Speakers: TBD

This year's Genetics SIG topic is Mutation Identification State of the Art. We will discuss current and emerging technologies for mutation identification in epilepsy patient populations. The topics will include detection of sequence variants, copy number variants, and cytogenetic abnormalities. In addition we will discuss issues related to sample collection efforts.

Ketogenic Diet

Hynes – Room 208, Level 2

Coordinator: Eric Kossoff, M.D.

Speakers: Elizabeth J. Donner, M.D., FRCP(C), Stephane Auvin, M.D., Ph.D. (1st debate), Douglas Nordli, Jr., M.D. (2nd debate), Carl E. Stafstrom, M.D., Ph.D.

This year we will have two debates, following the success of the 2007 AES ketogenic diet SIG debates. The first debate will discuss whether the ketogenic diet is effective mechanistically due to carbohydrate restriction or providing extra fats. The second debate will be regarding whether the ketogenic diet can be successfully (and practically) implemented as a first-line therapy.

Pediatric Epilepsy Case-Based Discussion

Hynes – Room 304/306, Level 3

Coordinator: Elaine Wyllie, M.D.

Speakers: TBD

Six dynamic faculty will each present an exciting case from his or her clinical experience that teaches an important clinical point and advances our field of pediatric epilepsy. Topics include EEG, seizure semiology, genetics, neuroimaging, antiepileptic drug therapy, epilepsy surgery, and psychosocial comorbidity. We encourage audience interaction!

Practice Management Course

Hynes – Room 206, Level 2

Moderator: Gregory L. Barkley, M.D.

Speakers: TBD

This year's course will discuss the healthcare reform package from Congress, if any. In addition, we will review updates to ICD9 codes and other financial issues for 2010 including the proposed elimination of reimbursement for outpatient consultations and the impact this could have on epileptologists.

SUDEP

Hynes – Room 210, Level 2

Coordinators: Jeffrey Buchhalter, M.D., Ph.D., Elson L. So, M.D.

Speakers: Jeffrey R. Buchhalter, M.D., Ph.D., Samuel Wiebe, M.D., Joan Austin, D.N.S., RN

As a result of the 2007 AES-EF SUDEP Task Force and the 2008 NINDS SUDEP Workshop, a SUDEP Coalition has been formed to advance research and education in SUDEP. The ongoing work of the Coalition will be presented, and input and participation will be sought from the SIG audience.

1:45 p.m. – 3:15 p.m.

Plenary III: ICU Monitoring (1.5 CME Credits)

Sheraton – Grand Ballroom, 2nd Floor

Overview

Continuous EEG (CEEG) is underutilized in encephalopathic, critically ill patients; thus, these patients either remain undiagnosed with non-convulsive seizures, or are diagnosed later when the seizures are more difficult to treat. Neurologists should be able to recognize the ictal and periodic patterns commonly seen in critically ill patients, and the large overlap in these patterns based on EEG alone. Some patterns are falsely considered definite seizures and others as definitively metabolic. We will review available evidence regarding these EEG patterns and their significance (are they harmful?), including data from well controlled animal studies and from invasive multimodality monitoring in humans. New official recommendations on when and how to perform CEEG will be presented. Discussions about the differences between current practice and expert consensus will be reviewed, with attention to areas of controversy.

Learner Outcomes

- ▶ Compare the EEG patterns seen in animal models of acute brain injury with those seen in critically ill patients, and evaluate evidence on whether these EEG patterns are associated with neuronal injury
- ▶ Identify EEG patterns commonly encountered in ICU patients (ictal and periodic patterns) to enable rational treatment decisions for nonconvulsive status epilepticus
- ▶ Describe the technical requirements for CEEG monitoring in the ICU to optimize utility of CEEG monitoring
- ▶ Evaluate the evidence that identification and treatment of nonconvulsive seizures improves neurologic outcome.

Target Audience

Neurologists, neuro-intensivists, electroencephalographers, neurosurgeons and neurodiagnostic technologists

Program

Co-Chairs: Susan T. Herman, M.D. and Lawrence J. Hirsch, M.D.

Secondary Brain Injury from Nonconvulsive Seizures, Periodic Discharges and Other Depolarizations: Evidence from Animals and Humans
Jed Hartings, Ph.D.

Periodic Discharges and Other Controversial EEG Patterns
Nathan B. Fountain, M.D.

The New ICU EEG Monitoring Consensus Statement: Rationale and Implementation

Susan T. Herman, M.D.

CEEG: The Cutting Edge and Beyond
Lawrence J. Hirsch, M.D.

Credit Designation

The American Epilepsy Society designates this educational activity for a maximum of 1.5 *AMA PRA Category 1 Credits*™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Pharmacy Credit

ACPE #073-999-09-128-L01-P; 0.15 CEUs

Acknowledgment

This program is supported by an educational grant from UCB, Inc.

2:30 p.m. – 4:00 p.m.

Special Interest Group Meetings

Location listed under each session

Neuroimaging: Imaging Evidence of White-Matter Damage in MTLE

Hynes – Room 210, Level 2

Coordinator: Fernando Cendes, M.D., Ph.D.

Speakers: Donald Gross, M.D., FRCP(C), Matthias Koepp, M.D.

White matter tracts have been considered to have a passive role in epileptogenesis restricted to seizure propagation. However, there has been increasing imaging evidence of extensive white-matter abnormalities in patients with mesial temporal lobe epilepsy (MTLE), in particular, but not exclusive, of the primary limbic pathways. These white-matter abnormalities have related to worse cognitive function, interictal psychosis, and seizure outcome. We will discuss recent studies using voxel-based morphometry (VBM), diffusion tensor imaging (DTI), and other imaging methods that investigated white-matter abnormalities in MTLE.

Psychiatry

Hynes – Room 208, Level 2

Coordinator: Andres M. Kanner, M.D.

Speakers: John J. Barry, M.D., Rochelle Caplan, M.D.

In December 2008, the FDA instructed all manufacturers of antiepileptic drugs (AEDs) to include a warning indicating an increased suicidal risk associated with these drugs. The warning clearly and unambiguously states the need to screen for psychiatric disorders associated with suicidality and to monitor the emergence of suicidal ideation or behavior while the patient is taking the AED. This year's SIG will focus on how clinicians can easily screen for suicidal risk in pediatric and adult populations of patients with epilepsy and will review practical algorithms to help decide when patients need to be evaluated immediately by mental health professionals. Finally, the medical-legal implications of the FDA warning will be discussed with a lawyer who has expertise in this field.

Women's Issues in Epilepsy

Hynes – Room 207, Level 2

Coordinators: Katherine Noe, M.D., Ph.D., Romila Mushtaq, M.D.

Speakers: Raj D. Sheth, M.D., Katherine Nickels, M.D.

The 2009 SIG will focus on issues specific to the adolescent female with epilepsy. The biologic and psychosocial impact of seizures and antiepileptic therapy in this age group will be discussed, with a focus on menstrual cycle disorders, contraception, and bone development.

The American Epilepsy Society is proud to offer repurposed Annual Meeting Sessions.

These online sessions deliver interactive knowledge as presented at previous Annual Meetings. These sessions are intended to provide quality continuing medical education for physicians, researchers and other professionals whose goal is to improve the quality of life for those afflicted with epilepsy and other seizure-related disorders. These programs can be accessed via the AES Web site. Repurposed programs from the 2008 Annual Meeting are noted below:

2008 ANNUAL MEETING SESSIONS

Annual Fundamentals of Epilepsy: Neurosurgical Evaluation

Childhood Absence Epilepsy Symposium: New Insights Into an Old Syndrome

Hot Topics Symposium: Improving Pregnancy Outcomes in Women with Epilepsy

Suicidality Forum Discussion

EMU Symposium: Expert Consensus Process on Patient Safety in the Epilepsy Monitoring Unit

Merritt-Putnam Symposium: Epileptogenic Cortical Dysplasia: Emerging Trends in Diagnosis, Treatment and Pathogenesis

AET Symposium: When Monotherapy Fails

Spanish Symposium: Malformations of Cortical Development: Pathogenesis, Neuroimaging, Clinical Spectrum and Treatment

Annual Course: Matching Treatments to Seizures and Syndromes

Professionals in Epilepsy Care Symposium: The Evaluation and Treatment of Patients with Developmental Delay and Epilepsy: A Multidisciplinary Approach

Presidential Symposium: Technology and Human Investigation in Epilepsy: A Window to Brain Function, a Bridge to Patient Care

Pediatric State of the Art Symposium: Infantile Spasms: Emerging Therapies, Novel Mechanisms

Epilepsy Around the World: Neuro-infections

Plenary II: Surgical Controversies in the Treatment of MTLE: How to Get There and What to Do When You Get There

Plenary III: Dravet Syndrome: Translational Research from Mouse to Man

EXHIBITOR FLOOR PLAN



Exhibit Hall Hours:

- Sunday, December 6 5:00 p. m. - 7:00 p. m.
- Monday, December 7 9:00 a. m. - 4:00 p. m.
- Tuesday, December 8 8:00 a. m. - 1:30 p. m.

Hynes - Exhibit Hall, Level 2

EXHIBITORS

EXHIBITOR LOCATIONS

*Denotes Passport to Prizes Participants as of 10/01/09

ABCN.....	Table 5	John Libbey EUROTExT.....	Booth 908
ABRET.....	Table 4	Kappametrics Inc.....	Booth 422
Ad-Tech Medical Instrument Corp.....	Booth 507	LEAD/Health Learning Systems.....	Booth 513
AED Pregnancy Registry.....	Booth 521	LGS Foundation.....	Table 11
American Express Open.....	Booth 323	Lippincott Williams & Wilkins.....	Booth 423
AnalyzeDirect, Inc.....	Booth 722	Lundbeck*.....	Booths 413 & 517
Angelman Syndrome Foundation.....	Booth 912	Meda Pharmaceuticals Inc.....	Booth 505
Angioma Alliance.....	Table 8	National Association of Epilepsy Centers.....	Booth 1025
The Anita Kaufmann Foundation.....	Table 2	Natus Medical Incorporated.....	Booth 713
Athena Diagnostics, Inc.....	Booth 319	Neuralynx Inc.....	Booth 811
Blackrock Microsystems.....	Booth 612	neuroConn GmbH.....	Booth 522
Cadwell Laboratories, Inc.....	Booth 412	NeuroLogica.....	Booth 600
CareFusion (formerly Cardinal Health).....	Booth 1001	NeuroNexus Technologies*.....	Booth 1029
Clever Sys., Inc.....	Booth 1019	Nihon Kohden America, Inc.....	Booth 607
CNS Vital Signs.....	Booth 418	NINDS – National Institute of Neurological Disorders and Stroke.....	Booth 424
Cochrane Epilepsy Group.....	Table 1	Nutricia North America.....	Booth 616
Compumedics USA*.....	Booth 707	Optima Neuroscience.....	Booth 1021
CURE: Citizens United for Research in Epilepsy.....	Table 15	Oxford University Press.....	Booth 622
Cyberonics, Inc.....	Booth 901	Pfizer Inc.....	Booth 101
Data Sciences International.....	Booth 910	Pinnacle Technology Inc.....	Booth 223
Demos Medical Publishing.....	Booth 1027	PMT Corporation*.....	Booth 813
DigiTrace – Subsidiary of SleepMed, Inc.....	Booth 620	Questcor Pharmaceuticals, Inc.*.....	Booths 313 & 801
Dixi Microtechniques.....	Booth 720	RhythmLink International, LLC.....	Booth 317
Eisai Inc.*.....	Booth 401	The Ring Chromosome 20 Foundation.....	Table 9
Electrical Geodesics, Inc. (EGI)*.....	Booth 606	Ripple LLC.....	Booth 1031
Elekta, Inc.....	Booth 719	Sepracor Inc.....	Booth 613
Elsevier Mosby Saunders.....	Booth 809	STATKING Consulting, Inc.....	Booth 523
Epilepsy Foundation.....	Booth 621	Stellate Systems*.....	Booth 701
Epilepsy Phenome/Genome Project*.....	Table 7	SynapCell.....	Booth 322
Epilepsy Therapy Project.....	Table 3	Transgenomic, Inc.*.....	Booth 416
www.epilepsycongress.org.....	Table 14	Tuberous Sclerosis Alliance.....	Table 10
Family Studies in Epilepsy at Columbia University....	Table 13	Tucker-Davis Technologies.....	Booth 1023
GlaxoSmithKline.....	Booth 601	UCB, Inc.*.....	Booth 201
Grass Technologies, An Astro-Med, Inc. Subsidiary ..	Booth 919	Valeant Pharmaceuticals.....	Booth 501
The IDEA League.....	Table 6	Wiley-Blackwell/John Wiley & Sons.....	Booth 914
Integra NeuroSciences.....	Booth 604		
Intractable Childhood Epilepsy Alliance.....	Table 12		

Participate in the AES PASSPORT TO PRIZES PROGRAM!



In your AES Annual Meeting tote, you will find a Passport brochure. To be included in the drawing to win a variety of great prizes, visit all of the participating exhibitors to get your Passport validated.

When all boxes have been validated, complete your contact information and drop the Passport in the raffle drum located in the Epilepsy Resource Center (Booth #819). All entries must be received by 11:00 a.m. on Tuesday, December 8. The drawing will be held during lunch in the exhibit hall on that day.

Participants must be present to win. See your Passport brochure for a list of participating exhibitors.

EXHIBITORS

ABCN

Table #5
2509 W Iles Ave - Ste 102
Springfield, IL 62704
Phone: 217-726-7980
Fax: 217-726-7989
Email: abcn@att.net
URL: www.abcn.org
Contact: Ms. Janice Walbert
The ABCN offers an advanced exam in central Clinical Neurophysiology. Candidates may select to focus on Epilepsy Monitoring, Intraoperative Monitoring, or on General Neurophysiology. ABCN certifications have been recognized as the gold standard in advanced Clinical Neurophysiology for over 60 years.

ABRET

Table #4
2509 W Iles Ave - Ste 102
Springfield, IL 62704
Phone: 217-726-7980
Fax: 217-726-7989
Email: abreteo@att.net
URL: www.abret.org
Contact: Ms. Janice Walbert
ABRET is the credentialing board for electroneurodiagnostic technologists, awarding the designations R. EEG T., R. EP T., CNIM, and CLTM, and offering a Lab Accreditation Program for EEG and NIOM Laboratories. ABRET has been credentialing technologists worldwide for 45 years.

Ad-Tech Medical Instrument Corp.

Booth #507
1901 William St
Racine, WI 53404
Phone: 262-634-1555
Toll-Free Phone: 800-776-1555
Fax: 262-634-5668
Email: lt@adtechmedical.com
URL: www.adtechmedical.com
Contact: Ms. Lisa Theama
For over 25 years, Epilepsy Centers have made Ad-Tech their choice for invasive electrodes for brain mapping and epilepsy monitoring. We offer a large variety of electrodes and accessories to meet you and your patients needs. Visit our Booth #507 to discover why Ad-Tech is your best choice.

AED Pregnancy Registry

Booth #521
121 Innerbelt Rd - Rm 220
Massachusetts General Hospital
Somerville, MA 02143
Toll-Free Phone: 888-233-2334
Fax: 617-726-1911
Email: csreilly@partners.org
URL: www.aedpregnancyregistry.org
Contact: Ms. Caitlin Smith
The North American AED Pregnancy Registry is the first hospital-based registry created to determine the safety of antiepileptic drugs taken by women during pregnancy. Established at Massachusetts General in 1997, the Registry has enrolled over 7,000 women to date. Please stop by our booth to learn more about our research and how you can refer your patients to participate.

American Express Open

Booth #323
200 Vessey St
New York, NY 10285
Phone: 212-640-2000
Toll-Free Phone: 866-690-9854
Fax: 212-640-9171
Email: cneese@czarnowski.com
URL: www.open.com
Contact: Ms. Christy Neese
American Express® Business Cards give you automatic access to the tools and resources that American Express OPEN(SM) has to offer, including benefits that can help you save money, gain control over your practice expenses, earn valuable rewards and much more.

AnalyzeDirect, Inc.

Booth #722
7380 W 161st St
Overland Park, KS 66085
Phone: 913-338-2527
Fax: 913-338-2554
Email: stuart@analyzedirect.com
URL: www.analyzedirect.com
Contact: Mr. Stuart Jackson
Epilepsy seizure focus localization can be quickly and accurately visualized using Analyze, a powerful stand-alone software suite for advanced 3D visualization and analysis of MRI, CT, PET, and SPECT images. Our SISCOM module is used by hundreds of researchers worldwide to accurately fuse subtraction ictal SPECT images with MR to accurately locate regions of hyperperfusion.

Angelman Syndrome Foundation

Booth #912
4255 Westbrook Dr - Ste 219
Aurora, IL 60504
Phone: 630-978-4245
Toll-Free Phone: 800-432-6435
Fax: 630-978-7408
Email: swenger@angelman.org
URL: www.angelman.org
Contact: Ms. Sheila Wenger
The Angelman Syndrome Foundation's mission is to advance the awareness and treatment of Angelman Syndrome through education and information, research, and support for individuals with Angelman Syndrome, their families, and other concerned parties.

Angioma Alliance

Table #8
520 W 21st St - Ste G2-411
Norfolk, VA 23517
Phone: 757-623-0615
Fax: 757-623-0616
Email: clee@angiomaalliance.org
URL: www.angioma.org
Contact: Dr. Cornelia Lee
Angioma Alliance is the patient advocacy organization for those with cerebral cavernous malformations. We perform patient and physician education, host scientific conferences, and maintain a Tissue/DNA Bank and Patient Registry.

The Anita Kaufmann Foundation

Table #2
1786 Lilbet Rd
Teaneck, NJ 07666
Phone: 201-655-0420
Fax 866-596-4973
Email: debra@akfus.org
URL www.akfus.org
Contact: Debra Josephs, Executive Director
The Anita Kaufmann Foundation is solely dedicated to educating the public about epilepsy and seizures. We have a ground-breaking fifth-grade program currently being taught in New York, New Jersey, Florida, California and Missouri. We publish seizure first aid material and epilepsy educational material and can send it to you FREE of charge. We give FREE seizure first aid sessions in stores, malls, restaurants, etc.

Athena Diagnostics, Inc.

Booth #319
377 Plantation St
4 Biotech Park
Worcester, MA 01605
Phone: 508-756-2886
Toll-Free Phone: 800-394-4493
Fax: 508-753-5601
Email: akeyes@athenadiagnostics.com
URL: www.athenadiagnostics.com
Contact: Mr. Aaron Keyes
Founded in 1989, Athena Diagnostics offered the first diagnostic service for muscular dystrophy. Since then, Athena has focused on neurological, renal and endocrine disorders by offering an extensive menu of tests and a wide range of diagnostic technologies. Athena focuses exclusively on assisting physicians in their efforts to provide the best possible diagnoses of these disorders.

Blackrock Microsystems

Booth #612
391 Chipeta Way - Ste G
Salt Lake City, UT 84108
Phone: 801-582-5533
Fax: 801-582-1509
Email: agotshalk@blackrockmicro.com
URL: www.blackrockmicro.com
Contact: Mr. Andy Gotshalk
Blackrock is a leading provider of electrophysiology equipment for both clinical and research applications. Our products include complete solutions for recording and analyzing brain signals for traditional EEG, ECoG and Epilepsy Monitoring.

Cadwell Laboratories, Inc.

Booth #412
909 N Kellogg St
Kennewick, WA 99336
Phone: 509-735-6481
Toll-Free Phone: 800-245-3001
Fax: 509-783-6503
Email: lorik@cadwell.com
URL: www.cadwell.com
Contact: Ms. Lori Kaufman
Founded in 1979 and still operated by brothers John and Carl Cadwell, Cadwell Laboratories sets new standards with innovations in Clinical EEG, 150+ channel Epilepsy monitoring, continuous EEG/ICU Monitoring, Sleep Diagnostics, Ambulatory EEG & PSG, Intraoperative Neuromonitoring, and EMG/NCV and Evoked Potential instrumentation.

CareFusion (formerly Cardinal Health)

Booth #1001
5225 Verona Rd - Bldg 2
Madison, WI 53711
Phone: 608-273-5000
Toll-Free Phone: 800-356-0007
Fax: 608-441-2002
Email: julie.phillips@carefusion.com
URL: www.carefusion.com
Contact: Ms. Julie Phillips
CareFusion offers leading edge solutions that address the unique needs of our customers through our comprehensive NicoletOne EEG portfolio. Products include EEG, LTM, PSG, ICU Monitor, connectivity solutions and the newly-released Cortical Stimulator. CareFusion is committed to improving patient care with the quality, service and support you expect with Nicolet products.

Clever Sys., Inc.

Booth #1019
11425 Isaac Newton Square - Ste 202
Reston, VA 20190
Phone: 703-787-6946
Fax: 703-757-7467
Email: nzhang@cleversysinc.com
URL: www.cleversysinc.com
Contact: Ms. Naili Zhang
Headquartered in the metropolitan Washington, D.C. area, Clever Sys., Inc. develops and sells products and services for lab animal behavior analysis. These products are built with technologies of next generation, utilizing information of animal full body and animal body parts, providing measurements of novel behavioral paradigms and new parameters.

CNS Vital Signs

Booth #418
1829 Franklin St - Bldg 500
Chapel Hill, NC 27514
Toll-Free Phone: 888-750-6941
Fax: 888-650-6795
Email: support@cnsvs.com
URL: www.cnsvs.com
Contact: Ms. Nancy Jo Chatham
CNS Vital Signs is a world leader in the design and development of neurocognitive assessment tools. CNS Vital Signs gives practicing clinicians and researchers assessment platforms that provide the ability to detect subtle cognitive deficits while creating a baseline of cognitive function (MEASURE) and track subtle cognitive changes (MONITOR).

Cochrane Epilepsy Group

Table #1
Department of Neurological Science,
Clinical Sciences Building, Lower Lane
Liverpool, United Kingdom L9 7LJ
Phone: 44-151-529-5405
Fax: 44-151-529-5465
Email: a.g.marson@liv.ac.uk
URL: www.epilepsy.cochrane.org
Contact: Professor Tony Marson
The Cochrane Epilepsy Group comprises an international network of healthcare professionals, researchers and consumers preparing, maintaining, and disseminating systematic reviews of randomised controlled trials in the treatment of epilepsy.

Compumedics USA*

Booth #707
6605 W WT Harris Blvd - Ste F
Charlotte, NC 28269
Phone: 704-749-3200
Toll-Free Phone: 877-717-3975
Fax: 704-749-3299
Email: tom.lorick@compumedicsusa.com
URL: www.compumedics.com
Contact: Mr. Tom Lorick
Compumedics Neuroscan produces world-leading solutions for Neuroscience Brain Research. Compumedics expands our clinical expertise in sleep diagnostics, EEG and long-term monitoring with our Neuvo EEG/LTM system. Neuroscan concentrates on advanced solutions for research applications. Neuroscan products: SCAN, SOURCE and CURRY plus SynAmps2 and MagLink hardware packages

CURE: Citizens United for Research in Epilepsy

Table #15
730 N Franklin St - Ste 404
Chicago, IL 60654
Phone: 312-255-1801
Toll-Free Phone: 800-765-7118
Fax: 312-255-1809
Email: danielle.davis@cureepilepsy.org
URL: www.cureepilepsy.org
Contact: Ms. Danielle Davis
CURE: Citizens United for Research in Epilepsy is a nonprofit organization dedicated to finding a cure for epilepsy by raising funds for research and by increasing awareness of the prevalence and devastation of this disease.

EXHIBITORS

Cyberonics, Inc.

Booth #901
100 Cyberonics Blvd
Houston, TX 77058
Toll-Free Phone: 800-332-1375
Fax: 281-218-9332
Email: kari.sokolow@cyberonics.com
URL: www.cyberonics.com
Contact: Ms. Kari Sokolow
Cyberonics, Inc., a medical technology company with core expertise in neuromodulation, developed and markets the Vagus Nerve Stimulation (VNS) Therapy™ System, which is FDA-approved for the treatment of refractory epilepsy and treatment-resistant depression. To date, more than 50,000 patients worldwide have received VNS Therapy for epilepsy and depression.

Data Sciences International

Booth #910
119 14th St NW
St. Paul, MN 55112
Phone: 651-481-7400
Fax: 651-481-7410
Email: shachtman@datasci.com
URL: www.datasci.com
Contact: Mr. Gary Miller
DSI offers a wide variety of physiological monitoring solutions for respiratory, cardiovascular, and CNS applications involving acute or chronic studies. Products include data collection and analysis systems coupled with hard-wired amplifiers, implantable telemetry, and externally worn telemetry.

Demos Medical Publishing

Booth #1027
11 W 42nd St - 15th Fl
New York, NY 10036
Phone: 212-683-0072
Fax: 212-941-7842
Email: thastings@demomedpub.com
URL: www.demomedpub.com
Contact: Mr. Thomas Hastings
Visit Demos Medical Publishing in Booth #1027 to see our new epilepsy and neurology titles including Fisch's new Epilepsy and Intensive Care Monitoring, Tautm's Epilepsy A to Z: A Concise Encyclopedia, Second Edition, Kaplan's Nonconvulsive Status Epilepticus, Brenner's EEG on DVD: Adult: An Interactive Reading Session and more.

DigiTrace – Subsidiary of SleepMed, Inc

Booth #620
200 Corporate Place - Ste 5B
Peabody, MA 01960
Phone: 978-536-7400
Fax: 978-535-9778
Email: stuthill@sleepmed.md
URL: www.sleepmed.md
Contact: Ms. Chimene Green
DigiTrace EEG Services is a division of SleepMed, Inc. We are the largest provider of sleep and EEG home monitoring services in the U.S. DigiTrace EEG products and services are used by dozens of U.S. comprehensive epilepsy centers as well as over 30 SleepMed service locations around the country. We conduct 25,000 EEG and video EEG test days annually.

Dixi Microtechniques

Booth #720
4 Chemin De Palente - BP889
Besancon Cedex, France 25025
Phone: 33-381-88-98-90
Fax: 33-38188-98-99
Email: j.moya@diximedical.com
URL: www.diximedical.com
Contact: Mr. Jose Moya
Medical devices used in stereotactic neurosurgery for the treatment of epilepsy and Parkinsons disease (depth electrodes, cortical electrodes, foramen oval electrodes, epidural electrodes, surgical implements, products developed according to your specific requirements ...) Main customers: neurosurgical departments of main centers in Europe, Canada, South America

Eisai Inc.*

Booth #401
100 Tice Blvd
Woodcliff Lake, NJ 07677
Phone: 201-746-2996
Fax: 201-746-3202
Email: christopher_fanale@eisai.com
URL: www.eisai.com
Contact: Mr. Chris Fanale

Electrical Geodesics, Inc. (EGI)**

Booth #606
1600 Millrace Dr - Ste 307
Eugene, OR 97403
Phone: 541-687-7962
Fax: 541-687-7963
Email: conferences@egi.com
URL: www.egi.com
Contact: Ms. Amy Patrick
Electrical Geodesics, Inc. (EGI) offers complete EEG systems from 32 channel routine digital video EEG and ambulatory EEG systems to 256 channel epilepsy monitoring dEEG systems. EGI provides whole-head, dEEG that is practical, cost-effective, and reliable. Designed to maximize patient comfort and satisfaction, while enhancing clinical performance and productivity.

Elekta, Inc.

Booth #719
4775 Peachtree Industrial Blvd - Bldg 300 - Ste 300
Norcross, GA 30092
Phone: 770-670-2592
Toll-Free Phone: 800-525-7355
Fax: 770-448-6338
Email: info.america@elekta.com
URL: www.elekta.com
Contact: Ms. Doris Aubuchon
Elekta Neuromag® is a magnetoencephalograph (MEG) that moves beyond conventional imaging and clinical neurophysiology tools to provide clinicians and researchers with precise millisecond resolution and accurate localization to open a revolutionary new window on human brain activity. For the latest Elekta Neuromag news, visit www.elekta.com/MEG.

Elsevier Mosby Saunders

Booth #809
PO Box 390
Humarock, MA 02047
Phone: 781-837-0797
Email: j.masley@elsevier.com
URL: www.elsevier.com
Contact: Mr. Joe Masley
ELSEVIER is a leader in the Health Science Publishing Industry. Please stop by our Booth, #809, to see our newest clinical references, journals and electronic media.

Epilepsy Foundation

Booth #621
8301 Professional PI E
Landover, MD 20785
Phone: 301-459-3700
Fax: 301-918-2103
Email: gjones@efa.org
URL: www.epilepsyfoundation.org
Contact: Ms. Gigi Jones
The Epilepsy Foundation is the national voluntary agency solely dedicated to the welfare of more than three million people with epilepsy in the U.S. The organization works to ensure that people with epilepsy are accepted and valued in society and to promote research for a cure.

Epilepsy Phenome/Genome Project*

Table #7
400 Parnassus Ave - Ste 847
University of California, San Francisco
San Francisco, CA 94143
Phone: 415-476-4495
Toll-Free Phone: 888-279-3747
Fax: 415-476-4498
Email: info@epgp.org
URL: www.epgp.org
Contact: Ms. Kristen Schardein, RN
The Epilepsy Phenome/Genome Project is a collaboration between the NINDS and epilepsy centers to identify genes that influence the development of epilepsy and pharmacoresponsiveness. The study is enrolling 1) siblings who both have nonsymptomatic epilepsy, and 2) participants with infantile spasms, Lennox-Gastaut Syndrome, polymicrogyria, or periventricular heterotopias.

Epilepsy Therapy Project

Table #3
PO Box 742
Middleburg, VA 20118
Phone: 540-687-8077
Fax: 540-687-8066
Email: kim@epilepsytherapyproject.org
URL: www.epilepsy.com
Contact: Ms. Kim Macher

EXHIBITORS

www.epilepsycongress.org

Table #14
7 Priory Hall
Stillorgan
Dublin, Ireland 18
Phone: 353-1-205-6720
Fax: 353-1-205-6156
Email: info@epilepsycongress.org
URL: www.epilepsycongress.org
Contact: Mr. Gus Egan
The ILAE / IBE Congress Secretariat (IDM Office) is the point of contact for the International Epilepsy Congress (IEC) and all regional epilepsy Congresses of the International League Against Epilepsy and the International Bureau for Epilepsy. For details on all upcoming Congresses, including the 9th ECE in Rhodes, please visit <http://www.epilepsycongress.org>.

Family Studies in Epilepsy at Columbia University

Table #13
722 W 168th - 6th Fl
New York, NY 10032
Phone: 212-342-0481
Fax: 212-342-0484
Email: jr2780@columbia.edu
URL: www.geneticsofepilepsy.org
Contact: Ms. Janine Rose
The Family Studies in Epilepsy is a program to discover genes that influence adolescent or childhood onset Idiopathic Generalized Epilepsy (IGE). Directed by Dr. David Greenberg, the study is located in the Mailman School of Public Health at Columbia University in New York City. Our research is designed to identify genes that cause either epilepsy or make it likely one can develop epilepsy.

GlaxoSmithKline

Booth #601
5 Moore Dr
Research Triangle Park, NC 27709

Toll-Free Phone: 800-421-9202

URL: www.gsk.com
Contact: Ms. Christy Soltes
GlaxoSmithKline is a leading research-based pharmaceutical company with a powerful combination of skills to discover and deliver innovative medicines. We offer a number of programs to support effective health management strategies and improve patient care. Please visit our exhibit to learn more about our products.

Grass Technologies, An Astro-Med, Inc. Subsidiary

Booth #919
600 E Greenwich Ave
West Warwick, RI 02893
Phone: 401-828-4000
Toll-Free Phone: 877-472-7779
Fax: 401-822-2430
Email: tpollard@astro-med.com
URL: www.grasstechnologies.com
Contact: Ms. Tina Pollard
Grass, a pioneer and leader in the long-term epilepsy monitoring field, is featuring the following new products: S12X Cortical Stimulator for intraoperative cortical stimulation mapping to aid in cortical resections; AURA-LTM64 64-128 channel amplifiers; Neurotrac III Neuromonitoring software for frequency, amplitude-integrated EEG, burst-suppression and DSA trending.

The IDEA League

Table #6
11 Nancy Dr
Monroe, CT 06468
Phone: 203-220-8274

Email: lori.o@idea-league.org
URL: www.idea-league.org
Contact: Ms. Lori O'Driscoll

Integra NeuroSciences

Booth #604
311 Enterprise Dr
Plainsboro, NJ 08536
Phone: 609-275-0500
Toll-Free Phone: 800-762-1574
Fax: 609-799-3297
Email: jon.trout@integra-ls.com
URL: www.integra-ls.com
Contact: Mr. Jon Trout
Integra Neurosciences offers a wide array of EEG electrodes and tools for Brain Mapping. Integra NeuroSciences' Auragen Cortical and Depth Electrodes are designed to maximize strength, sensitivity, and pliability to facilitate safe and accurate EEG monitoring. A wide range of features simplify the placement, performance, and identification of the electrodes.

Intractable Childhood Epilepsy Alliance

Table #12
464 Heritage Dr
Lewisville, NC 27023
Phone: 336-918-9440
Fax: 336-946-1197
Email: michellewelborn@gmail.com
URL: www.iceepilepsy.org
Contact: Ms. Michelle Welborn
ICE is a 501(c)3 organization that delivers information, education, and exchange of ideas through international alliances to improve lives of children affected by genetic intractable epilepsy and to expedite advancement towards a cure through strategic, measurable processes. ICE initiatives include an SCN1A registry and Centers of Excellence.

John Libbey EUROTEXT

Booth #908
127 Ave de la Republique
Montrouge, France 92120
Phone: 33-01-4673-0679
Fax: 33-01-4084-0999
Email: gilles.cahn@jle.com
URL: www.jle.com
Contact: Mr. Gilles Cahn
30 journals, 700 books, more twelve years of archives online. Excellence in medical and scientific information. A leader in the field of medical publishing for the past 20 years, John Libbey Eurotext has compiled a prestigious catalogue of books and publishes more than 60 new titles every year.

Kappametrics Inc.

Booth #422
14150 Newbrook Dr - Ste 105
Chantilly, VA 20151
Phone: 703-349-1860
Fax: 703-991-5958
Email: jzett@kappametrics.com
URL: www.kappametrics.com
Contact: Mr. John Zett
Kappametrics' fEEG™ product enables truly concurrent acquisition of EEG and fMRI data. Innovative analog noise cancellation techniques eliminate up to 99.99% of the MRI artifact, as induced on to the EEG signals, prior to digitization of the EEG signals. The combined imaging capability promises considerable advancement in epilepsy research.

LEAD/Health Learning Systems

Booth #513
402 Interpace Pkwy
Parsippany, NJ 07054
Phone: 973-353-3333
Toll-Free Phone: 800-366-4572
Fax: 800-375-0143
Email: cdufty@commonhealth.com
URL: www.commonhealth.com
Contact: Mr. Chris Dufty
LEAD (Leadership in Epilepsy, Advocacy, and Development) is an innovative initiative focused on addressing unmet educational needs within the epilepsy community. LEAD members are national thought leaders in the management of epilepsy who identify gaps in education and then work together to develop educational tools and programs to fill these gaps.

EXHIBITORS

LGS Foundation

Table #11
62 Washington St
East Setauket, NY 11733
Phone: 631-509-0206
Fax: 631-851-2020
Email: christina@lgsfoundation.org
URL: www.lgsfoundation.org
Contact: Ms. Christina SanInocencio
The LGS Foundation is a nonprofit organization dedicated to providing support and information about Lennox-Gastaut syndrome while raising funds to help pursue additional research and services for LGS families.

Lippincott Williams & Wilkins

Booth #423
31 Cove Rd
Salem, NH 03079
Phone: 215-521-8300
Toll-Free Phone: 800-634-4365
Fax: 215-521-8902
Email: dale.shaughnessy@wolterskluwer.com
URL: www.lww.com
Contact: Mr. Dale Shaughnessy

Lundbeck*

Booths #413 & 517
Four Pkwy N
Deerfield, IL 60015
Phone: 847-282-5768
Fax: 847-317-3356
Email: mtre@lundbeck.com
URL: www.lundbeckinc.com
Contact: Ms. Margaret Trempe
Lundbeck, located in Deerfield, Illinois, was established in March 2009 following the acquisition of Ovation Pharmaceuticals, Inc. by H. Lundbeck A/S. The company is committed to improving the lives of patients suffering from complex CNS disorders and rare diseases for which few, if any, effective treatments are available.

Meda Pharmaceuticals Inc.

Booth #505
265 Davidson Ave - Ste 300
Somerset, NJ 08873
Phone: 732-564-2326
Fax: 732-564-2300
Email: jrisimini@medapharma.us
URL: www.medapharma.us
Contact: Ms. Jean Risimini
Meda Pharmaceuticals is a global specialty pharmaceutical company that develops, markets, and promotes branded prescription products in the respiratory and pain therapeutic areas.

National Association of Epilepsy Centers

Booth #1025
5775 Wayzata Blvd - Ste 200
Minneapolis, MN 55416
Phone: 952-525-4526
Fax: 952-525-1560
Email: info@naec-epilepsy.org
URL: www.naec-epilepsy.org
Contact: Ms. Barbara Anstett
The National Association of Epilepsy Centers (NAEC), representing more than 100 member centers, works with public and private insurers, health agencies, and Congress to make quality healthcare accessible to people with epilepsy. NAEC's Guidelines are recognized as the standard of care for Level Three and Level Four epilepsy centers.

Natus Medical Incorporated

Booth #713
One Bio-logic Plaza
Mundelein, IL 60060
Phone: 847-949-5200
Toll-Free Phone: 800-303-0306
Fax: 847-949-8615
Email: castone@natus.com
URL: www.natus.com
Contact: Ms. Carol Stone
Natus Medical Incorporated designs, manufactures and distributes a wide range of neurology and sleep diagnostic systems and supplies. The XLTEK and Bio-logic product lines are designed to deliver the latest innovations in EEG, Epilepsy, ICU, Ambulatory, PSG, EMG and IOM needs.

Neuralynx Inc.

Booth #811
105 Commercial Dr
Bozeman, MT 59715
Phone: 406-585-4542
Fax: 406-585-9034
Email: ryan@neuralynx.com
URL: www.neuralynx.com
Contact: Mr. Ryan Olson
Neuralynx has been providing Electrophysiology and Neuroscience researchers with the highest quality single-unit, multi-channel Electrophysiology recording equipment since 1993. Our products represent the "state of the art" in high density Data Acquisition and Experiment Control solutions.

neuroConn GmbH

Booth #522
Ehrenbergstr 11
98693 Ilmenau, Germany
Phone: 49-3677-668-650
Fax: 49-3677-668-655
Email: klaus.schellhorn@neuroconn.de
URL: www.neuroconn.de
Contact: Mr. Klaus Schellhorn

NeuroLogica

Booth #600
14 Electronics Ave
Danvers, MA 01923
Phone: 978-564-8500
Fax: 978-560-0602
Email: achorzempa@neurologica.com
URL: www.neurologica.com
Contact: Mr. Andrew Chorzempa
The inSPira HD is the world's first portable High Resolution SPECT system. This battery-powered, high resolution portable SPECT, designed primarily for brain imaging is capable of imaging any radioisotope energies between 80 – 200 keV. for clinical applications such as Epilepsy, Parkinson's, Stroke and Alzheimer's.

NeuroNexus Technologies**

Booth #1029
3985 Research Park Dr
Ann Arbor, MI 48108
Phone: 734-913-8858
Fax: 734-786-0069
Email: kckong@neuronexustech.com
URL: www.neuronexustech.com
Contact: Mr. K.C. Kong
NeuroNexus is a global leader for innovative neural interface products and technologies to meet both current and upcoming needs in neuroscience research, neurosurgery, and neurostimulation. We have microelectrode arrays for surface/cortex/deep brain and the electrodes can be used for both recording (SU/MU/LPF/ECog) and stimulation; in vivo and in vitro!

Nihon Kohden America, Inc.

Booth #607
90 Icon St
Foothill Ranch, CA 92610
Phone: 949-580-1555
Toll-Free Phone: 800-325-0283
Fax: 949-580-1550
Email: info@nkusa.com
URL: www.nkusa.com
Contact: Ms. Deidra Miltimore
Nihon Kohden's family of products includes instrumentation for IOM, Epilepsy Monitoring, EEG, Ambulatory Recording for EEG and PSG, Polysomnography, Wireless EEG and PSG, Electromyography and Evoked Potentials. Nihon Kohden is a complete Neurodiagnostic solution and allows the flexibility and expandability needed to meet the changing demands of today's neurodiagnostic field.

EXHIBITORS

NINDS – National Institute of Neurological Disorders and Stroke

Booth #424
31 Center Dr - Bldg 31 - Rm 8A07
Bethesda, MD 20892
Phone: 301-496-5751
Fax: 301-402-2186
Email: brownann@ninds.nih.gov
URL: www.ninds.nih.gov
Contact: Ms. Ann Brown
The National Institute of Neurological Disorders and Stroke (NINDS) supports basic, translational, and patient-oriented research on epilepsy prevention, diagnosis and treatment, including mechanisms underlying seizures and epileptogenesis, gene discovery and targeted therapeutics, epidemiology, psychosocial and behavioral consequences, and development of new therapies.

Nutricia North America

Booth #616
9900 Belward Campus Dr - Ste 100
Rockville, MD 20850
Phone: 301-795-2300
Toll-Free Phone: 800-365-7354
Fax: 301-795-2302
Email: rkeys@shsna.com
URL: www.myketocal.com
Contact: Ms. Ronda Keys

Optima Neuroscience

Booth #1021
13400 Progress Blvd
Alachua, FL 32615
Phone: 352-371-8281
Fax: 386-462-0606
Email: info@optimaneuro.com
URL: www.optimaneuro.com
Contact: Ms. Amanda Burks
Optima Neuroscience is developing novel software, systems and devices for the diagnosis and treatment of neurological disorders. Founded by epileptologist J. Chris Sackellares, M.D., the company's initial product line includes EEG review software featuring high performance seizure detection.

Oxford University Press

Booth #622
198 Madison Ave
New York, NY 10016
Phone: 212-726-6000
Fax: 212-726-6494
Email: colleen.mccue@oup.com
URL: www.oup.com/us
Contact: Ms. Colleen McCue
Featuring: Reuber, *Epilepsy Explained*; Asadi-Pooya, *Antiepileptic Drugs*; DiMario, *Non-Epileptic Childhood Paroxysmal Disorders*; Schwartzkroin, *So You Want to Be a Scientist?*, and the full line of Oxford books in epilepsy and neurology.

Pfizer Inc.

Booth #101
235 E 42nd St
New York, NY 10017
Phone: 212-733-2323
Fax: 212-573-7049
Email: krista.j.busch@pfizer.com
URL: www.pfizer.com
Contact: Ms. Krista Busch
Founded in 1849, Pfizer is the world's largest research-based pharmaceutical company taking new approaches to better health. We discover, develop, manufacture and deliver quality, safe and effective prescription medicines to treat and help prevent disease for both people and animals.

Pinnacle Technology Inc.

Booth #223
2721 Oregon St
Lawrence, KS 66046
Phone: 785-832-8866
Fax: 785-749-9214
Email: donnaj@pinnacle.com
URL: www.pinnacle.com
Contact: Ms. Donna Johnson
Pinnacle Technology provides new tools for rodent research that simplify measurement, reduce cost and enable new discoveries. Current products include: wireless systems for the real-time measurement of neurotransmitters including glutamate and glucose, EEG/EMG systems for seizure and sleep monitoring, sleep deprivation chambers and integrated video recording.

PMT Corporation*

Booth #813
1500 Park Rd
Chanhassen, MN 55317
Phone: 952-470-0866
Toll-Free Phone: 800-626-5463
Fax: 952-470-0865
Email: info@pmtcorp.com
URL: www.pmtcorp.com
Contact: Mr. Eric Caille
PMT Corporation is the premier supplier of an extensive line of neurosurgical products. Offering highend neck braces, including halo systems and orthotic vests for cervical, thoracic and lumbar spinal immobilization. PMT also offers Cortac, cortical surface electrodes and Depthalon, depth electrodes for epilepsy monitoring; microsurgical, and Fukushima instruments.

Questcor Pharmaceuticals, Inc.*

Booths #313 & 801
3260 Whipple Rd
Union City, CA 94587
Phone: 510-400-0700
Fax: 510-400-0719
Email: agasperino@questcor.com
URL: www.questcor.com
Contact: Ms. Andrea Gasperino
Questcor is a specialty biopharmaceutical company focused on providing prescription drugs for rare central nervous system and inflammatory disorders. Questcor's lead product is H.P Acthar® Gel, a naturally-derived formulation of adrenocorticotrophic hormones used for disorders having an inflammatory component, including the treatment of exacerbations associated with MS.

Rhythmink International, LLC

Booth #317
PO Box 2045
Columbia, SC 29202
Phone: 803-252-1222
Toll-Free Phone: 866-633-3754
Fax: 803-252-1111
Email: sales@rhythmink.com
URL: www.rhythmink.com
Contact: Ms. Katie Okawa
As technologists working within the neurodiagnostic industry, we know what clinicians want: a company that listens, never has backorders and offers flawless, quality products for EEG, LTM, EP, IOM, ICU, EMG, NCV and PSG. That's why Rhythmink International is your most trusted source for neurodiagnostic accessories. Visit our Web site to order your FREE samples today.

The Ring Chromosome 20 Foundation

Table #9
1045 Park Ave
New York, NY 10028
Phone: 212-860-2668
Toll-Free Phone: 877-207-5520
Fax: 206-333-1359
Email: david@ring20.org
URL: www.ring20.org
Contact: Mr. David Barriera
The purpose of the Foundation is to promote awareness of Ring Chromosome 20 syndrome and the importance of chromosomal analysis (karyotype testing) in patients with refractory epilepsy. We work to connect patients and families to the best doctors, hospitals, and medical clinics internationally and seek to fund research on this syndrome.

EXHIBITORS

Ripple LLC

Booth #1031
1398 S 1100 E
Salt Lake City, UT 84105
Phone: 801-413-0139
Fax: 801-413-2874
Email: sales@rppl.com
URL: www.rppl.com

Contact: Ms. Christine McDonough
Ripple LLC provides neurophysiology data acquisition systems for research. Our systems are compact, portable, and heavily optimized for real-time, closed-loop control applications with hundreds of channels of EMG, EEG and microelectrode data. Many of our software components are available as Open Source with support for Windows, Mac OS X, and Linux.

Sepracor Inc.

Booth #613
84 Waterford Dr
Marlborough, MA 01752
Phone: 508-481-6700
Fax: 508-357-7490
Email: info@sepracor.com
URL: www.sepracor.com

Sepracor is a fully integrated specialty pharmaceutical company dedicated to discovering, developing and commercializing pharmaceutical products directed toward large and growing markets and unmet medical needs. Sepracor's drug development, corporate development, and licensing efforts have yielded a portfolio of products and candidates focused on respiratory and central nervous system disorders.

STATKING Consulting, Inc.

Booth #523
759 Wessel Dr - Ste 6
Fairfield, OH 45014
Phone: 513-858-2989
Fax: 513-858-3022
Email: jeff@statkingconsulting.com
URL: www.statkingconsulting.com

Contact: Dr. Dennis King
Since 1989, STATKING Consulting, Inc. has provided strategic protocol development and data related services (biostatistics, clinical data management, clinical study monitoring, medical writing, project management and clinical trial management) for clinical trials performed to obtain regulatory approval of new pharmaceutical and medical device products.

Stellate Systems**

Booth #701
376 Victoria Ave - Ste 200
Montreal, QC Canada H3Z 1C3
Phone: 514-486-1306
Toll-Free Phone: 888-742-1306
Fax: 514-486-0694
Email: nanda.varier@alpinebiomed.com
URL: www.stellate.com
Contact: Nanda Varier

Stellate provides advanced solutions for EEG, Epilepsy Monitoring, ICU Monitoring and Sleep Diagnostics. Products on display at Stellate's booth will include Vita

ICU Neurological Monitoring System, Aria-E Ambulatory Recorder, GridView 3-D Visualization Tool, Harmonie Routine EEG and Long-Term Monitoring systems and ScanFit imaging friendly electrodes.

SynapCell

Booth #322
1000 av des Jeux Olympiques
Grenoble, France 38100
Phone: +33-476-637-590
Email: contact@synapcell.fr
URL: www.synapcell.fr

Contact: Dr. Corinne Roucard
SynapCell is an innovative contract research company providing pre-clinical services based on translational models mimicking human CNS pathologies. SynapCell evaluates the therapeutic potential and/or side effects of new drug candidates in the field of epilepsy.

Transgenomic, Inc.*

Booth #416
12325 Emmet St
Omaha, NE 68164
Phone: 402-452-5473
Fax: 402-452-5401
Email: bkreifels@transgenomic.com
URL: www.transgenomic.com

Contact: Ms. Becky Kreifels
Transgenomic Molecular Laboratory is a clinical reference laboratory specializing in mitochondrial and molecular testing. Our expertise in SCN1A testing provides high sensitivity levels of mutation/deletion detection with fast turnaround times. Our portfolio also includes assays such as POLG, Whole Mitochondrial Genome Scan, and a 244K Chromosomal Micro Array.

Tuberous Sclerosis Alliance

Table #10
801 Roeder Rd - Ste 750
Silver Spring, MD 20910
Phone: 301-562-9890
Fax: 301-562-9870
Email: ksmith@tsalliance.org
URL: www.tsalliance.org
Contact: Ms. Katie Smith
Founded in 1974, the TS Alliance is the only national voluntary health agency dedicated to finding a cure for TSC while improving the lives of those affected. TSC is a genetic disorder characterized by seizures and tumor growth in vital organs such as the brain, heart, kidneys, lungs and skin.

Tucker-Davis Technologies

Booth #1023
11930 Research Cir
Alachua, FL 32615
Phone: 386-462-9622
Fax: 386-462-5365
Email: callredredge@tdt.com
URL: www.tdt.com
Contact: Ms. Cheryl Alldredge
TDT is a leading manufacturer of products ranging from electrodes to complete workstations for

neurophysiology and evoked potentials. Core product include: OpenEx Software Suite for multi-channel data acquisition and analysis, the Z-Series BioAmp (up to 256 channels), laser-cut microwire arrays, and ZIF-Clip® headstages.

UCB, Inc.*

Booth #201
1950 Lake Park Dr
Smyrna, GA 30080
Phone: 770-970-7500
Toll-Free Phone: 800-477-7877
Fax: 770-970-8917
Email: betsy.andrews@ucb.com
URL: www.ucb.com

Contact: Ms. Betsy Andrews
UCB is a biopharmaceutical company dedicated to the research, development and commercialization of innovative medicines with a focus on the fields of central nervous system and immunology disorders. Worldwide headquarters is located in Brussels, Belgium; U.S. headquarters is located in Atlanta, GA. Visit www.ucb.com for more information about UCB.

Valeant Pharmaceuticals

Booth #501
One Enterprise
Aliso Viejo, CA 92656
Phone: 949-461-6000
Toll-Free Phone: 800-548-5100
Fax: 949-461-6609
Email: regina.ruiz@valeant.com
URL: www.valeant.com
Contact: Ms. Regina Ruiz

Valeant Pharmaceuticals International is a multinational specialty pharmaceutical company that develops and markets prescription and nonprescription pharmaceutical products that make a meaningful difference in patients' lives. The company is proud to support the efforts of patients, caregivers, healthcare professionals, and patient advocates in the battle against epilepsy.

Wiley-Blackwell/John Wiley & Sons

Booth #914
350 Main St
Malden, MA 02148
Phone: 781-388-8200
Toll-Free Phone: 800-759-6102
Fax: 781-338-8552
Email: je Elliot@wiley.com
URL: www.wiley.com/go/neuro
Contact: Ms. Jennifer Elliot

Wiley-Blackwell is the international scientific, technical, medical and scholarly publishing business of John Wiley & Sons, with strengths in neurology and neuroscience and the official publishing partner of AES and ILAE. For more information on *Epilepsy Currents* and *Epilepsia*, please visit www.wiley.com/go/neuro.

ABSTRACT AUTHOR INDEX

A

- Aaron, G. 3.050
 Abbas, S. 1.190
 Abdelmoity, A. 1.280, 1.281
 Abend, N.S. 3.191
 Aboian, M. 2.167, 2.168
 Abou-Khalil, B.W. 1.074, 1.098, 1.105, 1.155, 1.176, 1.221, 2.026
 Abubakr, A. 1.070
 Acheson, J. 3.192
 Achilles, A. 1.267
 Ackerman, M. 2.253
 Adachi, N. 2.136
 Adam, C. 2.042
 Adams, E. 2.307
 Addis, M. 3.093
 Adhami, S. 2.199
 Adjei, P. 2.060
 Adjouadi, M. 2.115, 2.117, 3.254
 Adkins-Scholl, E. 2.236
 Adstamongkonkul, D. 3.131
 Aengenendt, J. 1.169, 1.171, 2.292
 Afra, P. 2.050
 Afroz, S. 2.239
 Agari, T. 2.004
 Agirre-Arrizubieta, Z. 2.029, 3.189
 Aguglia, U. 2.072
 Ahmed, S.N. 3.193
 Akakin, D. 3.117, 3.122
 Akamatsu, N. 2.273
 Akamine, Y. 3.310
 Akat, S. 2.322
 Akcali, A. 2.143
 Akenack, J.A. 3.201
 Aker, R. 3.002, 3.338
 Akhondi-Asl, A. 1.153
 Akin, D. 3.338
 Akiyama, M. 3.168
 Akiyama, T. 1.046, 1.277, 2.036, 3.281
 Akman, C. 1.310, 2.008, 2.297
 Akman, C.I. 2.291
 Albayram, S. 3.275
 Albiston, A.L. 3.318
 Aleissa, E.I. 1.014
 Alekar, S. 2.193
 Alexander, A. 2.266
 Alexandre, V. 1.012, 1.194
 Alexandre Jr, V. 1.299, B.05
 Alexopoulos, A. 1.040, 1.082
 Alexopoulos, A.V. 1.022, 2.040, 2.045, 2.047, 2.124, 2.243, 3.074, 3.157, 3.205, 3.221
 Alfstad, K. 2.103
 Ali, I. 1.190
 Alkonyi, B. 3.236
 Alku, P. 2.046
 Allen, J. 3.097
 Allison, K. 2.074
 Allison, M.J. 1.228, 1.233
 Almajano, J. 3.032
 Almas, M. 1.225
 Almeida, E.D. 1.012
 Almeida, L. 1.196, 1.223, 1.231, 1.241, 1.245, 1.246, 1.249
 Almãs, C. 2.208
 Alonso, M. 1.162
 Alonso, N.B. 1.009
 Alonso-Vanegas, M. 1.146, 3.333, 3.336
 Alper, K. 3.278
 Alsaihati, B.A. 2.177
 Altay, E.E. 1.040
 Altindag, A. 2.143
 Altinok, D. 3.250
 Alvarez-Croda, D.M. 3.339
 Alvarez-Garajo, J. 1.284
 Åmark, P. 1.273
 Amaro Jr., E. 2.325
 Amarouche, M. 2.086
 Amor, F. 2.003
 Amrom, D. 1.143, 1.325
 Amrom, D.R. 1.324
 Anami, K. 2.125
 Anaya, J. 2.174
 Andermann, E. 1.143, 1.324, 1.325
 Andermann, F. 1.143, 1.168, 1.324, 1.325, 2.032, 3.290
 Anderson, A. 3.005
 Anderson, A.E. 2.163, 3.041, 3.129
 Anderson, C. 3.171
 Anderson, C.T. 1.109, 3.288
 Anderson, M.L. 2.133
 Anderson, S.A. 3.006
 Anderson, W.S. 3.065, 3.148
 Andre, C. 1.314
 Andriola, M. 2.058, 2.197, 2.211
 Angle, M. 2.023
 Angus, W. 2.297
 Angwafor, S. 3.201
 Antel, J. 1.168
 Antony, A.R. 1.214
 Antunes-Rodrigues, J. 3.017
 Aourz, N. 1.263, 1.264
 Apice, G. 1.097
 Arain, A.M. 2.137, 2.160
 Araujo, D. 1.299
 Araújo Jr., D. B.05
 Archer, J.S. 1.092, 1.093, 1.094
 Argentoni-Balochi, M. 3.283
 Arico, I. 3.211
 Arif, H. 2.127
 Arisi, G. 1.266
 Arisi, G.M. 3.098, 3.344
 Arnedo, V. 2.157
 Arnold, S. 1.240, 1.279, 2.093
 Arnsperger, S. 3.028
 Aronica, E. 3.015, 3.070, 3.342
 Arshad, S.T. 1.028
 Arsov, T. 1.319
 Artan, N.S. 3.150, 3.151
 Arthur, T. 2.049
 Artsy, E. 1.113
 Arzimanoglou, A. 1.287, 2.225
 Asano, E. 1.043, 1.046, 2.013, 2.051, 3.236, 3.239, 3.252
 Ascher, S. 1.121
 Asconape, J. 3.228
 Ashalatha, R. 3.219
 Ashok, N. 2.129
 Ashwal, S. 3.303
 Asselin, M.C. 1.244
 Assem-Hilger, E. 1.291
 Assirati Jr., J.A. 1.299, 2.150, B.05
 Atkinson, P.B. 2.261
 Augustine, G.J. 3.046
 Aull-Watschinger, S. 1.291, 2.260
 Austin, J.K. 2.283
 Auvin, S. 3.108
 Avdievich, N.I. 3.268
 Avedissian, C. 3.264
 Avila, E.K. 1.124
 Avison, W.R. 2.328
 Avoli, M. 1.035
 Ayala, M. 2.117, 3.254
 Aylward, E. 2.272
 Azabou, E. 3.309
 Azar, N. 2.137, 2.160
 Azar, N.J. 1.074, 1.098
 Azevedo, A.M. 1.009
 Azevedo, C.J. 1.028
 Azhar, F. 3.148
 Azuma, Y. 3.237, 3.248
B
 Baba, H. 1.304
 Babbain, F. 2.032
 Bach, E.C. 3.130
 Bacsikai, B.J. 3.046
 Badawy, R. 1.319, 3.040
 Bae, E.H. 1.274
 Bae, M.H. 3.128
 Baeta, E.M. 1.129
 Bagic, A. 2.077
 Baheti, N.N. 2.266
 Bahlke, M. 3.156
 Bahlo, M. 1.311, 1.319
 Bai, X. 1.187, 3.082, C.08
 Baillet, S. 2.042
 Baise, C. 3.283
 Baker, C. 2.252, 2.319
 Baker, G. 2.180
 Baker, G.A. 2.288, C.03
 Baker, M. 1.298
 Baker, S. 3.005
 Baki, S.A. 2.332
 Balabanov, A. 3.155
 Balestri, M. 3.258
 Ballester, D. 2.294
 Balosso, S. 3.015
 Baltuch, G. 3.288
 Bamagous, G. 3.199
 Bamogaddam, F.A. 3.273
 Band, G. 1.218
 Bangalore-Vittal, N. 2.137, 2.160
 Banks, C. 3.227
 Banks, S.J. 2.275
 Bannout, F. 1.109
 Bansal, A.R. 2.266
 Baptiste, S.L. 3.150, 3.151
 Bar-Yosef, O. 3.253, C.02
 Baram, T.Z. 3.033, I.W.15
 Baranowska, I. 1.314
 Barbaro, N. 1.042, 3.308
 Barber, A. 2.154
 Barbieri, V. 2.138
 Barbosa, N.R. 3.331
 Barinka, F. 3.310
 Barka, N. 3.097
 Barkas, L.J. 2.258
 Barker, G. 1.180
 Barkmeier, D. 1.036, 1.039
 Barkovich, A. 3.308
 Barkovich, A.J. 3.243
 Barks, A.K. 2.108
 Barnes, B. 1.191
 Barragan, E.P. 3.184
 Barragán, E. 2.287
 Barreta, L.A. 2.325
 Barreto, A. 2.115, 2.117, 3.254
 Barry, B. 3.243
 Bartels, S. 2.204
 Bartha, R. 3.280
 Bartolomei, F. 1.181
 Barua, A. 3.049
 Basehore, H.K. A.05
 Basha, M. 1.036
 Basha, M.M. 1.039
 Bast, T. 2.183
 Bateman, L.M. 3.195, 3.197
 Batista, C.E. 3.359
 Bauer, S. 1.209, 3.044
 Baulac, M. 2.042, 3.146
 Baulac, S. 3.146
 Baum, L. 1.321, 2.201
 Baum, M. 3.145
 Baumann, A. 3.033
 Baumgartner, C. 1.047, 1.291
 Baxter, L. 2.081
 Baybis, M. 3.092, 3.342
 Baykal, B. 3.322
 Bayly, M.A. 1.317
 Bazam, N.G. 3.051
 Bazan, N.G. 3.322
 Bazil, C. 3.208
 Bealer, S. 3.103
 Bealer, S.L. 3.107
 Beaulieu, C. 3.276
 Bebek, N. 2.322
 Bebin, E.M. 3.303
 Beck, H. 2.203
 Beck, J. 3.156
 Beconi, M. 1.189, 2.230
 Beggs, J.M. 1.048
 Behnke, E. 1.297
 Beige, A. 1.240
 Bekersky, I. 1.189, 2.230
 Belfiore, E.B. 3.269
 Bell, G.S. 1.138
 Bell, W.L. 1.276
 Bellec, P. 1.175
 Bello, L. 2.211
 Belloch, V. 1.284
 Bellows, S. 1.317
 Bellows, S.T. 1.319
 Beltran, A. 1.284
 Ben-Menachem, E. 1.127, 1.196, 1.231, 2.218, 2.227
 Benbadis, S. 1.014, 1.120, 2.233, 3.216
 Benbadis, S.R. 1.080, 3.295
 Bender, R.A. 3.033
 Benes, L. 3.204
 Beniak, T.E. C.07
 Beniczky, S. 1.272
 Benke, T. I.W.010

ABSTRACT AUTHOR INDEX

- Benn, E.K. 2.094
 Bennett-Back, O. 1.277
 Bensalem-Owen, M. 1.037
 Bensalem-Owen, M.K. 1.224, 3.206
 Berdichevsky, Y. 3.039, 3.047, 3.068
 Berendt, M. 1.314
 Berg, A.T. 2.094
 Bergen, D. 3.155
 Bergey, G.K. 1.016, 1.064, 1.066, 3.065
 Bergholte, J. 1.112
 Bergin, A.M. 1.309
 Berkovic, S. 2.321, 3.040
 Berkovic, S.F. 1.092, 1.093, 1.094, 1.311, 1.317, 1.319, 1.323, 2.214, 2.316, 3.188, 3.242
 Berkowitz, A.L. 3.194
 Berl, M. 2.117, 2.293
 Berl, M.M. 2.279, 3.240, 3.254, 3.262
 Berliner, J.L. 3.213
 Berman, R. 1.187, C.08
 Bernal, B. 2.115, 2.117, 3.254
 Bernasconi, A. 1.182, 3.238
 Bernasconi, N. 1.159, 2.254, 3.238
 Bernedo, V. 1.154
 Bernhardt, B. 1.159
 Bernhardt, B.A. 1.005
 Bernhardt, B.C. 1.182
 Berning, S. 1.212
 Bero, A.W. 3.095
 Berrettini, W.H. 3.120, A.05
 Bertaso, F. 3.335
 Bertram, E.H. 3.055, 3.110, 3.134
 Besio, W.G. 3.158
 Betting, L.E. 1.116, 1.174
 Bezin, L. 3.309
 Bezuyen, A. 1.006
 Bhatia, S. B.04
 Bhatt, S. 1.288
 Bhimani, B.C. 3.217
 Bhupalam, R. 1.076
 Bianchi, M.E. 3.015
 Bianchin, M.M. 1.299, 2.312, B.05
 Bidlack, J.M. 2.207
 Biederman, J. 2.172
 Bien, C.G. 3.300
 Bill, P. 2.005, 3.245
 Billstrom, T. 3.097
 Bilo, L. 1.215
 Bindra, T. 2.197
 Bingaman, W. 1.101, 1.308, 2.047, 3.287, 3.289, 3.302
 Bingaman, W.E. B.02
 Biondi, D.M. 1.121
 Biraben, A. 1.287
 Birch, R. 3.350, C.04
 Birg, L. 2.044
 Birnbaum, A.K. 1.237, 1.243, 2.269, C.07
 Bischof, H. 3.147
 Bisping, F. 1.206
 Bisping, J.R. 2.073
 Bissonette, G.B. 3.128
 Biton, V. 1.216, 1.234
 Bitsche, G. 2.186
 Bjornson, B. 2.117, 3.254
 Bjurulf, B. 1.259
 Black, P. 1.113, 1.309
 Blackman, M. 1.037
 Blackman, M.A. 2.116
 Blackstone, K. 2.279, 2.293, 3.240
 Blake, S. 2.181
 Blatt, I. 1.218
 Blaya, C. 2.312
 Bleasel, A.F. 1.170, 2.298, 3.271
 Bleiss-Ahrens, M. 1.206
 Blendy, J. 3.088
 Blount, J. 1.305, 3.305
 Blumberg, J.M. 3.205
 Blumberg, M. 3.265, 3.278
 Blume, W.T. 3.212, 3.215
 Blumenfeld, H. 1.187, 2.174, 2.285, 3.082, 3.085, 3.100, C.08
 Bodmann, B. 3.049
 Boer, K. 3.070
 Boggs, J.G. 1.276
 Bohlmann, K. 1.207
 Boling, W. 3.193
 Bollo, R.J. 3.213
 Bond, T.L. 1.057
 Bonelli, S. B.07
 Bonilha, L. 1.167
 Boo, C. 3.265
 Boon, P. 2.041, 2.043, 2.218, 3.042, 3.066
 Boop, F. 2.044
 Boop, F.A. 2.048
 Boor, R. 2.183, 2.184
 Boothe, D.M. 2.194
 Bordet, R. 3.108
 Bordoley, M. 2.332
 Bordson, C. 1.003, 1.326
 Borges, K. 1.270
 Borghs, S. 2.224
 Borkowska, J. 2.091
 Borkowski, T. 1.088, 1.118
 Bortel, A. 1.035
 Botte, S. 3.345
 Botzolakis, E.J. 1.313
 Boulland, J.L. 3.319
 Bourgeois, B. 1.250
 Bourgeois, B.F. 1.032, 1.309
 Bourguignon, M. 2.041, 2.043
 Bouthillier, A. 1.282, 3.293, 3.297
 Bouvard, S. 3.309
 Bova, S. 1.312
 Bower, M.R. 1.062
 Boxer, M. 1.218
 Boyer, K. 2.172, 2.281
 Boyle, M.H. 3.177
 Bozorg, A.M. 1.014, 1.080, 1.120, 3.216
 Brace, D. 1.006, 2.336
 Bragatti, J.A. 2.312
 Bragin, A. 3.032, 3.152
 Bragin, D.E. A.08
 Brandal, K. 2.320
 Brandt, A. 2.010
 Brashear, H.R. 1.204
 Brazdil, M. 1.060, 1.294
 Brazzo, D. 2.005, 3.245
 Breier, J. 2.277
 Breit, T. 3.070
 Brenner, T. A.04
 Brewster, A.L. 2.163, 3.033, 3.041
 Briggs, M. C.03
 Bright, T. 1.205, 1.239
 Brill, J.A. 3.023
 Brilstra, E.H. 2.319
 Britto, L.R. 3.327, 3.334
 Britton, J. 2.095
 Britz, J. 1.106
 Briyal, S. 1.256
 Brock, M. 2.223
 Brodbeck, V. 2.009, 3.266
 Broderick, P.A. 1.090
 Brodie, M.J. 3.199, A.04, C.06
 Brodsky, A.C. 1.216, 1.219
 Brodtkorb, E. 2.320
 Bromfield, E.B. 1.089, 1.113
 Bromhead, C. 1.319
 Bromley, R.L. 2.288, C.03
 Brooks-Kayal, A.R. 3.025
 Brophy, S.E. 2.149
 Brown, C. 3.303
 Brown, D. 2.046
 Brown, L. 1.056, 1.250
 Brown, S. 1.201, 3.291
 Brown, T. 2.167, 2.168
 Browning, N. 2.180
 Brozickova, C. 3.314
 Brundage, R. 2.206
 Brunklaus, A. C.04
 Brunner, P. 3.147
 Bruno, P. 2.226
 Bruno, P.L. 3.225
 Bryant, A.S. 3.142, 3.143
 Brázdil, M. 1.292
 Bubrick, E.J. 2.335
 Buchanan, G.F. 3.102
 Buchhalter, J. 2.101
 Buchholz, H.G. 1.154
 Buckmaster, P. IW.07, 3.009, 3.323
 Budde, T. 3.033
 Buelow, J.M. 1.007, 2.132
 Buhrke, K. 2.307
 Bujarski, K.A. 1.028, 1.303, 2.250, 3.196, 3.279
 Bulacio, J.C. 2.047, 3.302
 Bulej, G. 2.236
 Bullis, J.B. 3.014
 Bullman, J.N. 1.203
 Buono, R.J. 3.083, 3.120, A.05
 Burattini, J. 3.283
 Burdette, D. 1.235
 Burdette, J.H. 1.151
 Burgerman, R. 1.250
 Burgess, R. 1.040, 2.170, 3.166
 Burgess, R.C. 1.022, 2.040, 2.045, 2.047
 Burneo, J. 2.017, 3.210, 3.290
 Burneo, J.B. 3.212
 Burneo, J.G. 1.084, 1.096, 3.280
 Busch, R. 1.184
 Busch, R.M. 2.243
 Busse, C. 3.243
 But, A. 1.314
 Buttinelli, C. 1.161
 Buzinec, P. 2.337, 2.338
 Byars, A. 2.046
 Byars, A.W. 2.283
 Byrne, R.W. 3.155, 3.286
 Byth, K. 3.271
 Byun, J. 3.181
- ## C
- Cabaniss, W. 1.041
 Caboclo, L.O. 1.009, 1.183, 3.233
 Cabrerizo, M. 2.117
 Caccioppo, D. 2.081
 Cadotte, A.J. 3.067, 3.330
 Caglayan, H. 1.317
 Cai, Y. 3.032
 Cain, S.M. 3.112
 Caldwell, P.T. 2.205, 2.216, 3.202, 3.203
 Calixto, E. 1.146
 Callaghan, B. 1.111
 Calleja, A. 1.162
 Camfield, C.S. 2.106, 2.118, 2.333
 Camfield, P.R. 2.106, 2.333, 3.290
 Campbell, J.N. 3.057
 Campbell, M.K. 2.328
 Campos, D. 1.162
 Camposano, S.E. 3.226
 Canbolat, A. 2.322
 Canevini, M.P. 1.029, 1.312, 2.138
 Canger, R. 2.138
 Cannata, V. 3.258
 Cannon, D. 1.178
 Cansel, N. 2.143
 Cantello, R. 1.274
 Caplan, L. 1.079
 Caplan, R. 2.161, 2.166, 2.282, 2.284, 3.249, 3.259
 Caporro, M. 1.161
 Carcak, N. 3.337
 Cardoso, T.A. 1.116
 Carius, A. 2.076
 Carlen, P. IW.09
 Carlotti Jr, C.G. 1.299, 2.150, B.05
 Carlson, C. 3.265, 3.278, 3.298, B.01
 Carlson, D. 3.097
 Carlson, S.L. 1.004
 Carmant, L. 1.282, 3.290, 3.297, 3.349
 Carmichael, D.W. 1.150, 1.181
 Carmignoto, G. IW.14
 Carney, P. 2.012, 3.153
 Carney, P.R. 3.067, 3.330
 Carney, P.W. 3.242
 Carpenter, J. 2.022
 Carrete Junior, H. 1.183
 Carrette, E. 2.041, 2.043
 Carreño, M. 2.075
 Carvalho, K. 2.024, 2.025, 2.109
 Cascino, G. 2.274, B.08
 Cascino, G.D. 2.158, 3.306
 Casella, B. 2.167, 2.168
 Cash, S. 1.045, 1.128
 Cash, S.S. 1.055, 3.194, 3.251
 Cassar, M. 2.314
 Castro, L.H. 1.072, 2.325
 Castro, O.W. 3.013, 3.029
 Catarino, C.B. 3.350
 Cavitt, J. 2.151
 Cavus, I. 3.037

ABSTRACT AUTHOR INDEX

- Cawello, W. 2.223
 Cendes, F. 1.116, 1.174, 1.315, 2.140, 2.147, 2.324, 3.269
 Centeno, R.S. 1.009, 1.183
 Cepok, S. 3.044
 Cervenka, M.C. 2.299
 Cha, B. 3.179
 Chabrol, E. 3.146
 Chachua, T. 3.113, 3.139
 Chae, J. 2.113, 3.170
 Chai, S.Y. 3.318
 Chalder, T. 2.135
 Chamma, M.T. 1.139, 3.345
 Chan, A. 3.253
 Chan, D. 2.038
 Chan, V.W. 2.097
 Chang, A. 3.034
 Chang, B.S. 2.015, 2.034, 3.243
 Chang, E.F. 1.042, 3.308
 Chang, T. 3.186
 Chao, H.J. 3.150, 3.151
 Chapieksi, M.L. 2.291
 Chapieski, L. 1.310, 2.286
 Chapin, J. 1.108, 1.184
 Chari, G. 2.332
 Charyton, C. 1.123
 Chassoux, F. 1.287
 Chatillon, C. 1.035
 Châtillon, C.E. 1.058
 Chaudhary, U.J. 1.150
 Chaudhry, F. 2.160
 Chauvel, P. 1.181
 Chavakula, V. 1.067
 Chen, D.K. 2.246
 Chen, H. 3.096
 Chen, H.X. 3.117, 3.122
 Chen, T. 3.157
 Chen, T.T. 3.109
 Chen, X. 1.124, 3.204
 Chen, Y. 2.037, 2.326
 Chen, Y.M. 2.052
 Cheng, S.H. 2.210
 Chernyy, N. 3.348
 Cheung, C. 1.096
 Cheung, R.Y. 1.236
 Chiapeski, M. 2.297
 Chico, M. 2.187
 Chien, J.H. 1.019, 1.054
 Chiesa, V. 1.029, 1.312, 2.138
 Chigwedere, C. 2.135
 Chihara, Y. 3.003, 3.019, 3.030
 Chin, R. 2.089, C.01
 Chin, R.F. 2.096
 Chitsazzadeh, V. 3.243
 Chiummiento, M. 1.193
 Chmielewski, D. 2.091
 Cho, C. 3.136
 Cho, K. 3.043
 Cho, Y. 1.318, 3.043
 Choi, B.S. 3.267
 Choi, E. 2.257
 Choi, J. 2.113
 Choi, K. 1.262
 Choi, N. 1.044, 1.086
 Choi, S.J. 3.200
 Choi, W. 3.084
 Chong, J. 2.261, 3.209
 Chong, W.K. 2.102
 Choy, M. 3.115
 Chrasina, J. 1.294
 Chrastina, J. 1.060
 Christensen, J. 3.231
 Chu-Shore, C.J. 2.018, 2.226, 3.251
 Chuang, S. C.02
 Chuang, S.H. 2.036
 Chugani, D.C. 3.359
 Chugani, H.T. 2.013, 3.236, 3.239, 3.241, 3.250, 3.252, 3.359
 Chumley, A.N. 3.206
 Chung, H. 2.190
 Chung, J. 3.235
 Chung, M. 2.285
 Chung, S. 1.020, 3.165, 3.294
 Chung, S.S. 1.122
 Churchward, T.J. 1.092, 1.093, 1.094
 Churillín, Y.Y. 3.224
 Churilov, L. 1.092, 1.093, 1.094
 Churn, S.B. 3.057
 Cianci, V. 2.072
 Cilio, M. IW.010
 Cilio, M.R. 3.258
 Cine, N. 2.322
 Cinkosky, M. 3.303
 Cios, J. 1.075
 Claassen, C. 1.037
 Clancy, R. 3.127
 Clancy, S. 3.335
 Clark, A. 3.127
 Clark, A.M. 2.206
 Clark, C.A. 2.096
 Clark, D.R. 2.330
 Clarke, D. 2.044
 Clayton, L.M. 3.192
 Clayton-Smith, J. 2.180, C.03
 Cleanthous, M.E. 2.178
 Clements, K. 2.142
 Clench-Aas, J. 2.103
 Climo, K. 1.216
 Clinckers, R. 3.066, 3.324, 3.326
 Cloyd, J. 2.240, 3.127
 Cloyd, J.C. 2.206
 Clusmann, H. 3.299, 3.300
 Cochran, E.J. 3.286
 Cock, H.R. 3.004
 Cockburn, L. 3.201
 Cohen, I. 3.146
 Cohen, M. 2.180
 Cohn, A. 1.220, 1.254
 Coimbra, E.R. 1.299
 Cole, A. 1.128
 Collier, A. 1.144
 Collins, R. 2.286
 Colonnelli, M.C. 1.302, 1.307
 Combs-Cantrell, D. 2.180
 Comi, A.M. 1.068, 2.194, 3.080
 Commissariat, P. 2.285, 2.290
 Compton, R. 1.025
 Concha, L. 1.159
 Conde, R. 1.284
 Condino, F. 2.072
 Conneely, T. 1.006
 Conner, C. 2.276
 Connolly, A. 1.002
 Connolly, E.S. 3.347, 3.357
 Connolly, M.B. 3.349
 Connor, J.A. A.08
 Connors, B.W. 3.021, 3.060
 Conry, J. 3.256
 Conry, J.A. 2.130, 3.262
 Constable, R.T. 3.274, C.08
 Constable, T. 1.187
 Constantino, T. 1.135
 Constantinou, J. 1.288
 Conurso, R. 3.211
 Conway, J.M. 1.237
 Conz, L. 3.269
 Cook, A.M. 1.224
 Cook, L.G. 2.068
 Cook, M. 3.220
 Cook, M.J. 2.316
 Coons, S.W. 3.329
 Copeland, L.A. 1.222
 Corcia, M. 3.351
 Corradini, B.R. 2.325
 Corral-Leyva, G. 1.077
 Cortez, J. 1.084
 Cortijo, E. 1.162
 Cosmo, G. 1.308
 Cossart, R. IW.08
 Cossette, P. 1.282, 3.293, 3.297, A.05
 Costa, A.C. 1.116
 Costa, A.F. 1.116
 Costa, A.L. 2.140
 Costa, L.A. 1.121
 Costello, D. 2.018, 3.232
 Coulter, D. IW.08, 3.136
 Cox, M. 3.156
 Cox, T. 2.102
 Cracco, R. 2.332
 Craigen, W.J. 3.005
 Cramer, J.A. 1.222, 2.145, 2.224, C.05
 Crawford, P. 2.270
 Crepeau, A.Z. 3.229
 Crespel, A. 1.287
 Cressman, J. A.01
 Crino, P.B. 3.070, 3.072, 3.092, 3.288, 3.34, IW.07
 Crisp, E.D. 2.200
 Crompton, D.E. 1.319, 2.316
 Crone, N.E. 1.066, 1.068, 2.299, 2.311
 Cross, J.H. 1.302, 1.307, 2.102
 Crowley, S. 1.002
 Cucherat, M. 2.213
 Cucullo, L. 2.221
 Cukiert, A. 3.283
 Cukiert, C.M. 3.283
 Culbertson-Brown, P. 3.267
 Cumberland, P. 2.089
 Cunningham, C.E. 3.177
 Cunnington, M. 1.197
 Curia, G. 3.101
 Czech, T. 1.291
 Czuczwar, S.J. 3.090, 3.091
 D'Argenzio, L. 1.302, 1.307
 D'Arrigo, S. 3.243
 D'Souza, W.J. 3.220
 Dabbs, K. 1.140
 Dabora, S. 3.226
 Dahl, E. 2.208
 Dahlin, M.G. 1.273
 Dalal, K. 1.271
 Dale, A.M. 1.156
 Daley, M. 2.161
 Dangel, J. 2.091
 Daniel, P. 1.060
 Daniels, D. 1.260, 2.112
 Danzer, S.C. 3.317
 Darcey, T.M. 1.024, 3.279
 Das, R. 1.113, 2.114, 2.124, 3.173, 3.221
 Date, I. 2.004
 Datta, A. 2.114, 2.128, 2.281
 Davenport, J. 3.290
 Davidson, B.L. IW.13
 Davis, L. 1.006
 Davis, P.E. 1.057
 Davis, S. 2.167
 Davis, S.M. 2.168
 Day, L. 1.239
 de Araújo Filho, G. 3.233
 De Bundel, D. 1.264, 3.318
 de Gooijer, K.L. 3.189
 de Gooijer-van de Groep, K. 2.029
 de Haan, M. 2.289
 De Herdt, V. 2.043, 3.042
 De Jonghe, P. 1.323
 de Kovel, C. 2.319
 De la Cruz, E. 3.006
 de La Loge, C. 2.224
 de Lange, E.C. 3.022
 de Leva, M.F. 1.215
 De Meirleir, L. 1.316
 de Oliveira, E. 1.315, 3.324
 de Souza, A.C. 2.312
 de Souza, D.O. 2.312
 De Tiège, X. 2.041, 2.043
 De Vlaeminck, Y. 1.316
 De Weerd, A.W. 3.020
 Dean, P. B.04
 DeAngelis, L. 1.124
 Dees, D. 2.195, 2.198
 Degrauw, T. 2.046
 deGrauw, T.J. 2.283
 Deherdt, V. 3.066
 Dehnicke, C. 2.204
 del Campo, M. 1.253
 del Cid, B. 2.212
 DeLance, A.R. 3.099
 Delanty, N. 1.103, 2.083, 2.329, 2.334
 Delazer, M. 3.260
 Delbeke, J. 3.042
 Delgado, J.C. 1.084, 1.096
 Demaegd, H. 3.318
 Demarin, V. 2.313
 Demidenko, E. 3.196
 Dempsey, E. 1.002
 Depireux, D.A. 3.128
 Depositario-Cabacar, D. 3.256, 3.262
 Derambure, P. 1.287
 D'Ambrosio, R. 3.094, 3.101, A.06
 D'Arcangelo, G. 3.129
 D'Argenio, M.R. 1.097

ABSTRACT AUTHOR INDEX

- Dergalust, S. 1.328
 Derosa, P.A. 3.357
 Desai, A. 1.283
 DeSalvo, M. 2.174, 2.285, 3.085, 3.100, C.08
 DeSalvo, M.N. 3.082
 Detyniecki, K. 2.174
 Devinsky, O. 1.090, 3.150, 3.151, 3.213, 3.265, 3.278, 3.298, B.01, P.L.03
 Dewar, S. 1.297
 DeWolfe, J.L. 3.207
 Dhaliwal, H. 1.296, 3.296
 Dhir, A. 2.212
 Di Iorio, W. 1.097
 Di Lorenzo, G. 2.005
 Diaz, J. 3.323
 Dibbens, L.M. 1.311, 1.317
 Dibernardo, A. 1.204
 Dickens, D. 2.035, 2.259
 Diehl, B. 1.022, 1.150, 1.184
 Dies, K. 3.243
 Diksic, M. 1.168
 Dilley, D. 2.222
 DiMario, F. 2.094
 Dineen, J. 2.083
 Ding, L. 1.313, 3.145
 Dionisio, J. 1.137
 DiSano, M. 1.300, 2.276, 2.277
 Ditto, W.L. 3.067, 3.153
 Djordjevic, J. 2.254, 2.271, 2.310
 Dlugos, D.J. 2.117, 3.178, 3.191, 3.254, A.05
 Dobesberger, J. 1.115, 3.260
 Doescher, J. 2.035
 Dogini, D.B. 2.324
 Doherty, C.P. 1.157
 Doherty, M. 1.143
 Doi, T. 3.003, 3.019, 3.030
 Domanska-Pakiela, D. 2.091
 Domingues, R.R. 1.315
 Donnelly, K. 2.157, 2.159
 Donner, E. 1.277, 2.117, 3.254
 Donner, E.J. 2.097, 3.253, 3.281, C.02
 Doss, J. 1.008
 Doss, R. 2.035, 2.255, 2.259
 Doss, R.C. 2.073
 Doty, P. 2.222, 2.227, 2.228, 2.231, 2.235
 Doucette, A. 2.333
 Dourado, M.V. 1.012
 Doyle, G.A. 3.120
 Doyle, W. 3.298, B.01
 Doyle, W.K. 1.090, 3.213
 Drake, J. 3.281
 Drake, K. 3.267
 Drane, D.L. 2.272
 Drazkowski, J. 1.130, 2.081
 Drazkowski, J.F. 1.107, 2.133, 2.248, 2.251
 Drechsel-Baeuerle, U. 2.321
 Dreyer, S.E. 1.300, 2.276, 2.277
 Driscoll, V. 1.280, 1.281
 Druga, R. 3.119
 Drögemüller, C. 1.314
 Dube, C. IW.03
 Dubeau, F. 1.034, 1.035, 1.058, 1.143, 1.147, 1.163, 1.168, 1.175, 2.023, 2.032
 DuBois, J. 3.265, 3.278
 Dubon, S.A. 2.061
 Dubucquoi, S. 3.108
 Dubé, C. 3.033
 Duchowny, M. 2.090, 2.105, 3.246, 3.303
 Duchowny, M.S. B.04
 Ducruet, A.F. 3.347, 3.357
 Dudek, F.E. 1.242, 3.053, 3.140, 3.161
 Duffy, F.H. 1.032, 1.309, 2.007, 3.173
 Duhaime, A. 1.303
 Duke, E. 2.293, 3.240
 Duke, E.S. 3.262
 Dula, C. 3.356
 Dulay, M. 2.146
 Dulay, M.F. 1.160
 Dulla, C.G. 3.023
 Dumont, G.A. 2.002
 Duncan, J. 1.180, 3.192, B.07, C.04
 Duncan, J.S. 1.150, 1.173, 1.181, 1.244
 Duncan, R. C.06
 Dunin-Wasowicz, D. 2.091
 Dunleavy, B. 2.334
 Dunn, D.W. 1.007, 2.283
 Dunn, M. 2.035
 Dunne, J. 1.117
 Dunne, J.W. 1.319
 Dunne, M. 2.334
 Dunoyer, C. 3.246, B.04
 Dunseath, R. 1.166
 Duplessis, A. 3.243
 Dupont, S. 1.287
 Durand, D. 2.054
 Durand, D.M. 3.123
 Durden, E. 1.121
 Duron, R. 2.287
 Dustin, I. 3.264
 Dvorak, D. 2.332, 3.141
 Dvorquez, D. 3.194
 Dworetzky, B.A. 1.089, 2.335
 Dyhrfeld-Johnsen, J. 3.047
 Dzakpasu, R. 3.038
 Dzhafarova, N. 2.197
 Dzhala, V.I. 3.046
- E**
 Eagan, C. 1.329
 Eastman, C.L. 3.094
 Eaton, M.J. 3.120
 Eatough, N. 1.331
 Eberl, S. 2.298, 3.271
 Eberly, L.E. 1.079, 2.269
 Ebersole, J. 2.019, 3.200
 Ebersole, J.S. 2.014
 Ebersole, S. 2.019
 Eble, I. 2.010
 Ebner, A. 1.169, 1.171
 Ebus, S. 1.110
 Edelman Lewis, B. 2.327
 Eden, U.T. 1.055
 Edmonds, M. 1.092, 1.093, 1.094
 Edwards, E. 1.042
 Edwards, J. 1.099
 Edwards, J.C. 1.167, 2.061
 Eggener, K. 2.187
 Eggert, A. 2.223, 2.228
 Eichler, E.E. 1.317, 2.319
 Eid, T. 3.037, 3.077
 Eisch, A.J. 3.001
 Eisenman, L.N. 3.018
 Eisenschenk, S. 1.208
 Eissa, I. 1.120, 3.216
 Ekenstedt, K. 1.314
 Eksioglu, Y.Z. 1.032, 3.173, 3.354
 El Mubarak, M. 3.273
 El Shakankiry, H.M. 3.172
 El Tahry, R. 3.042, 3.066
 Elanchezhyan, D. 1.271
 Elbakry, N. 2.165
 Elfgren, C. 1.145
 Elgavish, G. 1.186
 Elgavish, R. 1.041, 1.186, 1.191, 3.305
 Elgavish, T. 1.186
 Elger, C. 1.196, 1.231, 1.235, 2.063, 2.233, 2.317, 2.319, 3.285, 3.299, 3.300
 Elias, L.L. 3.017
 Eliashiv, D. 1.297, 3.235
 Elisevich, K. 1.153, 1.288, 2.031
 Elisevich, K.V. 3.361
 Elkhetali, A. 1.186
 Elliott, I. 3.201, 3.281
 Elliott, I.M. 2.280
 Elliott, J. 1.075
 Elliott, J.O. 1.123, 2.062, 2.232
 Elliott, R. 3.298
 Elliott, R.E. 3.213, B.01
 Ellis, T. 1.298
 Elmore, T. 2.276, 2.277
 Elmore, T.M. 1.300
 Eltze, C.M. 2.102
 Elwes, R.D. 1.181
 Elzagallai, A.A. 2.209
 Emerson, R. 3.161
 Emir, B. 1.247
 Emori, Y. 1.023, 1.026, 2.264
 Emrich, J.F. 3.147
 Enam, S.A. 3.193
 Enatsu, R. 1.101
 Engel Jr, J. 1.114, 3.032
 Engle, J. 2.278
 Englot, D.J. 3.085
 Eom, S. 1.261, 2.190
 EPICURE Consortium, E. 1.317
 Erbayat Altay, E. 1.184
 Ernst, J.P. 2.183
 Ertürk, Ö. 3.275
 Escalante-Santiago, D. 3.336
 Esclapez, M. 3.319
 Escorsi-Rosset, S. 1.299
 Eskandar, E.N. 1.055
 Eskazan, E. 3.002
 Espinosa, E. 2.287
 Espinosa, P.S. 3.194
 Esser, M.J. 1.010
 Ettinger, A. 2.253, 2.301, 2.337, 2.338
 Ettinger, A.B. 2.145, C.05
 Eun, B. 2.190
 Eun, S. 2.190
 Evancovich, K. 2.297
 Evankovich, K. 2.286
 Evankovich, K.D. 2.291
 Evans, A.B. 1.151
 Evans, D.B. 3.361
 Evans, J. 1.073
 Ewen, J.B. 1.068
 Eyal, S. 1.144
 Ezugha, H. 3.171
- F**
 Faber, P. 3.124
 Faberova, K. 3.118
 Fadel, J.R. 3.332
 Fadul, C.E. 3.196
 Fagnou, J. 1.148
 Faingold, C.L. 3.087
 Fakhoury, T. 1.031, 3.206
 Fakhoury, T.A. 1.224
 Falcao, A. 1.241
 Falcone, N.M. 3.194
 Falcone, T. 2.169
 Falter, U. 1.216, 1.219
 Fan, Q. 3.124, 3.125
 Fanselow, E.E. 3.060, 3.352
 Faraone, S.V. 2.172
 Faria, L. 3.008
 Fariello, G. 3.258
 Farmer, J.P. 3.290
 Farnarier, G. 2.072
 Farooque, P. 2.109
 Fasano, R. 3.256
 Fastenau, P.S. 2.283
 Faught, E. 1.136, 1.191, 2.337, 2.338
 Faught, R. 3.127
 Faught, R.E. 2.142
 Faught Jr, R.E. 1.250
 Fay, T.B. 2.306
 Fazio, V. 1.226, 2.221, 3.124
 Feddersen, B. 2.053
 Federico, P. 1.148, 3.261
 Federico, P.N. 1.149
 Fedorova, T. 3.188
 Fee, D.B. 3.194
 Felber, S. 3.260
 Feldmann, M. 1.244
 Feleppa, M. 1.097
 Fender, J.S. 3.094, 3.101, A.06
 Feng, G. 3.046
 Feng, H.J. 1.313
 Fenning, R.S. 3.092
 Fenton, A. 2.332
 Fenton, A.A. 3.141
 Fernández-Herranz, R. 1.162
 Ferenc, L.M. 1.068
 Ferguson, P. 2.164
 Ferguson, P.B. 1.298
 Ferguson, P.L. 2.296
 Ferguson, R. 3.144
 Ferhat, L. 3.319
 Feria-Romero, I. 3.336
 Ferland, R. 3.104, 3.105
 Ferman, T.J. 2.158, 2.274
 Fernandes, A. 3.013, 3.029
 Fernandes, R.D. 2.294

ABSTRACT AUTHOR INDEX

- Fernandez-Baca-Vaca, G. 2.056
 Ferraro, T.N. 3.083, 3.120, A.05
 Ferrier, C.H. 2.029, 3.189
 Ferro, M.A. 2.328
 Fertig, E. 2.220
 Fertig, E.J. 2.234
 Festrova, V. 3.314
 Feucht, M. 2.319
 Ficker, D.M. 2.151
 Fields, M. 2.238
 Finegersh, A. 1.178, 3.264
 Fiocchi, I. 1.312
 Fiol, M. 2.074
 Fiore, L. 2.262, 2.263
 Fiori, L. 2.268
 Fiorito-Grafman, M. 2.295
 Fisch, B.J. 1.104, 3.230
 Fitzgerald, C. 1.188
 Fitzgerald, E. 3.062
 Fitzgerald, M. 1.002
 Fitzsimons, M. 2.329, 2.334
 Flamini, J.R. 3.247
 Flashman, L. 2.250
 Flink, R. 1.290, 3.292
 Flinker, A. 1.042
 Flynn, C.T. 1.002
 Focke, N. B.07
 Fogel, T.G. 2.082
 Folami, K. 1.141
 Foldy, C. 3.341, 3.353
 Fongwa, M. 3.201
 Fontaine, F. 3.349
 Forcelli, P.A. 2.191
 Foresti, M.L. 1.266, 3.344
 Forlenza, J.B. 1.121
 Forman, O. 1.314
 Forster, C. 3.283
 Fountain, N.B. 1.250, 2.222, 3.198, 3.234
 Fountas, K.N. 1.285
 Foushee, R. 2.142
 Fowler, K.M. 1.077
 Fox, P.T. 3.121
 Franaszczuk, P.J. 1.016, 1.064, 1.066, 2.299, 2.311, 3.065, 3.148
 Franca, M.C. 2.140
 Franceschini, M.A. 3.251
 Francione, S. 1.029
 Franco, A. 1.033
 Frane, R. 1.149
 Franic, L. 3.132
 Frank, M. 3.182
 Franke, A. 1.317, 2.319
 Frankel, W.N. 3.061
 Franklin, C. 3.121
 Franklin, M.R. 1.200
 Franz, D. 2.037
 Franz, D.N. 2.039
 França, M.C. 2.140
 Frausto, S.F. 2.219
 Frayne, R. 3.261
 Frazier, C. 1.332
 Fredholm, M. 1.314
 Fregni, F. 1.139, 1.274
 Freitas-Lima, P. 1.194
 French, C. 2.215
 French, J. 1.111, 1.231, 1.247, 2.205, 2.227, 2.238, 3.150, A.05
 French, J.A. 1.250
 Frey, L. 3.111
 Fried, A. 2.301
 Friedman, A. 2.132
 Friedman, D. 3.114
 Friedman, D.E. 1.071, 1.085
 Friedman, L.K. 3.011, 3.351
 Friedman, M. 1.231
 Frim, D.M. 2.300
 Frost, J.D. 1.051
 Frost, M. 2.035, 2.122, 3.303
 Fucci, S. 1.097
 Fuchs, K. 2.319
 Fucic, A. 2.313
 Fuentes, D. 2.104, 2.262, 2.263, 2.268
 Fuerst, D. 1.036, 1.039
 Fujimoto, A. 1.030, 1.296
 Fujiwara, H. 2.037, 2.039, 2.046, 2.049, 2.052, 3.284
 Fukasawa, T. 3.237, 3.238, 3.248
 Fukatsu, H. 3.237, 3.248
 Fukuda, M. 1.043, 1.046
 Fukuyama, H. 1.152, 2.055, 2.125
 Fulham, M. 3.271
 Fulham, M.J. 2.298
 Funke, M. 2.050
 Fureman, B. 1.332
 Furtado, M.A. 3.013
 Furtado, M.D. 3.093
 Fusco, L. 3.258
- G**
 Gaddam, S. 2.031
 Gadian, D.G. 3.115
 Gaieski, D.F. 1.038
 Gaillard, W.D. 2.115, 2.117, 2.279, 2.293, 3.240, 3.253, 3.254, 3.256, 3.262
 Gaitanis, J. 3.243
 Gaitanis, J.N. 1.057
 Galanopoulou, A. IW.07
 Gale, K. 2.191, 3.158
 Gallagher, A. 2.018, 3.251
 Gallagher, M.J. 1.313
 Gambardella, A. 2.072
 Gambini, O. 2.138
 Gamulin, M. 2.313
 Gendelman-Marton, R. 1.027
 Gandrathi, A. 3.360
 Garcia, E. 1.089
 Garcia, P. 3.308
 Garcia-Cairasco, N. 3.013, 3.017, 3.024, 3.029
 Gardella, E. 1.029, 2.138
 Gardner, D. 1.303
 Garg, S. 1.057
 Garganta, C. 3.243
 Gargaro, A.C. 1.299
 Garnero, L. 2.042
 Garofalo, E. 1.202
 Garrard, J. 1.079
 Gasko, H. 1.205
 Gass, A. 1.158
 Gasston, D. 1.150
 Gast, H. 2.003
 Gastonguay, M. 3.127
 Gati, C.A. 3.017
 Gattaz, W.F. 3.331, 3.358
 Gaus, V. 2.319
 Ge, D. 1.198
 Gedela, S. 1.275, 2.088
 Geithner, J. 1.206
 Gelfand, M. 3.284
 Gelisse, P. 1.287
 Geller, E.B. 3.213, B.01
 Gemici, B. 2.128
 Genovese, E. 3.258
 George, A.L. 3.056
 Geraghty, M. 3.187
 Gerald, C.L. 1.299
 Germaine, D. 1.205
 Ghacibeh, G.A. 2.220, 2.234
 Gharapetian, L. 1.156
 Ghearing, G.R. 2.077
 Gholipour, T. 1.147, 1.175
 Ghosh, C. 1.226, 2.221, 3.125
 Giacino, J. 2.174
 Giannini, C. 3.306
 Giard, N. 3.293
 Giftakis, J. 3.097
 Gilbert, K. 1.267
 Gilio, A.E. 2.294
 Gill, M.B. 2.219
 Gill, R. 2.175
 Gill, S. 2.160
 Gillen, R.W. 2.245
 Gillespie, J. 2.242
 Gilliam, F. 1.329
 Gilmore, J.M. 1.327
 Giordano, S. 1.225, 1.236, 1.247
 Girard, H.M. 1.156
 Girvin, J. 3.212
 Giuliani, F. 3.328
 Giza, C. 3.032
 Gjergja, R. 2.313
 Gjerstad, L. 1.230, 2.103
 Glasscock, E. 3.109
 Glauser, T.A. 2.100, 2.112, 2.225, 2.229
 Gleason, K.A. 1.089, 2.335
 Gluckman, B.J. 3.348
 Glykys, J.J. 3.046
 Go, C. 2.036, 2.111, 3.281
 Go, T. 1.277
 Gobel, S. 2.143
 Godet, B. 2.042
 Goebel-Goody, S.M. 3.145
 Gohokar, N. 1.288
 Gökyigit, A. 2.322
 Gois, J.O. 2.263, 2.268
 Gokdemir, S. 3.275
 Goldin, A.L. 3.010
 Goldman, A. 3.109
 Goldman, S. 2.041, 2.043
 Goldstein, D.B. 1.198
 Goldstein, L.H. 2.135
 Golomb, D. 3.060
 Gombert, F. 2.042
 Gonzalez, A. 1.119
 Gonzalez, J. 1.232
 Gonzalez, J.C. 1.028
 Gonzalez-Heydrich, J. 2.172
 Gonzalez-Martinez, J. 2.047, 3.302
 Gonzalez-Sulser, A. 3.038
 Good, M. 2.337, 2.338
 Goodkin, H.P. 3.026
 Goodman, J. 2.239
 Goodman, R.R. 2.247, 3.072, 3.161, 3.357
 Goraya, J.S. 2.024, 2.109
 Gordon, K.E. 1.010
 Gorter, J.A. 3.020, 3.070
 Gotman, J. 1.034, 1.035, 1.058, 1.147, 1.163, 1.175, 1.179, 2.004, 2.020, 2.023, 2.032, 3.263
 Gotwald, T. 3.260
 Govindan, R.M. 3.359
 Goyal, M. 2.123
 Grabenstatter, H. 1.048
 Graber, K.D. 1.109, 3.054
 Graf, O. 3.155
 Graham, P. 1.099
 Grall, A. 1.314
 Gramling-Aden, M.L. 2.269
 Grant, A.C. 1.232, 2.131, 2.157
 Grant, P.E. 3.251
 Grasse, D. 1.049
 Graves, N. 3.097
 Gray, W.P. 2.258, 3.031, A.02
 Green, B.R. 2.236
 Greene, J. C.06
 Grefe, A. 1.276
 Gregas, M. 3.354
 Greger, B. 3.161
 Gregg, A. 3.187
 Gregoraszcuk, E.L. 3.071
 Greshake, B. 1.207
 Grigg-Damberger, M. 1.104
 Grill, M.F. 3.167
 Grimson, J. 2.334
 Grinton, B.E. 2.316
 Gröhn, O. IW.03
 Gross, D. 3.290
 Gross, D.W. 3.276, 3.328
 Gross, R. 1.052
 Grossman, R.G. 1.160
 Groth, D. 2.074
 Grova, C. 1.175, 3.277
 Guaranha, M.B. 3.233
 Guekt, A.B. 3.224
 Guerguerian, A.M. 1.018
 Guerreiro, C.A. 1.174
 Guerreiro, C.M. 1.116
 Guerreiro, M. 2.287
 Guerreiro, M.M. 1.116
 Guild, D. 2.172
 Guilhoto, L.F. 3.233
 Guilhoto, L.M. 1.009, 1.012, 2.294
 Guillen, M. 2.117
 Guillen, M.R. 2.115, 3.254
 Guiot, M.C. 1.168
 Gulati, D.K. 2.153
 Gullov, C.H. 1.314
 Gummery, A. C.03
 Guo, D. 3.028
 Guo, H. B.03
 Guo, J. 1.187
 Guo, L. 3.006
 Gupta, A. 1.308, 3.016, 3.303, B.02

ABSTRACT AUTHOR INDEX

Gupta, S.K. 3.162
 Gurbani, S. 2.161, 2.166, 2.282,
 2.284, 3.249
 Gürses, C. 2.322
 Gusev, E.I. 3.224
 Gutiérrez, A. 1.284
 Guye, M. 1.181

H

Haag, A. 3.204
 Haberlandt, E. 2.183, 2.186
 Haddad, E. 3.349
 Hader, W. 1.296, 3.290, 3.301
 Hadjilouzou, S. 2.178
 Haettig, H. 2.244
 Haginoya, K. 2.038
 Hagler Jr., D.J. 1.156
 Haglund, M.M. 3.035, 3.270
 Hahn, C.D. 1.018, 3.191
 Halamek, J. 1.060
 Halford, J. 1.127
 Halford, J.J. 1.019, 1.054, 1.167
 Halgren, E. 1.156
 Hall, C.B. 1.088, 1.118
 Hall, D.V. 3.145
 Hall, J. 1.324, 2.032
 Hall, J.A. 1.168
 Hall, S. 1.235, 1.238, 1.248
 Hallak, J.E. 2.150
 Hallaç, M. 3.275
 Halliday, W.C. 3.315
 Hallmann, K. 2.319
 Hamberger, M.J. 2.247
 Hamer, H.M. 1.100, 1.209, 2.319,
 3.044, 3.204
 Hamid, H. 2.174
 Hamill, I. C.06
 Hamilton, D. 2.258
 Hamilton, E. 1.099
 Hamiwka, L. 3.290, 3.304
 Hammer, A. 2.205, 2.216, 3.182
 Hammer, A.E. 3.202, 3.203
 Hammond, C.L. 1.320
 Hammoudi, M. 1.105
 Hamoda, H. 2.172
 Hampel, K.G. 2.318
 Hanakawa, T. 2.125
 Handler, M.H. 1.301
 Haneef, Z. 1.114, 1.161
 Hanna, J. 2.069, 3.214
 Hannan, S. 1.307
 Hara, K. 1.023, 1.026, 2.264
 Hara, M. 1.023, 1.026
 Harden, C. 1.220, 1.250, 1.254,
 2.193, 2.301
 Hardison, H.H. 2.109
 Hardwick, J.M. 1.269
 Harini, C. 2.199
 Harjen, H. 2.208
 Harkness, W. 1.302, 1.307
 Harms, S.L. 1.079
 Harnod, T. 1.061
 Harper, A. 1.276
 Harris, S. 2.230
 Harrison, S. 1.302
 Hart, S. 1.075
 Hart, Y. A.04

Hartman, A.L. 1.269, 2.121
 Hartman, J.T. 2.121
 Hartmann, M. 1.047
 Harty, R. 1.319
 Hartzema, B.G. 1.208
 Harvey, A.S. 3.242
 Hasegawa, H. 2.016
 Haselhorst, L.A. 3.130
 Hastriter, E.V. 2.171
 Hattemer, K. 1.100, 1.209, 3.204
 Hauser, W. 1.111
 Hauser, W.A. 2.134, 3.224
 Haut, S.R. 1.088, 1.118
 Havey, A. 1.125
 Hawes-Ebersole, S. 2.014, 2.300
 Hawkins, N.A. 1.322
 Hawkins, V. 2.265
 Hawley, J. 2.181
 Hayasaka, K. 3.045
 Hayes, L. 3.247
 Haywood, P. 3.180
 Hazra, A. 3.049
 He, B. 1.063, 1.065, 3.255
 Heath, C. 3.256, 3.262
 Hebb, A. 2.272
 Hebert, D. 2.227, 2.228, 2.231,
 2.233, 3.349
 Heck, C. 1.077, 1.119, 1.289
 Heck, C.N. 2.265
 Hecox, K.E. 2.001, 2.011
 Hedberg, T.G. 1.225, 1.236
 Hefft, S. 2.010
 Hegermiller-Smith, B. 1.001
 Heida, J.G. 1.266, 3.098
 Heinzen, E.L. 1.198
 Helbig, I. 1.005, 1.317, 2.319, 2.321,
 3.175
 Helbig, K.L. 1.005
 Helmstaedter, C. 2.228, 3.299
 Hemasilpin, N. 2.037, 2.039, 2.049,
 2.052
 Hemmer, B. 3.044
 Hempel, A. 2.122
 Henninger, H.L. 1.210
 Heo, K. 3.043
 Herman, S.T. 3.191, PL.04
 Hermann, B. 1.140, 3.249, 3.259
 Hermann, B.P. PL.03
 Hernandez, M.S. 3.334
 Hernandez, L. 1.106
 Hernandez, M. 2.287
 Hernandez, M.H. 3.184
 Hernandez, O.H. 1.033
 Hernandez-Frau, P. 1.120
 Hernandez-Frau, P.E. 3.216
 Hernandez-Ronquillo, L. 2.176, 3.290,
 3.296, 3.304
 Herrero, S. 1.162
 Herron, B. 3.105
 Herscovitch, P. 1.178
 Herzog, A.G. 1.077, 1.089
 Hesdorffer, D.C. 1.111, 2.094, 2.134
 Hetherington, H.P. 3.268
 Hetherington, S. 1.234
 Hetherington, S.H. 1.233
 Hetherington, S.V. 1.228
 Heuer, G.G. 3.092, 3.342

Heutinck, K.M. 3.110
 Heyman, I. 1.307
 Hicks-Smith, C.L. 3.080
 Higueta, A. 2.028, 2.030
 Hilgenberg, L. 3.353
 Hilger, E. 2.260
 Hill, K.D. 3.188
 Hill, S. 2.082
 Hirose, G. 1.087
 Hirsch, E. 1.287
 Hirsch, L. 2.127
 Hirsch, L.J. 3.191
 Hirshberg, J. 3.225
 Hiscock, M. 2.286
 Hitte, C. 1.314
 Hjalgrim, H. 2.319
 Hochman, D.W. 3.035, 3.270
 Hoepfner, T.J. 3.155
 Hoerth, M.T. 2.133
 Hoffmann, J.M. 2.063
 Hofmann-Peters, A. 2.184
 Hofstra, W. 3.020
 Holden, K.R. 2.061
 Holder, D. 1.275, 1.327, 2.088, 2.185
 Holland, K. 2.037, 2.049
 Holland-Bouley, K.D. 2.052, 2.107,
 3.284
 Holmes, G.L. 1.028, 1.303, 1.329,
 2.217, 2.305, 2.308, 2.309, 3.131,
 3.133, 3.138, 3.159, 3.182, 3.330,
 3.343
 Holmes, M.D. 2.006, 2.304
 Holtzman, D.M. 3.095
 Homewood, J. 2.298
 Hong, S.B. 2.303, 3.200, 3.272
 Hong, S.C. 2.303
 Horn, P. 2.046
 Horning, K. 1.101
 Hosmane, B. 1.221
 Hossain, M. 1.226, 2.221, 3.124
 House, P.A. 1.135, 3.161
 Howe, S.R. 2.078, 2.159, 2.252
 Howell, B.W. 3.001
 Howell, S.J. A.04
 Hráčková, A. 3.314
 Hrachovy, R.A. 1.051
 Hrisko, S. 2.164
 Hsieh, J. 3.320
 Hsin, Y. 1.061, 1.172
 Hsin, Y.L. 2.070
 Hsu, D. 1.048
 Hsu, F. 3.136
 Hsu, M. 1.048
 Hsu, T. 1.078
 Hu, D. 1.267
 Hugarir, R.L. 3.062
 Huggins, R.M. 1.083
 Huguenard, J.R. 3.023, 3.142, 3.143,
 3.356
 Huiskamp, G.J. 2.029, 3.189
 Huisman, M.C. 3.022
 Hum, K.M. 2.280
 Hunt, R.F. 3.130, A.07
 Huntsman, R. 3.290
 Huq, A. 2.315
 Hurst, D.F. 2.248, 2.251
 Husain, A.M. 1.001

Hutchison, J.S. 1.018
 Hwang, D. 3.067
 Hwang, H. 2.107, 3.170
 Hwang, S. 2.253
 Hwang, Y. 2.110, 2.113, 3.170
 Hyder, F. 3.082, 3.085, 3.100

I

Iacobas, D.A. 3.011
 Iacobas, S. 3.011
 Iasemidis, L. 1.069
 Iglesias, A.H. 3.063
 Ihle, M. 2.076
 Iino, H. 1.023, 1.026, 2.264
 Ikeda, A. 1.152, 2.055, 2.125
 Ikoma, M. 2.219
 Ikuta, T. 3.237
 Imai, K. 2.036
 Imamura, H. 1.152
 Imer, M. 2.322
 Immisch, I. 1.209, 1.212
 Inage, Y. 3.315
 Inaji, M. 1.023, 1.026, 2.264
 Indulkar, S. 2.170
 Inouchi, M. 2.055, 2.125
 Inyushin, M. 3.120
 Iragui, V.J. 1.025, 1.156, 1.295
 Iranzo, A. 2.075
 Irazoqui, P.P. 2.057, 3.162
 Irving, N.D. 2.194
 Irwin, B. 2.288
 Isaev, D.S. 2.217, 3.343
 Isaeva, E. 2.217, 3.343
 Ischebeck, A. 3.260
 Ishihara-Paul, L. 2.134
 Isojärvi, J. 2.222, 2.227, 2.228,
 2.231, 2.233, 2.235
 Isom, L.L. 3.016
 Ito, M. 2.136
 Ivaturi, V. 2.240
 Ives, J. 1.013
 Iwasaki, M. 3.307
 Iwinska-Zelder, J. 1.100
 Iwuchukwu, I. 1.070
 Iyengar, S.S. 3.355
 Iyer, P.M. 1.157
 Iyer, R.S. 3.219
 Izadyar, S. 2.246
 Izin, I. 2.322

J

Jääskeläinen, J. 2.098
 Jackowski, A.P. 1.183
 Jacks, L. 1.124
 Jackson, G.D. 3.040, 3.242
 Jacob-Filho, W. 2.325
 Jacobs, J. 1.034, 1.058, 2.020
 Jacobs, K. 3.056
 Jacobs, M. 1.332
 Jacobsen, D. 2.130
 Jacobson, M.P. 1.188, 1.213, 1.286
 Jaeger, R.K. 1.100
 Jahodova, A. 3.246
 Jain, S. 2.253
 Jan, M.M. 2.177
 Jang, S. 1.318
 Janigro, D. 1.226, 2.221, 3.124,
 3.125, 3.132

ABSTRACT AUTHOR INDEX

- Janousek, J. 2.154
 Jansen, A. 3.303
 Jansen, A.C. 1.316
 Jansen, F.E. 3.070
 Jansen, K. 1.056
 Jansen, L.A. 3.073
 Jardim, L.B. 2.312
 Jarrar, R. 2.101
 Jason, T. 3.314
 Jaussent, A. 1.287
 Javidan, M. 2.002
 Jayakar, P. 2.090, 2.105, 2.115, 2.117, 3.246, 3.254, B.04
 Jegla, T. 3.335
 Jehi, L. 1.108, 3.287, 3.289
 Jenrow, K.A. 3.361
 Jensen, F.E. 3.036, 3.062, 3.063, 3.074, 3.076, 3.135, 3.137
 Jensen, R. 3.097
 Jeong, G. 2.110
 Jeong, M. 3.176
 Jeong, S. 3.179
 Jetté, N. 2.176, 2.306, 3.290, 3.296, 3.301, 3.304
 Jimenez, M.E. 1.033
 Jimenez, N. 1.119
 Jin, K. 2.040, 2.045, 2.047
 Jo, K. 2.257
 Jobst, B.C. 1.024, 1.028, 1.267, 1.283, 1.303, 2.250, 3.196, 3.279
 Johnson, A. 2.230
 Johnson, A.L. 1.138
 Johnson, C.S. 1.007, 2.283
 Johnson, E.S. 3.328
 Johnson, G. 1.314
 Johnson, M.E. 1.216, 1.219
 Johnson, T.A. 1.168
 Johnston, J.A. 1.320
 Johnston, S.S. 1.121
 Jokinen, P. 1.314
 Jokinen, T. 1.314
 Jones, C. 3.280
 Jones, G.A. 2.200
 Jones, J. 1.140, 2.282
 Jones, N.C. 1.083, 2.155, 3.086, 3.340
 Jones, R.A. 3.247
 Jones-Gotman, M. 2.271, 2.275, 2.310
 Jonesgotman, M. 2.254
 Joo, E. 1.086
 Joo, E.Y. 2.303, 3.200, 3.272
 Jorge, M.S. 1.139
 Joseph, A. 3.074, 3.135
 Joshi, A.V. 2.238
 Joshi, C.N. 2.087
 Joshi, S. 3.026
 Joshi, S.M. 2.108
 Josic, K. 3.049
 Jouny, C.C. 1.016, 1.064, 1.066
 Jovanovska, V. 3.360
 Jovic, N.J. 2.179
 Jozwiak, S. 2.091
 Juhasz, C. 1.043, 1.046, 2.013, 2.051, 3.236, 3.239, 3.241, 3.359
 Jung, K. 3.190
 Jung, K.Y. 1.164
 Jung, R. 2.260
 Jung, R.L. 1.291
 Jung, S. 1.044, 3.014
 Jurak, P. 1.060
- K**
 Kadam, S.D. 2.194, 3.080
 Kahane, P. 1.287
 Kahlenberg, C. 3.196
 Kaido, K. 3.282
 Kakisaka, Y. 2.038
 Kalamangalam, G. 1.300, 2.277
 Kalayjian, L. 1.077, 1.119, 1.289, 2.180
 Kalayjian, L.A. 2.265
 Kaleyias, J. 2.124
 Kalhorn, S. B.01
 Kalhorn, S.P. 3.298
 Kalirao, S.K. 3.214
 Kalitzin, S. IW.09
 Källén, K. 1.145
 Kallis, C. 2.060
 Kälviäinen, R. 1.127
 Kaminski, R.J. 3.267
 KandrataVICIUS, L. 2.150
 Kaneko, Y. 3.282
 Kang, H. 1.044, 1.086, 1.261, 1.262, 1.306, 2.190
 Kang, J. 2.257, 2.303
 Kang, J.W. 3.200, 3.272
 Kang, K. 1.044, 1.086
 Kang, M. B.01
 Kang, T. 3.084
 Kanner, A. 1.250, 2.180
 Kanner, A.M. 2.152, 2.228, 3.155
 Kanner, H.R. 2.152
 Kanyshkova, T. 3.033
 Kao, A. 3.194
 Kaplan, P.W. 1.015
 Kapsalaki, E.Z. 1.285
 Kapur, J. 3.007
 Karakis, I. 1.192
 Karasu, A. 2.322
 Karekla, M. 2.302
 Karmonik, C. 1.160
 Karsten, S. 3.152
 Karvonen, M.K. 1.095
 Kass, J.S. 1.085
 Kasteleijn-Nolst Trenité, D.G. 1.221, 2.319
 Katic, J. 2.313
 Katki, K. 1.266, 3.098
 Kato, M. 2.136, 3.045
 Kato, T. 2.125
 Kauer, J.A. 3.021
 Kawai, M. 1.160, 2.146
 Kawamura, M. 2.273
 Kawamura, T. 1.087
 Kay, S. 3.158
 Ke, A. 1.144
 Keane, A. 1.331
 Kearney, J.A. 1.322
 Keller-Stanislawski, B. 2.321
 Kellinghaus, C. 1.212, 3.205
 Kelly, K. 1.131, C.06
 Kelly, K.M. 1.019, 1.054
 Kelso, A. 3.004
 Kendirli, M.T. 3.134
 Kent, G.P. 2.078
 Kerls, S. 3.182
 Kerls, S.P. 3.202, 3.203
 Kern, R.T. 1.019, 1.054
 Kerrigan, J.F. 2.171, 3.075, 3.329
 Kesner, L. 2.239
 Kessler, C. 1.206
 Keystone, J. 3.201
 Khan, M. 3.208
 Khan, O.I. 1.028, 3.133
 Khan, Y.U. 1.034
 Kharatishvili, I. 3.316
 Khargonekar, P. 3.153
 Khaund, M. 2.144
 Khurana, D. 2.024, 2.025, 3.171
 Khurana, D.S. 2.109
 Kikuchi, H. 3.079
 Kikuchi, T. 2.055
 Kilbride, R. 3.232
 Kilgore, M. 3.305
 Kim, D. 1.306, 2.190, 3.190
 Kim, G. 3.043
 Kim, H. 1.159, 1.182, 1.261, 1.262, 1.305, 1.306, 1.308, 2.190, 3.043, 3.181, 3.305
 Kim, J. 1.164, 1.306, 2.190, 3.190
 Kim, J.A. 3.021
 Kim, J.H. 1.164
 Kim, K. 2.113, 3.170
 Kim, M. 1.318, 3.034, 3.190
 Kim, P. 1.177
 Kim, S. 2.110, 3.244
 Kim, Y. 1.318, 2.142, 3.165, 3.190
 Kinirons, P. 1.128
 Kinjo, E.R. 3.327, 3.334
 Kinnischtzke, A.K. 3.352
 Kinoshita, M. 2.055
 Kipervasser, S. 1.027
 Kira, J. 3.079
 Kirlin, K.A. 2.248, 2.251
 Kirmani, B.F. 2.200
 Kirsch, H. 1.042
 Kkolou, E. 2.173
 Klaas, P. 2.169
 Klassen, T.L. 3.109
 Klatte, E. 1.075
 Kleefuss-Lie, A.A. 2.063, 2.319
 Kleen, J.G. 3.159
 Kleen, J.K. 2.305, 2.308, 2.309
 Klein, B.D. 2.236
 Klein, G. 2.253, 2.301
 Klein, K.M. 1.311, 2.319
 Klein, P. 2.154
 Klein, P.M. 3.036, 3.137
 Kluck, C. 2.319
 Kluge, T. 1.047
 Kluger, G. 2.183, 3.175
 Knaake, S. 1.100, 1.209, 1.212, 3.204
 Knape, K.D. 3.121
 Knecht, S. 2.292
 Knight, R. 1.042
 Knight, S. 1.286
 Knopman, A.A. 2.298
 Knowlton, R. 1.186, 1.305, 3.305
 Knox, K. 1.106
 Knupp, K. 1.260, 1.301
 Ko, D. 1.119, 1.177
 Ko, D.Y. 2.265
 Ko, T. 3.176
 Kobau, R. 1.331
 Kobayakawa, S. 2.273
 Kobayashi, E. 1.168, 1.175
 Kobayashi, K. 2.004, 2.020, 3.168
 Koby, D.G. 2.158
 Koeleman, B.P. 2.319
 Koeller, K. 3.306
 Koepf, M.J. 1.173, 1.180, 1.244, IW.06, 3.350, B.07
 Kogure, S. 1.053
 Koh, S. 1.260, 1.301, 3.034, 3.303
 Koh, S.B. 1.164
 Kohda, Y. 1.087
 Kohler, S. 2.181
 Kohrman, M. 3.255, 3.303
 Kohrman, M.A. 2.300
 Kokinos, V. 1.150
 Kolaczynski, E.D. 1.055
 Kolodny, E.H. 1.090
 Komaki, H. 2.126
 Kondratyev, A. 2.191
 Koppelstaetter, F. 3.260
 Korecka, M. 3.004
 Koren, G. 2.209
 Korman, B.M. 2.105
 Korn-Merker, E. 2.184
 Kornblum, C. 2.318
 Korostenskaja, M. 2.046
 Korzeniewska, A. 1.066, 2.311
 Kosior, R. 1.149
 Kosior, R.K. 3.261
 Kossoff, E.H. 1.068, 1.258, 2.121
 Kotagal, P. 1.308, 2.169, 3.287, B.02
 Kothare, S. 2.323
 Kothare, S.V. 1.032, 2.124, 3.173, 3.354
 Kotulska, K. 2.091
 Koubeissi, M. 2.056, 2.153
 Koubeissi, M.Z. 2.054
 Koumoutsos, J.E. 2.100
 Kovac, S. 2.243
 Kovur, J.M. 3.217
 Koyama, N. 3.045
 Kozlik, S. 1.037, 2.116
 Kozlowski, R. 2.191
 Kozuka, K. 1.053
 Kraemer, G. 1.126
 Kramer, M.A. 1.055
 Kratt, P. 2.142
 Krauss, G. 2.222, 2.223
 Krellman, J. 2.301
 Kriel, R. 2.206
 Kriel, R.L. 2.240
 Krikorian, R. 2.078
 Krishnaiengar, S. 1.108
 Krishnamurthy, K.B. 1.089
 Kroll, J.L. 1.250
 Kron, M.M. 3.001
 Krsek, P. 3.246
 Krusienski, D.J. 3.149
 Kryger, C. 2.249
 Kuba, R. 1.060, 1.292, 1.294
 Kubikova, R. 1.294
 Kubova, H. 3.118, 3.119, 3.314

ABSTRACT AUTHOR INDEX

- Kucheryavykh, L. 3.120
 Kucheryavykh, Y. 3.120
 Kuchukhidze, G. 1.115, 3.260
 Kuczynski, D. 2.091
 Kudela, P. 3.065, 3.148
 Kudin, A.P. 2.317, 2.318
 Kudo, L.C. 3.152
 Kudr, M. 3.246
 Kuester, H. 3.243
 Kuhn, G. 2.218
 Kujala, T.M. 2.046
 Kulikova, R. 2.220
 Kumar, A. 3.239, 3.252
 Kumar, G. 2.155, 3.340
 Kumar, H. 1.271
 Kumar, S. 3.215
 Kumari, V. 1.180
 Kuner, T. 3.046
 Kung, D. 1.085
 Kunitz, S. 1.332
 Kunz, W.S. 2.317, 2.318
 Kuo, A. 3.183
 Kuperman, J. 1.156
 Kupsky, W. 3.252
 Kurashvili, P. 2.174
 Kurlemann, G. 2.183, 2.184
 Kurth, T. 2.327
 Kurz, J.E. 3.057
 Kus, R. 1.066
 Kutluay, E. 1.112
 Kuzniecky, R.I. 1.090, 3.150, 3.151, 3.265, 3.278
 Kwan, P. 1.219, 1.321, 2.201, 2.210, 3.199
 Kwan, S. 1.078
 Kwiatkowski, D.J. 3.135
 Kwon, C. 3.290, 3.304
 Kwon, C.S. 3.301
 Kwon, J. 2.257
 Kwon, O. 1.044, 1.086
 Kymissis, I. 3.156
 Kyöstilä, K. 1.314
- L**
 La Briola, F. 1.312
 La Torre, G.N. 3.011, 3.351
 Labar, D. 2.301
 Labate, A. 2.072
 Labiner, D.M. 1.329, 2.261, 3.209
 Labovitz, D.L. 2.238
 Labudda, K. 1.169, 1.171
 Lacey, C.J. 3.142, 3.143
 Lach, L. 3.177
 Lachhwani, D.K. 1.308, B.02
 Lackner, T. 2.269
 LaFrancois, J. 3.114
 Lagace, D.C. 3.001
 Lagae, L.G. 1.056
 Lagrange, A. IW.04
 Lahtinen, L. 3.310
 Lai, Y. 3.005, 3.255
 LaJoie, J. 3.303
 Lakshmanan, B.M. 1.068
 Lamb, J.G. 1.200
 Lammertsma, A.A. 3.022
 Lamy, C. 1.287
 Lancman, M. 2.295, 2.301
- Landré, E. 1.287
 Landsteiner, J. 2.035
 Landvogt, C. 1.154
 Lang, B. A.04
 Langer, J.E. 3.234
 Langer, O. IW.06
 Lantz, G. 2.009, 3.266
 Laoprasert, P. 1.301
 Lapanowski, K. 3.361
 Lapp, K.J. 1.211
 Larch, J. 1.115, 3.260
 Larcos, G. 1.170
 LaRoche, S. 1.141
 Larson, J.S. 2.133
 Latella, M.A. 2.072
 Laufs, H. 1.181
 Lauzon, M.L. 1.149, 3.261
 Lavoie, J. 1.325
 Lawn, N. 1.117
 Lawrence, K. 1.092, 1.093, 1.094
 Lawrence, K.M. 1.311, 1.319, 2.316, 3.188
 Lax, I. 3.253
 Le, N.D. 2.170, 3.166
 Le Pichon, J. 1.280, 1.281
 Leach, J. 2.037, 2.052, 3.257
 Leach, J.L. 3.284
 Leach, J.P. C.06
 Lebel, C. 3.276
 Leclère, N. 1.217
 Lecointe, C. 3.108
 Lee, B. 3.043
 Lee, B.J. 3.135
 Lee, C. 1.305, 3.027
 Lee, C.L. 1.051
 Lee, E. 1.261, 3.176
 Lee, F. IW.04
 Lee, F.I. 2.120
 Lee, H. 3.141, 3.244
 Lee, H.E. 2.155
 Lee, I. 2.190, 3.165, 3.190
 Lee, J. 1.113, 1.117, 1.261, 1.262, 1.306, 2.110, 2.190, 3.181, 3.244
 Lee, J.K. 1.289
 Lee, J.Y. 2.303, 3.272
 Lee, K. 1.086, 2.037, 2.049, 2.052, 2.107, 2.157, 2.242, 3.257, 3.284
 Lee, K.H. 1.062, 2.039, 2.046, 3.267
 Lee, M.J. 2.303
 Lee, S. 2.257, 3.181, 3.190, 3.353
 Lee, S.H. 3.341
 Lee, Y. 1.261, 1.262, 1.306, 3.181
 Leeb, T. 1.314
 Leeman, B.A. 2.241
 Legido, A. 2.024, 2.025, 2.109, 3.171
 Legros, B. 2.028, 2.030, 2.041, 2.043
 Leguern, E. 3.146
 Lehmkuhle, M.J. 3.140
 Lehnhoff, L. 1.020
 Leighty, D. 3.164
 Leijten, F.S. 2.029, 3.189
 Leite, J.P. 2.150
 Leland, M.M. 3.121
 Lemieux, L. 1.150, 1.181
 Lenck-Santini, P.P. 2.305, 2.308, 3.138, 3.159
 Lenhart, G. 1.121
- Lentz, L. 3.097
 Leon-Columbo, T. 1.225
 Lepe, P. 3.032
 Lepkin, A. 3.111
 Leppik, I.E. 1.079, 1.237, 1.243, 2.193, 2.206, 2.269, C.07
 Lerche, H. 1.238, 1.323, 2.319
 Lesage, F. 3.277
 Leu, C. 1.317, 2.319
 Leung, S. 3.050
 LeVan, P. 1.163, 1.179, 3.263
 Levin, S. 2.118
 Levisohn, P. 1.260, 3.303
 Levitt, J. 2.161, 2.166, 2.284
 Levy, S.R. 2.094
 Lewis, D.V. IW.03
 Lewis, S.A. 1.252
 Lhatoo, S. 1.181
 Li, G. 3.044, 3.075
 Li, H. 3.054
 Li, L.M. 1.174
 Li, S. 1.079
 Li, Z. 1.251
 Liagkouras, I. 3.350
 Liang, L. 3.111
 Liang, L.P. A.03
 Liang, X. 1.176
 Liao, W. 2.210
 Liccardello, C.M. 3.361
 Lichtenstein, S. 3.093
 Lieblich, S.M. 1.117
 Liggan, B. 1.103
 Liguori, R. A.04
 Lim, B. 1.044
 Lim, B. 1.086
 Lim, B. 3.170
 Lima, M.C. 1.139
 Limdi, N. 3.305
 Lin, K. 1.012, 3.233
 Lin, T. 3.235
 Lin, Y. 1.078
 Lina, J.M. 3.277
 Lindblad-Toh, K. 1.314
 Lindhout, D. 2.319, 2.321
 Lindinger, G. 2.260
 Lindsell, C.J. 3.227
 Lineweaver, T. 2.243
 Ling, D. 2.239
 Link, J.M. 1.144
 Liporace, J. 2.180
 Lippman Bell, J.J. 3.036
 Lippmann, S. 1.134
 Lipton, J. 2.114
 Lipton, R.B. 1.088, 1.118, 2.145, 2.175, C.05
 Lissens, W. 1.316
 Litt, B. 1.038, 3.058
 Little, J.G. 3.103, 3.107
 Liu, C. 1.119, 2.265
 Liu, C.L. 2.070
 Liu, J. 3.015
 Liu, J.Y. 3.350
 Liu, M. 3.234, 3.276
 Liu, X. 3.158
 Liu, Y. 2.037, 3.016
 Liu, Y.C. 1.277, 2.097
 Liu, Z. 3.330
- Lizama, A.G. 2.265
 Ljungberg, M.C. 3.129
 Llorente, M. 1.237
 Lo, A. 1.010
 Lo, M. 1.061
 Lo, W. A.05
 Lo Russo, G. 1.029
 Locke, D.C. 2.248
 Locke, D.E. 2.251
 Loddenkemper, T. 1.021, 1.032, 1.067, 1.308, 2.119, 2.124, 2.170, 2.243, 2.281, 3.074, 3.166, 3.205, 3.221, 3.354
 Loeb, J. 1.036, 1.039
 Loepke, A.W. 3.317
 Loesch, I.K. 2.161
 Logan, W. C.02
 Logan, W.J. 3.253
 Logroscino, G. 1.015
 Lohi, H. 1.314
 Lohmann, H. 2.292
 Lohoff, F.W. 3.120, A.05
 Lojczyk, B. 2.091
 Lombroso, P.J. 3.145
 Londoño, L.V. 1.033
 Long, L. 1.075, 3.223
 Longo, D. 3.258
 Lopes-Cendes, I. 1.315, 2.324, 3.345
 Lopez, V. 3.184
 Lopez-Meraz, M.L. 3.313, 3.339
 Lopez-Santiago, L.F. 3.016
 LoPinto-Khoury, C. 1.073
 LoPresti-Solis, A. 2.225
 Loring, D. 2.180
 Loring, D.W. 1.208
 Lortie, A. 1.282, 3.297
 Lossin, C. 2.212
 Lossius, A. 1.230
 Lossius, M.I. 2.103
 Lott, R.S. 1.125
 Lotte, J. 3.175
 Loubersac, J. 1.287
 Louie, J. 2.021
 Low, B. 3.057
 Loyens, E. 3.318, 3.325
 Lu, B. 1.123
 Lu, X. 3.359
 Luat, A.F. 2.315, 3.359
 Lubin, F.D. 2.156
 Lucas, M. 2.308
 Lüders, H. 2.054, 2.056
 Ludvig, N. 3.150, 3.151
 Luef, G. 1.230, 2.186
 Lugo, J.N. 2.163, 3.129
 Lui, C.H. 1.321
 Luketich, C. 2.101
 Lumley, L. 3.093
 Luna, L.M. 2.172
 Lund, C. 2.320
 Lushnikova, I. 2.217
 Luszczki, J.J. 3.090, 3.091
 Lutz, M.T. 2.202
 Luurtsema, G. 3.022
 Lyeth, B.G. 3.099
 Lynch, T. 2.245
 Lythgoe, M.F. 3.115

ABSTRACT AUTHOR INDEX

M

- Ma, H. 3.006, 3.156
 Ma, Y. 3.052
 Macdonald, C. 2.226
 Macdonald, R.L. 1.313
 Macdonell, R. 3.040
 MacGarvie, D. 1.253
 MacGregor, L. 1.205
 Machado, A. 3.277
 Machado, H.R. B.05
 Maciunas, R.J. 2.054, 2.056, 2.267
 Macklin, E.A. 2.241
 Macrodimitis, L. 3.304
 Macrodimitis, S. 2.176, 3.290, 3.296
 Madan, N. 2.025
 Madhavan, D. 1.165, 1.214
 Madsen, J.R. 1.021, 1.067
 Maehara, T. 1.023, 1.026, 2.264
 Maertens, P. 2.195, 2.198
 Maguire, M. 2.059
 Mahadev, V. 3.032
 Mahadevan, A. 3.217
 Mahaffey, C.L. 3.061
 Maheshwari, A. 1.045
 Mahmoud, A. 2.165
 Mahmoud, R. 2.157
 Maia, J. 1.241, 1.245, 1.246, 1.249
 Major, P. 2.018
 Makowski, C. 2.183
 Malak, R. 1.282
 Malik, S. 2.151
 Malmgren, K. 1.290, 3.292
 Malone, S. 3.246
 Malphrus, A.D. 1.310, 2.291
 Malsin, L.S. 2.237
 Malter, M.P. 3.300
 Mancuso, J. 3.011
 Manfro, G.G. 2.312
 Mangano, F.T. 2.037, 2.039, 2.049, 2.052, 2.107, 3.257, 3.284
 Mani, R. 1.038, 1.133
 Manjunath, R. 2.337, 2.338
 Mankoff, D.A. 1.144
 Mann, A. 2.225
 Mann, E.O. 3.064
 Mansbach, H. 1.235, 1.238, 1.248, 2.240
 Månsson, J. 1.273
 Mantis, J.G. 3.106
 Manza, P. 2.174
 Manzo, J. 3.339
 Mapherus, A. 2.297
 Marafie, D. 2.114
 Marchal, C. 1.287
 Marchi, N. 1.226, 2.221, 3.124, 3.125, 3.132
 Marcus, E. 1.254
 Marcus, J. B.01
 Marcuse, L. 3.265
 Mareš, P. 3.116, 3.118, 3.119
 Mariani, P. 3.283
 Marín, E. 1.162
 Marino, S.E. 1.237, C.07
 Markandeya, H. 3.162
 Markowitz, G.J. 2.194
 Marks, H. 3.171
 Maroso, M. 3.015
 Marroni, S.S. 3.024
 Marsh, R. 1.062
 Marsh, S.L. 1.122, 3.144
 Marsh, W. B.08
 Marsh, W.R. 3.306
 Martin, M.G. 1.072
 Martin, R. 2.142
 Martines Gonzales, J. 1.226, 2.221
 Martinez, E.P. 1.104
 Martinez, H. 3.117
 Martínez, J. 1.284
 Martinian, L. 3.350
 Martinos, M. 2.096, 2.289
 Martins, H.H. 1.012
 Martz, G.U. 3.110
 Maruyama, K. 3.238
 Marwa, M.K. 2.165
 Masaryk, T. 3.132
 Maski, K.P. 2.114, 2.323
 Mason, J.P. 3.348
 Massaro, M. 1.033
 Massarweh, G. 1.168
 Massie, A. 3.324, 3.325
 Masterton, R. 3.242
 Mastrangelo, M. 1.312
 Matagne, A. 1.217
 Mathis, E. 1.329
 Mathurin, W. 1.201
 Matkovic, Z. 1.205
 Maton, B. 3.246
 Matos, G. 3.327, 3.346
 Matsuda, A. 1.023, 1.026, 2.264
 Matsushashi, M. 2.055
 Matsumoto, R. 1.152, 2.055, 2.125
 Matsuo, F. 1.091, 2.050
 Matsushima, E. 1.023, 1.026, 2.264
 Matsuura, M. 1.023, 1.026, 2.264
 Matthews, G. 2.078
 Maurer-Morelli, C.V. 1.315, 2.324, 3.345
 Mawer, G. C.03
 May, T. 2.184
 Mayer, T. 2.202
 Mayo, J. 2.279, 3.240
 Maytum, J. 3.164
 Mazarati, A. 3.078, 3.152, 3.311
 McAndrews, M. 1.253
 McAuley, J.W. 1.075, 2.232
 McAuliffe, C.L. C.08
 McCall, W.V. 1.276
 McCarten, J.R. 1.079
 McCarthy, T. 2.269
 McClelland III, S. B.03
 McClendon, J. 2.172
 McClintock, W. 3.303
 McCown, T.J. IW.13
 McCoy, K.J. 2.148
 McCredie, R. 1.170
 McCue, M.G. 3.159
 McDonald, B. 2.250
 McDonald, C.R. 1.156
 McEvoy, A.W. 1.181
 McGee, J.C. 3.228
 McGlone, F. 1.166
 McGlone, J. 2.242
 McGovern, R.A. 3.347, 3.357
 McGregor, A. 2.044
 McIntosh, A.M. 2.316
 McKay, M. 2.101
 McKee, H.R. 1.224, 3.206
 McKee, J. 2.300
 McKelvie, P.A. 2.316
 McKhann Jr, G.M. 2.247, 3.161, 3.072, 3.347, 3.357
 McKiernan, F. 1.211
 McLachlan, R. 3.210
 McLachlan, R.S. 3.212
 McMahan, D.J. 1.195
 McMahan, J.M. 1.311, 2.316
 McManis, M. 2.044, 2.048
 Meador, K.J. 1.208, 2.180
 Meaney, J. 1.157
 Medina, M.T. 2.061
 Medveczky, G. 3.150, 3.151
 Medvedev, A. 3.158
 Meencke, H.J. 2.204, 2.244
 Mefford, H.C. 1.317, 2.319
 Megova, S. 1.294
 Mehta, A. 2.253, 2.301
 Meidenbauer, J.J. 3.106
 Meikle, L. 3.135
 Meisler, M.H. 3.016
 Melguizo, I. 1.177
 Mellers, J.D. 2.135
 Mellersh, C. 1.314
 Mello, C. 2.262, 2.263
 Mello, V. 3.283
 Melvin, J.J. 2.024, 2.025
 Meng, L. 2.052
 Mennerick, S. 3.018
 Meo, R. 1.215
 Merrill, S.J. 2.011
 Mertens, M. 1.169, 1.171
 Mesquita, S. 1.012
 Messenheimer, J.A. 1.197, 1.203, 2.205, 2.216, 3.182, 3.202, 3.203
 Metcalf, A. 2.176
 Metcalfe, A. 3.290, 3.296, 3.304
 Meurs, A. 2.043, 3.042, 3.066
 Meuth, P. 3.033
 Meyer, F.B. 1.062, 3.306, B.08
 Michaelides, C. 2.302
 Michel, C.M. 2.009, 3.266
 Michelson, H. 2.239
 Michotte, Y. 1.263, 1.264, 3.066, 3.318, 3.324, 3.325, 3.326
 Micic, V. 1.310, 2.008, 2.297
 Mifsud, J. 2.314
 Mihaylova, T. 1.039
 Mihaylova, T.G. 1.036
 Mija, L. 1.084
 Mijovic, B. 1.056
 Mikell, C. 3.347
 Mikell, C.B. 3.072, 3.357
 Mikhly, M. 3.265, 3.278
 Mikulecká, N. 3.314
 Mikuni, N. 1.152, 2.055
 Milchakova, L.E. 3.224
 Miles, R. 3.146
 Milewicz, T. 3.071
 Miller, B. 1.260
 Miller, C. 3.235
 Miller, I. B.04
 Miller, I.O. 3.303
 Miller, J.M. 1.203
 Miller, J.W. 2.272, A.06
 Miller, K. 1.332
 Miller, P.P. 1.001
 Miller, S. 1.041
 Miller-Horn, J. 2.211
 Millett, D.E. 1.119, 2.265
 Milligan, H.L. 1.265
 Milteer, W. 1.076
 Mima, T. 2.125
 Minassian, B. 1.314
 Mintzer, S. 1.073
 Minuzzi, L. 1.168
 Miranda, M. 1.272
 Mirowski, P. 3.150, 3.151
 Mishra, A.M. 3.082, 3.085, 3.100
 Miskov, S. 2.313
 Mitchell, W.G. 2.099
 Mitsueda, T. 1.152
 Mittal, S. 1.036, 1.039
 Miura, K. 3.045
 Miyajima, M. 1.023, 1.026, 2.264
 Mlsna, L. 3.034
 Modi, A.C. 2.100, 2.112
 Modi, B. 3.085
 Modur, P. 1.050, 1.076
 Mody, I. 3.064
 Moechars, D. 3.325
 Moeddel, G. 2.243
 Moeller, F. 1.147, 1.163, 1.175, 1.179
 Moffett, M. 3.093
 Mohamed, A. 2.298, 3.271
 Mohamed, I. 1.037, 2.116
 Moien-Afshari, F. 1.106
 Molino, J. 3.354
 Møller, R.S. 2.319
 Mollet, L. 3.066
 Molnar, C.P. 2.116
 Molteni, M. 3.015
 Molthoff, C.F. 3.022
 Monahan, S. 2.112
 Mondick, J. 3.127
 Montañez, A. 1.266, 3.344
 Montanye, J. 1.028
 Montavont, A. 3.309
 Monteiro, E.A. 1.194
 Montenegro, M. 2.018
 Montouris, G.D. 1.192, 1.250, 2.193
 Monzoni, C. 1.081
 Moon, H. 2.190
 Moore, E.L. 1.228, 1.233, 1.234
 Moore, E.N. 2.279
 Moore, J.L. 1.075, 1.123
 Moore, K.T. 1.204
 Moosa, A. 1.308
 Moraes, J.E. 3.269
 Moreira, C.A. 2.325
 Morgan, P.S. 1.167
 Morgan, V.L. 1.155, 1.176
 Moriarty, J. 2.135
 Morita, D. 2.049
 Morita, M.E. 1.116, 2.140
 Morrell, M.J. 1.102
 Morris, D. 2.117, 3.253, 3.254, C.02
 Morris, G.L. 1.250
 Morris, H.R. 1.320

ABSTRACT AUTHOR INDEX

- Morris, M.J. 2.155, 3.340, 3.360
Morrison, G. 3.246
Morrow, J. 2.288
Morse, R.P. 1.028, 1.303
Morsi, A. B.01
Mortensen, E. 1.222
Mortensen, M. 1.272
Moschetta, S.C. 2.262, 2.263, 2.268
Moseley, B.D. 2.095
Moshel, Y. 3.298
Mosher, J.C. 2.040, 2.045, 2.047
Motamedi, G.K. 3.038
Motelow, J.E. 3.082, 3.100
Mott, D.D. 3.332, 3.355
Mouderres, E. 2.035
Moxon, K. 1.049
Mueller, A. 2.183, 3.175
Mueller, K. 2.224
Mueller, W.S. A.08
Muhle, H. 2.319, 2.321
Mujica, M. 1.146
Mulas, F. 2.192
Mullen, S. 1.317, 1.323
Muller, P.A. 3.063
Mulle, J.C. 1.317
Mulligan, J. 3.183
Munian Govindan, R. 3.250
Murphy, B.L. 3.317
Murphy, M. 3.194
Murphy, R.B. 2.212
Murphy, S. 1.002
Murphy, W.F. 1.092, 1.093, 1.094, 1.296
Murray, B. IW.09
Murro, A. 3.267
Murton, C. 1.201
Murugan, V. 3.180
Musachio, J. 1.178
Musto, A.E. 3.051, 3.322
Muthugovindan, D. 2.121
Muzi, M. 1.144
Muzik, O. 3.236, 3.239, 3.359
Myers, L.V. 2.336
Myers, S. 2.012, 3.067
Mynepalli, L. 2.134
Myriantopoulou, P. 2.173
- N**
Naatanen, R. 2.046
Naegel, J.R. 3.145
Nagasawa, T. 1.046, 2.051
Nagel, S.J. 3.157
Naggar, I.C. 3.312
Naidu, M. 2.174
Naiki, M. 3.237
Nair, D. 1.101, 2.047
Najm, I.M. 1.022, 1.108, 2.047, 3.074, 3.157, 3.287, 3.289, 3.302
Nakagawa, E. 2.038, 2.126, 3.282
Nakagawa, J. 3.303
Nakajima, A. 3.030
Nakano, F.N. 3.024
Nakasato, N. 2.038, 3.307
Nakata, T. 3.237, 3.238, 3.248
Nakhutina, L. 1.232, 2.131
Nam, S.O. 2.092
Nandan, M. 3.153
- Narayana, S. 3.121
Narayanan, J. 2.021
Narurkar, M. 2.225, 2.229
Nathan, J. 3.218
Natola, M.A. 1.024, 1.028
Natowicz, M. 3.016
Natsume, J. 1.182, 3.237, 3.238, 3.248
Navarro, F. 3.309
Navarro, V. 3.146
Naylor, D. 3.069
Ndode Ekane, X.E. 3.310
Negishi, M. 1.187, 3.274, C.08
Negoro, T. 3.237, 3.238, 3.248
Nei, M. 1.073
Neiman, E. 1.130
Neligan, A. 1.138, 2.086
Nellist, M. 3.070
Nenadovic, V. 1.018
Neophytou, M. 2.302
Neskovic, P. 1.057
Nesvadba, D. 1.292
Neto, A.R. 1.139
Neufeld, M. 1.027
Neville, B. C.01
Ng, C. 3.112
Ng, M.H. 2.210
Ng, P.W. 1.321
Ng, Y.T. 2.171, 3.167
Nguyen, C. 2.090
Nguyen, D.K. 1.282, 3.293, 3.297, 3.349
Nguyen, J.D. 2.261
Nguyen, M.H. 3.125, 3.132
Nguyen, N. 3.049
Nguyen, V.V. 1.328
Niamnshi, A. 3.201
Nicholas, J.A. 2.077
Nicholas, J.S. 2.061
Nicholas-Bublick, S. 1.190
Nicholls, A.P. 1.203
Nickels, K. 2.095, 2.167, 2.168, 3.169
Nicolaidis, P. 2.178
Nicoletti, P. 1.198
Nicolini-Sánchez, H. 3.336
Niehusmann, P. 3.285
Nielsen, H. 1.272
Niespodziany, I. 1.217, 2.203
Niquet, J. 3.313
Nishida, M. 1.043, 1.046
Nissinen, J. 3.316
No, Y. 2.257
Noachtar, S. 1.017, 2.053
Noe, K. 1.107, B.08
Noe, K.H. 1.130, 2.133, 2.248, 2.251
Noe', F. IW.13
Noebels, J.L. 3.109, 3.335
Noh, J. 3.201
Norcia, A. 3.012
Nordgren, R.E. 1.028
Normand, C. 2.329, 2.334
Northrup, H. 3.303
Novak, E. 1.108
Novak, G. 1.127, 1.134, 1.136
Novak, K. 1.291
Novak, Z. 1.060, 1.294
Novotny, E.J. 1.187, 3.274, C.08
- Nowak, M. 1.209, 3.044
Nowak, R. 1.293
NThai, J. 3.245
Nunes, T. 1.241, 1.245, 1.246, 1.249
Nürnberg, P. 2.319
- O**
O'Brien, T. 3.188, 3.220
O'Brien, T.J. 1.083, 1.205, 1.239, 2.155, 2.331, 3.086, 3.112, 3.337, 3.340, 3.360
O'Byrne, P. 2.334
O'Callaghan, C.J. 1.311
O'Connor, M.G. 2.241
O'Connor, S.E. 2.187
O'Connor, T. 1.040, 1.101, 2.047
O'Donovan, C.A. 1.151, 1.276, 1.298
O'Dwyer, R. 1.132, 3.074, 3.157
O'Muircheartaigh, J. 1.180
Oakley, J.C. IW.15
Obermeier, T. 1.317, 2.319
Oberst, E. 1.327
Ochi, A. 1.018, 1.277, 2.036, 2.111, 3.281
Ochoa, J.G. 1.033
Oddo, M. 1.015
Odenkirchen, J. 1.332
Oehl, B. 3.205
Oertel, W.H. 1.100
Ogg, R. 2.044
Ohta, K. 1.023, 1.026, 2.264
Ohta, M. 3.045
Ohtsuka, Y. 2.004, 3.168
Ohyagi, Y. 3.079
Oikawa, M. 2.219
Ojemann, G.A. 2.272
Ojemann, J.G. 2.272
Ojopi, E.B. 3.358
Oka, M. 2.004
Okazaki, M. 2.136
Okumura, A. 3.237
Okuyemi, K.S. B.03
Olaru, E. 1.112
Oliveira, E. 1.116, 3.269
Oliveira, J.A. 3.017
Oliveira, M.C. 1.072
Oliver, B. 1.293
Olivier, A. 2.032
Ollier, W. 1.314
Olsaker, I. 2.208
Olsen, J. 3.231
Olsson, I. 3.292
Oltmanns, F. 2.244
Omurtag, A. 2.332
Onat, F. 3.002, 3.337, 3.338
Onishi, H. 1.087
Ono, K. 1.304
Ono, T. 1.304
Onofrey, M. 1.329
Onuma, T. 2.136
Op De Beeck, M. 2.041, 2.043
Opitz, T. 2.203
Orlova, K. 3.092
Orlova, K.A. 3.342
Orman, R. 3.312
Orosz, I. 1.268
- Orozco-Suarez, S. 1.146, 3.333, 3.336
Ortiz, L. 1.326
Osborn, M.R. 1.221
Osborne, D. 2.248, 2.251
Osorio-Rico, L. 3.333
Ostertag, P. 2.319
Otahal, J. 3.314
Otsubo, H. 1.018, 1.277, 2.036, 2.038, 2.111, 3.281, 3.315, C.02
Otsuki, T. 3.282
Ottman, R. 2.145, 2.175, C.05
Quardouz, M. 3.349
Ouellette, E. 2.261
Oviedo, S. 1.077
Owens, B. 2.035
Owens-Acey, T.T. 1.224
Oyegbile, T. 1.140
Öz, B. 3.275
Ozbek, U. 2.322
Ozdemir, O. 2.322
Özkara, Ç. 3.002, 3.275
- P**
Pacheco, S.P. 2.294
Pacia, S.V. 1.090
Paciello, M. 1.193
Paciello, N. 1.193
Pack, A.M. 1.195
Paige, A.L. 3.305
Painter, E.M. 2.100
Pak, T. 3.093
Palace, J. A.04
Palasis, S. 3.247
Palestrant, D. 3.235
Pallin, D.J. 2.335
Palmer, A.A. 3.081
Pan, J.W. 3.268
Panageas, K. 1.124
Panelli, R.J. 1.083
Pantaleoni, C. 3.243
Pantzaris, M. 2.173
Paolini, J. 2.226, 3.225, 3.226
Papacostas, S.S. 2.173, 2.302
Papandrea, D. 3.104, 3.105
Papathanasiou, E.S. 2.173
Pape, H.C. 3.033
Pardalos, P.M. 1.019, 1.054
Pardos, M. 2.046
Parekh, R. A.01
Parent, J.M. IW.05, 3.001, 3.016
Pargeon, K.L. 2.080
Parghi, D. 3.129
Park, E.H. 1.067
Park, H. 3.200
Park, H.S. 2.303, 3.272
Park, J. 2.081, 3.145
Park, K. 1.044, 1.086
Park, K.H. 2.092
Park, Y.D. 3.267
Parker, P. C.06
Parker, W. 3.092
Parris, B. 2.300
Parrish, R.R. 2.156
Parsons, J. 1.260
Partikian, A. 1.119, 2.099
Partlow, J. 3.243

ABSTRACT AUTHOR INDEX

- Parvizi, J. 1.059
 Pascual-Leone, A. 1.274
 Pastuszko, A. 3.127
 Pastuszko, P. 3.127
 Patankar, S. 1.075
 Patarraia, E. 1.291, 2.260
 Patay, Z. 2.044
 Patel, A. 1.258
 Patel, M. 3.111, A.03
 Patel, S.S. 3.057
 Patterson, C. 2.185
 Patterson, E. 1.314
 Paulson, L. 2.218
 Pawlowski, M. 3.033
 Paz, J.T. 3.142, 3.143
 Peacock, M. 2.132
 Pearce, N. 3.220
 Pearce, P. 3.114
 Pearl, P.L. 3.256, 3.262, PL.02
 Peckham, C. 2.089
 Pedersen, C. 3.231
 Pelgrift, R. 1.195
 Penders, J. 1.056
 Penn, R. 2.019, 2.300
 Pennell, P.B. 1.202, 2.180
 Penovich, P.E. 1.329, 2.035, 2.069, 2.073
 Pereira, A. 2.120
 Pereira, A.R. 3.269
 Pereira, F.R. 2.147
 Pereira, T.C. 2.324
 Peris, M. 1.284
 Perkins, F. 2.044
 Perkins, F.F. 2.048
 Perkins, S.M. 1.007, 2.283
 Perko, H. 1.047
 Perrine, K. 2.253, 2.295, 2.301
 Perrine, K.R. 2.234
 Perry, M. 2.181
 Perry, M.S. B.04
 Perry, S. 2.090
 Persson, A. 2.218
 Perucca, E. 1.194
 Pestana, R.R. 3.327, 3.334
 Peterka, D.S. 3.154
 Peters, J.M. 3.185
 Petersen, L. 2.035
 Peterson, M.B. 1.022
 Peterson, S. A.08
 Petit, J. 1.287
 Petroff, O.A. 3.077
 Petrou, S. 2.214, IW.15
 Petrovski, S. 1.083, 1.205
 Pettus, T. 2.269
 Petty, S.J. 1.239, 3.188
 Peugh, L.D. 3.073
 Phanwar, I. 3.009
 Phatak, V. 2.272
 Phillips, A.G. 3.081, 3.083
 Pho, G. 3.123
 Piao, Z. 1.101
 Piazzini, A. 1.029, 2.138
 Picard, R.W. 1.021
 Picot, M. 1.287
 Pierce, R.J. 1.092, 1.093, 1.094
 Pierson, R. 1.140
 Pietteur, V.B. 1.219
 Pillay, N. 1.296
 Pina-Garza, E. 2.026
 Pinault, D. 3.337, 3.360
 Pineda, E. 3.078, 3.311
 Pinheiro-Martins, A.P. 1.299, B.05
 Pinto, A. 1.309
 Pirrozi, A. 3.235
 Pirzadeh, A. 3.127
 Pisano, T. 3.245
 Pisu, M. 2.142
 Pitiyanuvath, N. 1.074, 1.098
 Pitkänen, A. 3.310, 3.316
 Pittau, F. 1.175
 Pittman, Q.J. 3.126
 Pizarro-Otero, J. 1.120, 3.216
 Placette, J. 3.186
 Plueger, M.D. 1.003, 1.326
 Plug, L. 1.081
 Podariu, S. 1.165
 Poduri, A. 1.309, 2.128, 2.281, 3.243
 Poh, M. 1.021
 Pohlmann-Eden, B. 2.242, 2.333
 Polepally, A.R. 1.243
 Politsky, J.M. 2.149
 Politzer, N. 1.253
 Pollard, J. 1.111
 Pollo, C. 3.266
 Polster, T. 2.292
 Poma, R. 1.013
 Pomerants, P. 1.286
 Pomeroy, S.L. 2.119
 Pomicter, A.D. 3.056
 Poolos, N.P. 3.014
 Poon, C.C. 3.099
 Popescu, A. 2.026
 Portelli, J. 1.263, 1.264
 Porter, B.E. 3.027, 3.088
 Portilla, L. 1.084
 Pouliot, W.A. 1.242
 Povlsen, J.H. 1.272
 Powell, E.M. 3.128
 Powell, K.L. 3.112
 Powell, T. 3.187
 Power, C. 3.328
 Pradines, T.L. 2.104, 2.120
 Pramuka, M. 2.256
 Prasad, A.N. 2.209
 Prasad, D. 1.295
 Press, D. 3.038
 Preston, R. 1.237
 Prince, D.A. 3.008, 3.052, 3.054, 3.323
 Principe, K. 3.194
 Principe, W. 3.194
 Pritchard, P.B. 1.251
 Privitera, M.D. 2.151, 2.180, 2.252, 3.227, A.05
 Proctor, E. 3.115
 Provenzano, G. 3.146
 Pruess, T. 2.236
 Prus, N. 1.232, 2.131, 2.157
 Pugh, M.V. 1.222, 1.227
 Pujar, S. 2.089, C.01
 Pulur, G. 2.322
 Pun, R.Y. 3.317
 Purcaro, M.J. 3.082, 3.100
 Purnama, J. 2.331
 Puumala, T. 1.095
 Pyzik, P.L. 1.258, 2.121
- Q**
 Qian, S. 2.014, 2.019
 Quach, M. 1.040
 Quadri, S.A. 3.193
 Quan, H. 3.290
 Quattrocchi, C. 3.258
 Quattrone, A. 2.072
 Quebedeaux, T.M. 3.051
- R**
 Radhakrishnan, A. 2.266
 Radhakrishnan, K. 2.266, 3.219, 3.222
 Radtke, R.A. 1.198
 Radwani, R.R. 2.238
 Raedt, R. 2.043, 2.218, 3.042, 3.066
 Raffo, E. IW.07
 Ragheb, J. 3.246, B.04
 Raghunathan, S. 3.162
 Rahey, S. 2.333
 Rajasekaran, K. 3.007
 Rajasekaran, V. 2.153
 Rajdev, P. 2.057
 Rakhade, S.N. 1.067, 3.062, 3.063, 3.137
 Ramaswamy, V. 3.328
 Ramon, C. 2.006
 Ramos, P.L. 2.325
 Ramsay, R.E. 1.220, 1.237, 1.243, 1.254
 Rana, S. 1.131
 Randall, A. 1.195
 Randall, M. 3.087
 Randisi, F. 3.258
 Ransom, C.B. 2.174, 3.048
 Rantala, J. 3.310
 Rao, S. 2.172
 Raol, Y. 3.089
 Raol, Y.H. 3.025
 Rarick, J.O. 1.237, 1.243, 2.269
 Rasheed, I.Y. 2.207
 Rashid, S. 2.054, 3.123
 Rask, K. 2.181
 Rasmussen, P. 3.132
 Rastalsky, N. 1.158
 Rathakrishnan, R. 1.163, 2.023
 Rathke, K.M. 2.188
 Ratner, N.B. 3.240
 Rauchenzauner, M. 1.230, 2.186
 Raucy, J. 1.200
 Ravizza, T. 3.015, 3.316, 3.338
 Ray, A. 1.153
 Reddy, D.S. 1.255, 1.256
 Redhead, E.S. 2.258
 Reed, M.L. 2.145, C.05
 Reed, R.C. 1.221, 1.237
 Rees, M.I. 1.320
 Rees, S.M. 2.155, 3.086, 3.340
 Register, D. 3.057
 Reid, A.Y. 3.126
 Reid, C.A. 2.214, 3.112
 Reid, S. 1.189, 2.230
 Reif, P.S. 1.209
 Reimer, R.J. 3.023, 3.356
 Reinholz, J. 2.243
 Rekeate, H.L. 2.171
 Rektor, I. 1.060, 1.292, 1.294
 Rémi, J. 1.017, 2.053
 Rimmel, R. 1.237
 Rimmel, R.P. 1.243
 Resch, L. 3.328
 Resnick, T. 2.090, 2.105, 2.185, 3.246
 Resnick, T.J. B.04
 Respondek-Liberska, M. 2.091
 Reuber, M. 1.081
 Rey, G.J. 2.105
 Reyes, E. 1.057
 Rheims, S. 2.141, 2.213
 Rho, J.M. 1.265
 Richard, G. 2.309
 Richard, G.H. 3.159
 Richard, G.R. 2.308
 Richardson, K. 1.267
 Richardson, K.A. 3.060
 Richardson, M. 1.180
 Richerson, G.B. 3.048, 3.102
 Richman, J. 2.142
 Ridge, S. 1.022
 Rieder, M.J. 2.209
 Rigdon, G.C. 1.228, 1.233, 1.234
 Rikonen, R.S. 2.098
 Riley, K. 1.186, 3.305
 Riney, K. 2.330
 Rios, M. 2.162
 Rios-Pilier, J. 3.130
 Risbud, R. 3.027
 Rishu, N. 2.115, 2.117, 3.254
 Risner, M.E. 1.228
 Risse, G. 2.035, 2.307
 Risse, G.L. 2.259
 Risse, G.R. 2.255
 Ristic, A. 1.115
 Ritaccio, A.L. 2.245, 3.147
 Ritter, F. 1.008, 2.035, 2.122, 2.307
 Riva, D. 3.243
 Rivello, J. 1.310, 2.008, 2.297
 Rizutto, L.A. 2.149
 Roberts, D. 1.267
 Roberts, D.W. 1.283, 3.196, 3.279
 Roberts, H. 3.220
 Robertson, B. 3.093
 Robinson, A.A. 1.098
 Robitaille, Y. 3.349
 Rocha, C.S. 1.315, 2.324, 3.345
 Rocha, L.L. 1.146, 3.333, 3.336
 Roche-Labarbe, N. 3.251
 Rodemer, W. 1.111
 Roden, W.H. 3.073
 Rodionov, R. 1.150, 1.181
 Rodrigues, N.E. 1.139
 Rodriguez, A. 1.011, 2.144
 Roets, C. 2.249
 Rogawski, M.A. 2.212
 Rogers, L. 2.146
 Roh, D. 3.286
 Roivainen, R. 1.095
 Rolston, J. 1.052
 Romano, G. 1.204
 Romanyshyn, J.C. 3.037
 Ronen, G.M. 3.177
 Ropacki, M. 2.081

ABSTRACT AUTHOR INDEX

- Roper, S.N. 3.096, 3.117, 3.122
 Ropstad, E. 2.208
 Rorsman, I. 1.145
 Rosa-Neto, P. 1.168
 Rose, D. 2.037, 2.046, 2.049, 2.052, 3.284
 Rose, D.F. 2.039, 2.107
 Rose, S. 2.014, 2.019
 Rosenbaum, P.L. 3.177
 Rosenberger, L.R. 3.240, 3.262
 Rosenfeld, W. 1.134, 1.248, 2.231
 Rosenfeld, W.E. 1.221
 Rosenow, F. 1.100, 1.209, 1.212, 2.231, 2.319, 3.044, 3.204
 Rosenquist, P. 1.276
 Ross, E. 2.089
 Rossetti, A.O. 1.015, 1.212
 Rossetti, C. 3.015
 Rossetti, F. 3.093
 Rossi, M.A. 3.155
 Rostasy, K. 2.186
 Rotella, P. 2.172
 Roten, A. 1.205, 1.239
 Rotenberg, A. 1.032, 1.067, 1.274, 3.063, 3.354
 Roth, M. 2.290
 Rothermel, R. 1.043, 1.046, 2.051
 Rothman, S. 3.154
 Rothman, S.M. A.06
 Rougier, A. 1.287
 Rouleau, I. 3.293
 Rowley, J. 1.168
 Roy, K. 3.162
 Rozkhov, L. 3.284
 Rozzelle, C. 1.305
 Ruban, D. 3.286
 Rubenstein, J.E. 1.258
 Rückert, I. 2.319
 Rudy, L. 2.275, 2.310
 Ruegg, S. 1.158
 Ruiz-Gómez, M. 1.162
 Rummel, C. 2.003
 Runge, U. 1.206, 2.183
 Russ, P. 1.268
 Russek, S.J. IW.04
 Russi, A. 1.293
 Rutecki, P. 1.140
 Rutka, J.T. 3.281
 Rydenhag, B. 1.290, 3.292
 Ryvlin, P. 1.287, 2.141, 2.213, IW.06, 3.309
 Rzezak, P. 2.104
- S**
 Saatman, K.E. 3.130
 Sabau, D. 2.132
 Sabesan, S. 1.069, 3.144, 3.229
 Sabolek, H.R. 3.047, 3.059
 Sabtala, M.C. 1.021
 Sackellares, J.C. 1.019, 1.054
 Sadleir, L.G. 1.319
 Sadler, M. 3.290
 Sadler, R.M. 2.242
 Sagyhan, A. 3.011
 Sahin, M. 3.243
 Sahiner, M. 3.002
 Said, R. 1.279
- Saint-Hilaire, J. 3.293
 Sakai, R. 2.219
 Sakalli, E. 3.002
 Sakamoto, A.C. 1.194, 1.299, B.05
 Sakellarides, M. 1.239, 3.188
 Salamon, N. 1.297
 Salcedo, M. 2.162
 Salgado, P.C. 2.147
 Salinsky, M.C. 2.079
 Salpekar, J. 2.293
 Salzberg, M.J. 3.340
 Salzberg, M.R. 1.083, 2.155, 3.086
 Sambrook, P. 3.188
 Sameshima, K. 3.327, 3.346
 Samman, S.K. 2.165
 Sanchez, E. 2.152
 Sanchez, P. 3.309
 Sanchez, R.M. 1.266, 3.098, IW.13
 Sander, J.W. 1.138, 2.086, IW.09
 Sander, T. 1.317, 2.319
 Sanderson, J.L. A.08
 Sandison, E. 1.096, 2.017
 Sandok, E.K. 1.211, 2.237
 Sanford, N. 2.254
 Sankar, R. 3.078, 3.311
 Sanossian, N. 1.289
 Santana, B.V. 2.229
 Santana, M.C. 1.183
 Santini, P.P. 2.309
 Santiuste, M. 1.293
 Santos, A.A. 3.327
 Santos, J.C. 3.024
 Santos, V.R. 3.029
 Sapna, C.S. 2.071
 Saporta, A. 3.236
 Saraf, M. 1.256
 Sarco, D. 1.309
 Sarco, D.P. 1.032
 Saria, H.Y. 3.230
 Sarkis, R. 2.170, 3.166, 3.287, 3.289
 Sasaki, M. 2.126, 2.219, 3.282
 Sassen, R. 2.318
 Satishchandra, P. 3.217
 Sato, N. 3.282
 Sato, S. 3.256, 3.262
 Savrasova, A. 2.217
 Sawamoto, N. 1.152, 2.125
 Sayitoglu, M. 2.322
 Scanduzzi, R.C. 2.150
 Scarone, S. 2.138
 Schachter, S.C. PL.01, A.05
 Schaefer, P.A. 1.221
 Schaffer, S. 2.253
 Schalk, G. 3.147
 Schaller, K. 3.266
 Schallier, A. 3.318, 3.325
 Scharfman, H. 3.114
 Scheff, S.W. 3.130, A.07
 Scheffer, I.E. 1.311, 1.317, 1.319, 1.323, 2.316, 2.321, 3.242
 Scheffler, P. 2.310
 Schefft, B. 2.159, 2.252
 Schefft, B.K. 2.078
 Schelle, A. 2.076
 Schelstraete, I. 1.216
 Schenkel, L.C. 2.312
- Schevon, C.A. 3.161
 Schiff, S.J. 3.160, 3.348, A.01
 Schindeldecker, W. 3.097
 Schindler, K. 2.003
 Schlesinger, M. 1.111
 Schmedt, C. 3.335
 Schmitt, J. 1.127, 1.134, 1.136
 Schmitt, S. 1.252, 3.288
 Schmitt, S.E. 1.038, 1.133
 Schmitz, B. 2.319
 Schneider, F. 1.206, 2.183
 Schneider, S. 2.301
 Schoch, K.M. 3.130
 Schoenberg, M.R. 2.267
 Schomer, D.L. 2.015, 2.241
 Schramm, J. 3.299
 Schreckenberger, M. 1.154
 Schreiber, S. 2.319
 Schreibman Cohen, A. 2.161
 Schridde, U. 3.100
 Schuchmann, S. IW.15
 Schuele, S.U. 2.243, 3.205
 Schultz, L. 1.288
 Schultz, M. 3.093
 Schultz, R. 1.278, 1.310, 2.297
 Schultz, R.J. 2.291
 Schulze-Bonhage, A. 2.010, 2.076, 3.205
 Schwabe, M.J. 2.001
 Schwartz, J. 3.093
 Schwartz, T. 3.156
 Schwartz, T.H. 2.301, IW.011, 3.006
 Schwartzkroin, P.A. IW.13, 3.099, 3.321
 Schwebel, C.S. 3.120
 Scott, C.A. 2.060
 Scott, J.N. 1.148
 Scott, R. 3.115, 3.138, C.01
 Scott, R.C. 2.089, 2.096, 2.102, 2.289, 2.305, 2.308
 Seal, S. 3.081
 Secundo, L. 1.042
 Seeck, M. 2.009, 3.266
 Seetharam, R. 3.212
 Segal, E. 2.127
 Segal, S.L. 2.312
 Segura, R. 1.237
 Seidel, W.T. 2.247
 Seidenberg, M. 1.140, 3.259
 Selenica, M.B. 2.085
 Sellin, J. B.01
 Selmer, K.K. 2.320
 Selvitelli, M. 2.015
 Selwa, L. 2.068
 Semah, F. 1.287
 Sencer, A. 2.322
 Seneca, S. 1.316
 Seo, D.W. 2.303, 3.200, 3.272
 Seo, J. 2.049, 2.107, 3.257, 3.284
 Seo, J.H. 2.039
 Seol, H.Y. 1.164
 Seppälä, E. 1.314
 Serafini, R. 2.031
 Serajee, F.J. 2.315
 Seri, S. 2.005, 3.245
 Serpa-Alvarez, J.A. 1.085
 Sethi, N. 2.027, 2.084
- Seyal, M. 3.195, 3.197
 Seyfried, T.N. 3.106
 Shah, A.K. 1.036, 1.039, 2.013, 3.236
 Shah, M. 2.332
 Shahidi Zandi, A. 2.002
 Shallcross, R. 2.288, C.03
 Shanahan, C. 3.194
 Shane, E. 1.195
 Shankar, R. 1.201
 Shankar, S.K. 3.217
 Shao, L.R. 3.053
 Shapiro, L.A. 1.266, 3.098, 3.344
 Sharan, A. 1.073
 Sharkey, R. 1.149, 3.261
 Sharma, K.G. 1.271
 Sharma, R. 1.018
 Sharrack, B. 1.081
 Shatzmiller, R. 1.177
 Shaw, L. 3.004
 Shaw, S.J. 2.311
 Shear, N. 2.209
 Sheerani, M. 3.193
 Shellhaas, R.A. 2.108
 Shelton, V. 1.031
 Shen, T. 1.172
 Sheppard, E. 2.271
 Sherman, E.M. 2.176, 2.306, 3.290
 Sheth, R. 2.337, 2.338, 3.259
 Sheth, R.D. 2.182
 Shi, L. 3.208
 Shi, Y. 1.074
 Shi, Y.W. 2.210
 Shianna, K.V. 1.198
 Shiau, D. 1.054
 Shiau, D.S. 1.019
 Shibata, M. 2.125
 Shigeto, H. 3.079
 Shih, J.J. 3.149
 Shih, Y. 1.078
 Shilian, P. 2.265
 Shim, K. 1.306
 Shin, D. 2.257, 3.078, 3.311
 Shin, H.W. 1.276
 Shin, P. 1.235, 1.238, 1.248
 Shiraishi, H. 2.038
 Shiratori, K. 1.100
 Shiva Kumar, R. 3.222
 Shmerkovich, D. 2.058
 Shmueli, D. 3.025, 3.089
 Shneker, B.F. 1.075, 2.062, 2.232
 Shore, C.P. 2.132
 Short, A. 1.314
 Shorvon, S.D. 1.138, 2.060, 2.086
 Shpak, A.A. 3.224
 Shrubbs, V. 3.180
 Shtaya, A. A.02
 Shu, H.J. 3.018
 Siddarth, P. 2.161, 2.166, 2.282, 2.284, 3.249, 3.259
 Siddiqui, F. 3.193
 Siddiqui, K.A. 2.139, 2.165
 Sidenius, P.C. 3.231
 Siebzehnrubl, F.A. 3.117
 Sills, G.J. A.04, C.06
 Silva, D.F. 1.139
 Silveira, D.C. 1.108

ABSTRACT AUTHOR INDEX

- Silverberg, A. 3.213, B.01
 Silvestri, R. 3.211
 Simeone, K. 3.329
 Simsovits, D. 3.351
 Sin, N.C. 1.321
 Sinclair, D.B. 3.328
 Sinclair, K.G. 1.224
 Singh, D. 1.131
 Singh, N.A. IW.010
 Singh, P. 2.160
 Singh, R. 2.022
 Sinha, S. 2.139, 2.165, 3.217
 Sirsi, D. 2.093
 Sirven, J.I. 1.107, 1.130, 2.133, 2.248, 2.251
 Sisodiya, S.M. 1.244, 3.192, 3.342, 3.350, IW.06
 Sithinamsuwan, P. 1.092, 1.093, 1.094
 Sitwat, B. 2.088
 Sivaraaman, K. 1.213
 Sizinaskas, C. 1.314
 Skadsem, A.G. 1.017
 Skatchkov, S. 3.120
 Skibo, G. 2.217
 Skidmore, C. 1.073
 Skinner, H.J. 2.061
 Slater, J. 1.300, 2.277
 Sloan, D.M. 3.055
 Smart, O. 1.052
 Smeyers, P.M. 2.192
 Smith, B. 1.229, 1.288, 2.031
 Smith, B.N. 3.130, A.07
 Smith, C.A. 2.121
 Smith, D.R. 3.080
 Smith, G. 2.164
 Smith, G.G. 3.120
 Smith, G.M. 2.296
 Smith, J. 1.119
 Smith, J.C. 1.260
 Smith, J.R. 1.285
 Smith, K. 3.294
 Smith, M. 1.253, 2.117, 2.278, 3.201, 3.254, 3.353
 Smith, M.C. 3.155
 Smith, M.L. 2.118, 2.280
 Smith, P.E. 1.320
 Smith, T.M. 3.208
 Smithson, S.D. 1.077, 1.089
 Smolders, I. 1.263, 3.066, 3.318, 3.324, 3.325, 3.326
 Smolders, I.J. 1.264
 Smyth, M. A.06
 Snead III, O.C. 2.036, 2.111, 3.002, 3.201, 3.281, 3.290
 Snutch, T.P. 3.112
 Snyder, C. 2.191
 Snyder, T. 3.328
 So, E. 2.158, 2.274, B.08
 Soares-da-Silva, P. 1.196, 1.223, 1.231, 1.241, 1.245, 1.246, 1.249
 Sofue, A. 3.238
 Sohal, V.S. B.06
 Solanki, B. 1.204
 Solomon, G. 2.027, 2.084
 Soltanian-Zadeh, H. 1.153
 Soltész, I. 3.341, 3.353
 Somerville, E.R. 1.170, 2.298, 3.271
 Somma-Mauvais, H. 2.072
 Song, H. 3.084
 Song, Y. 2.137, 2.160
 Sood, S. 1.043, 1.046, 2.013, 3.250, 3.252
 Sosunov, A.A. 3.072, 3.347, 3.357
 Soucy, J.P. 1.168
 Sousa, P.S. 3.233
 Soussi, R. 3.319
 Souza, R.M. 1.194
 Spanaki, M. 2.031
 Spanaki-Varelas, M. 1.288
 Spann, M. 2.285, 2.290, C.08
 Sparagana, S. 3.303
 Spears, M. 1.279
 Specchio, N. 3.258
 Speechley, K.N. 2.118, 2.328
 Spencer, D.D. IW.12, 3.037, 3.077, 3.268, 3.274
 Spencer, S.S. 3.037, 3.268
 Sperling, M.R. 1.005, 1.073, 1.136, A.05
 Sperner, J.L. 1.268
 Spetzler, R. 3.294
 Spiegel, R. 2.058, 2.197, 2.211
 Spindler, M. 1.124
 Spinelli, L. 3.266
 Spitz, M. 3.195
 Spliet, W.G. 3.070
 Spray, D.C. 3.011
 Sreenivasan, A. 1.016, 2.174
 Staba, R. 3.032
 Stacey, W. 3.058
 Staley, K.J. 1.242, IW.08, 3.039, 3.046, 3.047, 3.059, 3.068
 Stamoulis, C. 2.034
 Stanley, E.M. 3.332
 Stannard, K. 2.049
 Starner, K. 3.278
 Starrevelde, Y. 1.296
 Stead, M. 1.062
 Stebbins, G. 3.155
 Steffens, M. 2.319
 Stein, M.A. 3.155
 Steindler, D.A. 3.117
 Steinhäuser, C. IW.14
 Stenhouse, S. C.04
 Stephani, C. 2.056
 Stephani, U. 2.319, 2.321
 Stephens, D. 3.201
 Stern, J. 1.114, 1.166, 1.297
 Stern, J.M. 1.161, 1.329
 Steven, D. 3.210, 3.290
 Steven, D.A. 3.212
 Stevenson, C. 3.257
 Stevenson, M. 1.260
 Stevenson, R.J. 2.298
 Stewart, C.P. 1.018
 Stöehr, T. 2.203
 Stögmänn, E. 2.260
 Stojic, A.S. 1.211, 2.237
 Stoll, J. 1.270
 Storm, P.B. 3.342
 Stoub, T.R. 1.185, 3.155
 Stout, A. 1.332
 Stracher, A. 2.239
 Strandberg, M. 1.145
 Straub, H. 1.207
 Strauss, K.A. 3.342
 Strauss, K.S. 3.092
 Streiner, D.L. 3.177
 Stretton, J. 1.173
 Strickland, S.M. 3.267
 Strobel, A. 3.329
 Strube, S. 2.290
 Struble, C.A. 2.011
 Strutt, A.M. 1.160, 2.081, 2.082
 Strzelczyk, A. 1.209
 Stute, C.F. 1.125
 Stypulkowski, P. 3.097
 Sugai, K. 2.038, 2.126, 3.282
 Sugiyama, I. 2.036, 3.281
 Suh, E. 2.190
 Suh, S.I. 1.164
 Sullivan, H. 3.291
 Sullivan, J. 2.117, 3.254, 3.308
 Suls, A. 1.323
 Sun, F.T. B.06
 Sun, G. 2.129
 Sunderam, S. 3.348
 Sundstrom, D. 1.089
 Sunnen, C. 3.129
 Surbeck, W. 1.282, 3.293, 3.297
 Sure, U. 3.204
 Surgenor, S.D. 1.028
 Surges, R. 2.060
 Surova, A. 3.251
 Sutula, T. 1.048
 Suzuki, H. 3.307
 Suzuki, S.O. 3.079
 Svalheim, S. 1.230, 2.186
 Svendsen, K. 1.079
 Swann, J.W. 1.051
 Swanson, G.T. 2.219
 Swartz, B. 1.250
 Swartz, K. 3.194
 Sweeney, C. 1.006
 Sweetman, L. 1.270
 Swenson, N.C. 1.021
 Swiercz, W. 3.039, 3.047, 3.059, 3.068
 Swinkels, M.E. 2.319
 Swint, C. 2.181
 Syed, T.U. 2.054, 2.153, 2.243
 Symms, M. 1.180, B.07
 Symms, M.R. 1.173
 Syvänen, S. 3.022
 Szabadics, J. 3.353
 Szabo, C.A. 2.148, 3.121
 Szaflarski, J. 2.159, 2.252, 3.227
 Szaflarski, J.P. 2.078, 2.151
 Sziklas, V. 2.254, 2.271, 2.275
 Szoeko, C.E. 1.083
- T**
 Taavoni, A. 2.033
 Tackenberg, B. 3.044
 Taggart, S. 2.059
 Taglialatela, M. IW.010
 Tahil, F. 2.149
 Takahashi, A. 3.282
 Takahashi, R. 2.055, 2.125
 Takaki, M. 3.003
 Takamiya, K. 3.062
 Takano, H. 3.136
 Takase, K. 3.079
 Takaya, S. 1.152
 Takeda, S. 1.022
 Takeoka, M. 1.032, 1.309, 2.007, 2.114, 2.128, 3.185, 3.354
 Takougang, I. 3.201
 Talathi, S. 2.012
 Talathi, S.S. 3.067, 3.153, 3.330
 Talib, L. 3.331
 Talos, D.M. 3.074, 3.076, 3.135
 Tampelini, E. 2.325
 Tan, W. 2.323
 Tanaka, B.S. 3.010
 Tandon, N. 1.300, 2.276, 2.277
 Tang, H.M. 3.150, 3.151
 Tani, H. 3.023, 3.356
 Tanner, A.S. 2.249
 Tao, J. 2.019
 Tao, J.X. 2.014, 2.300
 Tapsell, L.M. 1.107
 Tarancón, T. 1.293
 Tas, E. 1.032, 3.354
 Tassi, L. 1.029
 Tatum, W.O. 1.137, 1.250, 2.085, 3.205
 Tauboll, E. 1.230, 2.186, 2.208, 3.071
 Tavares, C. 1.012
 Taye, R. 2.153
 Taylor, D.S. 1.141
 Taylor, I. 2.316
 Taylor, N. 2.214
 Tecoma, E.S. 1.025, 1.156, 1.295
 Tedeschi, H. 1.116, 1.315, 2.324, 3.269
 Tellez-Zenteno, J.F. 1.106, 2.176, 2.306, 3.290, 3.296, 3.301, 3.304
 Temkin, N. 2.205
 Templeton, D. 1.199
 Teng, Q. 3.125, 3.132
 Terra, V.C. B.05
 Tervo, M. 3.164
 Tervo, R. 3.164
 Tesar, G.E. 1.142
 Teskey, G.C. 3.126
 Testa, F. 2.094
 Teter, B. 2.196
 Tezcan, K. 3.002
 Thadani, V.J. 1.028, 1.267, 1.303, 2.250
 Thadani, V.M. 1.283, 3.196, 3.279
 Thampratankul, L. 2.051
 The Progesterone Therapy Study Group 1.077
 The RNS System Pivotal Investigators 1.102
 Theodore, W.H. 1.178, 1.274, 3.262, 3.264
 Thesen, T. 3.265, 3.278
 Thibert, R.L. 2.226, 3.174, 3.225, 3.251,
 Thiel, P. 3.204
 Thiele, E.A. 2.018, 2.226, 3.174, 3.225, 3.226, 3.251, 3.303
 Thielemann, D. 3.163
 Thind, K. 3.009
 Thio, L. 2.189
 Tholpady, A. 3.234

ABSTRACT AUTHOR INDEX

- Thom, M. 3.342, 3.350
 Thomas, D.L. 3.115
 Thomas, F.M. 2.270
 Thomas, N.H. 3.180
 Thomas, P. 1.287
 Thomas, R.H. 1.320
 Thomas, S.V. 2.071
 Thome-Souza, S. 2.104, 2.120, 3.358
 Thompson, A. 2.008
 Thompson, A.R. 2.061
 Thompson, P. 1.173, 1.180, 3.264, B.07
 Thomson, K. 3.161
 Thomson, L. 1.267, 1.280, 1.281
 Thornton, R. 1.150
 Thornton, R.C. 1.181
 Thurman, D. 1.079
 Tihan, T. 3.308
 Tilelli, C.Q. 3.013, 3.029
 Ting, T. 2.080
 Tirupathi, S. 1.103, 2.083
 Tisi, G. 2.138
 Titus, J.B. 2.189
 Toda, K. 1.304
 Todaro, M. 1.205, 1.239
 Todorova-Rudolph, A. 3.044
 Toga, A. 3.259
 Tokuda, S. 3.061
 Tolbert, D. 1.189, 2.230
 Toledano, M. 1.162
 Tominaga, T. 3.307
 Tomlinson, B. 1.321
 Toone, B.K. 2.135
 Topcu, M. 3.243
 Torres, C.M. 2.312
 Tosun, D. 3.249, 3.259
 Towle, V.L. 2.300
 Tracy, M. 2.007
 Tracy, M.M. 3.173
 Tranel, D. 2.272
 Travis, A. 1.125
 Treiman, D.M. 1.069, 3.144, 3.229
 Treiman, L.J. 3.144
 Trenerry, M.R. 2.158, 2.274
 Trinka, E. 1.115, 1.126, 3.260
 Tripathi, M. 1.271
 Tripp, K. 1.196, 1.223, 1.231
 Tro-Baumann, B. 3.175
 Trobliger, R.W. 2.295
 Trollinger, S. 1.332
 Troost, D. 3.070
 Trucks, H. 1.317, 2.319
 Tsai, J.J. 1.202, 3.012
 Tsai, V. 3.342
 Tsang, V. 3.201
 Tschampa, H.J. 3.300
 Tschuluun, N. 3.321
 Tsimerinov, I. 3.235
 Tsuchida, T.N. 3.186, 3.256, 3.262
 Tsuchiya, K. 1.053
 Tsuji, S. 2.273
 Tucker, D. 2.009, 2.304
 Tuite, P. 1.079
 Tuohy, O. 2.083
 Tupal, S. 3.087
 Turner, K. 1.029, 2.138
 Turner, M. 2.151
 Turner, Z. 1.258
 Turpeinen, U. 2.098
 Tuxhorn, I. 1.132, B.02
 Tüzün, E. 2.322
 Tyrlikova, I. 1.294
 Tyson, J.R. 3.112
 Tyvaert, L. 3.263
- U**
 Uber-Zak, L. 2.081, 2.082
 Uebachs, M. 2.203
 Ueda, Y. 3.003, 3.019, 3.030
 Uhl, J. 3.323
 Ullah, G. 3.160
 Ulloa, C.M. 2.027, 2.084
 Ullrich, N.J. 2.119
 Umeoka, E.H. 3.017
 Unadkat, J.D. 1.144
 Undlien, D.E. 2.320
 Unkart, C. 3.111
 Unnwongse, K. 1.022, 1.082
 Unterberger, I. 1.115, 2.319, 3.260
 Upchurch, K. 1.297
 Urak, L. 2.319
 Urayama, S. 1.152, 2.125
 Urbach, H. 3.285, 3.300
 Urban, T.J. 1.198
 Ure, K. 3.320
 Uthman, B. 1.225
 Uzan, M. 3.275
- V**
 Vaidya, C.J. 2.279, 3.240
 Vaisleib, I. 2.088, 2.185
 Vale, F.L. 3.295
 Valencia, I. 2.024, 2.025, 2.109, 3.171
 Valente, K. 2.120, 2.262, 2.263, 2.268, 3.331, 3.358
 Valente, K.D. 2.104
 Valeriano, J.P. 1.019, 1.054, 1.131, 2.033
 Valle, A.C. 1.139, 3.327, 3.345, 3.346
 Vallee, L. 3.108
 Vallota Silva, A. 2.325
 Valsamis, H. 2.239
 Valton, L. 1.287
 Van, K.C. 3.099
 van Baalen, A. 2.321
 Van Bogaert, P. 2.041, 2.043
 Van Cott, A.C. 1.222, 1.227, 2.256
 van Drongelen, W. 3.255
 Van Dycke, A. 2.218, 3.042
 van Erp, G. 1.110
 Van Gompel, J.J. 3.306
 van Huffelen, A.C. 2.029, 3.189
 van Kempen, M. 2.321
 van Raay, L. 3.360
 van Rijen, P. 3.070
 van Roy, B. 2.103
 Van Vliet, E.A. 3.020
 Vanderheyden, P. 3.318
 Vanegas, F. 3.041
 Vanhuffel, S. 1.056
 VanMeter, J. 2.117, 3.240, 3.254
 Vanzulli, I. 3.015, 3.316, 3.338
 Vargas, M. 3.266
 Varley, J. 2.334
 Varley, J.D. 2.329
 Vasquez, B.R. 3.194
 Vaughn, L. 1.281
 Vauqelin, G. 3.318
 Vazquez, G. 2.074
 Vears, D.F. 2.316
 Veendrick, M. 1.110
 Vega, C. 2.285, 2.290, C.08
 Veggioni, P. 2.005
 Veilleux, M. 1.325
 Velakoulis, D. 2.331
 Velasco, A. 3.336
 Velasco, T.R. 1.299, B.05
 Velayudam, K. B.02
 Velez, A.M. 2.148
 Velísková, J. 3.113, 3.139
 Velíšek, L. 3.113, 3.139
 Vendrame, M. 2.281, 2.323, 3.076, 3.173
 Venkatasubramanian, A. 2.129, 3.178
 Venkatraman, G.K. 2.058
 Venna, P. 3.225
 Ver Donck, L. 1.263
 Verhaegen, S. 2.208
 Verhey, L.H. 3.177
 Verley, D.R. 3.094, A.06
 Verma, A. 1.160, 2.146
 Vermoesen, K. 3.324, 3.326
 Versavel, M. 1.223, 1.231, 1.241, 1.245, 1.246, 1.249
 Vervisch, J. 1.056
 Vesavel, M. 1.196
 Vestal, M. 1.187, 2.285, C.08
 Vestergaard, M. 3.231
 Vezina, L.G. 3.262
 Vezzani, A. IW.02, IW.14, 3.015, 3.316, 3.338
 Vi, N. 3.152
 Vicente, E. 3.327, 3.346
 Vicentiis, S. 2.268
 Vicini, S. 3.038
 Vigevano, F. 3.258
 Vignal, J.P. 1.287
 Vignoli, A. 1.029, 1.312, 2.138
 Vitmaa, R. 1.314
 Villanueva, V.E. 1.284
 Villeda, J. 3.333, 3.336
 Villeda-Hernandez, J. 1.146
 Vincent, A. A.04
 Vincent, K.P. 2.011
 Vicentiis, S. 3.331
 Vining, E.P. 2.121
 Virevan, S. 2.111, B.02
 Virnig, B. 1.079
 Vittal, N. 1.074
 Vives, K.P. 3.037
 Vollmar, C. 1.173, 1.180
 von Gaudecker, J.R. 3.198
 von Krogh, K. 2.208
 von Lehe, M. 3.299, 3.300
 von Roden, M. 3.302
 von Rosenstiel, P. 1.216, 1.219
 von Spiczak, S. 2.319, 2.321, 3.175
 Vonck, K. 2.041, 2.043, 2.218, 3.042, 3.066
 Voskuyl, R.A. 3.022
 Vulliemoz, S. 1.150, 1.173, 1.181
 Vuong, A. 1.203, 2.216, 3.202, 3.203
- W**
 Waber, D. 2.172
 Wadade, T. 3.049
 Wade, A. 3.012
 Wadiche-Overstreet, L. IW.04
 Wadman, W.J. 3.020, 3.042, 3.070
 Wagner, J. 2.164, 3.285
 Wagner, J.L. 2.296
 Wagner, K. 2.076
 Wahaas, S. 2.139, 2.165
 Walczak, T.S. C.07
 Waldbaum, S. A.03
 Walker, A.M. 2.327
 Walker, J. 3.050
 Walker, L.M. 2.015
 Walker, M.C. 1.181, 2.060
 Walkowiak, J. 2.293
 Wallace, D.J. 3.286
 Walley, N.M. 1.198
 Walsler, G. 1.115, 3.260
 Walsh, C.A. 3.243
 Walters, C. 2.249
 Walzer, M. 1.189, 2.230
 Wan, G.J. 1.121, 2.145, C.05
 Wang, C. 1.025, 1.222
 Wang, D. 3.308
 Wang, G. 1.065
 Wang, L. 1.074
 Wang, N. 1.069, 3.229
 Wang, W. 2.229
 Wang, X.S. 2.052
 Wang, Y. 2.037, 2.046, 3.063
 Wang, Y.Y. 2.052
 Wannamaker, B.B. 2.296
 Wargin, W. 1.228, 1.233, 1.234
 Wark, J.D. 1.239, 3.188
 Wasade, V.S. 1.288
 Wasterlain, C.G. 3.313
 Watanabe, K. 3.237, 3.238, 3.248
 Watanabe, M. 1.023
 Watanabe, S. 1.257
 Watanabe, Y. 1.023
 Webb, D.J. 2.134
 Weber, Y.G. 1.323, 2.319
 Webster, N.J. 2.270
 Wechsler, R.T. 1.125
 Wehbeh, R. 2.196
 Wehner, T. 1.022, 1.209
 Weil, A. 1.282, 3.293
 Weil, A.G. 3.297
 Weil, J. 1.197, 2.134

ABSTRACT AUTHOR INDEX

- Weinberg, M. 2.230
 Weiner, H. 3.298
 Weiner, H.L. 3.072
 Weinstein, S.L. 2.022, 3.186, 3.348
 Weinstock, A. 2.196
 Weinstock-Guttman, B. 2.196
 Weiss, S.K. 3.183, 3.201, 3.281
 Wellmer, J. 3.285
 Wells, J.A. 3.115
 Welty, T. 1.191
 Wen, H.T. 2.325
 Wen, L. 2.298, 3.271
 Wen, S.X. 1.208
 Wen, X. 3.009, 3.323
 Wenzel, H.J. 3.099, 3.321
 Werhahn, K.J. 1.126, 1.154, 1.216
 Werz, M.A. 2.267, 3.123
 Wesche, D. 1.189
 Wetzels, S. 1.158
 Whalen, E. 1.236, 1.247
 Whang, K. 3.179
 Wheatley, B.M. 3.328
 Wheatley, M. 3.290
 Wheless, J.W. 2.044, 2.048
 White, A.M. 3.089
 White, H.S. 1.200, 2.236
 White, J. 2.206, IW.08
 White, J.R. C.07
 White, M. 1.002
 White, M.L. 1.165
 Whitney, A. 2.102
 Whitney, J. 2.172
 Whittemore, V.H. 3.303
 Wical, B. 3.164
 Wichmann, H. 2.319
 Widjaja, E. 2.036
 Wiebe, S. 1.037, 1.296, 2.116, 2.118, 2.176, 2.306, 3.290, 3.296, 3.301, 3.304
 Wiegand, F. 1.127, 1.134, 1.136
 Wildt, L. 2.186
 Wilfong, A.A. 1.278, 1.310, 2.291
 Wilke, C. 1.063, 1.065
 Wilke, J.C. 1.265
 Wilkins, P. 3.201
 Williams, C. 2.235
 Williams, J.T. 3.121
 Williams, K. 2.101
 Williams, S. 1.275
 Williamson, A. 3.077
 Williamson, J.M. 3.110, 3.134
 Willis, S. 1.270
 Willmore, J.L. 3.003, 3.019, 3.030
 Wilson, E.A. C.06
 Winawer, M.R. 3.081, 3.083
 Windhorst, A.D. 3.022
 Wirrell, E. 1.037, 2.087, 2.095, 2.167, 2.168, 3.169, 3.290, B.08
 Wise, M.S. 2.025
 Wismeyer, M. 3.266
 Wittig, M. 1.317
 Wittink, F. 3.070
 Woermann, F.G. 1.169, 1.171, 2.292
 Wojtowicz, A.K. 3.071
 Wolff, C. 1.217, 2.203
 Womelduff, G. 1.281
 Wong, C. 3.271
 Wong, C.H. 1.170, 2.298
 Wong, K.S. 1.321
 Wong, M. IW.07, 3.028, 3.095
 Wong, V. 1.321
 Woods, A. 3.328
 Worley, A.V. 2.085
 Worley, P.F. 3.080
 Worrell, G. 1.048
 Worrell, G.A. 1.062, 1.063, 1.065, 3.306
 Worrrell, G. B.08
 Wright, Z.G. 3.347, 3.357
 Wu, J. 2.132, 3.075
 Wu, J.Y. 3.303
 Wu, W.P. 1.011
 Wu, X. 3.072, 3.347, 3.357
 Wu, Y. 3.048
 Wu, J. 1.141
 Wyckhuys, T. 3.042
 Wyllie, E. 1.308, B.02
- X**
 Xavier, G. 3.327
 Xiang, J. 2.037, 2.046, 2.052
 Xiong, X. 3.208
 Xue, Z. 1.160
 Xuefeng, W. 2.064, 2.065, 2.066, 2.067
- Y**
 Yacubian, E.M. 1.012, 1.183
 Yacubian, E.T. 1.009, 3.233
 Yalçinkaya, C. 3.275
 Yam, D. 3.210
 Yamamoto, T. 1.030
 Yamano, M. 2.273
 Yamawaki, R. 3.009, 3.323
 Yamazaki, M. 1.030
 Yanagihara, K. 3.248
 Yang, L. 1.065, 2.174, 2.239
 Yang, M. 2.145, 3.086
 Yang, X. 3.154
 Yapica, Z. 1.317
 Yarmush, M.L. 3.068
 Yasuda, C.L. 1.116, 1.174, 1.315, 2.140, 2.147, 2.324, 3.269
 Yaun, A. 3.256
 Yeh, S. 1.161
 Yen, D. 1.078
 Yerra, R. 1.205
 Yerra, S.R. 2.331
 Yim, S. 2.257
 Yiu, C. 1.078
 Yogarajah, M. 1.173, B.07
 Yoo, J. 3.109, 3.335
 Yoon, J. 3.092
 Yoong, M. 2.096, 2.289
 York, M.K. 1.160, 2.082
 Yoshikawa, H. 1.257
 Yoshinaga, H. 2.004
 Yoshor, D. 1.310, IW.01
- You, S. 1.261
 You, X. 2.115, 2.117, 3.254
 Yourick, D. 3.093
 Yu, H. 1.078
 Yuan, W.H. 2.052
 Yum, M. 3.113, 3.139, 3.176
 Yung, I. 2.014, 2.019
 Yuste, R. 3.154
- Z**
 Zaben, M. 3.031
 Zabramski, J. 3.294
 Zachry III, W. 1.229
 Zafar, A. 3.193
 Zak, M. 1.277, 2.097, 3.183
 Zakaria, T. B.08
 Zambrelli, E. 1.029, 1.312
 Zangaladze, A. 1.073
 Zannikos, P. 1.204
 Zapata, J.F. 1.033
 Zapata, W. 1.084
 Zaveri, H.P. IW.12
 Zawadzki, L. 1.301
 Zayachkivsky, A. 3.140
 Zeber, J. 1.222
 Zecavati, N. 2.022
 Zehtabchi, S. 2.332
 Zeljezic, D. 2.313
 Zemann, R. 1.034, 1.035, 1.058
 Zeng, L.H. 3.095
 Zepeda, R. 2.335
 Zgavc, T. 3.326
 Zhang, C. 1.321, 2.201
 Zhang, D.X. 3.055
 Zhang, G. 3.009
 Zhang, H. 3.001
 Zhang, J. 2.326
 Zhang, K. 3.098
 Zhang, S. 1.050, 1.076
 Zhang, W. 2.035, 2.259, 2.307, 3.323
 Zhang, X. 3.255, 3.335
 Zhang, Y. 3.145
 Zhang, Z. 2.326
 Zhao, M. 3.006, 3.156
 Zhao, Q. 2.308, 3.131, 3.133
 Zheng, T.W. 3.360
 Zhou, C. 3.062
 Zhou, F. 3.096
 Zhou, J. 3.067, 3.330
 Zhu, X. 3.088
 Ziburkus, J. 3.049, A.01
 Zifkin, B. 1.143, 1.324
 Zijlmans, M. 1.034, 1.058
 Zilberman, I. 2.058
 Zimmer, K. 2.208
 Zimprich, F. 2.319
 Zolkowska, D. 2.212
 Zorumski, C.F. 3.018
 Zou, G.Y. 2.118
 Zsurka, G. 2.317, 2.318
 Zuberi, S. C.04
 Zuberi, S.A. 2.177
 Zuberi, S.M. 3.350
- Zuo, Z. 2.201
 Zupanc, M.L. 2.187
 Zupec-Kania, B.A. 1.330
 Zuppa, A. 3.127

COMMERCIAL SUPPORTER RECOGNITION

(All as of 10/20/09)

Leadership Level

Special thanks to...

Pfizer Inc.

for supporting:

- Presidential Symposium
- Plenary II
- Exhibit Hall Lunch (Monday)
- Exhibit
- Special Interest Group (2)





Leadership Level

Special thanks to...

UCB, Inc.

for supporting:

- AET Symposium
- Presidential Symposium
- EMU Symposium
- Spanish Symposium
- Plenary III
- Scientific Exhibit (2)
- Exhibit



THE EPILEPSY COMPANY™

Sponsor Level

Special thanks to...

GlaxoSmithKline

for supporting:

- AET Symposium
- Merritt-Putnam Symposium
- PEC Symposium
- Year Round Education
- Exhibit



Supporter Level

Special thanks to...

Sepracor Inc.

for supporting:

- AET Symposium
- Scientific Exhibit (All Day)
- Special Interest Group (2)
- Exhibit



Supporter Level

Special thanks to...

Lundbeck

for supporting:

- ILAE Symposium
- Cyber Café in Exhibit Hall
- Scientific Exhibit
- Exhibit
- Special Interest Group



Supporter Level

Special thanks to...

Questcor Pharmaceuticals, Inc.

for supporting:

- Pediatric Symposium
- Special Interest Group
- Exhibit
- Cyber Café in Registration Area



QUESTCOR®

Supporter Level

Special thanks to...

Eisai Inc.

for supporting:

- Program Book Ad
- President's Reception
- Lennox and Lombroso Trust
- Susan Spencer Clinical Research Fund



Contributor Level

Special thanks to...

Nihon Kohden America, Inc.

for supporting:

- Exhibit
- Auction of Video EEG for Lennox and Lombroso Trust



NIHON KOHDEN

Contributor Level

Special thanks to...

Medtronic, Inc.

for supporting:

- Junior Investigator Awards
- Scientific Exhibit



Medtronic

Alleviating Pain • Restoring Health • Extending Life

Advocate Level

Special thanks to...

Cyberonics, Inc.

for supporting:

- Special Interest Group
- Exhibit



Elekta

for supporting:

- Exhibit



Compumedics Limited

for supporting:

- Exhibit



Natus Medical

for supporting:

- Exhibit



PMT

for supporting:

- Exhibit
- Program Book Ad



Care Fusion/ Cardinal Health

for supporting:

- Exhibit



Grass Technologies

for supporting:

- Exhibit



Stellate, An Alpine Biomed Company

for supporting:

- Exhibit



Ad Tech Medical Instrument Corp.

for supporting:

- Exhibit



Patron Level

Special thanks to...

Analyze Direct

for supporting:

- Exhibit

AnalyzeDirect
Visualization and Analysis Software

Cadwell Laboratories

for supporting:

- Exhibit

CADWELL[®]

NeuroLogica Corporation

for supporting:

- Exhibit



Ripple LLC

for supporting:

- Exhibit



Blackrock Microsystems

for supporting:

- Exhibit



Electrical Geodesics, Inc.

for supporting:

- Exhibit



Epilepsy Foundation

for supporting:

- Exhibit



Health Learning Systems/Lead

for supporting:

- Exhibit



Valeant Pharmaceuticals Inc.

for supporting:

- Exhibit



AES 63rd Annual Meeting

The Annual Meeting of the American Epilepsy Society is the largest meeting and exhibition in the world of those who share the common scientific and clinical interests of epilepsy and clinical neurophysiology. Each year close to 4,000 attendees gather who are dedicated to improving the quality of life for those afflicted with epilepsy. This meeting will be the top forum to examine common concerns and give the opportunity to gain insight from leading authorities.

Mission Statement

The American Epilepsy Society (AES) is one of 98 Chapters of the International League Against Epilepsy (ILAE). The American Epilepsy Society promotes research and education for professionals dedicated to the prevention, treatment and cure of epilepsy.

Target Audience

The meeting is designed for academic and practicing neurologists, neurophysiologists, epileptologists, neuroscientists, neurosurgeons, internists, pediatricians, pharmacists, nurses, social workers, and other epilepsy care professionals.

Policy on Commercial Support and Conflict of Interest

The American Epilepsy Society maintains a policy on the use of commercial support, which ensures that all educational activities sponsored by the AES provide in-depth presentations that are fair, balanced, independent and scientifically rigorous. All faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relevant relationships with any commercial interests related to the activity. The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentations. All educational materials are reviewed for fair balance, scientific objectivity and levels of evidence. Faculty disclosure will be made available through syllabus materials and faculty presentations.

Disclosure of Unlabeled/Unapproved Uses

This educational program may include references to the use of products for indications not approved by the FDA. These discussions are noted on the faculty's disclosure forms as well as during their presentations. Opinions expressed with regard to unapproved uses of products are solely those of the faculty and are not endorsed by the American Epilepsy Society or any other manufacturers of pharmaceuticals.

Abstracts

Abstracts from the 2009 Annual Meeting will be available on the Blackwell Synergy Web site www3.interscience.wiley.com/journal/117957420/home, the AES Web site www.aesnet.org, as well as on a CD-ROM in the October issue of *Epilepsia*. Abstracts will appear in the order they were presented.

Accreditation

The American Epilepsy Society is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to offer continuing medical education for physicians.

Membership

The American Epilepsy Society invites you to join one of the oldest neurological professional organizations in the United States. The American Epilepsy Society seeks to promote interdisciplinary communications, scientific investigation, and exchange of clinical information about epilepsy. Members include clinicians, scientists, and other professionals interested in seizure disorders, representing both pediatric and adult aspects of epilepsy.

AES members receive benefits that include: discounted fees for subscriptions to scientific journals and registration to the AES Annual Meeting; opportunities to apply for funding your research, participate in the Society through committee membership, and network with national and international colleagues.

Credit Designation

Physicians: The American Epilepsy Society designates this educational activity for a maximum of 29.0 *AMA PRA Category 1 Credits*[™]. Physicians should only claim credits commensurate with the extent of their participation in the activity.

Nurses: Continuing education credit will be provided through physician CME credit. The majority of state nursing boards accept physician CMEs. For specific questions, contact your state board of nursing. Nursing CE credit is available for the two Professionals in Epilepsy Care symposia. Use the Medical Education Evaluator, the online evaluation system, to access certificates for nursing credit.



Pharmacists: Extension Services in Pharmacy at the University of Wisconsin-Madison School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This program has been

designated as a knowledge-based program and is approved for up to 29 hours (2.9 CEUs) of pharmacy continuing education credit. A Statement of Credit will be provided after successful completion of an online learning assessment and evaluation (Medical Education Evaluator). The learning assessment and evaluation must be completed online prior to January 30, 2010.

International Credits: The American Medical Association has determined that non-U.S. licensed physicians who participate in this CME activity are eligible for *AMA PRA Category 1 Credit*[™].

Medical Education Evaluator[®] and Certificates

The Medical Education Evaluator[®] allows any attendee to self-manage the process of completing course evaluations, tracking credits and printing out the appropriate certificate for either *AMA PRA Category 1 Credits*[™], CE or ACPE pharmacy statement of credits.

Log on to the Evaluator via the AES Web site www.aesnet.org. Once you are on the Evaluator, you will be asked to enter your badge # and password (aescm). The certificate(s) are saved to your personal account page which is cumulative. You may print the certificate(s) in PDF format at any time.

The online Evaluator will be left open through January 30, 2010, so you must complete the evaluations and credit tracking by that date.

By completing this information online, attendees greatly assist the Council on Education and Annual Meeting Committee with important needs assessment data whereby the AES can further plan and address educational gaps to meet the needs of our learners.

A meeting attendance certificate will be available for international meeting attendees at the registration desk.

Syllabus

Syllabi for the educational symposia are available on the AES Web site and are available to print. Paper handouts will not be provided.

Audience Response System

This year, AES will be utilizing the Audience Response System (ARS) in every symposium. A limited number of keypads will be handed out to attendees when they enter the symposium. We request that if you take a keypad, to please ensure you answer the questions. Each faculty member will have an ARS question as part of their presentation with a multiple-choice answer. The ARS will allow for interactive audience participation and well as real time, immediate feedback to enhance the learning environment and ensure that we are meeting the learning objectives set forth for each symposium.

Exhibit Hall Opening and Lennox and Lombroso Trust for Research & Training Reception

Sunday, December 6, 5:00 p.m. - 7:00 p.m.

Hynes - Exhibit Hall, Level 2

Share the dream to cure epilepsy! Come mingle with your colleagues and show your support at the Annual Reception. A voluntary, tax deductible contribution of \$50, or whatever you can contribute, will benefit the Lennox and Lombroso Trust for Research & Training. To assist in planning, advanced registration is required.

GENERAL INFORMATION

Commercial Exhibits

The Exhibit Hall is an integral part of the learning experience. Meeting participants will have an ideal opportunity to learn about the latest in pharmaceuticals, publications, scientific equipment, and technology relevant to the fields of epilepsy and neurophysiology. Please check the AES Web site for an updated listing of exhibiting companies and organizations. To ensure safety and security, no children, strollers, carriages, wheeled luggage or wheeled briefcases will be allowed in the Exhibit Hall during exhibit hours.

Sunday, December 6	5:00 p.m. - 7:00 p.m.
Lennox / Lombroso Reception	5:00 p.m. - 7:00 p.m.
Monday, December 7	9:00 a.m. - 4:00 p.m.
Tuesday, December 8	8:00 a.m. - 1:30 p.m.

Scientific Exhibits

The American Epilepsy Society has adopted and approved guidelines for industry-sponsored scientific exhibits at the Annual Meeting. Scientific Exhibits differ from traditional poster presentations in that a broad range of material can be presented as a collection of topics, such as results of various clinical trials, or a thematic presentation of one aspect of drug development. Scientific Exhibits will be displayed on two days, Sunday, December 6 and Monday, December 7.

Cyber Café

Hynes – Exhibit Hall, Level 2

The Cyber Café will be available at the Convention Center during exhibit hall hours with e-mail and Worldwide Web access. Check in with family members and colleagues, and conduct online research while attending the meeting. You will also be able to complete the course evaluations and obtain your CME certificate online.

Language

The official language of the Annual Meeting is English. No simultaneous translation is available.

Photography and Recording of Programs

The AES strictly prohibits all photography (flash, digital, or otherwise), audio and/or videotaping during the Annual Meeting. Equipment will be confiscated. Photographs taken during this meeting by the American Epilepsy Society (AES) may be used in any of the Society's communications and materials in the furtherance of the organization's goals and purposes.

Press Room

Hynes – Room 107, Plaza Level

The American Epilepsy Society Press Room offers press releases, biographies, fact sheets, scientific abstracts, and other resources for journalists reporting on epilepsy study reports and educational presentations at this meeting. The AES staffs the on-site Press Room and works with journalists to develop stories, connect with experts and presenters, and research facts and information. Sponsors and exhibitors are encouraged to submit relevant press releases and media kits for on-site Press Room display and distribution. For more information, contact Peter Van Haverbeke at pvanhaverbeke@aesnet.org.

There will be a press briefing held on Friday, December 4 from 11:00 a.m.-12:30 p.m.

In addition, there will be mini press briefings in the Press Room through out the meeting.

Friday, December 4	7:30 a.m. - 7:00 p.m.
Saturday, December 5	7:30 a.m. - 6:00 p.m.
Sunday, December 6	7:30 a.m. - 6:00 p.m.
Monday, December 7	7:30 a.m. - 6:00 p.m.
Tuesday, December 8.....	7:30 a.m. - 3:00 p.m.

Program Changes

AES can not assume liability for any changes in the program due to external or unforeseen circumstances.

Hotel Information

Sheraton Boston Hotel (Headquarters Hotel)

39 Dalton Street, Boston, MA 02199 USA
Telephone: 617.236.2000
Fax: 617.236.1702

Marriott Boston Copley Place

110 Huntington Avenue, Boston, MA 02116 USA
Telephone: 617.236.5800
Fax: 617.236.5885

Hilton Boston Back Bay

40 Dalton Street, Boston, MA 02115 USA
Telephone: 617.236.1100
Fax: 617.867-6104

Early Departure Policy

Guests who check out of the hotel prior to their scheduled departure date will be charged a penalty of one night's room rate and tax.

Hotel Questions

E-mail Experient – the official AES Housing Bureau at AES@experient-inc.com or see the on-site housing representative at the AES registration desk.

Meeting Location

The meeting will take place at the Hynes Convention Center located within the Boston Convention Complex. The complex includes three hotels, the Hynes Convention Center, the Copley Place Shopping Galleries and the Prudential Center Shopping Arcades. All of these facilities are connected by indoor, climate-controlled walkways. Combined, these facilities include over 200 fine stores and boutiques as well as over two dozen restaurants and cafés.

Hynes Convention Center

900 Boylston Street
Boston, MA 02115 USA
www.mccahome.com/jhcc.html

FedEx Kinko's – Business Center

A full-service copy center is located on the Plaza Level of the Hynes Convention Center. For more information please call 617.954.2725 or e-mail usa1325@fedex.com.

No Smoking Policy

For the comfort and health of all attendees, smoking is not permitted at any AES functions. This includes educational sessions, meetings and all food functions. Both the Convention Center and Sheraton are 100% smoke-free facilities.

Meeting Attire

AES promotes business casual attire for the duration of the Annual Meeting. Consider bringing a light jacket or sweater to Annual Meeting activities since meeting room temperatures and personal comfort levels vary.

Information for International Travelers

Consulates and Embassies

All international embassies from other countries to the United States are located in Washington, D.C. There are a number of international embassy branch offices, called consulates, located in Boston. If your country does not have a consulate in Boston, call directory information in Washington, D.C. (phone: 202.555.1212), for the number of your national embassy.

Additional Information

Time Zone

During the month of December, Boston, Massachusetts operates in the Eastern Standard Time Zone (GMT -5 hours).

International Dialing

The country code to the United States is +1. The local area code for Boston, Massachusetts is 617.

Gratuities

Gratuities are not automatically added to the bill, except in some cases for large groups. Waiters and waitresses are usually given 15% to 20% of the bill. Taxi drivers usually receive 15% of the fare and doormen, skycaps and porters are normally tipped \$1 per bag.

Electricity

The electricity used in Boston, Massachusetts is standard 110 volt. European appliances will require a voltage transformer.

City Information

Boston, America's Walking City, has a great diversity of attractions to suit all interests. The city is known for its mix of colonial, historical sites and modern, urban sophistication. American history is prevalent with The Freedom Trail, Paul Revere's home, The Boston Tea Party Ship, Old State House and the Old North Church. Many top-rated museums are located in Boston including the Museum of Fine Arts, Museum of Science, and New England Aquarium. Shopping options, restaurants, theater and sporting events are also plentiful throughout the city. The weather in early December typically finds temperatures in the 30s and 40s.

Ground Transportation

Getting to / from Logan International Airport: The airport, located 4 miles from the Hynes Convention Center, is served by shuttle, taxi, bus and subway services. For detailed information please see www.massport.com/logan/getti.html.

Easy Transportation: 617.869.7760

Super Shuttle: 617.567.8900

Taxicab Service

Taxis are readily available at Logan International Airport 24 hours a day and are plentiful in the downtown area.

Rail Transportation

Amtrak trains arrive and depart at South Station in Boston (2 South Station, Summer Street & Atlantic Avenue). Tickets may be purchased online or at the station. For schedules and fares, contact Amtrak at 800.USA.RAIL or 800.872.7245.

Registration & Security

The American Epilepsy Society is committed to providing a secure meeting environment. A formal security plan is being developed in consultation with the Security Department at the Convention Center. All meeting attendees will be required to produce government-issued photo identification prior to receiving their badge and registration materials. Appropriate badges must be worn at all times while in attendance at the meeting and are required for admittance to all meeting activities. Special security procedures will also be in place for exhibition materials and all deliveries to the AES meeting. Additional security information will be available in the Program Book received at the on-site Registration Desk.

Insurance, Liabilities

The American Epilepsy Society cannot be held responsible for any personal injury, loss, damage, accident to private property or additional expenses incurred as a result of delays or changes in air, rail, sea, road, or other services, strikes, sickness, weather, acts of terrorism and any other cause. All participants are encouraged to make their own arrangements for health and travel insurance.

Food Service Information

A wide variety of dining options are available just steps from the Hynes Convention Center. Coffee, fast food, Japanese, Indian, Mexican, fine dining and more – all under the same roof! Detailed information can be found on the AES Web site under the Convention Center Information, Attendee Guide.

Safety and Security Information

First Aid Station

Plaza Level – Outside Entrance to Hall A, AES Registration

The American Epilepsy Society, in conjunction with the Convention Center staff, has taken careful security measures for the 2009 Annual Meeting. The following security measures have been designed to further enhance your personal and professional safety.

- Pick up any Convention Center house phone located in the facility and dial the Hynes Command Center at extension 2111. In addition, there are red "hot line" phones located throughout the facility that will connect you directly to the security department. Uniformed Convention Center employees have radios and are ready to assist you. Advise the dispatcher of the exact location within the Convention Center. We respectfully request that you do NOT call 911 directly.
- A nurse will be on duty in the Convention Center throughout the meeting.
- A government-issued photo identification is required to receive a badge and to replace a lost badge.
- Convention Center Security may randomly check packages and bags at the Convention Center entrances, meeting rooms and in the Exhibit Hall.
- You will be asked to always clearly display your name badge and to use only approved entrances and exits to the Convention Center.
- Appropriate badges will be required to enter all educational sessions, Poster Sessions, the Exhibit Hall and meetings.
Due to safety and fire regulations, doors will be closed to all session rooms that fill to capacity.
- Throughout the meeting, you will notice a presence of security staff to monitor the safety of all participants.
- Do not leave unattended packages (i.e., briefcases, laptops, purses, etc.) in any area of the Convention Center or hotel.
- Please report any suspicious activity to security staff or to the AES registration desk staff.

General Safety Tips

- Remove your badge once you leave the meeting facilities.
- Carry important telephone numbers with you.
- Do not display or carry large amounts of cash.
- Walk in groups, especially at night.
- Lock your hotel room door.
- Always verify hotel room repair or service calls.
- Do not disclose your room number to anyone.
- Never give your personal information (credit card, room number, etc.) over the phone; instead, go to the front desk if the hotel calls with questions.

Contact Information

American Epilepsy Society Phone: 860.586.7505
342 North Main Street Meeting Fax: 860.586.7550
West Hartford, CT 06117-2507 E-mail: info@aesnet.org
Web site: www.AESNET.org

Speaker Ready Room and Photos


Location: Hynes – Room 110, Plaza Level

Speakers need to have photos taken in Room 110 for repurposing of symposia on the AES Web site. All faculty PowerPoint presentations have already been uploaded through the AES Faculty Development Room. All speakers must stop by Room 110 to reconfirm their presentation with an audio visual technician.

Friday, December 4 8:00 a.m. - 8:00 p.m.
Saturday, December 5 8:00 a.m. - 6:00 p.m.
Sunday, December 6 8:00 a.m. - 6:00 p.m.
Monday, December 7 8:00 a.m. - 6:00 p.m.
Tuesday, December 8 8:00 a.m. - Noon

ELECTRODES

It's the dawn of a new era for a *new* generation of electrodes, and because the world isn't flat, we have engineered a *new* electrode that conforms to the brain for more precise mapping.



NOW available with...

- *New* colored tubing
- *New* low profile connector
- *New* brain conforming Cortac[®] grids

CALL TODAY FOR A FREE CONSULTATION!

Committed to neurosurgery advancements for 30 years! • Highly specialized direct sales force to serve you better!
25 years of commitment to advancements in epilepsy monitoring

PMT[®]
PMT CORPORATION
Quality, Innovation and Customer Driven

PMT[®] Corporation
1500 Park Road • Chanhassen, MN • 55317 • USA
PHONE: 1-800-MANKIND • FAX: 952-470-0865
Copyright © 2007 All Rights Reserved.

2010

AMERICAN EPILEPSY SOCIETY

3rd Biennial North American Regional Epilepsy Congress

64TH ANNUAL MEETING

MEETING HIGHLIGHTS

- CME Symposia and Lectures
- Platform Sessions
- Poster Sessions
- Commercial Exhibits
- Special Interest Groups



AMERICAN EPILEPSY SOCIETY
3rd Biennial North American Regional Epilepsy Congress

SAN ANTONIO, TX

HENRY B. GONZALEZ
CONVENTION CENTER

December 3 - 7, 2010

Future Annual Meeting Dates!



2011

Baltimore, MD

Baltimore Convention Center
December 2 - 6

2012

San Diego, CA

San Diego Convention Center
November 30 - December 4

2013

Washington, D.C.

Washington Convention Center
December 6 - 10